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Abstract 
 
The emergence and spread of resistance to antimalarial drugs has highlighted the 
demand to search for new drugs that target novel pathways in the human malaria 
parasite Plasmodium falciparum. This thesis explores the potential for targeting of the 
PfAtg8-PfAtg3 protein-protein interaction (PPI) that is required for lipidation of 
phosphatidylethanolamine (PE) within parasite autophagy pathway. Whilst P. falciparum 
lacks a complete cascade of the classical autophagy pathway, the homologues for key 
proteins such as PfAtg8 exist and have been shown to be involved in cellular processes 
such as vesicle trafficking and apicoplast biogenesis. Here, the antiplasmodial activity of a 
library of 131 compounds designed in silico to act as inhibitors of hLC3 (Atg8 homologue)-
Atg3 interaction were evaluated. Two hits, SK1.47 and SK1.49, have been identified and 
shown to have moderate antiplasmodial activity (EC50 of 1-2 µM) against intraerythrocytic 
parasites, produce a rapid cytocidal activity against trophozoite stage parasites and have 
selectivity for the parasites over HepG2 cells. As a first proof of concept, both compounds 
inhibit the formation of PfAtg8-labelled vesicles, potential autophagosomes, induced by 
nutrient starvation. Computational modelling of SK1.47 and SK1.49 docking to PfAtg8 
suggests that the naphthalene group binds to the W-pocket and the substituted phenyl 
binds to the L-pocket of the PfAtg3 interacting region of PfAtg8. This docking study also 
highlights aspects of the core structure of both molecules that should be further explored 
in terms of their antiplasmodial activity. 
Ultrastructural changes and induction of biochemical markers of apoptotic cell death 
appear to suggest that SK1.47 and SK1.49 treated parasites do not undergo apoptotic cell 
death. This study was extended to exploit a bioluminescence assay of parasite viability 
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following exposure to a range of benchmark antimalarial drugs, which allows samples to 
be prepared that match a defined and titrated kill effect applied using drugs of different 
chemical classes. These established the conditions for a comparative study of apoptotic 
markers of early cell death using these different chemical classes, and also highlighted the 
central role of mitochondrial membrane potential collapse for the majority of drugs that 
explored and Ca2+ redistribution from the digestive vacuole following treatment with 4-
aminoquinolines. 
This study also highlights the opportunity of autophagy related proteins (Atg) of P. 
falciparum parasite as a novel target for drug development. Although SK1.47 and SK1.49 
compounds are not considered as lead compounds for drug development due to lack the 
required potency with unfavourable physicochemical properties (high LogP), they are 
available now as chemical probes to explore the contested role of autophagy in malaria 
parasite homeostasis and response to drugs. 
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Chapter 1: General introduction 
1.1 Malaria is a global disease  
Malaria is a serious tropical parasitic disease with a global reach, affecting some 91 
countries. According to the World Health Organisation Report (2016), approximately 212 
million malaria cases with 429,000 deaths were reported in 2015 (WHO, 2016). The 
majority of this mortality occurs in African children aged under 5 years old. This 
estimation is likely lower than the actual malaria burden as most of countries affected by 
malaria have limited diagnostic resources, particularly in rural areas (Autino et al., 2012), 
and often lack the potential to survey malaria distribution and mortality due to mass 
migration of human groups; especially in conflict regions (Pindolia et al., 2014). The first 
global malarial risk map was produced by Lysenko and Semashko in 1960 (Fig. 1.1) 
(Dalrymple et al., 2015). Here they describe four categories of endemicity depending on 
the proportion of the population that carry blood-stage parasites, termed the parasite 
rate (PR); hypoendemic region (<10%), mesoendemic region (≥10% <50%), hyperendemic 
region (≥ 50% <75%), holoendemic region (≥75%) (reviewed in Dalrymple et al., 2015). 
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Fig. 1.1 A ‘Lysenko’ map of global malaria endemicity circa 1900. This historic map constructed 
by Lysenko and Semashko during the 1960s was based on a worldwide assembly of diverse 
malariometric data, simple climatic rules and expert opinion. The classic strata of malaria 
endemicity are described, each relating to infection prevalence (parasite rate, PR) in children: 
hypoendemic, PR <10 %; mesoendemic, PR ≥10 % and <50 %; hyperendemic, PR ≥50 % and 
<75 %; and holoendemic, PR ≥75 %. This is a reproduction of the map from Hay et al. (2004). 
 
The causative agent of malaria in humans is protozoan parasites of the Plasmodium 
genus, with five species causing infections in humans (Kwenti et al., 2017). Of these, P. 
falciparum is the most virulent species and is prevalent almost in all malaria endemic 
countries with its widest geographic range within Africa, and as a consequence the 
primary burden of mortality falling on this region (Fig. 1.2) (Gupta et al., 1994). Recent 
emerging populations newly at risk of malaria are arising as a result of climate changes 
affecting the anthropogenic vector of Plasmodium spp. (Okonko et al., 2009) as well as 
the emergence and spread of drug resistant parasites (White et al., 2014) and insecticide 
resistant mosquitoes (Ranson et al.,2011). 
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Fig. 1.2 The global map of P. falciparum parasite rates (proportion of population infected with 
blood-stage parasites) in 2010. Note the residual spatial distribution of high parasite rates in 
children in Sub-Saharan Africa (Source: Gething et al., 2011). 
 
The first regional eradication campaign for malaria was launched in the 1940s and 
represented a stationary base upon which the Global Malaria Eradication Program 
(GMEP) was launched in 1955 (Carter and Mendis, 2002). These elimination programmes 
utilised insecticide-treated nets (ITNs), the insecticide dichlorodiphenyltrichloroethane 
(DDT) for indoor residual spraying and mass administration of chloroquine (CQ) 
chemoprophylaxis. The success of this campaign resulted in the elimination of malaria 
from Europe, North America, the Caribbean and some parts of Asia and South-Central 
America (Carter and Mendis, 2002). Regretfully, a decline in global efforts to eliminate 
malaria between 1968 and 1991, due to economic, financial and institutional challenges 
(Mills et al., 2008), in addition to spread evolution of antimalarial drug resistance led to 
resurgence in the malaria burden in sub-Saharan Africa (Plowe, 2005). The hope for 
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malaria elimination and eradication was revived following the declaration of the Roll Back 
Malaria initiative by the World Health Organisation (WHO) in 1998 (Tanner and Savigny, 
2008). Despite progression in malaria control in Africa, resulting in falls of 21% in new 
cases of malaria and 31% in deaths between 2010 and 2015 (WHO, 2016), the challenge 
of malaria, particularly in Sub-Saharan Africa is still significant. 
1.2 Parasite life cycle 
Unicellular protists of the Plasmodium genus, the causative agent of malaria, are 
transmitted to humans through the bite of an infected female anopheles mosquito vector 
during the course of a blood meal. To date, five species of Plasmodium have been 
reported to cause clinical malaria, including; P. falciparum, P. vivax, P. ovale (there are 
two subspecies; P. ovale curtisi and P. ovale wallikeri (Sutherland et al. 2010), P. malariae, 
and P. knowlesi. For successful completion of the parasite complex multistage life cycle, 
two hosts are required, the human vertebrate and the mosquito invertebrate (Fig. 1.3 
illustrates the life cycle of P. falciparum). The key stages of this life cycle are described 
below. 
1.2.1 Parasite life cycle in the human host 
1.2.1.1 Pre-erythrocytic phase or Hepatic schizogony phase 
Hepatic schizogony of malaria parasites in human is characterised as an asymptomatic 
phase of infection (Derbyshire et al., 2012). During this stage, intracellular and 
extracellular development of parasite occurs. Human infection is initiated by transmission 
of infectious sporozoites from the salivary glands of an infected female Anopheles 
mosquito into the subcutaneous tissues during a blood meal (Burkot et al., 1986). 
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Sporozoites migrate though the bloodstream to the liver. During this migration, some 
sporozoites are engulfed by local macrophages and some migrate to the lymphatic 
system and induce protective immunity (Good and Doolan, 2007). In hepatocytes, exo-
erythrocytic forms are created within a protective vacuole called the 
parasitophorous vacuole (PV). In order to establish infection within the hepatocytes, the 
PV and circumsporozoite surface (CS) proteins (surface proteins of sporozoites) isolate 
the parasites from the host cell cytoplasm and suppress pro-inflammatory cytokines 
production, respectively. These represent the key mechanisms of immune evasion in the 
hostile human environment (Eksi and Williamson, 2011; Singh et al., 2007). In infected-
hepatocytes, sporozoite development occurs over 5-16 days, depending on the parasite 
species, producing thousands of hepatic merozoites within a host-derived vesicle called 
merosome (Kebaier et al., 2009). The liver-stage represents a key difference between 
Plasmodium spp. that infects humans. P. vivax and P. malariae infections can result in the 
formation of dormant forms termed hypnozoites (Collins, 2007). Delayed activation and 
maturation of these hypnozoites are related to relapsing malaria, which can occur several 
months to several years after the initial infection (Collins, 2007; Imwong et al., 2007; Siala 
et al., 2005) and lead to a phenomenon termed post-treatment relapse (Greenwood et 
al., 2008; Szmitko et al., 2008; Theunissen et al., 2009; Zenz et al., 2000). 
Following completion of hepatic development, the merosomes are released into 
circulatory system and burst in the pulmonary capillaries releasing thousands of hepatic-
merozoites into the bloodstream to initiate the next step of asexual development of life 
cycle in humans, the intraerythrocytic phase, which is characterised by the patent 
pathophysiology of infected red blood cells (Fig. 1.3) (Chotivanich et al., 2000). 
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Fig. 1.3 The life cycle of P. falciparum. Infectious sporozoites are transferred to humans via the 
bite of an infected female Anopheles mosquito. The sporozoites migrate to, invade, and then 
replicate within hepatocytes, termed the exo-erythrocytic phase. After a clinical sub-patent 
period of some 10 days, tens of thousands of hepatic merozoites are released into the 
bloodstream. Here, the intraerythrocytic phase is established when red blood cells (RBCs) are 
infected by the merozoites. Parasites inside RBCs undergo several rounds of asexual multiplication 
(These include the well described morphological stages of ring, trophozoite and then schizont), 
with a release of merozoites after 48 hrs, which can reinitiate RBC infection – leading to 
development of high levels of parasitaemia and the pathophysiology of disease. A proportion of 
infected RBC commit to sexual differentiation instead of multiplication, producing micro- and 
macrogametocytes stages infectious to mosquitoes when taken up in a blood meal. Completion of 
sexual commitment and gamete fusion form the zygote and then ookinete in the mosquito 
midgut. Migration of the ookinete through the basement membrane of the gut to reside against 
the haemocoel results in the formation of oocyst. Here, meiotic division, followed by mitotic 
replication generates thousands of haploid sporozoites, which are released from ruptured 
oocysts. These sporozoites migrate to the salivary glands of the mosquito, where they become 
available to be transmitted to humans (Source: Josling and Llinas, 2015). 
 
 
 
7 
 
1.2.1.2 Intraerythrocytic schizogony – infection of the red blood cells 
This phase is characterised by symptomatic features of infection and rapid expansion of 
the parasite burden. During this phase, growth within, and then release of new 
merozoites from infected red blood cells repeats over several cycles. The virulence of P. 
falciparum parasites depends, in part, on their ability to infect all RBCs, irrespective of 
their age (red blood cells circulate for approximately 120 days), using a range of variety 
receptor-ligand interactions (Cooke et al., 2004) mediated through merozoite surface 
proteins and proteins released from organelles located at their apical end (Fig. 1.4). RBC 
age appears to play a critical role in determination of infection based on Plasmodium spp. 
infection, with P. vivax and P. ovale invasion restricted to young circulating age RBCs, also 
termed reticulocytes, and P. malariae invasion restricted to the oldest circulating red 
blood cells (McQueen and McKenzie, 2004).  
 
Fig. 1.4 Scheme illustration of a merozoite. The image highlights major organelles and cellular 
structures, with the penetrative organelles (micronemes, rhoptries and dense granules) located in 
the apical anterior end of merozoite (Source: Cowman and Crabb, 2006). 
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Following invasion of RBCs, a programme of architecture remodelling is launched 
including loss of penetrative organelles such as apical rings, conoid, rhoptries and 
micronemes and modification of the host erythrocyte to adapt to the new 
intraerythrocyte environment (Field and Shute 1956). Infected RBCs (iRBCs) undergo 
parasite-directed modifications to their cytoskeleton (increase their deformability), an 
increase in plasma membrane permeability to nutrients located in serum, as well as the 
export of proteins from the parasite to the erythrocyte surface. The latter proteins, such 
as Erythrocyte Membrane Protein 1 (PfEMP1), which located on electron-dense knobby 
structures are critical to the pathology of disease (Cooke et al., 1998; Gruenberg et al., 
1983). PfEMP1 are critical to the ability  of parasite to persist in red blood cells against the 
human immune response through clonal antigenic variation of PfEMP1 (Kyes et al., 2007) 
and avoidance of splenic clearance by PfEMP1 binding to a wide of host receptors (Craig 
and Scherf, 2001). 
Following infection of the red blood cell, the parasite undergoes a number of well-
described morphological changes (Fig. 1.5) over the next 48 hrs (red blood cell 
development takes 24 hrs for P. knowlesi and 72 hrs for P. malariae). The first are the 
round and hollow cytoplasm shapes termed the ring stage. The ring stage is characterised 
by a low metabolic activity and minimal remodelling of iRBCs with the lack of any obvious 
cytoplasmic organelles (Spielmann et al., 2006). Ring stage iRBC are often visualised in 
diagnostic microscopic tests as this stage of iRBC freely circulate in the bloodstream, 
lacking the surface expression of PfEMP1 that would be required to mediate 
sequestration of the iRBC in the microvasculature (Langreth and Peterson, 1985). In P. 
falciparum, this stage continues for approximately 24 hrs post infection with the size of 
the ring increasing as well as the thickness of the cytoplasmic ring (Bannister and 
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Mitchell, 2009). At this point, the parasite is typically termed trophozoites – the name 
derived from the parasite feeding (Greek trophe) on the RBC haemoglobin to provide 
both space and nutrients for growth and replication (Sherman, 2012). Trophozoites are 
highly metabolic active, with key activities including haemoglobin trafficking to the 
parasite acidic digestive vacuole (DV) and protein export, such as PfEMP1, to the 
erythrocyte surface. The trophozoite stage proceeds up to about 32 hrs post-invasion and 
is followed by the schizont stage. Within the schizont, multiple rounds of 
deoxyribonucleic acid (DNA) replication and cytoplasmic division result in the 
characteristic large and segmented morphology as new merozoites are formed (Bannister 
et al., 2000). Several physical and biochemical events such as increases in intracellular 
pressure, destabilisation of iRBCs membrane integrity and proteolysis of the 
parasitophorous vacuole membrane (PVM) are thought to trigger RBCs rupture and 
release of between 16-32 new merozoites into the bloodstream. These merozoites are 
now available to reinvade uninfected erythrocytes (uRBCs), this process represents an 
exponential growth phase in parasite population  (Glushakova et al., 2005).  
 
. P. falciparum he major morphological stages of intraerythrocytic development inT  51.Fig. 
2015).et al.,  Cantero-Mata(Source:  
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tosquito hosmthe ife cycle in larasite P 22.1. 
Under conditions of stress such as those induced under high parasitaemia, nutrient-poor 
conditions or antimalarial drug exposure, a proportion of newly invaded RBCs trigger 
gametogenesis instead of entry in a new cycle of asexual intraerythrocytic development 
(Carter and Miller, 1979; Dyer and Day, 2002). Here, two types of gametocytes, termed 
microgametocytes (males) and macrogametocytes (females), are formed and complete 
development of several days before being taken up into a female Anopheles mosquito 
during a blood meal (see review by Josling and Llinas, 2015). During the growth and 
development of gametocytes, these iRBCs are primarily sequestered in bone marrow 
(Farfour et al., 2012). Five distinct morphological forms or stages (stages I–V) were first 
described by Field and Shute (1956). Gametocyte stage-I is morphologically similar to an 
asexual trophozoite stage whilst the subsequent gametocyte stages can be 
microscopically differentiated and specifically recognized by a characteristic sickle-like 
shape. Gametocyte stage-V is the only infectious form for mosquito vector as it no longer 
sequesters in the bone marrow and can be found in peripheral blood (Carter and Miller, 
1979). After being taking up by the mosquito, within the midgut both microgametocytes 
and macrogametocytes initiate the terminal developmental process producing flagellated 
microgametes and macrogametes, respectively. Fertilization of macrogametes by 
microgametes produces zygotes (diploid) which rapidly develop into a motile ookinete 
(Bennink et al., 2016). Penetration the midgut wall of mosquito by ookinetes leads to 
them residing against the basement wall of the haemocoel, with ookinetes developing to 
oocysts. Oocysts undergo meiotic division to the haploid state and then undergo mitotic 
division to generate thousands of haploid daughter sporozoites within an oocyst. 
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Following rupture of the oocyst, sporozoites migrate through the haemocoel to the 
mosquito salivary glands to be available to infect a human host (Sinden, 1999). 
1.3. Malaria pathogenesis 
Although the liver stages of the life cycle plays a central role in infection by providing 
hepatic merozoites into the bloodstream, this stage of the infection is characterised by 
subclinical symptoms and is often termed the pre-patent period (Lindblade et al., 2013). 
P. falciparum, the most virulent species of human malaria parasite, is highly endemic in 
sub-Saharan Africa, where infection correlates with severe malaria and mortality, 
particularly in children aged under 5 years (Nankabirwa et al., 2014). Malaria 
pathogenesis is characterised by a complex network of host-parasite interactions 
(Acharya et al., 2017). Differences in pathology depend on environmental factors 
(primarily related to conditions that favour the presence of the mosquito vector as well as 
local health infrastructure), host factors (history of exposure to parasite, immune status 
and presence of protective factors such as haemoglobinopathies) and parasite factors 
(expression of virulence proteins that interact with human host ligands and capacity to 
evade host immune response) (Schofield and Mueller, 2006). Pregnant women, 
particularly primigravida, represent a particular risk group due to their modified immune 
status and the existence of a novel organ, the placenta, for parasite sequestration (Uneke, 
2007). This pre-symptom period of infection (incubation period) ranges between one to 
few weeks relying on the infecting Plasmodium spp., chemoprophylaxis therapy 
(Schlagenhauf-Lawlor, 2007) and immune response based on previous exposure to 
infection (White, 2009). Clinically, malaria is generally classified into two sub-groups 
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(uncomplicated and complicated or severe malaria) according to the clinical 
manifestation of the infection (Patel et al., 2003). 
1.3.1 Uncomplicated malaria 
Uncomplicated malaria is characterized by a range of primary malaria symptoms.  These 
are clinically similar to flu-like symptoms and include; mild fever, periodic chills, mild 
anaemia, nausea, headaches and fatigue (White et al., 2014). The Plasmodium parasite 
obtains the majority of its synthetic nutritional requirements through digestion of 25 to 
80% of host red blood cell haemoglobin during intraerythrocytic phase (Goldberg, 1993), 
a process that affects the osmotic balance within the host cell (Lew et al., 2003). The 
release of free haem, which is toxic, is detoxified by the formation of an insoluble haem 
polymer called haemozoin crystals (Olivier et al., 2014). Release of haemozoin during 
schizont rupture is considered the likely cause of fever through induction of a 
proinflammatory immune response. This proinflammatory response, however, is also 
likely contributed to by the recognition of free parasite DNA that may also be recognised 
by toll-like receptors on monocytes and dendritic cells (Parroche et al., 2007). The fever is 
usually irregular at the beginning of a malaria infection, although the classical periodic 
appearance of fever occurs a few days later as a result of synchronised schizont rupture 
and development of parasite load within the patient (Bartoloni and Zammarchi, 2012). 
1.3.2 Complicated or severe malaria 
Efficient treatment of malaria can be achieved if the disease is diagnosed early and an 
effective drug given rapidly. Failing this, the disease may develop and the effect of the 
high parasite load on organs can occur leading to severe malaria. Severe malaria is 
defined as a complex multi-system disorder with several clinical manifestations. Critical to 
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this pathology, is the role of P. falciparum erythrocyte membrane protein 1 (PfEMP1) 
(Montgomery et al., 2007). PfEMP1 is exported from the parasite to the surface of the 
erythrocyte infected by mature stages of parasite (trophozoite and schizont). PfEMP1-
decorated infected erythrocytes are less available in peripheral blood due to their ability 
to cytoadhere to endothelial cells of host organs via a wide range of host receptors 
including; cluster determinant 36 (CD36), intercellular adhesion molecule 1 (ICAM1), 
thromobospondin (TSP), complement receptor 1 (CR1)and chondroitin sulfate A (CSA) 
(Chan et al., 2014). Through this cytoadhesion process, the parasite sequesters itself in a 
low oxygen environment necessary to complete its development (it is a microaerophilic 
organism) and also provide protection to mature iRBCs from splenic clearance (Franke-
Fayard et al., 2010). PfEMP1 on the surface of iRBCs also have the ability to bind to other 
uRBCs, forming rosettes, or other iRBCs, forming clumps that are considered likely to 
block post-capillary venules and result in poor development of tissue and localised 
inflammatory hypoxia pathology (Newton et al., 1994). PfEMP1 also has a second 
function, where clonal antigenic variation of the PfEMP1 expressed by the parasite 
population supports the establishment of a long-term chronic infection despite the host 
ability to generate antibodies against PfEMP1 on the surface of infected erythrocytes 
(Pasternak and Dzikowski, 2009). 
Cerebral malaria cases are caused by parasite sequestration within the microvasculature 
of the brain and are particularly noted for their high mortality rates (MacPherson et al., 
1985). A more common pathology, particularly in young children, is severe malarial 
anaemia (SMA) (White et al., 2014). A number of mechanisms contribute to this severe 
anaemia, including; splenic destruction of infected erythrocytes (Buffet et al., 2009), 
macrophages phagocytosis of infected erythrocytes (Biemba et al., 1998), infection and 
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destruction of erythrocytes during its normal intraerythrocyte development and 
suppression of bone marrow activity and dyserythropoiesis (Perkins et al., 2011). 
Infection during pregnancy (congenital malaria) is caused by iRBCs binding to CSA on the 
surface of syncytiotrophoblasts in the placenta (Uneke, 2007). As a result localised 
proinflammatory responses decrease the function of the placenta and lead to low birth 
weight, premature delivery and may result in still birth (Steketee et al., 2001). 
1.4. Malaria prevention and control 
Malaria control strategies have been successfully applied over the last fifteen years to 
reduce the overall global burden of this disease. These strategies rely on the treatment of 
infections by targeting the parasite using small molecule drugs, or through the use of 
insecticides to block the transmission by the Anopheles vector. Comparisons of malaria 
burden with and without these interventions over the last 15 years highlight the 
considerable success of transmission blocking interventions, primarily usage of ITNs, 
artemisinin combination therapy (ACT) and indoor residual spraying (IRS) of surfaces that 
mosquitoes rest on (Fig. 1.6).  
Insecticide treated bed nets offer a simple, safe and environment friendly method to 
prevent malaria infection. These nets were introduced during World War II to protect 
soldiers against vector-borne diseases (specifically malaria and leishmaniasis) in Europe 
(Curtis et al., 1990). Modern bed nets are treated with one or more pyrethroids and have 
been shown to efficiently protect against infection through repelling and actual killing of 
the mosquito vector (Curtis et al., 1990). The use of more permanent insecticide 
treatment of the bed nets have created long-lasting insecticide-treated nets (LLIN) that 
are used in current malaria control strategies. 
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Fig. 1.6 Influence of different control tools on malaria burden in Africa from 2000 to 2015. 
Where percentage of parasite rate under three different malaria interventions including; 
insecticide treated bed nets (ITN), artemisinin combination therapy (ACT) and indoor residual 
spraying (IRS) as well as non-intervention were applied during study period (Source: Bhatt et al., 
2015).  
 
According to a survey study done by Wanzira et al. (2016) in Uganda, a significant 
population coverage of LLIN contributed to a significant decrease of malaria infection in 
the study region and that the effectiveness of LLINs was raised when it is used in 
combination with IRS (Hailu et al., 2016). Despite resistance to DDT being reported in 
some malaria endemic regions, the WHO strongly recommends using DDT-indoor residual 
spray in West and Central Africa due to the prolonged efficacy of DDT (approximately 12 
months) compared to other insecticides such as pyrethroids (4–6 months), 
organophosphates or carbamates (2–6 months). Thus one spray cycle/year of DDT IRS 
reduces the total insecticide cost and also minimizes its level in environment (WHO, 
2006). 
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In terms of vaccination against the malaria parasite, significant efforts have been focussed 
on the development of a vaccine to support malaria eradication. Despite decades of basic 
and clinical research, production of a cheap, safe and effective vaccine is still not 
promising (Ballou, 2009).  There are a number of challenges that have obstructed 
progression in this field, including; the complexity of the parasite life cycle, extensive 
antigenic variation and polymorphic strains, as well as an incomplete understanding of 
what aspects of the host immune response actually provides the protection seen in 
people exposed to infections repeatedly by the malaria parasites (Langhorne et al., 1989). 
The multistage life cycle of malaria parasite determines that there are three types of 
stage-based vaccines; pre-erythrocytic stage, intraerythrocytic stage and transmission 
blocking vaccines (Guilbride et al., 2010; Hill, 2011). Currently, the target of the most 
active vaccine is the sporozoite surface protein of P. falciparum, CS protein (Gardner et 
al., 2002). RTS, S/AS01, type of CS vaccine, is a pre-erythrocytic vaccine that is also called 
MosquirixTM and has been developed by GlaxoSmithKline (Kaslow and Biernaux, 2015). It 
is a formulation of repeated region of conserved motifs from CS incorporated with a C-
terminal region that contains T cell epitopes from the surface protein of hepatitis B. An 
adjuvant AS01, consisting of a monophosphoryl lipid A fused with QS21, is added to 
enhance its overall immunogenicity (Stoute et al., 1997). The RTS, S/AS01 vaccine can 
induce a short life protection in immunized children and is still under phase-III of clinical 
trials (Crompton et al., 2010; WHO, 2017) with approval for larger field studies in 2017/18 
(Han et al., 2017). Further trials to improve the protection ability of RTS, S/AS01 using 
different adjuvants (Genton et al., 2010) or a virus delivery vector are also ongoing 
(Walther et al., 2006). Blood stage vaccines show less promise than CS-based vaccines 
due to high antigenic variation in the intraerythrocytic stage of malaria parasite (Takala et 
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al., 2009) and only modest antibody levels are reported even when incorporated with 
adjuvants (Ellis et al., 2009). Suppression of parasite transmission through the use of 
transmission blocking vaccines have focussed on a prefertilization antigen of P. falciparum 
(Pfs48/45) expressed in gametocytes (Outchkourov et al., 2008), with the number of 
oocysts dramatically reduced in mosquitoes fed with blood that contains antibodies 
obtained from immunized mice or monkeys (Chowdhury et al., 2009). Importantly, the 
short half-life of potential malaria vaccines and appropriate means to deliver them where 
most needed in resource-poor areas, provide important challenges in the delivery of an 
efficient vaccine against malaria parasites (Crompton et al., 2010; Hill, 2011).  
1.4.1 Antimalarial drugs  
Treatment of malaria currently relies upon small molecule drugs. The first antimalarial 
drug widely used was quinine (QN), originally isolated in 1820 from the bark of the 
Cinchona tree (Willcox et al., 2004). The bark of this tree, termed “Jesuit’s powder” was 
introduced to Europe, from South America, in the early 17th Century for the treatment of 
malarial fevers (Achan et al., 2011). Despite emerging resistance to QN in some parts of 
world by 1910, it is still used widely and is a drug on the WHO list of essential medicines. 
The emergence of resistance as well as challenges in production of a cost-effective 
synthetic QN prompted the search for alternatives at the start of the 20th Century. This 
pattern of introduction of a new drug, use and then emergence of resistance was 
repeated several times during the 20th Century (Fig. 1.7) (Wells et al., 2015). The 
development of CQ in 1934, the first of several 4-aminoquinolines introduced in this 
century, was eventually delivered widely as an antimalarial in 1945, replacing mepacrine 
based on its improved tolerability and safety profile (Famin and Ginsburg, 2002; Slater, 
1993). However, the first case of CQ resistant P. falciparum was documented at the Thai-
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Cambodian border in 1957 and was followed by the emergence of resistance in South 
America in 1959, with resistance eventually spreading to Africa in 1978 (Packard, 2014). 
Other quinoline-containing drugs such as amodiaquine (AQ) and mefloquine (MQ) were 
introduced in 1950 and 1977, respectively (Mein, 1951; MMV, 2015). Resistance to AQ, a 
4-aminoquinoline, was reported in Thailand in 1975 (Hall et al., 1975), while resistance to 
MQ, an aminoalcohol, reported in Asia in late 1990.  
 
Fig. 1.7 A timeline of antimalarial drugs development and the emergence of resistance. 
Abbreviations: Sulphadoxine–Pyrimethamine (SP), Drugs for Neglected Diseases initiative (DNDi), 
World Health Organization (WHO), Medicines for Malaria Venture (MMV) (Source: Wells et al., 
2015). 
 
The last new class of antimalarial, prior to artemisinins, was atovaquone (ATQ), a 
naphthoquinone that was combined with proguanil (PG) in the prophylactic drug 
malarone. Unfortunately, resistance to ATQ emerged almost immediately after its 
introduction (Vaidya and Mather, 2000). 
The digestive vacuole (DV) is a key target for quinolone antimalarial drugs. The DV is an 
acidic lysosomal-like compartment within intraerythrocytic parasites which haemoglobin 
digestion takes place. As a result of haemoglobin digestion, the toxic haem moiety 
(ferriprotoporphyrin IX, FPIX) is released and is available to damage the DV membrane 
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(Leed et al., 2002; Sullivan et al., 1996; Ginsburg et al., 1998). FPIX is detoxified by 
biocrystalization to generate haemozoin, also termed malaria pigment, as well as by 
glutathione mediated degradation. Quinoline drugs, particularly the 4-aminoquinolines 
(including chloroquine, amodiaquine, pyronaridine and piperaquine) and aryl amino 
alcohol (including quinine and mefloquine, see Fig. 1.8) have a high affinity for FPIX, with 
the subsequent FPIX conjugate no longer being capable for biocrystalization. Thus, toxic 
levels of FPIX conjugate accumulate within the DV in the presence of quinolone drugs 
(reviewed in De Villiers and Egan, 2009). A key aspect of the targeted accumulation of 
quinolones is their weakly basic properties. In neutral conditions (outside of the DC), 
these molecules are neutral and have the capacity to readily transit membranes. 
However, within the acidic DV, these quinolines becomes protonated and this positive 
charge means that they are no longer capable of transiting membranes, accumulating to 
high concentrations with the consequential effect of generating toxic FPIX conjugates 
(Famin et al, 1999; Ginsburg et al., 1998; Auparakkitanon et al., 2006; Fivelman et al., 
2007; Warhurst et al., 2007). Of note is that the aryl amino alcohols mefloquine and 
quinine are weaker basic properties and less affinity to FPIX, suggesting these drugs may 
also share additional modes of action (Foley and Tilly, 1997).  
Of note is therapeutic potential of chloroquine against other conditions such as 
dermatological, immunological, rheumatological and infectious diseases (reviewed in Al-
bari, 2015). Here the acidotropic properties of the weak base chloroquine has been noted 
to cause an accumulation in acidic lysosomes where it can interfere with antigen 
presentation on the surface of dendritic cells and/or block cytokine production by 
macrophages as well as inhibiting Ca2+ and Toll-like receptors signalling in B and T cells 
(Kyburz et al., 2006; Ma et al., 2012). Similarly, a role for chloroquine as an adjunct for 
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cancer therapy has been previously reported to be associated with its ability to modulate 
the autophagy pathway (Farrow et al., 2014) and/or induce apoptosis (Park et al., 2016). 
 
Fig. 1.8 Chemical structure of antimalarial drugs (Sours: Delves et al., 2012). 
Artemisinins, sesquiterpene lactones that contain an endoperoxide bridge, are the latest class of 
antimalarials to be introduced. Artemisinins were discovered in 1972 in China by a team led by Tu 
Youyou, research that led in 2015 to her being jointly awarded the Nobel Prize for Medicine or 
Physiology (Croft and Ward, 2015). Artemisinin are a natural product isolated from the 
plant Artemisia annua, a plant used in Chinese traditional medicine for the treatment of fevers. 
This natural product was isolated and modified by Tu’s team to reduce its toxicity and improve its 
antimalarial efficiency (Miller and Su, 2011). Artemisinin and its derivatives became the first line 
for both uncomplicated and severe malaria infections at the start of the 21st Century (Maude et 
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al., 2010). Artemisinins’ antimalarial action arises as a result of the scission of the 
endoperoxide bridge within artemisinin molecules by free iron or iron within FPIX to 
produce free radicals or reactive oxygen spices (ROS) (Antoine et al., 2013; Meshnick et 
al., 1993). During this process, ferrous iron binds with either oxygen in the bridge cleaving 
the endoperoxide bond producing oxygen radical intermediates, which then undergo 
rearrangement process producing carbon-centred radicals (Butler et al., 1998). These 
carbon-centred radicals have high affinity to bind with macromolecules such as protein, 
lipid, DNA and carbohydrate. Given the wide range of apparent targets of action, 
treatment with artemisinins is characterized by a fast reduction of parasitaemia, their 
high potency and gametocytocidal effects (Balint, 2001). Artemisinin was originally 
introduced as a monotherapy, although concerns regarding 28-day clearance rates (a key 
concern given the short serum half-life of artemisinins) and the risks of drug resistance, 
led to the introduction of artemisinin combination therapies (ACT) and are now 
recommended by the WHO (Sagara et al., 2012). ACT use an artemisinin in combination with 
a partner drug such as lumefantrine, piperaquine (PPQ) or pyronaridine (PYRD), with the latter 
drugs providing protection against recrudescence based on their longer serum half-lives (Eastman 
and Fidock, 2009; Henrich et al., 2013). Unfortunately, recent reports describing the failure of ACT 
and the emergence of resistance to artemisinin, MQ and PPQ in South East Asia referring to a 
challenge to the future of this highly effective combination therapy (Dondorp et al., 2009; 
Dondorp et al., 2017; Na-Bangchang et al., 2013; Saunders et al., 2014). 
1.4.2 The search for future antimalarial drugs 
Although decades of the global efforts to combat malaria have led to the reduction of 
mortality and morbidity by 60% and 37%, respectively, emergence of resistance to ACT 
highlights the demand for new treatment strategies to face a future with widespread 
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multidrug resistant malaria parasites (Hemingway et al., 2016). A global strategy has been 
set by the WHO, includes achieving a 90% reduction in malaria burden between 2016 and 
2030 (WHO, 2016). To meet this ambitious strategy, the antimalarial drug community 
came together to describe two new antimalarial medicines; a single exposure radical cure 
and prophylaxis (SERCaP) for the treatment of malaria cases and a new prophylactic 
treatment that would be suitable for a mass drug administration (Burrows et al., 2013). 
This work included the development of target product profiles (TPP) for each medicine; 
with target candidate profiles (TCP) indicating the ideal and minimal requirements for the 
different component parts of what will be a combination therapy drug. These TCP and 
TPP represent key platforms for antimalarial drug discovery and development, and this 
need to be renewed regularly according to changes in requirements that relate to the 
needs of patients and the current status of malaria parasite resistance (Burrows et al., 
2017). Four different therapeutic strategies have been proposed relating to the phase of 
parasite infection; (1) a liver stage therapy to target hepatic schizonts and dormant 
hypnozoites, (2) an intraerythrocytic stage therapy to target the parasite burden causing 
disease (3) a transmission blocking therapy to work either in humans or the mosquito and 
(4) production of small molecules that provide chemoprophylaxis in migrant population 
and asymptomatic cases suitable for mass distribution (Leroy et al., 2014). 
Based on these requirements, several TCPs were proposed (Fig. 1.9). These include; TCP1, 
this was previously used for rapid clearance of asexual blood stage parasites, although 
now also includes drugs with long duration of action through a long serum half-life 
(Flannery et al., 2013a). This merging of two previous TCP addresses the need for a rapid 
elimination the majority of parasites from blood stream by a fast acting candidate with 
residual parasites being removed by the long duration of action of the partner candidate 
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potentially providing post-treatment prophylaxis. An additional candidate to be included 
in the combination therapy needs to target hepatic hypnozoites directly as well as 
preventing relapses, mainly P. vivax, from dormant hypnozoites. This was previously 
termed TCP3a and is now TCP3 and TCP4, respectively (Burrows et al., 2017). The final 
human stage target are the gametocytes, the candidate previously called TCP3b, and now 
is TCP5 focusses on the blocking of malaria transmission through targeting the parasite 
gametocytes and TCP6, an endectocide molecule that blocks parasite transmission by 
targeting the insect vector (Burrows et al., 2017). 
 
 
Fig. 1.9 Correlation between target product profiles (centre) and target candidate profiles (left) 
of the proposed combination therapies. The uses of each product were summarized on the right 
(Source: Burrows et al., 2017). 
 
Phenotypic screening of massive chemical libraries to date have explored the antimalarial 
activity of over six million compounds (Gamo et al., 2010), identifying 20-30,000 
compounds that exhibit sub-micromolar potency against the blood stage of malaria 
parasite P. falciparum. This search resulted in a significant progress over the past decade, 
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with many new chemicals entering the pipeline for antimalarial drug development (Wells 
et al., 2015). To provide a sustainable pipeline, however, there remains a requirement to 
discover and develop new antimalarial chemotypes that have modes of action distinct to 
those that currently exist.  
These distinct modes of action are typically attributed to biological processes that are 
both essential and unique to the parasite. Biological processes that occur in both 
mammalian and mosquito host are generally are less favourable, although parasite-
specific differences may afford an opportunity to develop drugs that are more selective 
for the parasite over the host. Towards this end, my thesis explores the potential of a 
non-canonical autophagic pathway in P. falciparum. In addition, I explore here how a 
better understanding of how parasites die following drug perturbation may provide 
insights to a process of programmed cell death that may be exploited in the search for 
parasite-specific biological processes.  
1.5 Programmed cell death  
To support ongoing of antimalarial drug discovery, there is an urgent demand to explore 
novel modes of drug action. One opportunity depends on understanding the potential of 
programmed cell death (PCD). The existence, and indeed the role, of PCD within malarial 
parasites is controversial (discussed below), and although several recent reports have 
described features typical of apoptotic PCD following drug treatment (Ch'ng et al., 2010, 
2011; Gaviria et al., 2013; Gunjan et al., 2016; Meslin et al., 2007, 2011a, b; Picot et al., 
1997; Rathore et al., 2015; Roberts et al., 2008), others do not (Nyakeriga et al. 2006; 
Porter et al., 2008; Tomlins et al., 2013; Totino et al., 2008). These reports together do 
not currently provide a conclusive view on what features of cell death following drug 
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treatment could be attributed to PCD, or even a pathway that would link these features 
together. For example, the importance of PCD in parasite cell death, and the potential for 
such a pathway as a new drug target, represents a significant gap in our understanding of 
the malaria parasite. 
1.5.1 The nomenclature of programmed cell death  
Cellular death has an essential role in maintaining the morphological and physiological 
balance in health and disease (Fuchs and Steller, 2011). Hence, the study of phenotypic 
and biological changes that correlated with cell death are fundamental in disease control 
and treatment. The term of cellular death is complex, and has developed with increases in 
our understanding of the mechanisms by which cells die. Prior to 1970, all cell death was 
considered necrosis (accidental cell death) before the discovery of apoptosis, a PCD that 
forms a part of the normal function of the cells (Kerr et al., 1972). PCD can be triggered in 
both normal and infected cells, while necrosis just occurs in pathological cases (Nabben 
and Glatz, 2015; Kroemer et al., 2009). However, it has since been proposed that two 
main categories of PCD exist; autophagic-like cell death and apoptotic-like cell death 
(formerly apoptosis) (Bursch et al., 2000) (Fig. 1.10). PCD are regulated programmes of 
cell death that follow distinct pathways with both apoptosis and autophagy acting as 
positive or negative regulators in cell maintenance during health and disease (Dockrell, 
2001; Shintani and Klionsky, 2004). Apoptosis (type I of PCD) can be a normal 
development response when death signals are received, or could results from trauma 
such as drug treatment (Sanz et al., 2008). Apoptosis is characterised by specific features, 
such as; plasma membrane blebbing, collapse of the mitochondrial outer membrane 
potential (ΔΨm) and increase its permeability, nuclear compaction (pyknosis), DNA 
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fragmentation and caspase activation. The cells ultimately shrink and show signs of 
cytoplasmic and nuclear fragmentation. Autophagic cell death is a more recent 
classification of PCD (type II) and is often termed macroautophagy. This type of PCD is 
generally induced by nutrient starvation, but has been shown to result from normal cell 
differentiation (Nunes et al., 2014), as well as pathological processes such as 
neurodegenerative disease and cancer (Levine and Kroemer, 2008). Cells undergoing 
autophagic-cell death show the development of large autophagosome structures that 
enclose part of cytoplasm and organelles, delivering and fusing them to lysosomes to 
degrade their contents. 
 
Fig. 1.10 Scheme illustrating morphological differences between necrosis, apoptosis and 
autophagy cell death in metazoan cells (Source:  Nunes et al., 2014). 
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1.5.2 Programmed cell death in malarial parasites 
Whilst the study of cell death, and that of PCD, has primarily focussed on their effects in 
metazoans, features related to PCD have been increasingly observed in unicellular 
organisms including Leishmania spp., trypanosomes, S. cerevisiae, Trichomonas vaginalis 
(Deponte, 2008) and Toxoplasma gondii (Ghosh et al., 2012). The existence of PCD in 
Plasmodium spp. remains the subject of debate with some studies suggesting that PCD is 
apoptosis (Ch’ng et al., 2010, 2011; Mutai and Waitumbi, 2010; Pattanapanyasat et al., 
2010), whilst others support the occurrence of autophagic-like cell death (Cervantes et 
al., 2014; Eickel et al., 2013; Gaviria et al., 2013; Porter et al., 2008; Totino et al., 2008). 
Some studies favour the presence of both apoptosis and autophagic-like cell death 
(Engelbrecht and Coeltzer, 2013; Oakley et al., 2007). Perhaps the most interest is why 
would a protozoan parasite undergo PCD? PCD is widely studied in metazoan organisms, 
where there PCD plays a critical role in development, normal homeostasis and response 
to environment or infective agents (Gavrilescu and Denkers, 2013). Looking at protozoan 
cell death using “language” developed for metazoans is likely the basis for this ongoing 
debate about whether true PCD exists in the malaria parasite. During evolution, however, 
the malaria parasite has selected a set of biological pathways to support its development. 
These would include many pathways that allow the parasite to infect, colonise and 
reproduce in two very different host environments (Coppens, 2011). 
As well as the key morphological features described above, a critical molecular marker of 
autophagic-like cell death is the autophagy related protein 8 (Atg8), a protein located in 
the membrane of autophagosomes, whilst a key marker of apoptosis are caspase 
enzymes (the absence of a role of caspases in autophagic-like cell death has also led to 
this process being termed caspase-independent PCD). The molecular markers of 
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autophagy in Plasmodium are discussed in more detail below. However, true caspases 
have not been identified in Plasmodium parasite, although caspase-like cysteine 
proteases (metacaspases) found in plants, fungi, and protozoan, which also lack true 
caspases are found (Meslin et al., 2011b). 
Three metacaspase genes, PfMCA1 (PF13_0289), PfMCA2 (PF14_0363) and PfMCA3 
(PF14_0160) have been found in the genome of P. falciparum, although the actual role(s) 
of these molecules has not been yet resolved (Meslin et al., 2011b). The expression of 
PfMCA1 is limited to the intraerythrocytic stages of development (Meslin et al., 2011b), 
whereas expression of its homologue PbMCA1 in P. berghei was restricted to female 
gametocytes, oocysts and sporozoites, and did not correspond with significant 
observations of apoptosis (Le Chat et al., 2007). Some features of apoptotic-like cell death 
have been described in P. falciparum following stress although with only limited evidence 
of metacaspase activity (Ch’ng et al., 2010, 2011; Eda and Sherman 2002; Picot at al., 
1997; Rathore et al., 2011, 2015). 
1.6 The autophagic pathway 
Autophagy is a lysosome-mediated degradation pathway by which abnormal proteins and 
injured organelles can be recycled providing micromolecules, mainly amino acids, as an 
endogenous source of energy (Eskelinen and Saftig, 2009). This process supports cell 
survival during different cellular stresses such as nitrogen starvation (Angcajas et al., 
2014) or oxidative stress (Scherz-Shouval et al., 2007). Additionally, information obtained 
via electron microscopic studies has shown that autophagy is part of developmental 
process supporting the life cycle of eukaryotic cells, where recycling of organelles by the 
autophagy machinery is a key response to deprivation of growth factors or nutrients (Lum 
et al., 2005). These observations are supported by developmental phenotypic studies of 
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mammalian cells cultured under different conditions (Cecconi and Levine, 2008). These 
studies demonstrated that the autophagy pathway has an ability to mimic PCD in a 
caspase-independent manner, and is termed autophagic cell death or programmed cell 
death type II (PCD II). Accordingly, autophagy can play a negative or positive role in cell 
survival (Deretic, 2006). Moreover, genetic and phenotypic studies of malignant tumours 
indicated that disease progression is mediated by autophagy and thus provides a 
potential new therapeutic target for drug discovery (Rubinsztein et al., 2012b; Sui et al., 
2013). 
Autophagy was first described following the observation in the cytosol of cells of 
cytoplasmic content sequestrated by a double or multiple membrane structure that were 
then fused  to lysosome. These double or multiple membrane structures, later termed 
autophagosomes, contained mitochondria, endoplasmic reticulum (ER) and lysosomal 
hydrolytic enzymes. Presenting autophagy in 1963 as the mechanism for the degradation 
and recycling of intracellular macromolecules by lysosomes, Christian de Duve opened up 
a new field of autophagy that has impacted significantly on our understanding of normal 
and pathological cell biology (Klionsky, 2008). The origin of autophagy is Greek: “auto” 
meaning self and “phagy” meaning eating and specifically refers to the recycling of 
cellular macromolecules or organelles under specific physiological or limited nutrient 
conditions (Reuck and Cameron, 1963). 
Several broad patterns of autophagy have been identified based on the processes of 
cargo packaging and delivery to the lysosome (Glick et al., 2010), and are broadly termed 
microautophagy, macroautophagy or chaperone-mediated autophagy (Fig. 1.11). In 
microautophagy, direct engulfment of targeted materials occurs by the lysosome 
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membrane. Macroautophagy refers to the process that includes autophagosome 
formation, where selected substances are processed, vesiculated and trafficked to 
lysosome for degradation (reviewed in Rigden et al., 2009). While in chaperone-mediated 
autophagy, chaperone-tagged proteins are guided to interact selectively with chaperone 
receptors on the lysosome membrane following by transferring them through the 
lysosome membrane to the lysosome lumen to be degraded (Kaushik and Cuervo, 2012). 
However, alternative classifications of autophagy detail the type of cargo, including 
mitophagy, pexophagy, ribophagy and lipophagy for the degradation of mitochondria, 
peroxisomes, ribosomes and lipid droplets, respectively (He and Klionsky, 2009). 
 
 
 
Fig. 1.11 Illustrates the different forms of autophagy. Microautophagy initiates with direct 
engulfment of the targeted materials at lysosome membrane followed by membrane 
invagination, protrusion and separation of contents into the lysosome lumen. Macroautophagy 
involves formation of C-shape double membrane structure (phagophore) that sequesters a 
portion of cytoplasm (or organelles) producing an autophagosome, which subsequently fuses with 
the lysosome membrane to produce an autolysosome. Chaperone-mediated autophagy is where 
the substrate-chaperone complex is driven to lysosome via lysosomal chaperone receptors LAMP-
2A. The key refers to the involvement of different protein complexes during macroautophagy and 
are described further in the main text (Source: Periyasamy-Thandavan et al., 2009). 
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Macroautophagy is characterised by the formation of a pre-autophagosomal structure 
termed the phagophore assembly site (PAS) (Mizushima et al., 2001; Suzuki et al., 2001). 
PAS grow and elongate to produce initial sequestering compartment, a double-
membrane structure named phagophore. The targeted materials are enclosed by 
phagophore, with a range of organelles or plasma membrane thought to provide lipid 
membrane for its growth   (Axe et al., 2008; Hailey et al., 2010; Ravikumar et al., 2010; 
Simonsen and Tooze, 2009). Although the exact origin of the phagophore in mammalian 
cells is questioned, the double membrane autophagosome is generated as a result of 
expansion and completion of the phagophore (Rubinsztein et al., 2012a). When the 
autophagosome docks with a lysosome, the outer membrane of the autophagosome 
fuses with the lysosome single membrane and its cargo along with the inner 
autophagosome vesicle are released into the lysosomal lumen to undergo digestion 
(reviewed in Duszenko et al., 2011). The lysosome lumen provides an acidic environment 
with hydrolysis enzymes that digest the targeted proteins, lipids, carbohydrates and 
nucleic acids forming recyclable materials that are recycled back to the cytosol through 
transport proteins (permeases) located in the lysosome membrane (Russell et al., 2014).  
Both selective and non-selective autophagy of aggregated proteins and organelles has 
been described in eukaryotic cells (Kraft et al., 2009). Selective autophagy is considered a 
receptor-based autophagy pathway, where a specific cargo (e.g. mitochondria, ribosome, 
nucleus) are tagged in response to internal signals derived from the cargo itself (Yu et al., 
2008).The alternate, non-selective autophagy, results when cytoplasmic components are 
randomly sequestrated by a phagophore in response to environmental signals such as 
nutrient starvation or hormone limitation (Kim and Klionsky, 2000; Yin et al., 2010). 
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1.7 Regulation of the macroautophagy pathway 
Investigation of response to nutrient depravation in the yeast Saccharomyces cerevisiae 
has proven critical in determining the regulated cascade of molecular events in 
macroautophagy (Inoue and Klionsky, 2010). The most common naming for the 
component parts of the macroautophagy system uses the prefix Atg, based on their 
homology to autophagy mutants originally described in S. cerevisiae (Rose et al., 2006; 
Suzuki et al., 2001). Biochemical and electron microscopy studies complement genetic 
and modern bioinformatics approaches to extend our understanding of how 
macroautophagy operates, allowing consensus aspects of this process to be described. 
These fall into six main steps, detailed below (He and Klionsky, 2009). 
 (i) Nutrient sensing and induction of autophagy. 
Sensing and responding to nutrient availability is essential for cell viability. Under normal 
nutrient conditions, nutrient sensing pathways engage with biosynthesis and storage 
pathways of macromolecules, whilst under starvation conditions new micromolecule 
homeostasis mechanisms are required (Efeyan et al., 2015). Nutrient-poor conditions 
promote cells to use autophagy to provide endogenous micromolecules. In starved cells, 
target of rapamycin (TOR)-dependent triggers are initiated as the first step of the 
autophagy pathway (Diaz-Troya et al., 2008). TOR complexes are fundamental in 
maintaining a balance between biosynthetic and catabolic processes within cells. There 
are two multiprotein complexes of TOR; TOR complex 1 (TORC1) and TOR complex 2 
(TORC2), both are implicated in the autophagy regulatory machinery (reviewed in 
Brennand et al., 2011). Only TORC1 (mTOR1 in mammals) is sensitive to rapamycin 
antibiotic treatment (Loewith et al., 2002). Under nitrogen-poor conditions, TORC2 
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through its downstream target protein kinase (Ypk1) inducing factor-2α (eIF2α) kinase (an 
amino acid sensor) to upregulate the macroautophagy pathway (Vlahakis et al., 2014). 
TORC1 operates differently, and inhibits the eIF2α kinase which causes down regulation 
of macroautophagy under normal growth condition (Valbuena et al., 2012). When 
nutrients become limited, or after exposure to rapamycin, macroautophagy is 
upregulated. Induction of this autophagy pathway follows from dephosphorylation of 
Atg13 that increases its affinity for the autophagy initiator protein (Atg1) (Puente et al., 
2016; Wu et al., 2013). Under nutrient rich conditions, TORC1 blocks the autophagy 
process by hyperphosphorylation of Atg13 that inhibits the interaction between Atg1 and 
Atg13. As such, the Atg1-Atg13 complex is a key operator regulating these early initiator 
events (Kamada et al., 2000). The activity of Atg1-Atg13 complex is required for the 
formation of the phagophore in yeast, likely by guiding transmembrane protein Atg9 to 
accumulate at the PAS site to promote lipid collection to the expanding phagophore (He 
et al., 2008; Simonsen and Tooze, 2009). Other Atg proteins are recruited to the PAS; the 
transmembrane protein (Atg18) contains a phenylalanine-arginine-arginine-glycine 
(FRRG) motif, which is essential for combination with phosphatidylinositol-3 phosphate 
(PI3P) and Atg18-Atg2. Atg18 serves as a platform for Atg8 translocation to the PAS, a key 
biomarker for autophagic activity, as well and protects it from the premature cleavage 
activity of Atg4 (Nair et al., 2010). 
(ii) Cargo selection and packaging 
Although the term of autophagy often refers to non-selective degradation of cytoplasmic 
components by macroautophagy, specific selection of cargo to the PAS operates using 
receptor and adaptor proteins to specifically isolate a cargo. Our understanding of this 
selective targeting is based primarily on information obtained from studies of cytoplasm 
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to vacuole targeting (CVT) process originally described in yeast (Lynch-Day and Klionsky, 
2010). Atg19 is a key protein in cargo selection in the CVT signalling route (Scott et al., 
2001). Association of Atg19 with precursor aminopeptidase I (PrApe1) and precursor α-
manosidase I (PrAm1) produce the CVT complex, which binds later with Atg11. Both 
Atg19 and Atg11 work to drive CVT cargo to the PAS site. The Atg19 provides a binding 
site to Atg8-PE complex on the PAS (reviewed in Duszenko et al., 2011) (Fig. 1.12). For 
more specific organelle cargo, a range of additional CVT proteins have been identified. 
These include Atg30, which has been identified as a central protein for pexophagy (Farre 
et al., 2008). Selection of peroxisomes for degradation is mediated by two peroxisomal 
membrane proteins (PEX3 and PEX14). These proteins also participate in biogenesis of the 
peroxisomes. The phosphorylated form of PEX14 interacts with Atg30 to target 
peroxisomes and drive them to the PAS site (Manjithaya et al., 2010). Furthermore, 
mitochondria can be targeted and degraded under low oxygen conditions, where yeast 
uses a fermentation process instead of a respiratory process. Both Atg32 and Atg33 
proteins have been reported as essential proteins in mitochondria targeting in S. 
cerevisiae (Kanki et al., 2009; Okamoto et al., 2009). 
 
 
Fig. 1.12 Molecular events of cargo selection in the cytoplasm to vacuole targeting (CVT) 
pathway. Accumulation of precursor aminopeptidase I (prApe1) and Ams1 with Atg19 to 
produce the CVT complex, which combines with Atg11 to be transferred to Atg8 on the PAS site 
(Source: Klionsky, 2005). 
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(iii) Vesicle nucleation 
Phosphorylation of PAS as a result of the activity of the phosphatidylinositol-3-kinase 
(PI3K)-III complex triggers the nucleation process. Initially, vacuolar protein sorting 
(Vps34) combines with the phagophore membrane following activation of Atg1 kinase 
(ULK1) (Itakura and Mizushima, 2010). Vps34 is a catalytic component of multiple protein 
complexes, some of which implicate in autophagy-independent machinery, whilst others 
are involved in the distinct stages of autophagy process (Koyama-Honda et al., 2013) (Fig. 
1.13). The PI3K-III complex is composed of Vps15, Vps34, Atg6 and Atg14 that converts 
phosphatidylinositol (PI) to PI3P on the PAS and this is followed by recruitment of Atg18, 
Atg2, Atg20, Atg21 and Atg24 (Obara et al., 2008; Suzuki et al., 2001). In addition, 
colocalization of At18 and Atg2 provides a binding site for other related proteins on the 
PAS and phagophore membrane (Burman and Ktistakis, 2010). Activation of Atg9 is 
required to modify PAS to the phagophore membrane during initiation step of 
macroautophagy. The Atg9 also serves as platform for binding At18-Atg2 complex to the 
PAS (Nair et al., 2010). Webber et al (2007) confirmed that mammalian Atg9 (mAtg9) 
traffic between Golgi complex and endosomes suggesting involvement of Golgi complex 
in autophagy pathway. 
(iv) Vesicle maturation and completion 
During this step, maturation of the phagophore membrane is completed producing an 
autophagosome (Fig. 1.13). Two complexes belong to families of ubiquitin-like proteins 
participate in this process; the Atg12-Atg5 conjugation system and the Atg8-PE 
conjugation system (Geng and Klionsky, 2008; Nakatogawa et al., 2009). In the first 
system (the Atg12-Atg5 complex), the activity of Atg7 and Atg10, which represent E1-like 
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activating enzyme and E2-like ligase enzyme, respectively, are required for covalent 
conjugation between Atg12 and Atg5 (Walczak and Martens, 2013). Dimerizing two 
molecules of Atg16 causes non-covalent interactions between Atg16 and Atg12-Atg5 
producing the Atg12-Atg5-Atg16 complex (E3-like ligase enzyme). In the second 
conjugation system, Atg4 cleaves the Atg8 to expose its C-terminal glycine which allows 
Atg8, through the action of Atg7 (an E1-like activating enzyme), to bind covalently to Atg3 
(an E2-like ligase enzyme) producing Atg8-Atg3 complex. The Atg12-Atg5-Atg16 complex 
now acts on the Atg8-Atg3 complex to add phosphatidylethanolamine (PE) to Atg8 and 
deposit the Atg8-PE within the phagophore membrane (Nakatogawa, 2013). It has been 
shown that the Atg8-PE complex localizes on both the outer and inner membranes of 
phagophore, whilst the Atg12-Atg5-Atg16 complex is only placed on the outer membrane 
(Brennand et al., 2011). 
In human cells, hLC3 (Light Chain 3) (Atg8 homologue) is reported in most cells as being in 
an inactivated form. During induction of autophagy, proteolysis of the LC3 substrate by 
the Atg4 cleavage enzyme produce LC3-I, which is reprocessed to LC3-II by Atg7 and Atg3 
activities. In order to find a foothold on the phagophore membrane, the LC3-II conjugates 
with PE (Barth et al., 2010). After completion of the autophagosome, reprocessing of the 
Atg8-PE complex by the Atg4 activity is required to deconjugate the Atg8 from the outer 
membrane of autophagosome and that facilitates maturation of this structure into fusion-
capable autophagosome (Yu et al., 2012), whilst a minor population of the Atg8 remains 
linked with the inner surface of autophagosome until it is fused with the lysosome. Thus 
Atg8 is considered as a core marker in identification of the autophagy machinery (Fig. 
1.13) (reviewed in Duszenko et al., 2011).  
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Fig. 1.13 Molecular events during autophagosome formation. Formation of the double-
membrane bound autophagosome involves a sequential series of steps from induction, 
membrane nucleation, phagophore formation and autophagosome elongation to form the 
complete autophagosome. These steps are controlled by at least five different functional groups 
of proteins: 1) The Atg1/ULK1 initiation complex; 2) the PI3-kinase nucleation complex; 3) the 
PI3P-binding complex; 4) the Atg5-Atg12 conjugation system; and 5) the Atg8/LC3 conjugation 
system (Source: Gelino and Hansen, 2012). 
 
(v) Trafficking, docking and fusion to the lysosome 
Atg proteins which are involved in the earlier steps of autophagosome formation are 
deconjugated and relocalized to be reused in a new cycle of autophagy. Accordingly, Atg8, 
Atg5, Atg12 and Atg16 leave the outer membrane of the autophagosome or CVT vesicle 
and recycled in order to be used in a new autophagy cycle (Legakis et al., 2007; 
Nakatogawa et al., 2007). The autophagosome, with its cargo, is now ready to fuse with 
the lysosome with Atg8 and Rab7 acting as key regulators in this trafficking. Although 
direct fusion between the autophagosome and lysosome to produce an autolysosome is 
the most common outcome, in mammalian cells the autophagosome under unknown 
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conditions can also combine with late endosomes to generate an amphisome, which 
subsequently fuses with the lysosome to form an autolysosome (Klionsky and Schulman, 
2014). 
(vi) Vesicle breakdown within the lysosome 
Acidic hydrolysis degrades the autophagosome cargo components during this last step of 
the autophagy process. As described earlier, the autophagosome docks to lysosome and 
the outer membrane of the autophagosome fuses with the lysosome single membrane 
and its cargo along with the inner autophagosome vesicle are released into the lysosomal 
lumen to undergo digestion (reviewed in Duszenko et al., 2011). The membrane of the 
internalized autophagosome undergoes delipidation and proteolysis through the action of 
lipase Atg15 and peptidase B in order to release the cargo and consume its components. 
As a final step, the Atg22 efflux system, which is found in the lysosome/ vacuole 
membrane, is responsible for the transport of amino acids (the end products of 
autophagy process) into the cytosol (Yang et al., 2006). 
1.8 The role of autophagy in Plasmodium parasites 
Recent studies over the last 2 decades have provided evidence of autophagy-like 
trafficking in apicomplexan parasites (for reviews see Besteiro, 2017; Hain and Bosch, 
2013; de Late et al., 2017; Mizushima and Sahani, 2014). Autophagic vesicles have been 
described under conditions of nutrient starvation in T. gondii (Besteiro et al., 2011) and P. 
falciparum (Tomlins et al., 2013). However, the (i) lacking of full components (Atg 
proteins) of the canonical autophagy cascade (see below), (ii) as well as these parasites 
both being predominantly obligate intracellular parasites, and (iii) the lacking of 
lysosomes (the DV has been proposed to be the site of autophagosome targeting in P. 
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falciparum) have led some authors to suggest an alternative or additional roles for 
components of the classical autophagy pathway remaining in these parasites (reviewed in 
Besteiro, 2017). These alternatives explore the role of autophagy in the significant 
morphological changes of P. falciparum and apicoplast biogenesis (an organelle essential 
for parasite viability). It may well be that autophagy in P. falciparum, and other 
apicomplexan parasites, has been developed to have catabolic roles (cell cycle 
morphology changes and nutrient stress) as well as a role in maintaining an apicoplast 
and controlling its inheritance into daughter cells (Fig. 1.14). Importantly, from this figure, 
we see a key role for the autophagy biomarker Atg8 in all autophagy processes. 
 
 
Fig. 1.14 Scheme illustrating the central role for the Atg8 autophagy marker in formation of the 
autophagosome and in apicoplast maintenance in apicomplexan parasites (Source: Besteiro, 
2017). 
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1.8.1 Trafficking vesicles to the digestive vacuole  
A role for the autophagy pathway during endocytic transport of P. falciparum has been 
explored by employing two different stress conditions. CQ perturbation and nutrient 
starvation have been used to study endocytosis in Plasmodium species (Gaviria et al., 
2013; Hoppe et al., 2004). CQ is a lysosomotropic agent that blocks fusion between 
autophagosomes and the DV in P. falciparum causing an accumulation of endocytic 
vesicles in the parasite cytoplasm (Roberts et al., 2008). Disruption of endocytic 
trafficking and accumulation of PfAtg8-decorated vesicles in the cytoplasm of P. 
falciparum challenged with CQ has been reported (Gaviria et al., 2013). Cervantes et al. 
(2013) also observed involvement of PfAtg8 in both cytoplasmic vacuolation and 
apicoplast segmentation in P. falciparum treated with two lysosomotropic agents (CQ and 
bafilomycin A). Furthermore, immunofluorescence and ultrastructural studies suggested 
the role of Rab7a in endocytic vesicle trafficking in P. falciparum and P. berghei (Krai, 
2013; Lopes da Silva et al., 2012; Tomlins et al., 2013). Similarly, Rab membrane markers 
such as Rab4, Rab5 and Rab11 in Trypanosoma brucei (Pal et al., 2002), Rab5 in T. gondii 
(Robibaro et al., 2002) and Rab7 in Leishmania donovani (Patel et al., 2008) have been 
reported to be associated with intracellular trafficking of autophagosome-like vesicles in 
these protozoan parasites. 
1.8.2 Clearance of organelles 
Metamorphosis in Plasmodium parasites follows successful infection and development in 
different host cells (Coppens, 2011).  After the penetration of hepatocytes, the 
Plasmodium parasite undergoes morphological and physiological changes transforming 
from a motile and elongated form (sporozoite) to a non-motile and round-shaped form 
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(hepatic schizont) (Jayabalasingham et al., 2010).  During this transformation, clearance of 
organelles such as the inner membrane complex, rhoptries and micronemes occur 
(Jayabalasingham et al., 2010). Two autophagy-mediated pathways are hypothesized to 
be involved in this organelle recycling, either organelle expulsion (exophagy) or vacuolar 
degradation of organelles (endophagy). Jayabalasingham et al. (2010) reported 
engulfment of micronemes and they were subsequent transported to the 
parasitophorous vacuole for expulsion. Immunofluorescence and fluorescence tagging 
studies indicates that micronemes expulsion was most likely included Atg8 proteins 
involvement (Coppens, 2011). This expulsion mechanism is widely reported in metazoans, 
including the maturation of RBCs, where the reticulocyte nucleus is expelled into bone 
marrow by an exosome-mediated pathway (Blanc et al., 2005). During sporozoite 
metamorphosis, the biosynthetic organelles (e.g. ER, mitochondria and apicoplast) appear 
the only organelles protected from autophagic degradation (Coppens, 2011).  
Ultrastructural and biochemical studies of P. berghei liver stages revealed that PbAtg8-
decorated vesicles in the parasite cytoplasm contain micronemes. Despite cytoplasmic 
vacuolation being shown in P. berghei following rapamycin treatment, the existence of 
PbAtg8-mediated mitophagy is still questioned (Eickel et al., 2013). In T. gondii, 
starvation-induced mitophagy can be blocked by exposing parasites to the autophagy 
inhibitor 3-methayl adenine (3-MA), suggesting a similar role for autophagy in this 
parasite transformation (Ghosh et al., 2012). 
1.8.3 Apicoplast maintenance 
The apicoplast is a non-photosynthetic plastid related to parasite survival in apicomplexan 
parasites, where it is involved in the synthesis of fatty acid, isoprenoid and iron-sulphur 
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clusters (Lim and McFadden, 2010). In P. falciparum, upregulation of Atg8 proteins during 
apicoplast biogenesis and partial localization with an apicoplast marker, acyl-carrier 
protein (ACP) suggesting a role of Atg8 in apicoplast maintenance (Kitamura et al., 2012; 
Tomlins et al., 2013). These observations were supported in a study performed by 
Cervantes et al., where Atg8-labeled vesicles detected in both the cytoplasm of the 
intraerythrocytic stage of P. falciparum as well localized onto the apicoplast organelle 
(Cervantes et al., 2014). Challenging parasites with the lysosomotropic agents CQ and 
bafilomycin A blocked endocytosis and caused apicoplast fragmentation supporting the 
proposed dual role of autophagy in degradation of intracellular proteins and biogenesis of 
apicoplast organelle (Cervantes et al., 2014). 
1.9 P. falciparum lacks a complete set of canonical autophagy proteins 
Bioinformatic analyses of the P. falciparum genome, like other apicomplexan parasites, 
shows that whilst homologues of some members of the canonical autophagy pathway are 
present, many are not (Cervantes et al., 2014; Hain and Bosch, 2013; Navale et al., 2014). 
The apparent lack of some components, particularly those for induction and cargo 
selection, underpin arguments that autophagy as a response to nutrient stress may not 
be a key function for these parasites. That said, components for PAS formation specially 
Atg9 and autophagosome expansion exist, and support electron micrographs of these 
structures, particularly in T. gondii (Nguyen et al., 2017), but not in P. falciparum 
(Cervantes et al., 2014; Navale et al., 2014). The presence or absence of these 
components is reviewed below. 
Autophagy is typically induced by nutrient starvation or rapamycin treatment, but P. 
falciparum apparently lacks TOR proteins and hence this would explain the lack of 
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induction of autophagy in rapamycin treated P. falciparum parasite (Cervantes et al., 
2014). However, genes associated with phagophore expansion and vesicle completion 
have been found (Cervantes et al., 2014). These analyses reveals that P. falciparum also 
lacks Atg13 and its C-terminal binding site on Atg1 (Hain and Bosch, 2013). This evidence 
together with distribution of autophagosome-like vesicles in the parasite cytoplasm 
suggests the existence of an Atg1-independent induction of autophagy in P. falciparum. 
The observation of autophagic vesicles in Atg knockout mice suggests that not all steps of 
the autophagy cascade are necessary (Mizushima and Levine, 2010). To date, a number of 
putative Atg homologues have been identified in malaria parasites (Hain and Bosch, 
2013). See Fig. 1.15 for a summary. These include; Atg1 and Atg17 of the Atg1 complex 
(Navale et al., 2014); Vps15, Vps34 (Navale et al., 2014), Atg6 and Atg14 of the PI3K-III 
complex (Cervantes et al., 2014); Atg18 and Atg2, but not Atg9, of the Atg9 cycling system 
(Cervantes et al., 2014); Atg12, Atg5 and Atg16, but not Atg10, of the Atg12 ubiquitin-like 
conjugation system (Cervantes et al., 2014) as well as all components (Atg8, Atg3, Atg4 
and Atg7) of the Atg8-PE ubiquitin-like conjugation system (Cervantes et al., 2014; Hain 
and Bosch, 2013; Navale et al., 2014). More recently, putative homologues of additional 
Atg1 complex members (e.g. Atg29 and Atg31 genes) have not observed in whole genome 
sequences of P. falciparum (de Late et al., 2017). Despite Atg6 but not Atg14 has been 
detected in T. gondii (de Late et al., 2017) it seems that both of these proteins are existed 
in autophagy cascade of P. falciparum (Cervantes et al., 2014). Moreover, it has been 
proved that homologue of Atg18 and its motif FRRG (the binding site of P3K and Atg2) are 
expressed by in P. falciparum. Based on above, existence of PI3K enzyme and Atg2 
homologues have been suggested in P. falciparum (Hain and Bosch, 2013). Altogether, 
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unlike higher eukaryotes and T. gondii, P. falciparum lacks critical proteins of nutrient 
sensing and induction of regular autophagy process (Cervantes et al., 2014) (Table 1.1). 
Process Atg gene Navale et al. 
(2014) 
Hain and Bosch 
(2013) 
Cervantes et al. 
(2014) 
Nutrient 
sensing and 
induction 
 
Atg1   -2 
Atg13   - 
Atg17  P1 - 
Atg29 - P - 
Atg31 - P - 
Cargo selection  
 
Atg11  - - 
Atg19  - - 
Vesicle 
nucleation 
 
Vps15   - 
Vps34    
Atg6    
Atg14    
Vesicle 
expansion and 
completion 
 
Atg3    
Atg4  P  
Atg5    
Atg7    
Atg8    
Atg10    
Atg12    
Atg16    
Atg21  - - 
Trafficking, 
docking and 
fusion to the 
lysosome 
Rab7   - 
Ykt6 -  - 
VAMP8 -  - 
Vesicle 
breakdown  
 
Atg15    
Atg22   - 
Prb1 -  - 
Others Atg2  P  
Atg9    
TG18    
Atg23  - - 
Atg24  - - 
 
Table 1.1 The plasmoDB (Plasmodium Database) identifier for P. falciparum homologues 
described in three genome wide researches (Cervantes et al., 2014; Hain and Bosch, 2013; 
Navale et al., 2014) are shown against the different steps of the autophagy cascade, induction, 
cargo selection, nucleation, expansion and completion, docking and fusion, vesicle degradation 
and others. Note P1 indicates that the gene probably exists, while -2 indicates that the gene was 
not checked in the study.  
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In P. falciparum, PfAtg8 is a part of membranous system under normal growth conditions. 
The exposed C-terminal glycine of the PfAtg8 covalently attaches to PfAtg7 through a 
thioester bond (Tomlins et al., 2013). PfAtg7 transfers PfAtg8 to PfAtg3 to form another 
thioester bond before binding to PE on the phagophore membrane (Yamaguchi et al., 
2010). Hain et al. (2014) reported that inhibition of the PfAtg8 and PfAtg3 interaction 
prevents PE lipidation of the PfAtg8 and blocking of phagophore development. To date, 
an Atg10 homologue in Plasmodium parasite, which would normally participate in of the 
binding of Atg12 to Atg5, has not been found (Cervantes et al., 2014; de Late et al., 2017). 
Additionally, unlike S. cerevisiae and mammalian cells, the binding site of PfAtg5 (glycine 
residue) required for interaction with PfAtg12, is lacking in P. falciparum (Navale et al., 
2014). A set of endosomal markers belonging to the Rab protein family have been 
described in apicomplexan members (Langsley et al., 2008; Quevillon et al., 2003). In 
higher eukaryotes, Rab7 and Atg8 with other trafficking proteins guide the 
autophagosome to the lysosome membrane for fusion (Wang et al., 2011). It is therefore 
likely, like in S. cerevisiae, PfRab7 is involved in trafficking and fusion of autophagosome-
like vesicles with the DV which would act as a lysosome given the absence of these 
structures in P. falciparum (Teter et al., 2001). The Plasmodium parasite also has a 
homologue of Atg15 lipase. So, DV may have function similar to that of lysosome in 
eukaryotic cells (Navale et al. 2014) Interestingly, a homologue for Atg22, an efflux pump 
for recycled amino acids has been identified in P. falciparum genome (Yang et al., 2006), 
although the DV also has the capacity to export amino acids derived from the digestion of 
haemoglobin. 
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Fig. 1.15 Conservation of the canonical autophagy pathway in Plasmodium. Proteins essential 
for macroautophagy in other eukaryotic systems are depicted as rounded rectangles. Ovals 
represent proteins whose essentiality is not known. Black filling indicates strong evidence for 
homology in P. falciparum, where grey filling indicates where homology is weaker. White filled 
boxes indicate where no homologue was identified. *Human proteins FIP200 and Atg101 thought 
to be functional homologues of yeast Atg31/Atg17Atg29. (Source: Hain and Bosch, 2013). 
 
1.10 Atg8-Atg3 Protein-Protein Interaction (PPI) as a target for small inhibitor molecules 
in P. falciparum  
 
Recently, the Atg8-Atg3 PPI in P. falciparum has been given more attention as a target for 
new antimalarial drug development due to its potential in parasite survival (Hain et al., 
2016). Atg8 (which is already produced in an active form) is attached covalently with PE 
on the phagophore membrane initiating autophagosome formation (Walker et al., 2013). 
As mentioned previously, this process (Atg8-PE interaction) occurs through serial 
reactions of Atg7 (E1-like activating enzyme) and Atg3 (E2-like ligase enzyme) and 
eventually involved by action of Atg12-Atg5 (E3-like ligase enzyme) to lipidate Atg8 with 
PE (Fig. 1.16) (Suzuki and Ohsumi, 2007).  
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Fig. 1.16 Illustrating Atg8-PE conjugation system (A) and Atg12-Atg5 conjugation system (B) in P. 
falciparum parasite (Source: http://ruo.mbl.co.jp/bio/g/product/autophagy/article/Atg.html).  
 
Co-crystallization of PfAtg8-PfAtg3 molecules has been performed by Hain et al. (2012), 
where they described the PfAtg3 binding site on the surface of PfAtg8 molecule as 
follows: two hydrophobic pocked named W and L-pockets which are occupied by the 
tryptophan and proline amino acids of the PfAtg3 peptide, respectively. The space 
between W and L-pockets seems to be important in this interaction. Furthermore, PfAtg8 
has an extra pocket, named the A-pocket, created by the A-loop which is specific to 
apicomplexan species. X-ray crystallography of PfAtg8-PfAtg3, however, offers 
opportunities to explore specific selectivity for compounds that specifically inhibit this 
interaction in P. falciparum (a wider discussion of these in the introduction to chapter 4). 
In this context, a library of Medicines for Malaria Venture (MMV) compounds were 
screened against the blood stage of P. falciparum parasite to evaluate their autophagy 
inhibitory potential using Malaria SYBR Green I Fluorescence (MSF) and Surface Plasmon 
Resonance (SPR) assays as well as docking-based virtual screening against a PfAtg8 crystal 
structure (Hain et al., 2014). Interestingly, MSF assay showed inhibition of parasite 
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growth after treatment with compound 1 (IC50= 1.4 µM) and that was supported by 
significant decrease in PfAtg8 lipidation at 50 µM of the same compound using 
immunoblot assay. Additionally, the molecular model docking showed consistent docking 
mode of compound 1 (Fig. 1.17) across PfAtg3 binding site on surface of PfAtg8 molecule 
(Hain et al., 2014). 
 
Fig. 1.17 Chemical structure of compound 1 (MMV007907) compound.  
In 2016, a virtual library of synthetic compounds was screened against blood and liver 
stages of P. falciparum parasite. The outcome data indicated inhibition of parasite growth 
in both blood and liver stages upon drug treatment. There was a shift from lipidated 
PfAtg8 to unlipidated PfAtg8 level indicating decrease in the interaction between PfAtg8 
and PfAtg3 molecules under drug treatment. In blood stage of 3D7 P. falciparum parasite, 
the best compound (ALC25) (Fig. 1.18) reported IC50= 18.5 µM and 19.0 µM by MSF and 
SPR assays, respectively. Interestingly, cross reaction with other apicomplexan species 
such as Eimeria, Toxoplasma, Neospora, Cryptosporidium, Theileria, and Babesia were 
predicted using bioinformatics. Accordingly, the potential of small molecules to inhibit 
this novel target (protein-protein interaction) may offer a route forward for antimalarial 
drug development.  
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Fig. 1.18 Chemical structure of ALC25 compound. 
1.11 Objectives of this study 
The role of autophagy in P. falciparum is relatively poorly understood. Whilst key proteins 
in the canonical pathway exist, whether autophagy, as described in other eukaryotes, is 
used by the parasite as a response to nutrient stress and/or a potential mechanism for 
programmed cell death is debateable. The potential for small molecule inhibitors of the 
PfAtg8-PfAtg3 interaction as a new target for antiplasmodial action is of particular 
interest given the current demand for new target pathways for future antimalarial drug 
development. 
This project therefore set out with two key objectives. The first was to evaluate a library 
of compounds, provided through collaboration with Dr Johannes Reynisson of the 
University of Auckland, New Zealand, that had been shown to modulate autophagy in 
cancer cell lines, with one mode of action predicted to be through inhibition of the Atg3-
Atg8 interaction. This study screened the library against P. falciparum intraerythrocytic 
stages, identified and characterised leads, and explore their potential as small molecule 
inhibitors of PfAtg8- PfAtg3 interaction. 
These hits were taken forward into a second part of the study. The objective of this 
second part was to explore early morphological and biochemical events in P. falciparum 
cell death, correlating the data from these putative autophagy inhibitors against a range 
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of current antimalarial compounds. A critical aspect of this second part of the study is 
that the use of a genetically modified P. falciparum that expresses a luciferase reporter 
gene (Wong et al., 2011), allowed us to assay parasites that had been subject to a known 
cytocidal effect (Ullah et al., 2017). Thus, parasite cultures were exposed to a 
concentration of compound that caused a 50% reduction in viability within a fixed 
timeframe, 6 hrs, and were compared against each other to determine what early events 
in cell death were common following drug treatment, and whether there were features of 
cell death that are specific to the autophagy inhibitor or antimalarial drug being tested. 
The objectives above were listed here as follow:  
1. Evaluation of antiplasmodial activity of a library of putative autophagy inhibitors, 
selecting the most potent hits to explore their selectivity against intraerythrocytic 
parasites, their rate of kill and timing of action. 
2. Model the interaction of the putative autophagy inhibitors against the Atg8 of P. 
falciparum to explore any potential of structure activity relationships.  
3. Perform a comparative study of drug action against the intraerythrocytic 
trophozoite stage of P. falciparum to explore whether ultrastructural or 
biochemical markers can be attributed to a programmed cell death phenotype.  
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Chapter 2: Materials and methods 
2.1 Stocks and reagents  
Note: Unless otherwise indicated, the materials were provided as follows; chemicals from 
Sigma-Aldrich Company Ltd., cell culture reagents from Gibco-Thermo Fisher Scientific, 
Abcam/UK and Millipore/USA, laboratory plasticware from Star lab Ltd, Greiner Bio-
One/UK and Sarstedt/GmbH-Germany. 
Complete growth medium 
500 mL of RPMI (Roswell Park Memorial Institute)-1640 medium was supplemented with 
10 mΜ D-glucose solution, 5 mΜ Sodium Hydroxide (NAOH), 2 mΜ glutamine, 100 µΜ 
hypoxanthine, 25 µg/mL gentamycin sulphate and 37.5 mΜ (4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonic acid (HEPES) buffer. This was further supplemented with 0.25% 
(w/v) albumax-II and 5% (v/v) heat-deactivated human serum. 
Incomplete growth medium 
This medium is prepared as per instructions for complete growth medium. The albumax-II 
and heat-deactivated human serum are omitted from this buffer.  
Albumax-ll solution  
5% (w/v) albumax-II solution was achieved by dissolving 25 g albumax-II powder (Thermo 
Fisher Scientific, UK-Invitrogen) in a total of 500 mL of incomplete growth medium. The 
albumax-ll solution was sterilized by filtration (0.45 µm filter) and aliquots were stored at 
-20 °C.   
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Blasticidin S HCl stock  
To make 10 mg/mL Blasticidin S HCl, 50 mg of Blasticidin S HCl (Thermo Fisher Scientific, 
UK-Invitrogen) were dissolved in 5 mL of incomplete growth medium. The aliquots were 
stored at -20 °C. The complete growth media of Dd2luc parasite cultures were 
supplemented with 2.5 µg/mL of Blasticidin S HCl solution.  
D-glucose solution  
45% (w/v) D-glucose solution was prepared by adding 225g D-glucose to a total of 500 mL 
sdH2O. The solution was sterilized (0.2 µm filter). The aliquots were stored at 4 °C.    
Embedding Agar  
3% (w/v) embedding agar was prepared by dissolving 0.3 g of agar powder (BDH, UK) in 
10 mL of sdH2O. The agar was allowed to cool to approximately 30-40 °C before being 
used.   
Glycerolyte freezing solution  
57 g glycerol, 1.6 g sodium lactate, 300 mg KCl, 124 mg disodium phosphate (Na2HPO4) 
and 51 mg monosodium phosphate (NaH2PO4) were dissolved into 80 mL of sdH2O. The 
pH was adjusted to 6.8. The volume made up 100 mL with sdH2O, filter sterilised (0.2 µm 
filter) and stored at 4 ˚C. 
Hoechst 33342 nucleic acid stain 
A 10 µg/mL Hoechst 33342 working reagent was prepared by dilution 1 µL of 10 mg/mL 
Hoechst 33342 (Thermo Fisher Scientific, UK) in to 1 mL of complete medium. The 
reagent was prepared immediately prior to use. 
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 Hypoxanthine solution (1 M) 
1 M hypoxanthine stock solution was prepared by dissolving 544.4 mg hypoxanthine in 40 
mL of 1N NaOH. The solution was sterilised (0.2 µm filter) and aliquots stored at -20 °C. 
Malaria SYBR Green I Fluorescence (MSF) lysis buffer  
10XMSF lysis buffer stock was prepared as Tris (200 mM, pH 7.6), EDTA (50 mM), saponin 
(0.08%, w/v) and Triton-X 100 (0.8%, v/v) in sdH2O and stored at room temperature. 
Immediately prior to use, this was diluted to 1XMSF lysis buffer in sdH2O. 
Paraformaldehyde solution   
To prepare 1 L of 4% (w/v) paraformaldehyde, 800 mL of 1XPBS was added into a glass 
beaker on a magnetic stirrer inside a fume cabinet. Heating and stirring was applied up to 
60 °C following by addition 40 g of paraformaldehyde (Sigma-Aldrich, UK) to the heated 
1XPBS. 1N NaOH was added drop by drop until the solution became clear. The volume 
was made up to 1 L by 1XPBS and pH adjusted at 7.4 using HCl. The solution was filtered, 
aliquoted and stored at -20 °C (Ljungström et al., 2008).      
Saponin lysis buffer  
10% (w/v) saponin lysis buffer was prepared by adding 10 g of saponin (Thermo Fisher 
Scientific, UK) into a total of 100 mL 1XPBS. The lysis buffer was filter sterilized (0.2 µm 
filter) and stored at 4 °C. 
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Sorbitol lysis buffer  
5% (w/v) sorbitol lysis buffer was made by dissolving 5 g of D-sorbitol in a total of 100 mL 
sdH2O. The buffer was filter sterilised (0.2 µm filter). The solution was aliquoted and 
stored at 4 °C.  
Tris-HCl buffer (0.5 M) 
0.5 M Tris-HCl buffer was prepared by dissolving 60.6 g Trizma base into 800 mL of sdH2O 
and pH adjusted to 7.6 using concentrated HCl. The buffer volume was made up to 1000 
mL using sdH2O and stored at room temperature (Dawson et al., 1986). 
WR99210 stock  
A long-term stock (25 mM) of WR99210 drug was made by dissolving 50 mg WR99210 
(kindly provided by D. Fidock, Columbia University) in 1 mL of dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, UK) and kept at -20 °C. Further dilution at 1:1000 was made in incomplete 
growth medium as a 25 µM working stock. The complete growth media of NF54luc 
parasite cultures were supplemented with 5 nM of WR99210.  
2.2 P. falciparum cell culture methods 
2.2.1 Human blood and serum preparation  
Leukocyte-depleted human blood type ORh⁺ and human serum were provided by the 
National Blood and Transfusion Services (Bristol, UK). All blood samples are stored, used 
and disposed of according to the Human Tissue Licence (HTA 12349) held by Keele 
University. All work using human blood products with P. falciparum were performed in 
Health and Safety Executive approved Biological Containment 3 (derogated based on the 
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non-aerosol nature of work) facilities according to Standard Operating Procedures 
detailing training and work practices in these facilities.  
Leukocyte-filtered blood was aliquoted in to 50 mL tubes and refrigerated at 4 °C up to 
three weeks. For parasite cultivation, a 50% haematocrit stock was prepared by first 
collecting the RBC by centrifugation at 1520 g for 8 min at room temperature. The upper 
serum phase was removed and stored as collected pooled samples for use in 
supplementing complete growth medium. The RBC pellet was washed using 1 volume of 
incomplete cell culture medium, mixing and collection of RBC by centrifugation at 850 g 
for 5 min at room temperature. This process was repeated twice. The pelleted RBC were 
suspended in one volume of incomplete growth medium and stored at 4 °C for up to 2 
weeks.  
For human serum preparation, serum was collected from the blood deliveries or provided 
as a separate product. Serum was heat-deactivated at 56 °C for 30 min in a water bath 
before being aliquoted as 40 mL samples and stored at -20 °C. These serum samples were 
used in the preparation of complete growth medium. 
2.2.2 In vitro continuous culture of P. falciparum  
Three clones of P. falciparum; namely 3D7, NF54Luc (kindly provided by Muqdad Hmoud, 
Keele University) and Dd2luc (Wong et al., 2011) were used in this study. The 
intraerythrocytic stages were cultured continuously in human RBC (typically between 1-
2% parasitaemia and 2% haematocrit) in complete growth medium at 37 °C under 1% 
oxygen, 3% carbon dioxide and 96% nitrogen atmosphere (BOC, UK) (Trager and Jensen, 
1976). The parasite was sub-cultured with daily replacement of complete growth medium 
and addition of fresh uninfected RBC. Light microscopic determination of the 
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parasitaemia and staging of iRBCs were performed using Giemsa (10%, v/v) stained thin 
blood smears of methanol-fixed iRBCs (Petithory et al., 2005). 
2.2.3 Synchronization of in vitro parasite cultures by the sorbitol-lysis method 
P. falciparum cultures were synchronized according to the protocol of Lambros and 
Vanderberg (1979). Light microscopy was used to determine a predominance of ring 
stage parasites suitable for this synchronization process. IRBCs were collected by 
centrifugation at 830 g for 5 min at room temperature. These were suspended in five 
volumes of pre-warmed (37 ˚C) 5% sorbitol. After 5 min incubation at 37°C, iRBCs were 
collected by centrifugation as above. The upper sorbitol phase was discarded and the 
pelleted iRBCs (containing viable ring stage parasite only) suspended in complete growth 
medium (2% haematocrit). The culture was gassed and returned into the incubator at 37 
˚C.  
2.2.4 Cryostorage of P. falciparum intraerythrocytic culture 
Liquid nitrogen provides an environment for long-term preservation of ring stage P. 
falciparum. Intraerythrocytic cultures were enriched (5-10 % parasitaemia of which >80% 
were ring stage) and the iRBCs collected by centrifugation at 850 g for 5 min at room 
temperature. Three volumes of iRBCs were mixed with 5 volumes of glycerolyte freezing 
solution. This was completed in two stages. For the first stage, one volume of glycerolyte 
freezing solution was added drop by drop to collected iRBC, with continual mixing before 
being left standing upright to equilibrate over 5 min at room temperature. This process is 
repeated, again drop by drop, with the remaining four volumes of glycerolyte freezing 
solution. The iRBCs/glycerolyte freezing mixture was then divided into 1 mL aliquots in 
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labelled cryotubes. The cryotubes were transferred to -80 ˚C for at least 24 hr before 
being stored in liquid nitrogen for long term storage.  
To thaw P. falciparum parasite cultures, cryotubes were taken out from liquid nitrogen 
storage and defrosted at 37 ˚C in the culture incubator. The thawed iRBCs (typically 
between 0.8-1 mL) were placed in a 50 mL centrifuge tubes. A one-fifth volume of 12% 
(w/v) NaCl was slowly added, drop by drop with gentle mixing, and then the mixture left 
for 5 min at room temperature. Next, ten volumes of 1.8% (w/v) NaCl is added, one 
volume at a time with gentle mixing. After an additional 5 min equilibration at room 
temperature, ten volumes of 0.9% (w/v) NaCl and 0.2% (w/v) D-glucose was added, one 
volume at a time with gently mixing. The iRBCs were collected by centrifugation at 850 g 
for 5 min at room temperature. The iRBCs were resuspended in complete culture medium 
and fresh RBCs, typically to a 2% haematocrit. The flask was gassed and placed into the 
incubator at 37 ˚C with examination of the success of thawing demonstrated by 
trophozoite stage culture 24 hrs later.  
2.3 Drug assays 
2.3.1 Compound library screening  
For the initial screening of the LC3 (Atg8)-Atg3 PPI, all 131 compounds were tested at 2, 
10 and 50 µM concentrations. Each experiment was carried out as a technical duplicate, 
with three biological replicates (n=6 total). To prepare this five-fold serial drug dilution, 
125 µL of complete growth medium was placed into starting wells in the first column of a 
96-multiwell clear tissue culture plate, with the adjacent two wells loaded with 100 µL of 
complete growth medium. 2.5 µL of 5 mM stock solution of the compound to be tested 
was added into the starting well in the first column providing a 100 µM concentration of 
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this compound. This was carefully mixed by repeated pipetting and 25 µL transferred 
from the starting well across the next two wells, with complete mixing in each well. 25 µL 
of the last well contents was discarded to provide three wells, each containing 100 µL of a 
five-fold dilution of compound. 100 µL of an iRBC mastermix (1% parasitaemia, 
predominantly early to mid-trophozoite, 4% haematocrit) was added into each wells, 
effectively having the drug concentration in each well as well as the haematocrit (final 
was 2%). Three wells containing 100 µL of iRBC mastermix with 100 µL of complete 
growth medium served as a control positive (+ve) (no drug), whilst an additional three 
wells containing 100 µL of iRBC exposed to a 10 µM supralethal concentration of CQ 
served as a negative (-ve) control (no viable parasites). The 96-well tissue culture plates 
were placed in a humidified airtight box under a low oxygen atmosphere 1% O2, 3% CO2 
and 96% N2 (BOC, UK) at 37 ˚C for 48 hrs.  
A standard MSF assay (Smilkstein et al., 2004) was used to determine the inhibitory effect 
of the compounds tested. After the incubation period, 100 µL of parasite cultures were 
mixed with equal volume of 1XMSF lysis buffer supplemented with 1X SYBR Green I 
(supplied as a 5000x stock by Invitrogen, UK) on a black 96-well tissue culture plate and 
incubated for 1 hr at room temperature in the dark. The fluorescent signal was measured 
using the blue fluorescence module (excitation λ= 490 nm, emission λ= 570 nm) in a 
Glomax-Multi Detection System (Promega, UK). Growth following exposure was 
determined as a proportion of the untreated (no drug) control (i.e. 100%), with a 
background subtraction using the negative control (supralethal CQ) (i.e. 10 µM) applied. 
The % relative growth was calculated as follows: 
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Where μ(S), μ(+) and μ(−) represent the means for the sample in question and positive 
(100%) and negative (0%) controls, respectively.  
2.3.2 Determination of 50% Effective Concentration (EC50)  
Following an initial screen, compounds of interest were taken forward for nine 
concentrations (2-fold dilution) to enable the EC50 to be determined. These 96-multiwell 
plates were set up using a variation of the experiment shown above – with plates 
formatted as shown in Fig. 2.1. Triplicate serial compound dilutions in complete growth 
medium were made across the 96-multiwell plates – with two compounds being tested 
on each plate. Starting wells contain 200 µL of the initial drug dilution, with 100 µL of 
mixed well contents moved across the plate to produce a 2-fold dilution between each 
column. 100 µL of the final well volume was discarded. 100 µL of iRBC mastermix (1% 
parasitaemia at early to med trophozoite stage, 4% haematocrit) was added into each 
well. As a control positive (+ve), 100 µL complete growth medium plus 100 µL of iRBC 
mastermix (no drug) was used whilst iRBCs exposed to a 10 µM supralethal concentration 
of CQ served as a negative (-ve) control (no viable parasites). The 96-multiwell tissue 
culture plates were placed in a humidified airtight box under a low oxygen atmosphere 
1% O2, 3% CO2 and 96% N2 (BOC, UK) at 37 ˚C for 48 hrs.  
After incubation, the fluorescence signal from a standard MSF assay was determined for 
each well and the mean % relative growth determined as described above in 2.3.1. To 
determine the EC50, a non-linear regression (log10-concentration versus normalised-
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60 
 
response) was analyzed using GraphPad Prism5 v5.0 software (GraphPad Software, Inc., 
San Diego, California, USA). At least 3 different biological replicates with triplicate 
technical repeated were used to provide the mean and standard deviation for this 
regression analysis. This analysis provides the EC50 and the 95% confidence intervals (95% 
CI) reported in this study.                                                            
 
Fig. 2.1 Schematic of a 96-multiwell plate used to determine EC50. Compounds are added into 
the loading column in triplicate, two compounds are therefore tested per plate. The dilution 
columns provide for a two-fold serial dilution of the compound being tested. Positive controls 
(+ve) consist of mastermix exposed to no compound (100% relative growth) and the negative 
control (-ve) wells each contain a supralethal dose of chloroquine (10 µM). Outer wells are filled 
with incomplete medium to reduce edge-effects from evaporation during incubation. 
 
2.3.3 Determination of 50% Lethal Dose (LD50)  
Estimation of a 50% Lethal Dose (LD50) were carried out according to the bioluminescent 
protocol reported in Ullah et al. (2017) based on those originally described by Paguio et 
al. (2011) using a fluorescent reporter system. In the Ullah et al. (2017) report, it was 
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demonstrated that a 6 hrs exposure to compound, followed by immediately reading the 
residual bioluminescence signal, provided equivalent data to a 6 hrs drug bolus followed 
by washing and re-culture for 42 hrs. Assays were set up in the same way as those for the 
determination of the EC50 (2.3.2) although with a higher staring concentration. The same 
controls were used throughout. The residual bioluminescence signal was measured using 
the simple one-step lysis protocol described originally by Hasenkamp et al. (2012). Briefly, 
40 μL samples of culture were transferred to a white 96-multiwell plate and 10 μL of 
passive lysis buffer (Promega, UK) added and mixed by pipetting. 50 μL of luminogenic 
substrate (Promega, UK) was mixed with the lysed parasites and the bioluminescence 
signal measured for 2 sec in a Glomax-Multi Detection System (Promega, UK).  Data were 
collected and analysed using Instinct software (Promega) and the LD50 estimated from 
non-linear regression (log10-concentration versus normalised-response) using GraphPad 
Prism5 v5.0 software (GraphPad Software, Inc., San Diego, California, USA).  At least 3 
different biological replicates were performed for each compound, with each experiment 
using three technical repeats (n=9). 
2.3.4 Bioluminescence Relative Rate of Kill (BRRoK) assay 
The BRRoK assay was carried out as originally described by Ullah et al. (2017). 
Trophozoite-stage cultures of Dd2luc or NF54luc (100 μL, 2% parasitaemia, 4% haematocrit, 
n= 3) were added to 96-multiwell plates containing 100 μL of pre-dosed (final three-fold 
EC50 dilution series from 9 to 0.33x EC50) complete culture medium and mixed by 
pipetting (see plate set up in Fig. 2.2). The 96-multiwell plate was then incubated for 
either 3, 6 or 48 hrs at 37 °C. The bioluminescent signal measured using the luciferase 
single-step lysis protocol described by Hasenkamp et al. (2012) as described above in 
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2.3.3.  Controls in each biological replicate consisted of trophozoite stage culture with no 
drug added (100%) or uninfected erythrocytes (0%). The mean and standard deviation 
(SD) of bioluminescence data from three independent biological repeats were expressed 
as a proportion of the untreated control (100%) and reported as the % normalized 
bioluminescence signal.  
 
 
Fig. 2.2 Schematic of a 96-multiwell plate used to measure BRRoK. Compounds are seeded into 
the loading column in triplicate at a final 9xEC50 concentration; four compounds are tested per 
plate. The dilution columns provide for a three-fold serial dilution of the compound being tested. 
Positive controls consist of mastermix exposed to no compound or control positive (+ve) and the 
negative control (-ve), wells each contain uninfected erythrocytes (0% relative growth). Outer 
wells are filled with incomplete medium to reduce edge-effects from evaporation during 
incubation. 
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2.3.5 Time course-exposure assay 
To investigate the effect of compounds on different intraerythrocytic stages of Dd2luc P. 
falciparum parasite, highly synchronized early ring stage (up to 10 hrs post infection) or 
early trophozoite (20 to 26 hrs post infection) were prepared as follows; a 1% 
parasitaemia, 2% haematocrit, culture was exposed to a 50% kill concentration of CQ and 
the two most potent autophagy inhibitors, SK1.47 and SK1.49. After 6 hrs of incubation 
with drug/compound, the samples were divided to two equal portions. The first portion 
was washed with ten volumes incomplete growth medium three times, with collection of 
the iRBC pellet by centrifugation (1800 g, 5 min), to remove the drug/compounds. In the 
second portion, the drug/compound was maintained in the culture medium. For both 
experiments, thin blood smears were prepared after 16, 24 and 48 hrs incubation, Giemsa 
stained and examined by light microscopy to stage the culture and monitor presence of 
abnormal iRBC morphology. To capture images, slides were observed using a LETZ Dialux 
20 EB microscope (x100 oil immersion objective lens) coupled with a digital camera 
system (Wetzlar, Germany). 
2.4 Cytotoxicity assays using HepG2 cell lines 
HepG2 (ATCC HB-8065) cell lines were cultured in Dulbecco Modified Eagle Medium 
(DMEM, Invitrogen, Gibco-BRL 11995-065) supplemented with 10% (v/v) fetal bovine 
serum and 0.2% (v/v) penicillin/streptomycin solution (Invitrogen). The culture flasks 
were incubated for 3 days at 37 °C in a 5% CO2 incubator. The culture medium was 
replaced every 2-3 days. Cells were harvested following aspiration the supernatant and 
addition of 10 mL 1XPBS to wash the residual cell culture medium from the HepG2 
monolayer and followed by addition of 2.5 mL of 0.2% Trypsin-EDTA (5 mM) for 5 min at 
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37 °C. After trypsinization, 6 mL of DMEM culture medium was added to the cells, mixed 
and the released HepG2 collected by centrifugation (590 g for 3 min at room 
temperature). A HepG2 cell suspension at 1X105 cells/mL was prepared as a mastermix 
for the cytotoxicity assay. To determine the effect of the putative autophagy inhibitors on 
HepG2 viability, a triplicate of 100 µL serial drug dilutions in DMEM medium were 
performed in 96-multiwell plates and followed by addition 100 µL of the HepG2 
mastermix into each well (see Fig. 2.1 to illustrate how serial dilution plates are set up).  
The wells without compounds served as positive controls (+ve) and for negative controls 
(-ve), 2 µL of 50 μM actinomycin-D was added to provide a 500 nM final concentration 
(supralethal dose). After incubation for 48 hrs at 37 °C, 20 µL of Alamar Blue cell viability 
reagent (Thermo Fisher Scientific, UK) was added into each well, incubated at 37 °C for 6 
hrs to allow a colour change across the serial compound dilution. The fluorescent signal 
was measured using the blue fluorescence module (excitation λ= 490 nm, emission λ= 570 
nm) in a Glomax-Multi Detection System (Promega, UK). The 50% cytotoxic concentration 
(CC50) of compounds was determined using the same non-linear log10 concentration-
normalised response method described in 2.3.1. At least three different biological 
replicates were obtained for each compound, with each experiment having three 
technical repeats (n=9).  
2.5 Molecular docking study  
Computational docking of a ligand into putative binding site of the target protein can be 
applied as a useful tool in the structure-based drug design. In this study, X-ray 
crystallography of PfAtg8 protein was obtained from the database of Protein Data Bank 
(PBD ID 4EOY) (www.rcsb.org/pdb/home/home.do). This molecule is usually provided as 
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a co-crystallized form with its regulator (PfAtg3 protein) which occupied W and L pockets 
on the surface of PfAtg8 (Fig. 2.3), thus a single 3D crystal model of PfAtg8 was prepared 
using UCSF Chimera 1.11.2 software (www.cgl.ucsf.edu/chimera/) and this single chain of 
PfAtg8 molecule saved as a PDB file format for following molecular docking.  
 
Fig. 2.3 The left image indicates 3D co-crystal structure of PfAtg8 (homologue of Human LC3) 
and PfAtg3 which represented as a stick model in green (PDB ID 4EOY) in P. falciparum. Two 
hydrophobic pockets W and L on the anterior surface of PfAtg8 represent a functional parts of 
PfAtg8 which occupied by PfAtg3 peptide inducing lipidation of PfAtg8 molecule and resumption 
phagophore development to autophagosome. In addition, Apicomplexan members have extra 
pocket called A-pocket on the posterior surface of Atg8 which is generated by A-loop. Right image 
displays single model of PfAtg8 prepared after removing PfAtg3 using UCSF Chimera 1.11.2 
software to be applied as a receptor for ligand in computational molecular docking assay. 
 
The SMILES (Simplified Molecular Input Line Entry System) of interested compounds were 
determined by ChemDraw Ultra 7.0 software and saved for later docking steps. Ligand-
PfAtg8 molecular docking was obtained using Mcule software package (www. 
mcule.com). Initially, the ligand was figured by ChemWriterTM 2.15.2 screen of the Mcule 
software using ligand SMILES and this followed by upload PfAtg8 molecule as a receptor 
which already saved as a PDB file format as described above. The PfAtg8 PDB file format 
is automatically added into the Mcule software database by which allowed to be 
requested in future docking assays. The two putative binding centres [Lysine 48 (LYS48) 
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and Leucine 50 (LEU50) amino acids] as well as LYS47 amino acid within PfAtg8 molecule 
were predicted according to the previous studied (Hain et al., 2014; Dr Johannes 
Reynisson’s group, unpublished data) and also via molecular visualisation of PfAtg8 
protein surface features (Fig. 2.4). 
 
Fig. 2.4 The overall structure of PfAtg8 in P. falciparum. Left image, a ribbon structure of PfAtg8, 
displays two amino acid residues (LYS48 and LEU50) of PfAtg8 molecule which putatively 
contribute in H-bond generation with PfAtg3 molecule in the cargo binding site of PfAtg8. LYS48 
and LEU50 as well as LYS47 were selected as biding centres according to the previous studies 
(Hain et al. (2014); Dr Johannes Reynisson’s group, unpublished data) and molecular visualisation 
of PfAtg8 protein surface features. Right image, surface presentation of PfAtg8 showing three 
hydrophobic pockets (W, L and A-site) with LYS48 and LEU50 positions presented as yellow and 
green areas, respectively. LYS48 is located next to W pocket while LEU50 residue is near to space 
between W and L-pocket of PfAtg8.  
 
Hit/lead optimization is required in order to improve the docking score, which is usually 
given by negative values and high negative scoring represents high binding affinity. Once 
the docking centre was specified, the scheme applied for ligand-protein molecular 
docking of 5 more potent compounds (putative autophagy inhibitors) and 2 compounds 
(structurally related) added for comparative analysis. 7-8 binding points (7-8 atoms) for 
LYS48, LYSY47 and LEU50 binding centres with 4 docking poses of each binding point were 
assayed by Mcule software (www. mcule.com). All docking poses were visualised by 
Mcule before being saved as PDB file format for further analysis. The docking outcome 
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data was analyzed by UCSF Chimera 1.11.2 software and ligand-PfAtg8 restricted H-bonds 
viewed.  
2.6 Transmission Electron Microscopy (TEM) 
To study ultrastructure changes in intraerythrocytic stages of P. falciparum under drug 
stress, early trophozoite stages (20 to 26 hrs post invasion) at    10% parasitaemia and 4% 
haematocrit were exposed to 50% lethal concentrations of 4-aminoquinolines (CQ, AQ, 
PYRD, and PPQ), amino alcohols (QN and MQ), artemisinins (dihydroartemisinin, DHA, 
and artemether, ARM), DBeQ and 2 putative autophagy inhibitory compounds (SK1.47 
and SK1.49) for 6 hrs at 37 °C. All samples imaged underwent a bioluminescence assay to 
determine the actual reduction in viability achieved in each experiment (See section 
2.3.3). Cultures were harvested by centrifugation at 1800 g for 5 min at room 
temperature. The harvested cells were resuspended in 1XPBS and pelleted using the 
same centrifugation conditions above. Washing process was repeated two more times 
and the collected red blood cells lysed in 0.1% (w/v) saponin solution (1:20 volume) for 1 
min on the ice following by centrifugation at 400 g for 10 min at 4 °C as described 
previously (Totino et al., 2008). Fixation of parasites was performed using a protocol 
described originally by Beaumelle et al. (1987). Briefly, the released parasites were 
washed twice in 10 volumes of 1XPBS, with centrifugation (400 g for 10 min at 4 °C) used 
to collect the parasite pellet. These were then fixed with 2% (w/v) glutaraldehyde/1XPBS 
overnight at 4 °C and then washed twice with 0.1 M cacodylate buffer in 0.2% CaCl2 using 
centrifugation (400 g for 10 min at room temperature) to collect the parasite pellet. The 
pellet was gently resuspended in 100 µL of 1% (w/v) osmium tetroxide for 1 hr at room 
temperature before being embedded in 3% (w/v) agar (Agar Scientific Ltd., UK). For 
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dehydration, a graded ethanol series was used on the fixed parasites before being 
embedded in Spurr resin overnight at 60 °C. Ultrathin sections (80-90 nm thickness) were 
prepared using a Reichert-JUNG Ultracut E microtome (Leica-Microsystems, Wetzlar, 
Germany). The ultra-sections were loaded on 200-mesh thin bar grids-copper (Agar 
Scientific Ltd, UK) and air dried. With support from the Keele Electron Microscopy Unite, 
sections were stained with uranyl acetate dye and imaged using a Transmission Electron 
Microscope (JEOL-1230, USA).    
2.7 Biochemical methods 
2.7.1 Mitochondrial outer membrane potential (ΔΨm) assay   
To evaluate effect of drug/compound on the ΔΨm, the MitoProbe cell-permeable 
lipophilic JC-1 dye (5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbocyanine 
iodide (Thermo Fisher Scientific, UK) was used with different techniques (Fluorescence 
microscope, plate reader  and flow cytometry) to monitor fluorescence signal. The 
cytoplasmic monomeric form of JC-1 has maximum emission wavelength at 525 nm 
(green fluorescence) whilst functional mitochondria accumulate an aggregated JC-1 dye 
which emits red fluorescence at 590 nm. The ratio between red and green fluorescence 
was used as an indicator of ΔΨm. A low ratio of red/green reflects loss of the ΔΨm. In all 
experiments, the ionophore carbonyl cyanide m-chlorophenylhydrazine (CCCP), that 
rapidly collapses the ΔΨm was used as a control negative (-ve) whilst untreated samples 
served as a positive control (+ve). As mitochondrial depolarisation is described as an early 
feature of apoptosis, parasite cultures were exposed to concentrations of 
drug/compounds being tested that achieved 25%, 50% and 90% loss of viability over 6 hrs 
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at 37 °C (see 2.3.1).  All experiments were prepared in triplicate and at least three 
biological replicates performed (n=9). 
2.7.1.1 ΔΨm assay using fluorescence microscopy  
Fluorescence microscopy analysis of ΔΨm was obtained according to manufacturer’s 
instructions and as described previously by Pasini et al. (2013). Cell suspensions (1X106 
iRBCs/mL) were mixed with a 2 µM final concentration of JC-1 for 30 min at 37 °C in the 
dark. Post-stained cells were washed twice with ten volumes of 1XPBS and the iRBCs 
collected by centrifugation (400 g for 10 min at room temperature). The nucleic acid of 
iRBCs were stained with Hoechst 33342 (Thermo Fisher Scientific, UK) at a 1 µg/mL final 
concentration for 10 min at 37 °C. Stained iRBCs were collected by centrifugation (400 g 
for 10 min at room temperature) and then suspended in anti-fade mounting solution 
(Vectashield) before being mounted on microscopic slides. The iRBCs were covered with a 
coverslip, sealed using nail varnish and stored in the dark at 4 °C prior to imaging 
(performed the same day). The cells were microscopically visualised and counted using 
100X objective lens of EVOS microscope (EVOS® Cell Imaging Systems, Life Technologies, 
Carlsbad, CA, USA) with appropriate filters (DAPI filter for blue Hoechst fluorescence 
signal: excitation/emission λ= 357 nm/447 nm, and the GFP filter for JC-1 green 
fluorescence signal: excitation/emission λ= 470 nm/525 nm, RFP filter for JC-1 red 
fluorescence signal: excitation/emission λ= 531 nm/593 nm). 60-70 iRBCs/sample were 
counted for each replicate, with three biological repeats performed.  
2.7.1.2 ΔΨm assay using a fluorescence plate reader   
An early trophozoite stage (20 to 26 hrs post invasion) of parasite culture was exposed to 
drugs/compounds in 96-multiwell plate for 6 hrs at 37 °C. After this incubation period, the 
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96-well plates were centrifuged (400 g for 10 min at room temperature) and the 
supernatant discarded. The treated iRBCs were washed twice with 100 µL of 1X PBS 
followed by centrifugation as above. The collected iRBCs (1x106 iRBCs/mL) were mixed 
with 2 µM final concentration of freshly prepared JC-1 regent using instructions provided 
by the manufacturer and modified by Pasini et al. (2013). The 96-well plates were 
incubated for 30 min at 37 °C in the dark. For the controls, 200 µΜ final concentration of 
CCCP was added for 1 hr at 37 °C (Porter, 2007) as a negative control (-ve) whilst 
untreated iRBCs represented a positive control (+ve). These controls were treated, 
washed and stained as above. The fluorescence signals were measured using the GloMax-
Multi Detection System (Promega, UK) with appropriate filters for red fluorescence 
(excitation/emission λ= 525/590 nm) and green fluorescence (excitation/emission λ= 
490/520 nm) used sequentially.  
2.7.1.3 ΔΨm assay using fluorescence flow cytometry 
For assessment of ΔΨm by fluorescence flow cytometry, 6 hrs drug-treated samples were 
washed twice with 10 volumes of 1X PBS using centrifugation (500 g for 5 min at room 
temperature) to collect iRBCs. Suspensions (1x106 iRBCs/mL) of drug-treated, positive and 
negative control samples were prepared in 1.5 mL microculture tubes and JC-1 (2 µM final 
concentration) loaded for 30 min at 37 °C in the dark. The stained iRBCs were washed 
twice with 10 volumes of 1X PBS using centrifugation (400 g for 10 min at room 
temperature) to collect iRBCs. Following the respective incubation and staining period, 
cell suspensions (≤ 500 cells/µL) were prepared in 1XPBS for flow cytometry analysis.  
Flow cytometry analysis was initiated by determination forward scatter (FSC) versus side 
scatter (SSC) of treated and untreated iRBCs. 100,000 RBCs/sample were analyzed using 
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FL1 for JC-1 green fluorescence (excitation/emission λ= 488nm/525nm) and FL2 for JC-1 
red fluorescence (excitation/emission λ= nm535/575nm) using Beckman Coulter FC500 
Flow Cytometry (Beckman Coulter, Inc. 250 S. Kraemer Blvd. Brea, CA 92821 USA). The 
data was analyzed and plotted using Flowing software 2.5.1.   
2.7.2 In Situ DNA fragmentation assay  
2.7.2.1 In Situ DNA fragmentation assay by flow cytometry cell sorting   
This assay is called also Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP 
nick end labelling (TUNEL) assay. Drug-induced DNA fragmentation in Dd2luc and NF54luc of 
P. falciparum parasites were investigated based on labelling of DNA strand breaks using 
the commercial In Situ Cell Death Detection Kit, Fluorescein (Sigma-Aldrich, UK). In drug-
treated groups, concentrations required to achieve 50% and 90% kill in 6 hrs were 
determined using the bioluminescence-based assay described above (see 2.3.3). Both 
treated and untreated groups of iRBCs were analysed at three different time points; 6, 24 
and 48 hrs following drug exposure, to assess DNA fragmentation at single-cell level as 
assessed by flow cytometry. Drug was washed off tested iRBCs using 10 volumes of 1XPBS 
and iRBCs collected by centrifugation (500 g for 5 min at room temperature). The 
subsequent TUNEL assay was carried out according to instructions provided by the 
manufacturer as modified by Oakley et al (2007). Briefly, one volume (50 µL) of 1X106 
iRBCs suspension was mixed with three volumes (150 µL) of fixative (4%, w/v, 
paraformaldehyde/ 0.015%, w/v, glutaraldehyde) for 1 hr at 4 °C. Post-fixed iRBCs were 
washed twice with 1XPBS and collected by centrifugation (400 g for 10 min at 4 °C). The 
iRBCs were permeabilized by the addition of 100 µL of 0.1% (w/v) Triton X-100 and 
incubated for 3 min on ice. The Triton X-100/iRBCs were washed twice with 1XPBS and 
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collected by centrifugation (400 g for 10 min at 4 °C). 50 µL of permeabilized iRBCs were 
mixed with an equal volume of labelling solution of TUNEL kit (prepared freshly for each 
experiment) following by incubation for 1 hr at 37 °C in the dark. The sample tubes were 
gently flicked twice during the incubation period to suspend any settled iRBCs. To provide 
a positive control (+ve), 50 µL of fixed and permeabilized iRBCs were mixed with an equal 
volume of 50U/mL DNase I (Invitrogen) in 50 mM Tris-HCl pH 7.5, containing 1 mg/mL 
bovine serum albumin (BSA) (Sigma-Aldrich, UK) (see Totino et al., 2008) and incubated 
for 20 min at room temperature to artificially induce DNA-nicks. DNase I-treated cells 
were washed and subjected to TUNEL staining as described above.  
Treated iRBC suspensions (≤ 500 cells/µL) were prepared in 1XPBS with the samples kept 
away from direct light until analysed by flow cytometry cell sorting (FACS) machine. A 
sample was removed from the original iRBCs used at the start of the experiment to 
determine parasitaemia with SYBR Green I dye. Parasitaemia was determinate according 
to protocol initially developed by Jang et al. (2014), where 10,000X SYBR Green I dye 
(Invitrogen) was freshly diluted with 10% ethanol/ 1X PBS (1:1000 ratio) and 125 µL of 
untreated iRBCs in complete growth medium (4% haematocrit) were mixed with same 
volume of this 1:1000 SYBR Green working solution for 30 min at room temperature in 
the dark. 
Forward scatter (FSC) versus side scatter (SSC) of treated and untreated iRBCs were found 
(Fig. 2.5) and following by adjustment appropriate filters, where Green-Blue (GRN-B) filter 
used for TUNEL green fluorescence signal, whilst Yellow-Blue (YEL-B) filter used for red 
fluorescence of SYBR Green I. 20,000 cells were analysed for each sample. The data was 
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analysed and graphed using Guava EasyCyteTM HT System and GuavaSoft 3.1.1 software 
(Millipore, USA).     
 
Fig. 2.5 Flow cytometry dot plot graphs of DNA fragmentation assay (TUNEL assay) using In Situ 
Cell Death Detection Kit, Fluorescein. Top row represents drug-untreated iRBCs sample and 
stained with SYBR Green I only to identify parasitaemia percentage. Middle row indicates drug-
untreated sample loaded with TUNEL labelling solution only to identify DNA fragmentation. The 
bottom row shows DNase-treated sample (control positive) and stained also with TUNEL labelling 
solution only. 20,000 cells of both infected and uninfected RBCs were gated and labelled as RBCs 
(A, D and G), and the remaining particles represent debris and components of destroyed cells. B, E 
and H represent gated RBCs only. R3 in the dot plot graph (C) indicates percentage of 
parasitaemia at 6 hrs of experiment period, R2 in graph (F) represents percentage of TUNEL 
positive cells in drug-untreated sample while R2 in graph (J) shows TUNEL positive cells in DNase I-
treated sample.  
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2.7.2.2 In Situ DNA fragmentation by fluorescence microscope 
Fluorescence microscopic analysis of the TUNEL-treated iRBCs was also carried out. After 
TUNEL staining (2.7.2.1), samples were stained with a 0.5 µg final concentration of 
Hoechst 33342 (Thermo Fisher Scientific, UK) for 10 min at 37 °C. Stained iRBCs were 
collected by centrifugation (400 g for 10 min at room temperature) and then suspended 
in 1XPBS before been placed on microscopic slide. The iRBCs were covered with a 
coverslip, sealed using nail varnish and stored in the dark at 4 °C prior to imaging 
(performed the same day). The iRBCs were visualised and counted using an EVOS 
microscope  (EVOS® Cell Imaging Systems, Life Technologies, Carlsbad, CA, USA) using 
100X objective lens with appropriate filters  (DAPI filter for blue Hoechst fluorescence 
signal: excitation/emission λ= 357 nm/447 nm, and the GFP filter for TUNEL-green 
fluorescein fluorescence signal: excitation/emission λ= 470 nm/525 nm). A least 60 cells/ 
sample were counted with all experiments sat up in triplicate with three independent 
biological replicates (n=9). 
2.7.3 Caspase-like cysteine protease activation assay  
2.7.3.1 Caspase-like cysteine protease activation assay by flow cytometry 
To investigate caspase activation in drug-treated P. falciparum intraerythrocytic stages, 
the CaspaTag Pan-Caspase In Situ Assay Kit, Sulforhodamine kit (Millipore, USA) was used. 
Sulforhodamine-labelled caspase inhibitor (SR-VAD-FMK) is cell permeable, non-toxic and 
covalently binds to the active site cysteine of caspase heterodimer. Bound reagent, 
indicating the presence of caspases, is retained in the cell on washing. The protocol used 
below was based on that originally described in Ch’ng et al (2010). 
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 Infected iRBCs were exposed to 50% and 90% kill concentrations as determined from 
bioluminescence assay (see 2.3.3). Drug-treated and untreated cells were loaded with 
freshly prepared SR-VAD-FMK reagent according to manufacturer instructions. In brief, 
trophozoite stage (20-26 hrs post-invasion) parasite cultures (1X106 cells/300 µL) were 
mixed with 7 µL of a freshly prepared 30X stock of SR-VAD-FMK reagent for 1 hr at 37 °C 
in the dark (Ch’ng et al., 2010). The tubes were gently flicked twice during incubation 
period to suspend settled cells. Post-stained cells were washed twice with 1XPBS and the 
iRBCs collected by centrifugation (400 g for 10 min at room temperature). The iRBCs were 
resuspended in 1 mL of 1XPBS (≤ 500 cells/µL) for flow cytometry analysis. To 
determinate the parasitaemia, SYBR Green I-stained sample of the initial RBC mastermix 
was done as described above (see 2.7.2.1). The green fluorescence signal of SYBR Green I 
was being detected using the Green-Blue (GRN-B) filter, whilst the red fluorescence signal 
of CaspaTag was detected using the Yellow-Blue (YEL-B) filter. For each sample, 20,000 
total erythrocytes were required. Analysis and plotting data were carried on via Guava 
easyCyteTM HT System and GuavaSoft 3.1.1 software, respectively (Millipore, USA). 
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Fig. 2.6 Flow cytometry analysis data of caspase-like cysteine activation assay enzyme using 
CaspaTag Pan-Caspase In Situ Assay Kit, Sulforhodamine kit (Millipore, USA). The top row 
indicates drug-untreated cells which stained with SYBR Green I only as indicator of iRBCs to 
calculate parasitaemia percentage (see section 2.7.2.1). The bottom row displays drug-untreated 
and SR-VAD-FMK-labelled sample as indicator of caspase-like enzyme activation. Forward scatter 
and side scatter were obtained and overall, 20.000 of infected and uninfected cells were gated 
and labelled as RBCs (A and D). B and E indicates isolated-RBCs only. Parasitaemia was calculated 
using SYBR Green-labelled iRBCs [C (R2)] whilst (R3) in (F) represents CaspaTag-positive cells as an 
indicator of caspase-like enzyme activation in P. falciparum trophozoite stage. 
 
2.7.3.2 Caspase-like cysteine protease activation assay by fluorescence microscope 
 
Further analysis of caspase-activation was also done by florescence microscopy, where 
treated and untreated cell groups were stained with SR-VAD-FMK as described above. 
After staining, samples were stained with a 1 µg/mL final concentration of Hoechst 33342 
(Thermo Fisher Scientific, UK) for 10 min at 37 °C. The iRBCs were visualised and counted 
by EVOS microscope using 100X objective lens with appropriate filters (DAPI filter for blue 
Hoechst fluorescence signal: excitation/emission λ= 357 nm/447 nm, and the RFP filter 
for CaspaTag-red fluorescence signal: excitation/emission λ= 531 nm/593 nm). A least 60-
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70 cells/sample were counted with all experiments sat up in triplicate with three 
independent biological replicates (n=9).  
2.7.4 Intracellular calcium distribution assay  
 
 
The dynamics of intracellular calcium localization following drug/compound treatment 
was investigated using the protocols originally described by Ch’ng et al (2011). Early 
trophozoite stage (20 to 26 hrs post invasion) parasites were challenged with 25%, 50% 
and 90% kill concentrations of each drug for 6 hrs. After drug treatment, the samples 
were washed twice in 10 volumes of 1XPBS and collected by centrifugation (500 g for 5 
min at room temperature). The treated and untreated iRBCs were loaded with 2 µM of 
green fluorescence calcium indicator (Fluo-4 AM, freshly was prepared using the 
instructions provided by Thermo Fisher Scientific) following by incubation for 30 min at 
37 °C in the dark. Post-stained cells were washed twice with ten volumes of 1XPBS and 
the iRBCs collected by centrifugation (400 g for 10 min at room temperature). The nucleic 
acid of iRBCs were stained with Hoechst 33342 (Thermo Fisher Scientific, UK) at a 1 µg/mL 
final concentration for 10 min at 37 °C. The dye-stained samples were washed and 
mounted on a microscopic slide as described above (see section 2.7.1.1). The stained 
iRBCs were observed using the 100X objective of an EVOS microscope using a DAPI 
fluorescence filter for blue Hoechst fluorescence signal (excitation/emission λ= 357 
nm/447 nm) and GFP fluorescence filter for Fluo-4 AM-green fluorescence signal 
(excitation/emission λ= 470 nm/525 nm). At least 60-70 cells/sample were quantified for 
each sample. All experiments were obtained from triplicate technical replicates from 
three biological replicates (n=9). 
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2.7.5 Phosphatidylserine detection using the FITC-Annexin V assay 
Fluorescence microscopic analysis of phosphatidylserine (PS) exposed on the iRBC surface 
following different stress conditions in trophozoite stage (20-26 hrs post-invasion) P. 
falciparum were performed using a commercial FITC-Annexin V kit (Abcam, UK). The 
experiments were established using antimalarial drug stress (50% and 90% kill 
concentrations) as well as exposure to febrile temperature (40 °C).  
2.7.5.1 Phosphatidylserine detection following drug-induced stress 
After 6 hrs of drug treatment that induced 50% and 90% kill, 1X105 iRBCs were suspended 
in 500 µL of 1X binding buffer provided with the kit. 5 µL of freshly prepared FITC-Annexin 
V reagent according to manufacturer's instructions and as originally described by Totino 
et al (2011) with 1 µg/mL final concentration of Hoechst 33342 were added to the 
iRBCs/binding buffer and incubated for 30 min at 37 °C with protection from light. The 
iRBC were washed twice in 10 volumes of 1XPBS with iRBCs collected by centrifugation 
(400 g for 10 min at room temperature). The iRBCs were visualised and counted by an 
EVOS microscope using 100X objective lens with appropriate filters  (DAPI filter for blue 
Hoechst fluorescence signal, excitation/emission λ= 357 nm/447 nm, and the FITC filter 
for FITC-Annexin V fluorescence signal, excitation/emission λ= 494 nm/518 nm). A least 60 
cells/ sample were counted with all experiments sat up in triplicate with three 
independent biological replicates (n=9).  
2.7.5.2. Phosphatidylserine detection following heat stress 
The effect of febrile temperature on PS localization was investigated using a protocol 
originally described by Engelbrecht and Coetzer (2013). Experiments were initiated by 
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incubating trophozoite stage (20-26 hrs post-invasion) iRBCs for 2, 4 or 8 hrs in a water 
bath at 40 °C. Parasite viability was measured following these three time points using the 
bioluminescence-based assay (See section 2.3.2). After heat shock, samples were 
returned to 37 °C and incubated until 48 hrs after the start of the experiment. The heat-
shocked iRBC cultures were stained with FITC-Annexin V reagent and Hoechst 33342 dye 
and visualised as described above (see section 2.7.5.1).  
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Chapter 3: Screening for potential inhibitors of the PfAtg8-PfAtg3 protein-
protein interaction (PPI) 
 
3.1 Introduction  
Autophagy offers a potential drug target due to its central role in the maintenance of 
cellular homeostasis in both normal and pathological situations. Drug development 
programmes have been linked a diverse range of diseases such as cancer, 
neurodegeneration and cardiac disorders (Levine and Kroemer, 2008; Rubinsztein et al., 
2012b). As such, a range of drugs and compounds have been identified that modulate 
the function of proteins within the autophagy cascade (Chuo et al., 2011; Hain et al., 
2012; Mizushima et al., 2001; Liu et al., 2011; Powis et al., 1994; Wu et al., 2010). 
Examples of these compounds are shown in Fig. 3.1 and the site of action for a number 
of autophagy inhibitors in a classical autophagic cascade in Fig. 3.2.  
 
Fig. 3.1 Examples and structures of exemplar autophagy inhibitors.   
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Fig. 3.2 Sites of action for autophagy inhibitors. A generic macroautophagy cascade is shown 
with key regulatory steps in initiation (mTOR, PI3K signalling), phagophore maturation, 
autophagosome formation and trafficking to the Lysosome.  Compounds that inhibit autophagy 
(black) and drugs under development (red) are indicated against where they act in this cascade. 
(Source: Feitelson et al., 2015). 
 
A number of these inhibitors have been assessed for their antiplasmodial effects 
against the intraerythrocytic stages of P. falciparum. Exposure to 5 mM of 3-MA, which 
inhibits autophagosome formation by targeting PI3K, leads to a small reduction in Atg8 
levels assessed using western blotting and immunofluorescence assays (Navale et al., 
2014). Wortmannin, which also targets PI3K activity, has an EC50 of between 40-70 µM 
(Tomlins et al. 2013), although exposure to 10 µM of wortmannin for 6 hrs did not affect 
the localization or production of Atg8 in pre-starved P. falciparum. Increasing the 
concentration to 100 µM for a 1.5 hr pulse reduced PI3K activity by 58%. The 
accumulation of autophagosome-like vesicles containing undigested haemoglobin in the 
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cytoplasm of P. falciparum parasites pre-treated with 3 µM wortmannin suggests that 
PI3K involves in P. falciparum in autophagosome formation and the subsequent 
trafficking of these vesicles to the DV (Vaid et al., 2010). The same trafficking disruption 
was observed in this same study using a second PI3K inhibitor LY294002 (50 µM) which 
has an apparent EC50 of 26 µM against intraerythrocytic parasites.  
In 2012, Hain et al. determined the structure of PfAtg8 from a co-crystal with the Atg8 
family interacting motif (AIM) of PfAtg3. This structure revealed some distinct features of 
PfAtg8 distinct to the LC3 homologue found in humans. These included a change in the 
orientation and distribution of charge over the Atg3 interacting region of Atg8, a shallow 
cleft that contains two hydrophobic pockets termed W and L (based on the proximity of 
tryptophan and leucine residues). The implications of these structural differences and 
compound docking are developed in the next chapter. PfAtg8 also includes an A-loop, 
with an adjacent A-pocket, that result from an insertion of 9 amino acids that is found in 
the Atg8 of a range of apicomplexan parasites. In this study, the authors screened a small 
fragment library to determine their ability to block an interaction between PfAtg8 and the 
PfAtg3 AIM as detected by SPR. Here they showed that 1,2,3-trihydroxybenzene 
(common name is pyrogallol) inhibited this interaction with an EC50.SPR of 150 µM. A 
second related compound, 1,2,4-trihydroxybenzene, also inhibited the same interaction 
although with a much higher EC50.SPR potency of 1 mM.  
The potential for the PfAtg8-PfAtg3 protein-protein interaction as a novel target for drug 
development was developed by the same team when they reported a SPR screen of the 
open access MMV Malaria Box resource (Hain et al., 2014). Here they report three 
structurally related hits with EC50.SPR ranged between 6.0-18.1 µM that appear to act in a 
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concentration-dependant manner. The best hit, compound 1 (MMV007907) [common 
scaffold is a 4-pyridin-2-yl-1,2-thiazol-2-amine (PTA)], that has an EC50 against 
intraerythrocytic stages between 1.4 µM and against the liver stage of approximately 30 
µM. In the latter case, this concentration of the PTA did not appear to affect the human 
liver cell line used in the in vitro assay. In silico docking studies suggest that PTA, with 
three structures tested, block the PfAtg8-PfAtg3 protein-protein interaction when they 
bind at the W and L-pocket sites. Increasing concentrations of compound 1 result in an 
accumulation of the unlipidated PfAtg8 as assessed by western blot, supporting the role 
of PfAtg8-PfAtg3 in the cascade that adds phosphatidylethanolamine to PfAtg8. Two 
years later, a second report outlined a similar approach to the discovery of potential 
PfAtg8-PfAtg3 protein-protein interaction inhibitors (Hain et al., 2016). Here the team 
used an initial virtual screen between approximately 370,000 structures in the 
ChemBridge chemical library and PfAtg8. Thirteen hits were validated using the SPR assay 
to show inhibition of PfAtg8-PfAtg3 interaction. One compound, ALC25 (1-[(3-
methylphenyl) methyl]-3-([1-(pyridine-2-ylmethyl) pyrrolidin-3-yl] methyl) urea, proved to 
inhibit intraerythrocytic growth, but not liver stages, with an EC50 of 19 µM and result in 
the accumulation of unlipidated PfAtg8. In silico docking studies suggested, however, that 
ALC25 interactions were more likely occurring at the A-pocket on PfAtg8.  
Through collaboration with Dr Johannes Reynisson, a molecular modeller and 
computational chemist from the University of Auckland, New Zealand, a library of 
compounds related to molecules that modulate autophagy in human cell lines were 
provided to our research team. In addition to this library, Dr Anthony Curtis (Keele 
University) added additional compounds that he has synthesised for a research project 
with Dr Alan Richardson (Keele University) for his research project on autophagy 
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inhibitors in human ovarian cell cancer lines.  These compounds are considered likely to 
act as protein-protein interaction inhibitors in the Atg8 and/or Atg12 cascade. Here I 
provide a report of the antiplasmodial screening of these compounds against the 
intraerythrocytic stages of P. falciparum, with an initial characterization of the 
pharmacodynamic and toxicity properties of two hits that were taken forward, in 
collaboration with Professor Roepe (Georgetown University) to provide initial evidence 
for their potential as inhibitors of PfAtg3-PfAtg3 interaction. 
 3.2 Results  
3.2.1 Screening the compound library for activity against intraerythrocytic asexual 
stages 
 
A chemical library of 131 compounds was provided by Dr Johannes Reynisson from 
Auckland University, New Zealand, and Dr Anthony Curtis from the School of Pharmacy 
School at Keele University. Appendix 1 provides a table of their ID number and chemical 
structure. Antiplasmodial activity was determined against intraerythrocytic trophozoite 
stages of P. falciparum over 48 hrs using a MSF assay. Serial drug dilution provided a 
screen at three concentrations (2, 10 and 50 µM), with technical duplicates and three 
biological replicates (n=6) were performed. The fluorescence data was normalized against 
untreated controls and a mean ± SD of n=6 of relative growth (%) plotted (Fig. 3.3 and 
3.4). The compounds were provided in two tranches, the first 64 compounds (Fig. 3.3) 
were screened against 3D7 (CQ sensitive, CQS, laboratory clone) then switched to Dd2luc 
(CQ resistance, CQR, laboratory clone) for the remaining 67 compounds (Fig. 3.4). This 
switch was done as it was decided that the subsequent assays would be done using the 
Dd2luc line for the relative rate of kill assays. 
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Fig. 3.3 Initial screening data for the 64 potential autophagy inhibitors at 2, 10, 50 µΜ (see key 
for labelling) after 48 hrs exposure of intraerythrocytic trophozoite stages of 3D7 clone using 
the MSF growth assay. The data shown is a normalised growth, compared to untreated controls, 
with the mean ± SD (n= 6) shown. See appendix 1 for chemical structures for the ID shown on the 
x-axis. 
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Fig. 3.4 Initial screening data for the 67 potential autophagy inhibitors at 2, 10, 50 µΜ (see key 
for labelling) after 48 hrs exposure of intraerythrocytic trophozoite stages of Dd2luc clone using 
the MSF growth assay. The data shown is a normalised growth, compared to untreated controls, 
with the mean ± SD (n= 6) shown. See appendix 1 for chemical structures for the ID shown on the 
x-axis. 
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3.2.2 Determination of the 50% effective concentration (EC50)  
The screen identified 56 compounds that showed > 50% reduction in relative growth at 
the highest concentration 50 µM. Of these, 18 showed a >50% reduction at 10 µM with 
only two, SK1.47 and SK1.49, showing the same reduction in relative growth at 2 µM. The  
EC50 of these 56 compounds was determined using the MSF assay using a two-fold drug 
dilution series, each experiment done as a technical triplicate with three biological 
repeats (n=9). The EC50 was first done in either 3D7 and Dd2
luc clones depending on the 
initial tranche of compound library screened. However, compounds with EC50 <10 µM in 
either tranche were repeated in the other parasite clone. Eight most potent compounds 
therefore had their EC50 determined in both CQS (3D7) and CQR (Dd2
luc) parasites (Fig. 
3.5, Table 3.1) (See appendix 2 for more information about EC50 for tested compounds). 
The EC50 determined in both 3D7 and Dd2
luc were similar. A linear correlation of these 
values revealed a strong correlation (r2= 0.9, P < 0.0001), although the slope of 1.6±0.15 
suggests a slightly higher in EC50 value in the CQR clone Dd2
luc (Fig. 3.6). This is unlikely to 
reflect a cross resistance to existing drug resistance in Dd2luc compared to 3D7 as the 
resistance index (EC50 in Dd2
luc/3D7) is low (1.4-1.6) and in several cases the 95% CI for 
EC50 in the two strains overlap or are very close (Table 3.1). 
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Fig. 3.5 Log10 concentration-normalised response curves for the eight most potent compounds 
against 3D7 (blue) and Dd2luc (red). The mean and SD are represented by dots and error bars, 
respectively. The estimated EC50 values are shown on each graph (see table 3.1). 
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Compound ID EC50 (µΜ) 
in 3D7 
(95% CI) 
EC50 (µΜ) 
in Dd2luc  
(95% CI) 
Chemical structure 
 
 
SK1.49 
 
 
0.8 
(0.6 to 1.0) 
 
 
1.1 
(1.0 to 1.1) 
 
 
 
SK1.47 
 
 
1.6 
(1.3 to 2.0) 
 
 
2.1 
(1.7 to 2.6) 
 
 
              
SK1.108 
 
 
3.9 
(3.0 to 5.0) 
 
 
6.2 
(5.4 to 7.1) 
 
 
 
SK1.63 
 
 
4.0 
(3.0 to 5.2) 
 
 
6.6 
(5.9 to 7.3) 
 
 
 
7315922 
 
 
4.2 
(3.3 to 5.3) 
 
 
4.9 
(3.6 to 6.5) 
 
 
 
SK1.109 
 
 
4.5 
(3.5 to 5.6) 
 
 
5.0 
(4.0 to 6.0) 
 
 
 
LO9  
 
 
7.9 
(7.0 to 8.9) 
 
 
12.5 
(10.9 to 14.2) 
 
 
 
5217339 
 
 
9.1 
(8.6 to 9.5) 
 
 
15.4 
(11.8 to 20.0) 
 
 
Table 3.1 Estimated EC50 values of the eight most potent compounds in 3D7 and Dd2
luc clones of 
P. falciparum parasite. 
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Fig. 3.6 Correlation of the mean EC50 values determined for the eight most potent compounds in 
3D7 and Dd2luc. Results of a linear regression are shown on the graph.  
 
A selected range of commercially available autophagy inhibitors were also screened to 
compare their antiplasmodial effects. These autophagy inhibitors include; DBeQ (p97 
ATPase inhibitor) (Chou et al., 2011), pyrogallol (LC3-Atg3 inhibitor) (Hain et al., 2012), 3-
MA, wortmannin, LY294002 (PI3K inhibitors) (Curran and Smith, 2014) and spautin-1 
(PI3K inhibitor) (Shao et al., 2014). EC50 values of these autophagy inhibitors were 
determined in Dd2luc using the MSF assay for 48 hrs (n=9) (Fig. 3.7). Except for DBeQ, they 
all showed a low antiplasmodial potency which correlates with previously described 
observations (Hain et al., 2012; Navale et al., 2014; Shao et al., 2014; Tomlins et al. 2013; 
Vaid et al., 2010) although these studies used a range of techniques such as SPR and PI3K 
activity assays. Only DBeQ was taken forwarded as a described autophagy inhibitor for 
comparison due to its low-micromolar (1.7 µM) EC50 value.  
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Fig. 3.7 Log10 concentration-normalised response curves for the commercial autophagy 
inhibitors against Dd2luc. The mean and SD are represented by dots and error bars, respectively. 
The estimated EC50 values are shown on each graph. 
 
3.2.3 In vitro determination of estimated 50% lethal dose (LD50) in Dd2
luc  
The EC50 data provides a key pharmacodynamic property of a compound over 48 hrs, but 
does not explain initial activity of the compound in terms of whether it is cytostatic or 
cytocidal. This killing effect can be determined using a lethality assay developed originally 
by Paguio et al. (2011). This assay is based on a modified MSF assay, but requires a 
complex procedure including drug bolus, washing and regrowth to determine the lethal 
effect after 48 hrs of additional growth in the absence of drug. However, a 
bioluminescence assay developed in our laboratory by Ullah et al. (2017) provides the 
ability to measure the viability of cells immediately after the 6 hrs drug-bolus treatment, 
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removing the need for washing and regrowth, with data from this simpler assay was 
shown to correlate with the 48 hrs MSF/wash-off assay. This parameter, termed here the 
50% Lethal dose (LD50), was determined for a range of benchmark antimalarial drugs 
which reflect distinct classes of chemical structure and mode of actions. These included; 
4-aminoquinolines (CQ, AQ, PYRD and PPQ), amino alcohols (QN and MQ), artemisinin 
derivates (DHA and ARM) and ATQ. These data will be compared against those for the 
eight most potent compounds from the library with four additional library compounds 
selected that share structural similarities to one or more of these original eight, as well as 
DBeQ as a described autophagy inhibitor.   
The assay was performed as originally described (Ullah et al. 2017), measuring the 
remaining luciferase activity after 6 hrs exposure to a serial two-fold dilution of 
drugs/compounds (Fig. 3.8 and 3.9). The data shown are the mean ± SD of three 
independent experiments, each with three technical replicates (n=9). For comparison, the 
previous EC50 determination after 48 hrs using the MSF assay is plotted on the same 
graph.  
The LD50 of seven of the benchmark antimalarial drugs (Fig. 3.8) used were previously 
reported (Ullah et al. 2017) and are in close agreement with those obtained in this study 
using the same Dd2luc clone. The data clearly show the expected right-shift of the LD50 
curves compared to the EC50 curve, a result of the effect of the drug/compound being 
exposed for different lengths of time. A similar right-shift of the LD50 curves was observed 
for a majority of the library compounds (Fig. 3.9). All LD50 values are reported in Table 3.2. 
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Fig. 3.8 Log10 concentration-normalised response curves for benchmark antimalarial drugs and 
DBeQ. The normalised response curves provide either the LD50 from a 6 hrs bioluminescence 
assay (red lines) or the EC50 from a 48 hrs MSF assay (blue lines). All values are reported on the 
graphs and in Table 3.2. The mean and SD (n=9) are represented by dots and error bars, 
respectively.  
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Fig. 3.9 Log10 concentration-normalised response curves for 12 library compounds. The 
normalised response curves provide either the LD50 from a 6 hrs bioluminescence assay (red lines) 
or the EC50 from a 48 hrs MSF assay (blue lines). All values are reported on the graphs and in Table 
3.2. The mean and SD (n=9) are represented by dots and error bars, respectively.  
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The rank order of the LD50 shift appears to show artemisinins < 4-aminoquinolines < 
amino alcohols < ATQ. This is interesting as is an exact inverse correlation of the same 
rank order when considering their relative rate of kills (Ullah et al. 2017). Here the rapid 
cytocidal action known for artemisinins and 4-aminoquinolines over the first 6 hrs 
provides a small shift (see Table 3.2 for the LD50/EC50 ratio) and contrasts with the initial 
cytostatic effect of ATQ over the first cycle of cell growth, termed a lag-phase, which 
would be captured in the 6 hrs assay performed here. The LD50/EC50 ratio for the majority 
of library compounds is between 2 and 4, ratios that would include the rapid initial 
cytocidal activity of artemisinins and 4-aminoquinolines. Of note is that the autophagy 
inhibitor DBeQ has a ratio of 3.2, well within the range that would suggest a rapid 
cytocidal effect.  
 
Compound 
ID 
EC50 (nM) 
in Dd2luc 
LD50 (nM) 
In Dd2luc 
LD50/EC50 
Ratio 
DHA 8.2 12.9 1.6 
ARM 8.1 15.4 1.9 
AQ 36.3 101.1 2.8 
PYRD 21.6 72.0 3.3 
MQ 17.0 65.3 3.8 
CQ 195.2 790.2 4.0 
PPQ 62.7 297.3 4.7 
QN 258.4 2236.0 8.6 
ATQ 10.8 10451 967.7 
Compound 
ID 
EC50 (µM) 
in Dd2luc 
LD50 (µM) 
In Dd2luc 
LD50/EC50 
Ratio 
7311494 42.2 47.5 1.1 
SK1.63 6.6 12.8 1.9 
LO8 69.1 134 1.9 
SK1.109 5.0 10.7 2.1 
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SK1.108 6.2 16.5 2.7 
7221498 19.6 60.6 3.1 
DBeQ 1.7 5.4  3.2 
SK1.49 1.1 3.6 3.3 
SK1.47 2.1 7.2 3.4 
6555142 26.4 90.2 3.4 
6596157 12.7 53.2 4.2 
7315922 4.9 35.8 7.3 
LO9 12.5 280.5 22.4 
 
Table 3.2 LD50 and EC50 values and their ratios of the benchmark antimalarials and library 
compounds.  
 
3.2.4 In vitro determination of Bioluminescence Relative Rate of Kill (BRRoK)  
 
The BRRoK assay was developed in our laboratory to provide an indication of the initial 
RoK (Ullah et al., 2017). Using fold-EC50 concentration exposures between 0.3 to 9x EC50 
provides a series of curves that demonstrate the initial concentration-dependant killing 
effect of the drug/compound tested. Comparison of these effects, using these equipotent 
concentrations, allows the relative initial killing effects for different drugs/compounds to 
be determined, particularly when benchmarked against antimalarial drugs for which 
other in vitro and in vivo RoK data is available. Given the suggestion from the LD50 
assessment that the library compounds may exhibit an initial rapid cytocidal effect, the 
BRRoK assay was used to confirm this observation.  
The BRRoK assay was done as previously described (Ullah et al., 2017), although here 
three endpoints to the assay were determined; 6 hrs (as in the original report) as well as 3 
hrs and 48 hrs. Four of the benchmark antimalarials were used; DHA, CQ, QN and ATQ as 
these represent the full range of initial RoK previously demonstrated (Fig. 3.10). The same 
assay was performed under the same conditions for the 12 library compounds for which 
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the LD50 data was done (Fig. 3.11). In all experiments each timepoint was performed as 
three technical replicates, with three biological repeats (n=9). The bioluminescence signal 
was normalised in all experiments against an untreated control at the same timepoint.  
Comparing of the 6 hrs benchmark antimalarials (Fig. 3.10) to data published by Ullah et 
al. (2017), our data provided the same rank order in terms of speed of action as follows; 
DHA > CQ > QN > ATQ. As well as a concentration-dependant effect on parasite viability, 
data here also shows a time-dependant effect. Interestingly, when ATQ is exposed for 48 
hrs, the lag-phase finished and the killing effect of ATQ becomes apparent.  The 
prediction that DBeQ would have a rapid initial cytocidal affect is demonstrated here, 
with it appearing to have an initial rate of kill between DHA and CQ. 
 
 
Fig. 3.10 BRRoK assay curves representing concentration (x-axis) and time-dependant (see key) 
killing effects for benchmark antimalarials and DBeQ. The mean and SD (n=9) normalised 
bioluminescence signal are represented by dots and error bars, respectively. 
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Fig. 3.11 BRRoK assay curves representing concentration (x-axis) and time-dependant (see key) 
killing effects for 12 library compounds. The mean and SD (n=9) normalised bioluminescence 
signal are represented by dots and error bars, respectively.  
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A similar time and concentration-dependent killing effect was observed for all the library 
compounds. The rank order ranged from 7311494 with an initial cytocidal effect most 
similar to that of DHA to LO9 which appear to be initially cytostatic with its lethal effect 
only appear after 48 hrs, essentially similar to that of ATQ (Fig. 3.11). This gross ranking 
agrees with the prediction based on the LD50/EC50 ratios (Table 3.2). The majority of the 
12 compounds, however, appear to share similar BRRoK profiles that suggest an initial 
rate of kill similar to that of CQ. This similarity may reflect that these compounds may also 
share a similar mode of action – at least with each other, if not with CQ. A more complete 
analysis between the structures of these compounds with their BRRoK data will follow in 
the discussion.    
 
3.2.5 In vitro determination of cytotoxic effects against the human HepG2 cell line 
 
 
Two of the eight best library compounds contain a thiourea motif, a known toxicity risk 
(Pingaew et al., 2013). To explore this as well as any potential toxicity risks in the other 
library compounds, an initial toxicity assay was performed using the human HepG2 cell 
line. This assay could only be done using six of the eight compounds as 7315922 and 
5217339 were not available. The toxic effect on HepG2 was assessed using the Alamar 
blue assay that relies on viable cells producing NADPH, NADH and FADH which can reduce 
the oxidized and non-fluorescent Alamar blue dye to a pink fluorescent state (Rampersad, 
2012). HepG2 cells were exposed to a 2-fold serial compound dilution in triplicate for 48 
hrs, with three biological replicates done. The fluorescence data was normalized against 
an untreated control and the mean ± SD (n=9) of relative growth plotted (Fig. 3.12). Log 
concentration-response curves were produced and the 50% cytotoxic concentration 
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(CC50) estimated, on all graphs the EC50 of the same compound against P. falciparum 
(3D7) are also shown. 
 
 
 
Fig. 3.12 Cytotoxic effects of library compounds against the HepG2 cell line using the Alamar 
blue assay. The log concentration-normalised growth curves were fitted (red line) and the CC50 
estimated (shown on each graph). The log concentration-normalised growth curves for 
antiplasmodial action (blue lines) are also shown along with the EC50 from3D7.  
  
 
The relative selectivity of these compounds against P. falciparum when compared against 
the HepG2 line was determined to provide the selectivity index (SI) (Table 3.3). Here, the 
SI is CC50 in HepG2/EC50 in 3D7. Interestingly, the two most potent antiplasmodial 
compounds, SK1.47 and SK1.49, also showed a high selectivity; SI > 90.9 and > 47.6, 
respectively, given their low cytotoxic effect against HepG2. For compound LO9, the SI 
can only be determined at > 8.0 given the maximum concentration HepG2 were exposed 
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to. As expected, the thiourea motif-contained compounds, SK1.108 and SK1.109 both 
showed high toxicity and low selectivity as a result. Surprisingly, SK1.63 showed the most 
cytotoxic effect against HepG2, despite its structural similarity to SK1.47 and SK1.49. 
 
Compound  
ID 
CC50 in HepG2 
(µM) 
EC50 in Dd2
luc  
(µM) 
Selectivity Index 
(SI) 
SK1.49 > 100 1.1 > 90.9 
SK1.47 > 100 2.1 > 47.6 
SK1.108 33.6 6.2 5.4 
SK1.109 31.1 5.0 6.2 
SK1.63 13.2 6.6 2.0 
LO9 > 100 12.5 > 8.0 
 
Table 3.3 CC50 HepG2 and EC50 values for P. falciparum 3D7 parasites. Selectivity index (SI) 
determined as CC50/EC50.  
 
 
3.2.6 Prediction of bioavailability from physicochemical properties 
 
The oral bioavailability of drugs can be predicted from their molecular properties. A range 
of observations established by Lipinski et al. (1997) and Veber et al. (2002), called 
Lipinski's rule-of-five (RO5) and Veber’s rules, respectively, explored the correlation 
between physicochemical properties of molecule and its determined bioavailability. 
According to RO5, four physicochemical criteria best describe a compound likely to give a 
chance for achieving a high oral bioavailability. These include; (i) the number of H-bond 
donor (HBD) ≤ 5, (ii) the number of H-bond acceptor (HBA) ≤ 10, (iii) the molecular weight 
(MW) ≤ 500 and (iv) a LogP (octanol-water partition coefficient) of ≤ 5. Veber’s rules are 
similar, and include two additional criteria; (i) the number of rotatable bonds (NROTB) as  
≤ 10 and (ii) that the total polar surface area (TPSA) should be ≤ 140  Å2. These 
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physicochemical properties were determined for the 56 library compounds that were 
initially demonstrated to show some antiplasmodial effect (i.e. > 50% reduction in growth 
at 50 µM) using ChemDraw Ultra 7.0 and Molinspiration software 
(www.molinspiration.com) computational tools. The combined data for each compound 
was compared to the RO5 and Veber’s rules (Table 3.4). Of the top eight compounds, four 
compounds failed the RO5 test due to their high lipophilicity (LogP > 5) suggesting that 
they would likely have low absorption and distribution in an aqueous phase. Generally, 
the majority of the rest of the compounds have a high LogP (> 4), reflecting a common 
structure around hydrophobic moieties connected with alkyl chains (Fig. 3.13) 
 
 
Compound        
ID 
 
MW
1
  
 
HBA
2
 
 
HBD
3
 
 
LogP
4
 
 
   TPSA
5
 
    (Å
2
) 
 
NROTB
6
 
 
Vol.
7
 
(Å
3
) 
 
Lipinski’s   
RO5 
 
Veber’s 
rule 
SK1.49 417.5 3 1 7.5 38.3 8 422.5 Fail Pass 
SK1.47 417.5 3 1 7.6 38.3 8 422.5 Fail Pass 
7315922 297.4 3 1 4.6 38.3 8 296.3 Pass Pass 
SK1-109 364.5 3 2 5.3 33.2 9 344.8 Fail Pass 
SK1.108 364.5 3 2 5.3 33.2 9 344.8 Fail Pass 
SK1.63 339.8 3 1 4.9 38.3 6 303.7 Pass Pass 
LO9 313.4 4 1 4.1 47.5 8 305.1 Pass Pass 
6596157 299.3 4 2 4.3 58.5 6 287.3 Pass Pass 
SK1.70 309.4 3 1 3.7 38.3 6 302.6 Pass Pass 
SK1.104 346.4 5 2 3.3 51.7 10 318.6 Pass Pass 
JM.16 334.4 3 1 3.7 32.3 4 329.1 Pass Pass 
5217339 358.5 3 2 1.8 33.8 8 369.3 Pass Pass 
SK1.64 384.2 3 1 5.0 38.3 6 308.1 Fail Pass 
ke-4a 325.4 3 2 3.5 27.2 7 310.8 Pass Pass 
SK1.107 360.4 5 2 3.6 51.7 10 335.4 Pass Fail 
JM3 346.4 5 1 2.9 58.6 6 310.7 Pass Pass 
SK1.83 381.2 3 1 4.1 38.3 6 270.2 Pass Pass 
SK1.50 365.4 5 1 4.2 56.8 8 341.3 Pass Pass 
SK1.87 347.8 4 1 4.6 55.4 8 324.8 Pass Pass 
SK1.102 300.4 3 2 3.6 33.2 9 284.3 Pass Pass 
SK1.72 315.3 5 1 3.6 56.8 8 297.3 Pass Pass 
7221498 295.4 2 1 5.2 29.1 6 304.0 Fail Pass 
ke-4d 339.5 3 2 4.1 27.2 7 327.4 Pass Pass 
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JM-15 330.4 3 1 4.1 32.3 4 316.7 Pass Pass 
SK1.35 331.4 2 1 5.8 29.1 7 331.4 Fail Pass 
ke-4e 375.5 3 2 4.7 27.2 7 354.8 Pass Pass 
SK1.85 321.4 5 1 3.0 64.6 8 284.2 Pass Pass 
JM-13 330.4 4 1 3.3 49.4 5 301.8 Pass Pass 
SK1.53 365.4 5 1 4.3 56.8 8 341.3 Pass Pass 
6555142 311.4 3 1 5.2 38.3 7 312.7 Fail Pass 
SK1.101 286.4 3 2 3.3 33.2 8 267.5 Pass Pass 
6115259 239.3 2 1 3.4 29.1 5 237.2 Pass Pass 
5522477 283.3 3 1 3.7 38.3 7 279.5 Pass Pass 
9108417 297.4 3 1 4.2 38.3 6 295.9 Pass Pass 
9090513 267.3 2 1 4.3 29.1 6 270.6 Pass Pass 
7311494 281.4 2 1 4.9 29.1 6 287.1 Pass Pass 
7737951 299.3 4 1 3.8 47.5 7 288.3 Pass Pass 
   LO8 313.4 4 1 4.3 47.5 8 305.1 Pass Pass 
9148206 329.8 5 1 3.5 56.8 8 313.8 Pass Pass 
5335716 271.3 2 1 3.8 29.1 6 258.9 Pass Pass 
7661021 373.9 4 1 4.4 55.4 6 313.2 Pass Pass 
5337355 287.8 2 1 4.4 29.1 6 267.5 Pass Pass 
5334050 332.2 2 1 4.5 29.1 6 271.9 Pass Pass 
7226051 322.2 2 1 5.1 29.1 6 281.1 Fail Pass 
7264596 322.2 2 1 4.9 29.1 6 281.1 Pass Pass 
7668219 401.5 6 1 3.8 71.0 8 370.8 Pass Pass 
5361579 306.5 4 1 2.9 35.9 6 316.1 Pass Pass 
7260078 287.8 2 1 4.3 29.1 6 267.5 Pass Pass 
5557287 322.2 2 1 5.1 29.1 6 281.1 Fail Pass 
6525395 381.4 5 1 3.6 61.7 6 346.6 Pass Pass 
7669739 443.6 6 1 3.4 78.8 6 384.9 Pass Pass 
5334466 287.8 2 1 4.3 29.1 6 267.5 Pass Pass 
7685637 368.9 4 0 4.9 32.7 2 328.5 Pass Pass 
5334325 191.2 3 2 1.1 49.3 4 184.4 Pass Pass 
5329246 271.3 2 1 3.8 29.1 6 258.9 Pass Pass 
6067284 439.3 6 2 2.2 65.9 6 343.7 Pass Pass 
 
Table 3.4 Physicochemical properties of 56 library compounds. These Include; 1Molecular weight 
(MW), 2 H-bond acceptors (HBA), 3H-bond donors (HBD), 4Log partition coefficient, a measure of 
lipophilicity (LogP), 5Total polar surface area (TPSA),6Number of rotatable bond (NROTB), 
7molecular volume. The final two columns indicate whether they meet the RO5 or Veber’s rules 
criteria for predicted bioavailability. The eight compounds explored in this study head the list in 
bold. 
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Fig. 3.13 Illustrating the correlation between compounds’ antiplasmodial potency and their 
physicochemical properties. These were represented by pEC50 versus Log partition coefficient 
(LogP, A), total polar surface area (TPSA, B) and number of rotatable bonds (NROTB, C). For 
ease, SK1.49 (red dot) and SK1.47 (blue dot) are highlighted on each graph. 
Given the importance of the total polar surface area (TPSA) and number of rotatable 
bonds (NROTB), in addition to LogP, in terms of defining the likely bioavailability, the 
correlation of these parameters with antiplasmodial activity were also explored (Fig. 
3.13B and C). Like LogP, no direct correlation was observed (regression lines show 
negligible slope or are not significant).    
3.2.7 In vitro assessment of serum albumin-drug binding for SK1.47 and SK1.49 
 
The prediction of SK1.47 and SK1.49 being highly hydrophobic (LogP > 7) would suggest 
that they would have low distribution in aqueous phase and that within blood they would 
likely bind and sequester to serum albumin. To explore this potential serum binding 
effect, the EC50 of SK1.47 and SK1.49 in Dd2
luc was repeated in a culture medium lacks 
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human serum (i.e. contained only 0.25% albumax as the 5% human serum would be 
omitted). We predicted that if a compound has affinity to bind with human serum, it 
should result in left shift in concentration-response curve (lower EC50) when the majority 
of the serum albumin was removed. The EC50 were determined in both normal (NS; 0.25% 
albumax and 5% human serum) and low serum (LS; contains 0.25% albumax only) growth 
media. SK1.47 and SK1.49 were tested along with CQ (LogP=5) as well as two additional 
compounds SK1.104 and SK1.107from the library with LogP values of 3.3 and 3.6, 
respectively. Each experiment was controlled against untreated parasites grown in the 
same medium, with each performed as technical triplicates and three biological repeats 
(n=9). The Log concentration-normalised response curve was plotted and the EC50 
estimated (Fig. 3.14).  
All compounds had lower EC50 values in LS medium, suggesting that more compounds 
were available to exert their effect in a low serum environment. The ratio of EC50 in NS/LS 
was determined for each compound (Table 3.5). Comparison of the LogP of the library 
compounds against this ratio supported a prediction that reduced lipophilicity, leading to 
reduced serum binding, would result in more compounds to affect the parasite. That is, 
the difference in EC50 NS/LS is higher for SK1.47 and SK1.49, with an almost 50% lower 
EC50. This correlation does not hold as true when CQ, with an intermediate LogP, is 
included although CQ has a distinct chemical structure to the library compounds.  
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Fig. 3.14 Log10 concentration-normalised response curves in either Normal Serum (NS, blue 
lines) or Low Serum (LS, red lines). The mean and SD (n=9) of growth relative to a matched 
untreated NS or LS control are represented by dots and error bars, respectively. 
 
 
Compound 
ID 
EC50 
(LS) 
EC50 
(NS) 
Ratio of 
EC50 
(NS/LS) 
LogP 
CQ 149 195.2 1.31 5.0 
SK1.49 0.6 1.1 1.83 7.5 
SK1.47 1.0 2.1 2.1 7.6 
SK1.104 10.1 14.7 1.45 3.3 
SK1.107 13.3 17.9 1.35 3.6 
 
Table 3.5 Reports EC50 values of the indicated compounds in Low Serum (LS) or Normal Serum 
(NS) as well as their ratio and the LogP value of each compound. 
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3.2.8 In vitro stage-dependant effects of SK1.47 and SK1.49 against asexual 
intraerythrocytic P. falciparum  
Thus far we have demonstrated that SK1.47 and SK1.49 are the most potent inhibitors of 
intraerythrocytic growth, exerting a rapid cytocidal effect that appears to be selective for 
the parasite. To establish at what stage(s) during the intraerythrocytic cycle that these 
compounds exert this cytocidal effect, a light microscopic visualising was employed. 
Microscopic observation provides an appropriate tool to understand drug susceptibility 
on the different developmental stages of the parasite (Rosenblatt et al., 2002). The 
experiment plan contains four treatment courses; 
Troph-A; commencing in mid-trophozoites (24-28hr post invasion), the parasites were 
exposed to a continuous concentration of compound that would elicit a 50% kill in 6 hrs 
(the LD50) over 48 hrs to complete one cell cycle. 
Troph-B; commencing in mid-trophozoites, the parasites were exposed to 6 hrs bolus at a 
LD50 concentration after which the parasites are washed to remove the drug and allowed 
to complete one cell cycle. 
Ring-A; commencing in mid-rings (6-12 hrs post invasion), the parasites were exposed to 
a continuous concentration of the trophozoite LD50 over 48 hrs to complete one cell cycle. 
Ring-B; commencing in mid-rings, the parasites are exposed to 6 hrs bolus at the 
trophozoite LD50 concentration after which the parasites are washed to remove the drug 
and allowed to complete one cell cycle. 
These treatment courses are summarised in Fig. 3.15. This approach allows the stage 
specific effect of SK1.47 and SK1.49 to be determined from the A-treatments, but also 
whether a developmental stage is also unaffected from the B-treatments. The latter is a 
characteristic property of CQ. CQ primarily exerts its effect on trophozoite stage parasites 
108 
 
but not ring stages (Gligorijevic et al., 2008; Yayon et al., 1983). Exposure of ring stage 
parasites to a CQ drug bolus that is removed, allows the parasites to continue developing 
normally into the trophozoite stages (Paguio et al. 2011). As such, CQ was included in this 
experimental plan as well as untreated parasites.  Each treatment was carried out in 
triplicate, starting with appropriate stage synchronised cultures of a 1-2% parasitaemia. 
Thin blood smears were collected at the start, and then after 16 hrs, 24 hrs and 48 hrs 
and Giemsa stained. At least 100 infected erythrocytes were staged at each time point. 
Fig. 3.16 shows examples of stained parasites defined as ring, trophozoite or schizont 
stages as well as those determined to be abnormal (dead or dying) following 
drug/compound treatment.  
 
 
Fig. 3.15 Experimental plan to determine the stage-dependent effects of SK1.47 and SK1.49. 
Each experiment is represented as a bar, with yellow indicating when the parasites were exposed 
to SK1.47 and SK1.49 or CQ and blue where these had been removed by washing after 6 hrs of 
exposure. The timepoints for microscopic examination are indicated above each line, as are 
examples of parasites that are untreated and show expected progression of development. 
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Fig. 3.16 Giemsa-stained images of ring, trophozoite and schizont intraerythrocytic parasites as 
well as those defined as abnormal (shrunken, uneven shape etc.).  
  
Two biological repeats of all treatments were carried out, with the data presented 
separately in Fig. 3.17 and Fig. 3.18 As these experiments were carried out on different 
days, there were likely differences in the relative proportion of age of ring and 
trophozoite synchronised cultures. 
In both biological repeats the expected development of untreated parasites was as 
expected 16 hrs, 24 hrs and 48 hrs following the start of the experiment, with the same 
stage at the start of the experiment the predominant stage after 48 hrs (Fig. 3.17 and 
3.18). The CQ gave results that were expected, specifically;  
(i) In Troph-A, there was no apparent progression to schizonts, with the 
proportion of abnormal parasites increasing, eventually to 100%, over the 
course of the experiment. 
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Fig. 3.17 Stage-dependent effects of SK1.49, SK1.47 and CQ on synchronised intraerythrocytic 
parasites (see key). See Fig. 3.15 for a description of treatments used for Troph-A, Troph-B, Ring-
A and Ring-B. The relative proportion of intraerythrocytic stage determine from Giemsa-stained 
slides taken at the indicated timepoint is shown. This panel represents data from the first 
biological replicate.  
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Fig. 3.18 Stage-dependent effects of SK1.47, SK1.49 and CQ on synchronised intraerythrocytic 
parasites. See also legend for Fig. 3.17. This panel represents data from the second biological 
replicate of this experiment. 
 
 
112 
 
(ii) Continuous exposure of rings to CQ in Ring-A results in a delayed progression 
into trophozoites. After 24 hrs, no schizonts are apparent and the proportion 
of abnormal cells increases, with 100% abnormal after 48 hrs. 
(iii) Trophozoites that are exposed to a pulse of CQ (Troph-B) appear delayed after 
16 hrs, with abnormal cells apparent. There is, however, progression into 
newly invaded rings after 24 hrs and trophozoites are the predominant stage 
at 48 hrs. The reduction in proportion of abnormal cells would result from the 
increase in healthy parasite stages after reinvasion. 
(iv) Rings that are exposed to a pulse of CQ (Ring-B) appear delayed after 16 hrs, 
but with many less abnormal cells apparent when compared to the 
trophozoite pulse. After 48 hrs, ring stage parasites are the predominant 
stage. 
Together, these data indicate that CQ primarily kills trophozoite stage parasites, with 
some effect on delaying both rings and trophozoites when provided as a pulse. However, 
removal of CQ allows the ring stages to progress, with the proportion of unaffected 
trophozoites also being capable of reinvasion. 
Exposure to SK1.47 and SK1.49 shows clear evidence of trophozoite kill following both 
continuous and pulse exposure. The effect of SK1.47 and SK1.49 contrasts with the effect 
of CQ following a pulse treatment (Troph-B), however, where we see in both biological 
replicates an absence of reinvasion and > 80% of abnormal cells, compared to < 30% after 
CQ treatment. This difference could be accounted by SK1.47 and SK1.49 having a more 
profound killing effect, although the BRRoK data would suggest they have similar RoK 
within the 6 hrs pulse. Alternatively, it could be that SK1.47 and SK1.49 are less efficiently 
removed by the washing protocol used in the pulse experiment. The ring stage 
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treatments suggest this is also unlikely. SK1.47 and SK1.49, like CQ, delay ring stage 
development and ultimately kills the trophozoites when continuously exposed (Ring-A). 
However, that SK1.47 and SK1.49 can be washed out appears to be evidenced in both 
Ring-B experiments, where a delay in development was evident, but ultimately ring stage 
parasites predominate after 48 hrs, albeit with higher proportions of abnormal cells. 
This phenomenon was further investigated using a bioluminescence based assay. SK1.47, 
SK1.49 and CQ were exposed to Dd2luc for 6 hrs at an LD50 dose. After which, the culture 
was split, one half maintaining exposure to the drug/compound and the other washed 
before being allowed to continue growth for a further 42 hrs to allow one complete cycle 
of growth. Bioluminescence signals, relative to a matched untreated control, were 
measured immediately after the drug bolus and at both 48 hrs endpoints. The experiment 
was carried out as a technical triplicate with two biological repeats (n=6) with the mean ± 
SD plotted (Fig. 3.19).  
 
Fig. 3.19 Bioluminescence assay data of trophozoite parasites treated with 50% kill  
concentration of CQ, SK1.49 and SK1.47 for 6 hrs. Following the pulse, bioluminescence was 
determined at 48 hrs following continuous exposure (unwashed) or after wash and regrowth 
(washed). The data represents mean activity ± SD normalised to an untreated control (n=6).  
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Comparison of the bioluminescence signals after the drug bolus reveals the expected 50% 
loss in bioluminescence signal following exposure to a LD50 concentration. Similarly, after 
a continuous exposure of drug/compound for 48 hrs, no bioluminescent signal is evident 
as all the parasites are dead. The pulse/wash with CQ provides a mean signal slightly less 
than that immediately after the pulse, but does suggest that parasites not killed within 
the first 6 hrs are viable 42 hrs later as the CQ has been effectively removed. The same is 
not apparent for SK1.47 and SK1.49 which both show < 20% of parasites survived the 
pulse/wash. The implications of this are discussed in the discussion. 
 
3.2.9 Proof-of-concept: SK1.47 and SK1.49 exposure affects the distribution of PfAtg8-
labelled vesicles in starved intraerythrocytic parasites 
Declaration: note that the spinning disk confocal immunofluorescence microscopy assay 
in this section was kindly carried out by Paul Roepe’s group of Georgetown University, 
USA. I contributed to the planning of the experiment and the analysis of data, but did 
not perform the spinning disk confocal microscopy or prepare the figures.  
A characteristic morphological feature of autophagy in eukaryotes is the redistribution of 
Atg8 upon starvation (Shpilka et al., 2011). Upon starvation, Atg8 is reorganised from a 
separated localization within the cytoplasm to form widely distributed puncta throughout 
the cell, these puncta representing the Atg8-labelled autophagosomes containing cargo 
for recycling under nutrient stress. Gaviria et al. (2013) showed a similar reorganisation of 
PfAtg8 in infected erythrocytes grown in starvation medium (SM) (depleted of amino 
acids). Here, immunofluorescence assay (IFA) microscopy of parasites grown in complete 
medium (CM) show a single point of PfAtg8 labelling within the parasite cytoplasm with a 
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small number of discrete puncta located elsewhere in the infected erythrocyte. Following 
starvation, large numbers of dispersed separate puncta of Atg8-labelled are located 
throughout the infected erythrocyte (see Fig. 3.20 for examples). Gaviria et al. (2013) 
were also able to show that (i) infected erythrocytes grown in complete medium exposed 
to increasing concentrations of CQ accumulated more PfAtg8-labelled puncta, 
corresponding to a proposed role of lethal concentrations of CQ in inducing an 
autophagosomal-like response and thus a potential mechanism of cell death, and (ii) that 
the number of PfAtg8-labelled puncta in starved cells decreases when exposed to the 
PI3K inhibitor 3-MA (although the concentration of 3-MA is not described). Thus, IFA of 
PfAtg8 (using an antibody originally raised against the similar Atg8 from T. gondii) imaged 
using a spinning disk confocal fluorescence microscopy, allows measurements of the 
distance of PfAtg8-labelled puncta from the DV (those > 3.5 µm from DV counted) to 
determine the effect of drugs on PfAtg8 redistribution. 
SK1.47 and SK1.49 were provided to the research team of Professor Roepe at 
Georgetown University where the Gaviria study was originally done (Gaviria et al. 2013). 
Using their IFA approach on HB3 (CQS strain), they imaged the effect of these library 
compounds on PfAtg8 redistribution in parasites grown in complete medium (CM) and 
starvation medium (SM). Images were provided to me for analysis. Initial analysis of PfAg8 
distribution in CM and SM showed the expected results (Fig. 3.20) with parasites grown in 
SM revealing large numbers of discrete puncta. Similarly, parasites grown in CM and 
exposed to increasing concentrations of CQ show a significant and concentration-
dependant effect (Fig. 3.21) as originally reported by Gaviria et al. (2013).   
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Fig. 3.20 PfAtg8 redistribution and localisation in HB3 clone of P. falciparum cultured in 
complete (CM) and starvation medium (SM) for 6 hrs. The first column from left is Differential 
Interference Contrast (DIC, brightfield imaging), the second column from left (green) is florescent-
tagged α- TgAtg8 antibody, the third column (blue) is DAPI-stained nucleus and the last column is 
overlay of DIC, Atg8 and DAPI.   
 
Fig. 3.21 Distribution of PfAtg8 puncta for HB3 strain of P. falciparum parasite cultured in 
complete medium (CM), starvation medium (SM) or CM with increasing concentrations of CQ 
(counts are from 20 cells/sample). CQ exposure at 2xEC50 lead to a significant increase in 
distributed puncta (p<0.05, ANOVA) compared to untreated CM, increasing the concentration to 
2xLD50, again leads to a significant increase in puncta numbers (P < 0.05, ANOVA) compared to 
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untreated and 2xEC50 CQ. Note, these data are consistent with observations by Gaviria et al. 
(2013). 
Exposure of HB3 infected erythrocytes, grown in CM, to 10xEC50 SK1.47 and SK1.49 
(roughly equivalent to a 2xLD50) did not result in an increase in PfAtg8-labelled puncta 
numbers or distribution (Fig. 3.22 and Fig. 3.23), an observation distinct to that of CQ. 
Exposure of infected erythrocytes to 6 hrs of SM was next done in the presence of 
increasing concentrations (2xEC50 and 10xEC50) of SK1.47 and 1.49. Here we were able to 
show that both library compounds significantly reduce (P < 0.05, ANOVA) the numbers of 
PfAtg8-labelled puncta compared to SM parasites alone in a concentration-dependant 
manner (Fig. 3.23, Fig. 3.24 and Fig. 3.25). 
 
 
Fig. 3.22 PfAtg8 redistribution and localisation in HB3 clone of P. falciparum cultured in 
complete medium (CM) for 6 hrs in the presence of 10xEC50 of SK1.47 and SK1.49. Panels 
arranged as per Fig. 3.20. 
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Fig. 3.23 Distribution of PfAtg8 puncta for HB3 strain of P. falciparum parasite cultured in 
complete medium (CM) or starvation medium (SM) with increasing concentrations of SK1.47 
and SK1.49 (counts are from 20 cells/sample). Library compound exposure at both 2xEC50 and 
10XEC50 in SM leads to a significant decrease in distributed puncta (P < 0.05, ANOVA) in 
comparison to SM only, but no significant effect on parasites grown in compound-containing CM 
in comparison to CM only (P < 0.05, ANOVA). 
 
 
Fig. 3.24 PfAtg8 redistribution and localisation in HB3 clone of P. falciparum cultured in 
starvation medium (SM) for 6 hrs in the presence of 2xEC50 of SK1.47 and SK1.49. Panels 
arranged as per Fig. 3.20. 
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Fig. 3.25 PfAtg8 redistribution and localisation in HB3 clone of P. falciparum cultured in 
starvation medium (SM) for 6 hrs in the presence of 10xEC50 of SK1.47 and SK1.49. Panels 
arranged as per Fig. 3.20. 
 
The same methodology was also used to explore the effect of the commercial autophagy 
inhibitor DBeQ, a compound thought to modulate autophagy through the inhibition of 
the p97 ATPase associated with the proteasome (Fig. 3.26). Although insufficient numbers 
of images were available for a quantitative analysis, a qualitative analysis of the IFA reveal 
that DBeQ appears to similarly reduce the numbers of PfAtg8-labelled puncta in starved 
parasites in a concentration-dependant manner 
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Fig. 3.26 PfAtg8 redistribution and localisation in HB3 clone of P. falciparum cultured in 
starvation medium (SM) for 6 hrs in the presence of increasing concentrations (2xEC50 and 
10xEC50) of DBeQ. Panels arranged as per Fig. 3.20. 
 
 
3.3 Discussion  
 
Here we describe the screening and initial characterisation of the antiplasmodial activity 
of a library of 131 compounds developed as potential modulators of autophagy in human 
cell lines (Reynisson and Richardson, pers. comm.). One specific proposed mode of action 
is that they would interfere with the interaction between Atg8 and Atg3, resulting in a 
reduction of the levels of lipidated Atg8 and affect the function and/or distribution of 
Atg8. Initial screening of the 131 compounds focussed on the identification of compounds 
that have an effect against intraerythrocytic stages, in two genetically different CQS and 
CQR parasite lines and have limited, or no, evidence of toxicity in HepG2. This screen 
provided two initial hits, SK1.47 and SK1.49, which share a similar structure (Fig. 3.27), 
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low µM potency against intraerythrocytic parasites irrespective of their CQ resistance 
phenotype (Fig. 3.5), good selectivity against HepG2 (Fig. 3.12) as well as a rapid cytocidal 
action (Fig. 3.11) against trophozoite stage of parasites (Fig. 3.17). Both compounds also 
appear to modulate the distribution of PfAtg8 when the parasites are exposed to 
starvation conditions (Fig. 3.23). 
 
 
Fig. 3.27 Structures of SK1.49 and SK1.47. 
SK1.47 and SK1.49 share structural features with other library compounds identified a 
potential priorities based on their low EC50 against intraerythrocytic stage of parasite 
(Appendix 1). Specifically, the compounds share two hydrophobic ring moieties, linked 
with an alkyl chain (preferably 6 or more heavy atoms in length) that contains either an 
amide or thiourea group. Based on modelling of compounds predicted to block PfAtg8-
PfAtg3 interactions (Hain et al., 2014, 2016), this structure would make some sense. The 
hydrophobic ends would be available to dock within the W and L hydrophobic pockets 
across the PfAtg3 interaction region of PfAtg8, with the alkyl linker providing the length 
and flexibility for these ends to dock as well as the amine or thiourea moiety available to 
form hydrogen bonds. This molecular modelling is explored in the next chapter. 
We have been cautious in how these library compounds are described – avoiding the 
term “autophagy inhibitor”. This is because classical autophagy, or macroautophagy, may 
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not be a normal function in the protozoan P. falciparum. Whilst features like autophagy 
have been described in P. falciparum (Gaviria et al. 2013), and are perhaps illustrated 
here with the increased number and distribution of Atg8-labelled vesicles on starvation 
(Fig. 3.23)- these Atg8-labelled puncta may not be autophagosomes (containing 
cytoplasmic cargo for recycling as part of a stress response) as classically described. It is 
clear that parts of the canonical autophagy components can still be found in the parasite 
genome, it may be, however, that the remaining processes have been retained for an 
alternative function. These have been suggested to include apicoplast function and 
biogenesis, recycling of organelles no longer required (reviewed in Besteiro et al., 2011) 
or the trafficking of lipid bound cargo through the parasite (Walczak et al., 2018). Based 
on these potential functions in the normal growth and development of the parasite, 
compounds SK1.47 and SK1.49 may kill the parasites by interfering with the regulation of 
PfAtg8-PE levels required for these processes rather than inducing autophagic cell death.  
The IFA data provided from our collaboration with Professor Roepe provided proof-of-
concept for SK1.47 and SK1.49 interfering with PfAtg8 redistribution. These data showed 
that, unlike CQ, SK1.47 and SK1.49 treatment did not result in an accumulation of PfAtg8-
labelled puncta in parasites grown in complete medium. Here, CQ is thought to either 
interfere directly with the trafficking of PfAtg8-labelled vesicles to the DV or by 
preventing their fusion as CQ accumulation within the DV leading to increases the pH and 
blocks this process (Gaviria et al., 2013). This is perhaps expected as SK1.47 and SK1.49 
are predicted to prevent the lipidation of PfAtg8 by PfAtg3 – therefore blocking the early 
stage of the cascade before formation of the PfAtg8-labelled puncta. That there was no 
effect compared to untreated cells in complete medium may be because the fluorescent 
imaging assay did not readily allow any potential changes in levels of PfAtg8 to be 
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detected. This instead would require a western blot – although these are challenging with 
PfAtg8 as you are comparing lipidated versus unlipidated forms, and such assays 
presented in published papers (Hain et al., 2014, 2016) are of low resolution. Instead, it 
was clear that when PfAtg8-labelled puncta are induced by starvation, the formation of 
these is reduced by SK1.47, SK1.49 and DBeQ. Although all of the components of 
autophagy cascade in P. falciparum have not been discovered yet, features that related to 
autophagy are proposed, i.e. the puncta, on starvation do exist. Whilst not explored in 
this study, it may be that the parasite has conserved some capacities to undergo some 
forms of autophagy when amino acids are limiting. Such hypothesis has been suggested in 
non-unikont parasites under starvation in which autophagy pathway can be induced in 
Atg1-independent manner (Földvári-Nagy et al., 2014). As SK1.47 and SK1.49 would block 
PfAtg8 lipidation which required in formation of these puncta, their effect in reducing the 
numbers of them is seen here (see Fig. 3.28 for model that integrates the IFA 
observations). Interestingly, the Gaviria et al. (2013) study also reports that 3-MA inhibits 
PI3K activity that required to initiate autophagosome nucleation, also reduces the 
number of PfAtg8-labelled puncta in starved parasites. The function of DBeQ in the same 
effect is less clear. DBeQ is an inhibitor of the p97 ATPase associated with the proteasome 
degradation pathway (Chou et al., 2011) and one of its effects include reduction the levels 
of lipidated Atg8. A similar or related effect in P. falciparum may also reduce the levels of 
lipidated PfAtg8 and thus block the synthesis of the PfAtg8-labelled puncta. 
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Fig. 3.28 Model of action of SK1.47, SK1.49, 3-MA, DBeQ and CQ in modulating the distribution 
of PfAtg8-labelled puncta in P. falciparum under normal and starvation stress conditions. Under 
conditions of nutrient stress, structures that may be PfAtg8-labelled autophagosomes would be 
induced and trafficked to the digestive vacuole for lysis of their contents. Under normal growth 
conditions, PfAtg8-labelled structures may function in the normal development to turn over 
organelles or traffic materials such as haemoglobin to the digestive vacuole. Under these normal 
conditions, the site of action of CQ in blocking transport or fusion of PfAtg8-labelled structures to 
the digestive vacuole would result in their accumulation – and thus result in the observed 
accumulation of dispersed PfAtg8-labelled puncta. SK1.47 and SK1.49 are predicted to act before 
the formation of these structures, and would therefore not be seen. Under conditions of nutrient 
stress where the number and distribution of PfAtg8-labelled puncta increase, the action of 3-MA 
(Gaviria et al., 2013) on the phosphatidylinositol 3-kinase (PI3K), SK1.47 and SK1.49 on PfAtg8-
PfAtg3 and DBeQ (modulating PfAtg8 levels through the inhibition of the P97 ATPase) in blocking 
the formation of these structures would result in the observed concentration-dependant 
reduction of their number and distribution. 
 
Definitive proof for the action of SK1.47 and SK1.49 in inhibiting the interaction between 
PfAtg8 and PfAtg3 are not provided by the data shown here. Attempts to gain support 
were done by providing Dr Jürgen Bosch (lead author of the Hain et al. studies) with these 
compounds for SPR. Unfortunately issues in his laboratory prevented these studies to be 
completed. He did respond to say that the initial studies suggested that the interaction of 
the PfAtg3 AIM domain with PfAtg8 was reduced in the presence of both SK1.47 and 
SK1.49. However, he also noted that the compounds also inhibited PfAtg8 dimerization in 
a control well. This could be the result of these compounds binding to PfAtg8 and altering 
125 
 
their conformation, which may in turn affects PfAtg3 binding. This may be relevant in vivo 
of the action of PfAtg8-PfAtg3 is act as a multimeric complex, noting that the crystal 
structure of PfAtg8 and AIM of PfAtg3 was a trimer (Hain et al., 2012). Dr Jürgen Bosch 
personal communications with us indicated this looked promising, but the data was not 
sufficient to demonstrate SK1.47 or SK1.49 binding to PfAtg8. Attempts to repeat these 
experiments during the course of this study did not succeed. 
An alternative approach that could be adopted here is a genetics approach following 
drug-selection pressure to generate a resistance phenotype (Flannery et al., 2013b, 
Cowell et al., 2018).  Here, whole genome sequencing of sensitive and resistant 
phenotype parasites offers the opportunity to identify potential targets based on 
association with mutations in the resistant parasite genome. Validation of the causative 
nature of these mutations in generating the resistant phenotype would require the 
specific introduction of this mutation into the sensitive parasite genotype, an editing 
technology now supported by the introduction of CRISPR-Cas9 into P. falciparum 
(Crawford et al., 2017; LaMonte et al., 2016). 
The rate of kill studies used here took advantage of our laboratory specific work in 
understanding how quickly drugs kill parasites (Ullah et al., 2017). That the compounds in 
the library were synthesised to explore their action in inhibiting protein-protein 
interactions in autophagy, this was an opportunity to explore whether structurally related 
compounds, predicted to share the same or a similar mode of action, would provide a 
similar rate of kill. Comparison of the reduction in bioluminescence after 6 hrs against the 
benchmark antimalarials shows that SK1.47 and SK1.49 have a relative initial rate of kill 
similar to that of CQ (Fig. 3.29). This is promising for a component of a future antimalarial 
combination therapy that would have to quickly reduce the parasite burden, defined in 
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Target Candidate Profile 1 (Burrows et al., 2013). Here, SK1.47 and SK1.49 meet the 
minimum essential criteria of a rate of kill at least as good as CQ. The majority of the 
compounds tested also share the same kill profile to SK1.47 and SK1.49. The exceptions 
are, however, quite interesting. SK1.108 and SK1.109, both containing the toxic thiourea 
group, both appear to have a more rapid initial rate of kill, closer to artemisinin (the ideal 
TCP criteria reference) than CQ (Fig. 3.29). Another pair of related structures that share a 
similar rate of kill is 6596157 and 6555142, differing only by the 2-O-methyl substitution 
to a phenyl ring.  
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Fig. 3.29 Comparison of 6 hrs BRRoK data for structurally related library compounds. The top 
panel illustrates the 6 hrs BRRoK data for benchmark antimalarials. The subsequent panels 
illustrate the similar or differences in initial rates of kills for the indicated structurally-similar 
compounds.  
 
 
From this comparison, that closely related structures share the same rate of kill does not 
appear to be true all the time. Comparison of the rates of kill of LO8 and LO9, with a small 
difference in the 2,3 versus 2,4 organisation of the O-methyl substitutions to a phenyl 
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ring, reveal a dramatic difference in rate of kill (Fig. 3.29). LO8 has a rate of kill more 
comparable to artemisinins, with LO9 essentially being cytostatic over the first 6 hrs. 
Similarly, although without as large a difference in the rate of kill, is a comparison of 
7221498 (similar to CQ) and 7311494 (similar to artemisinin) where the compounds differ 
by the difference of one carbon length in the alkyl linker (Fig. 3.29). This may be a useful 
observation if taken forward to develop modifications to these compounds to improve 
their activity. Currently, only SK1.47 and SK1.49 have been shown to affect PfAtg8 
distribution. It would be interesting to see whether compounds that have a different rate 
of kill, e.g. LO8 and LO9, also similarly affect PfAtg8 redistribution. If it were the case that 
they did not, then it would be relatively easy to screen both the EC50 and BRRoK activity 
of many derivatives, with the BRRoK assay acting as a simpler marker of what could be 
expected from the more complex PfAtg8 IFA.   
SK1.47 and SK1.49 appear to have trophozoite stage-dependent effects, suggesting that a 
target of normal PfAtg8 function exists at this stage. This may correlate with a role in 
increased vesicular trafficking in the growing trophozoite or an additional demand for 
fatty acids or isoprenoids from the apicoplast, all presumably requiring PfAtg8. The 
observation that a pulse of either compound at trophozoites is not reversible, or at least 
not as much as that from a pulse of CQ, is interesting. This could be due to both 
compounds not being readily removed by washing. Although more lipophilic, these 
compounds could be removed after a pulse in ring stages. Perhaps then, the effect of 
these compounds in the 6 hrs exposure is more rapid than that of CQ – but this is not 
really evident from the BRRoK assay data. This non-reversible effect cannot be readily 
explained either by its structure – with no moiety that could lead to a covalent bond 
forming to the target, in the same way that artemisinin forms covalent adducts when the 
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endoperoxide bond is broken. Whilst it is clear that SK1.47 and SK1.49 preferably kill the 
trophozoite stages, more work in identifying potential targets from transcriptomic, 
proteomic and metabolic approaches are needed to try and understand the mode of 
action at this stage. 
At the moment, we would suggest that SK1.47 and SK1.49 are very preliminary hits. They 
show only moderate potency against intraerythrocytic stages- but this activity is also 
rapidly cytocidal, reasonably selective and shown to affect PfAtg8 redistribution (a novel 
target). These compounds are perhaps best described as “chemical probes” that could be 
exploited at this stage to explore the function of PfAtg8 – particularly to define whether 
autophagy-like processes are active in the normal development of parasites. The role of 
PfAtg8 in apicoplast function and whether autophagic processes turnover specialist 
organelles after invasion would be obvious initial targets for these chemical probes. In 
terms of drug development, the high LogP is a particular risk for these compounds, 
restricting its bioavailability. Exploring how modifications can be made to the 
hydrophobic ends (e.g. how hydrophobic do they need to be?) or modifications to the 
alkyl linker may offer the opportunity to reduce the LogP, potentially increasing the 
potency and provide a hit to be taken forward for proper development.  
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Chapter 4: Molecular Modelling to explore ligand docking to PfAtg8 
 
4.1 Introduction  
Lipidation of Atg8 with phosphatidylethanolamine (PE) in eukaryotes requires an 
interaction with the ubiquitin-like conjugating enzyme Atg3 (Brennand et al., 2011; Hayat, 
2014; Nakatogawa et al. 2009; Xie and Klionsky, 2007). This interaction takes place 
between the Atg8 family interacting motif (AIM) of Atg3 and a conserved docking surface 
of Atg8 that contains two deep hydrophobic pockets, the W and L-pockets. The 
conservation of these features in P. falciparum was confirmed by X-ray crystallography of 
a PfAtg3 AIM peptide docking to PfAtg8 (Hain et al., 2012).  
Despite the only 54% conservation of amino acids between PfAtg8 and the human 
homologue (microtubule-associated protein 1A/1B-light chain 3, hLC3), there is a broad 
secondary and tertiary structural similarity between these proteins (Fig. 4.1). Importantly, 
the PfAtg3 AIM docking region is consistent with that of hLC3 in terms of existence the W 
and L-pockets, within a positively charged electrostatic surface (Fig. 4.2). Whilst there are 
structural similarities, several differences are found; 
(i) The amino acids that form the PfAtg3 AIM docking regions are distinct 
between PfAtg8 and hLC3. 
(ii) The size of Atg3 AIM docking pocket is larger in PfAtg8 at 511Å3 compared to 
403 Å3 in hLC3. This is reflected in a larger W and L-pocket of PfAtg8, which are 
377 Å3 and 271 Å
3 in size, respectively.  
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Fig. 4.1 Conservation between PfAtg8 and the human hLC3 homologue. (A) Sequence alignment 
of the primary and secondary structures of 10 apicomplexan Atg8 with homologues from human 
and budding yeast illustrates the conservation of secondary structural features amongst these 
Atg8 proteins. The position of alpha-helices and beta-sheets are shown over the primary 
sequences, Note the yellow highlighted insertion – termed the Apicomplexan loop found only in 
the apicomplexans in the alignment. (Source: Hain et al., 2012). (B) Comparison of the tertiary 
structure illustrates the structural similarity between PfAtg8 and hLC3 (with the Atg3 AIM 
illustrates as a green stick projection. Note the A-loop insertion (yellow) forms a novel tertiary 
structure in PfAtg8 features, forming an adjacent novel A-loop pocket (A-site) (Source: Hain et al., 
2016).  
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Fig. 4.2 Structural models of P. falciparum Atg8 (PfAtg8) and human LC3 (hLC3). The images in 
the top panel were generated here using the UCSF Chimera 1.11.2 software 
(www.cgl.ucsf.edu/chimera/) and are compared here to images illustrating the positive 
electrostatic charge (blue) found around the W and L-pockets in both PfAtg8 and hLC3 from Hain 
et al. (2012). The electrostatic surface potential indicates that a positively charged band in PfAtg8 
is tilted by 56° compared to only 2° in hLC3.  
 
(iii) There is a significant difference in the tilt of the positively charged band over 
the Atg3 AIM docking region. 
(iv) The existence of the A-loop in PfAtg8, a critical region for PfAtg3 AIM docking 
(Hain et al., 2012), which is not located within the docking region, creates a 
large (513Å3) A-loop pocket next to this projection. This A-loop is lacked in the 
hLC3.  
The amino acid residues of the PfAtg3 AIM lay over the docking region, with the side 
chain of tryptophan 105 (TRP105) projecting into the W-pocket and the side chain of 
proline 108 (PRO108) projecting into the L-pocket (Fig. 4.3). These interactions are 
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stabilised by hydrogen bonds to lysine 48 (LYS48) and leucine 50 (LEU50) of PfAtg8 (Hain 
et al., 2012).  
 
Fig. 4.3 Modelling the interaction of PfAtg3 AIM into its docking site on PfAtg8.  On the left, the 
hydrogen bonds (H-bond) formed between LYS48 and LEU50 of PfAtg8 (brown sticks) with the 
PfAtg3 AIM (blue sick) are illustrated. On the right, the X-ray crystallography of PfAtg8 with PfAtg3 
AIM (stick form), the projection of the side chains of TRP105 and PRO108 of PfAtg3 AIM into the 
W and L-pockets of PfAtg8, respectively, as illustrated. Both images prepared using UCSF 
Chimera 1.11.2 software (www.cgl.ucsf.edu/chimera/).  
 
Disruption of protein-protein interaction (PPI) using small molecules or peptides have 
been demonstrated to modulate biochemical pathways and has some therapeutic 
potential (Sable and Jois, 2015; Scott et al., 2016). This approach is usually supported by 
X-ray crystallography of the target protein to explore its structure and determine putative 
binding residues (or binding centres) for ligands which can be then exploited using 
computational analysis methods (Capra et al., 2009). PfAtg8-PfAtg3 interaction is an 
example for this approach, where reported by Hain et al. (2016) using the ChemBridge 
library. Here, they identified ALC25 compound which binds to the A-pocket of PfAtg8 (Fig. 
4.4).  Previous work by this research team had also screened the MMV Malaria Box to 
identify MMV007907 (termed in their study compound 1) which binds across the PfAtg3 
AIM docking site, with a pyridine moiety docked into the L-pocket and a methylbenzene 
group bound into the W-pocket (Fig. 4.5) (Hain et al., 2014).  
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Fig. 4.4 Modelling of ACL25 docking into the A-pocket of PfAtg8.  (Source: Hain et al., 2016) 
 
 
 
 
 
 
Fig. 4.5 Modelling of compound 1 docking into the W and L-pockets of PfAtg8. Note that 
alternative docking simulations are shown in the inset in different colours, This model developed 
by constraining the modelling through selecting LYS47 of PfAtg8 as a binding centre for ligand 
(Source: Hain et al., 2014). 
 
Based on availability of the crystal structure of PfAtg8, the opportunity to model hits from 
the compound library against this target was attempted here. It was decided to use a 
commercially available online drug discovery platform called Mcule software 
(Mcule.com). This is an accessible molecular docking program, supported with online 
tutorials and was available for a paid licence fee. The aim of the study is to explore how 
modelling of interactions between our hits and PfAtg8 would provide information about 
135 
 
docking status of these compounds. This information would then be used to look at the 
antiplasmodial activity data for the compounds screened in chapter 3 and start to explore 
how the structure of the compounds can be exploit to define the interaction between 
compound and PfAtg8. This probably allows understanding how the structure is 
potentially related to the activity of the compounds screened. 
4.2 Results and discussion  
4.2.1 Workflow for modelling studies and initial validation  
The Mcule docking models of the small molecules against protein targets are provided in 
a Protein Data Bank (PDB) format. PDP files for PfAtg8 and hLC3 were available in PDB 
files 4EOY and 2ZJD, respectively. For both of these files, the respective protein structures 
are available as multimers – PfAtg8 bound to the AIM of PfAtg3 is present as a trimer (Fig. 
4.6) and hLC3 bound to p62 is present as a dimer. By using the free online software UCSF 
Chimera 1.11.2 (www.cgl.ucsf.edu/chimera/), these PDB could be imaged and peptide 
chains that not required were removed and a single chain of PfAtg8 and hLC3 saved and 
uploaded into the Mcule database as a new PDB files.  
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Fig. 4.6 PDB file 4E0Y shown using UCSF Chimera 1.11.2 imaging tool. Here the PfAtg8-PfAtg3 
AIM complex represents 6 chains in which 3 chains of each molecule were co-crystallized. Three 
PfAtg3 chains and two PfAtg8 chains are removed to prepare the final PDB file of PfAtg8 for the 
Mcule software. 
 
The structures of the library compounds to be explored in the modelling were provided as 
Simplified Molecular entry Input Lines Entry System (SMILES) formats produced using the 
ChemWriterTM 2.15.2 screen of the Mcule software. Mcule requires the selection of 
binding centres to restrain the docking simulation; these binding centres are amino acids 
in the protein structure (PfAtg8) (Fig. 4.7). For this study, three binding centres were 
selected based on the current knowledge about the PfAtg3 AIM binding with PfAtg8. 
These were included; LYS48 and LEU50 based on their formation of hydrogen bonds to 
the PfAtg3 AIM peptide and LYS47 based on its formation of hydrogen bonds to 
compound 1 (Hain et al., 2012, 2014). Each of these binding centres contains a number of 
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binding points – heavy atoms within the chain that may act as hydrogen bond donors or 
acceptors. Lysine amino acid contains eight binding points, and leucine has seven (Fig. 
4.8). 
 
Fig. 4.7 Selection of amino acids within PfAtg8 as binding centres for Mcule docking simulations. 
The image on the left is a ribbon representation of PfAtg8, with the three binding centres of as 
lysine 47 (LYS47, green), lysine 48 (LYS48, yellow) and leucine 50 (LEU50, red). The space 
occupying model to the right shows the position of these binding centres relative to the W and L-
pockets.  
 
 
Fig. 4.8 Chemical structure of lysine (LYS) and leucine (LEU) amino acids. The eight or seven 
heavy atom binding points within LYS and LEU, respectively, are identified with black stars. 
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With three binding centres providing a total of 23 binding points, the Mcule software 
predicts for each binding point four top poses (Fig. 4.9), providing 92 docking simulations 
for each compound over these three binding centres. Each simulation provides a docking 
score – this is a score of predicted binding affinity of the ligand to PfAtg8 using an energy 
component method which attempts to minimise the energy required for this interaction, 
an approach widely used in docking simulation software (Kroemer, 2007). As such, the 
lower score meaning the more likely that interaction occurs as modelled. 
 
Fig. 4.9 Example docking of SK1.49 to the C385 binding point of LYS48 within PfAtg8. The images 
represent the top four ranked docking poses for SK1.49 to this binding point on LYS48. The poses 
are ranked in their relative docking score rank, with pose 1 the highest ranked, and pose 4 the 
lowest ranked.   
 
The pose of the ligand provided the following data that was recorded in appendix 3. 
These are included; the docking score, the potential to form a hydrogen bond (and to 
which binding centre) as well as a pose prediction in terms of docking into the W and L-
pockets. As an example in Fig. 4.9, poses 1 and 2 dock within both pockets (W and L-
pockets), whereas poses 3 and 4 only docking within the W-pocket. Docking Simulations 
were carried out for (i) SK1.47 and SK1.49 as the best hits in the compound library, (ii) 
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SK1.108 and SK1.109 as whilst toxic, they were potent inhibitors of intraerythrocytic 
growth and share the naphthalene moiety with SK1.47 and SK1.49, (iii) SK1.63 is also 
moderately potent (EC50 of 4 µM) against intraerythrocytic stages and also shares a 
naphthalene moiety and (iv) compound 1 from the Hain et al. (2014) study that was 
predicted to bind into the PfAtg3 AIM docking site. The highest scoring pose (i.e. best 
docking score) of the 92 simulations performed for each compound, are shown in Fig. 
4.10. In addition, molecular docking of SK1.49 and compound 1 with hLC3 were 
performed against the equivalent binding centres in hLC3. Together, over 1100 docking 
simulations are reported here.  
 
Fig. 4.10 The top scoring docking pose for the compounds modelled for binding to PfAtg8. Note 
the docking score is provided in brackets for each compound.   
 
Compound 1 was included as previous modelling of its interaction with PfAtg8 had been 
reported (Hain et al., 2014) using the OpenEye software package. In this work, the 
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prediction of compound 1 to interact with PfAtg8 (bound to the LYS47 binding centre) 
reports that the pyridine ring of compound 1 is occupied the L-pocket, the 
methylbenzene group lies across the W-pocket and the thiazole ring is positioned 
between the 2 pockets as a bridge. This simulation is not the best docking pose that 
predicted using Mcule package (Fig. 4.10), where the pyridine ring of compound 1 placed 
in the W-pocket and the methylbenzene group projects away towards the A-pocket. The 
Mcule prediction, however, of the top score docking poses provided alternative docking 
simulation to that described by Hain et al. (2014), and the OpenEye prediction is one of 
the lower ranked Mcule poses using the LYS47 binding centre (Fig. 4.11). Also, another 
slight difference is that whilst the OpenEye software predicts a H-bond to LYS47 using this 
amino acid as the binding centre, Mcule, using the same binding centre, instead predicts 
two H-bond – neither to LYS47, instead these forming with LYS48 and LEU50 (Fig. 4.12). 
These data suggest that similar modelling data can be obtained with Mcule in modelling 
compound 1 interaction with PfAtg8 – but also a need to recognise that these are models 
and that modification within these models need to be considered carefully in any 
discussion about ligand interactions with PfAtg8. 
 
Fig. 4.11 Comparison of docking models from Mcule (left) and OpenEye (right; Hain et al., 2014) 
for compound 1 interaction across the W and L-pockets of PfAtg8. Note that whilst the OpenEye 
data are the best docking scores for the LYS47 binding centre, those for Mcule on the right are 
not. 
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Fig. 4.12 Stick model projection of the H-bond predictions of Mcule docking of compound 1 to 
PfAtg8. H-bonds to compound 1 from O383 and N400 binding points of carbonyl and amino 
groups of LYS48 and LEU50 binding centres, respectively. This pose developed using the O374 
binding point of the LYS47 binding centre- the equivalent centre that predicts a H-bond to LYS47 
using the OpenEye software by Hain et al., (2014). 
 
4.2.2 Ligand docking to PfAtg8  
As indicated earlier, 92 docking poses are available for each compound docked to PfAtg8. 
These are the top four scoring docking poses for each binding point within the three 
binding centres that chosen. For each pose, the docking score, the potential to form a H-
bond and whether the ligand docked within the W and L-pockets were recorded (see 
appendix 3). Given the number of docking poses available, the data presented for each 
ligand here is the top scoring docking pose for the eight binding points in LYS47 and LYS48 
and the seven binding points for LEU50. These are presented as stick images, without 
PfAtg8, to allow variations in ligand position to be clearly seen (see Fig. 4.13 as an 
example). To provide context, the final merged image of all the top scoring docking poses 
includes X-ray crystallography of PfAtg8, with the W-pocket at the top of the images and 
the L-pocket at the bottom. In these images, the A-pocket would be located to the left. A 
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summary schematic is used to present what is the most common orientation of the ligand 
with respect to the W and L-pockets based on all the docking poses available. 
 
Fig. 4.13 SK1.49 and SK1.47 docking to PfAtg8. (A) Panels left to right represent the top scoring 
docking pose to the eight or seven binding points present in LYS47/48 or LEU50, respectively, for 
the indicated compound (with EC50 also indicated). For each binding centre these are shown 
separately, with a final merged image that includes the model of PfAtg8. The W-pocket at the top 
and the L-pocket at the bottom. (B) and (C) Show a schematic representing the apparent 
preferred docking of the ligands to the W and L-pockets.   
 
SK1.47 and SK1.49 provide the most consistent ligand docking poses using the LYS48 and 
LEU50 binding centres with all poses docking closely together. This was more clearly for 
the more potent, SK1.49 (Fig. 4.13). This molecular docking predicted that the 
naphthalene group docks within the larger W-pocket, with the amine/alkyl chain forming 
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a bridge between two hydrophobic pockets, whilst L-pocket occupied by the trimethyl 
substitution of the phenyl ring. For SK1.49, the 4-trimethyl substitution is clearly 
preferred, with a slight preference in SK1.47 for the 2-trimethyl substitution positioned in 
the L-pocket. This would suggest that the difference in spacing which is provided by the α 
or β naphthalene in SK1.49 and SK1.47, respectively, determines how the 2, 4-trimethyl 
substitutions present in both molecules docks into the L-pocket. Additionally, the amine 
group, in both cases, forms a H-bond to LYS48, although not consistently for all the 
docking poses.  
Docking of the next two most potent compounds, SK1.108 and SK1.109, supports the 
previous preference for positioning of the naphthalene group in the W-pocket, with both 
compounds sharing an α naphthalene group (Fig. 4.14). The unsubstituted phenyl group 
at the other end of the ligands is typically positioned in the L-pocket. The data showed 
that formation of H-bond by both amine groups within the thiourea of the linker region is 
specified to LYS48. A third library compound containing an α naphthalene group, SK1.63 
(EC50 of 4 µM), was also modelled to explore this preferential location of the naphthalene 
group in the W-pocket (Fig. 4.15). Interestingly, this preference here was less clear, with 
variation in the orientation at high scoring docking poses producing a new docking 
simulation by which 3-chlorophenyl group positioned into the W-pocket. This alternate 
orientation may reflect that the modelling is attempting to fit the large 3-chlorophenyl 
group in the larger W-pocket. Interestingly, where the 3-chlorophenyl group is docked in 
the W-pocket, the naphthalene group is rarely located in the L-pocket, suggesting this 
large group may not fit in this smaller pocket (L-pocket). 
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Fig. 4.14 SK1.108 and SK1.109 docking to PfAtg8. (A) Panels left to right represent the top scoring 
docking pose to the eight or seven binding points present in LYS47/48 or LEU50, respectively, for 
the indicated compound (with EC50 also indicated). For each binding centre these are shown 
separately, with a final merged image that includes the model of PfAtg8. The W-pocket at the top 
and the L-pocket at the bottom. (B) and (C) Show a schematic representing the apparent 
preferred docking of the ligands to the W and L-pockets.     
 
Analysis of the top scoring docking poses of compound 1 (MMV007907) identified from a 
screen of the MMV Malaria Box (Hain et al., 2014) shows a consistent orientation of the 
pyridine ring in the W-pocket and the docking of the 4-methylphenyl group away from 
the L-pocket (Fig. 4.15). This group, 4-methylphenyl, is now orientated towards the A-
pocket. Such orientation was observed by Hain et al. (2016) in a subsequent study, where 
they identified ACL25 compound that is predicted to bind within this A-pocket. These 
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observations lead us to suggest that linking of these two compounds together may 
provide a highly specific inhibitor of the PfAtg8-PfAtg3 interaction.  
 
Fig. 4.15 SK1.63 and Compound (Comp.) 1 docking to PfAtg8. (A) Panels left to right represent 
the top scoring docking pose to the eight or seven binding points present in LYS47/48 or LEU50, 
respectively, for the indicated compound (with EC50 also indicated). For each binding centre these 
are shown separately, with a final merged image that includes the model of PfAtg8. The W-pocket 
at the top and the L-pocket at the bottom. (B) and (C) Show a schematic representing the 
apparent preferred docking of the ligands to the W and L-pockets. Note for SK1.63 that the 3-
chlorophenyl group may occupy either the W or L-pocket. For Comp.1, the 4-methylphenyl group 
is positioned away from the L-pocket, and is now orientated towards the A-pocket.  
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The last two compounds docked were LO8 and LO9 (Fig. 4.16). Although these two 
compounds differ just on the basis of the position of one O-methyl substitution, with 2,4-
O-methyl in LO8 and 2,3-O-methyl in LO9, were shown in chapter 3 to have very distinct 
potencies against the intraerythrocytic trophozoite stages and initial kill dynamics.  
 
Fig. 4.16 LO8 and LO9 docking to PfAtg8. (A) Panels left to right represent the top scoring docking 
pose to the eight or seven binding points present in LYS47/48 or LEU50, respectively, for the 
indicated compound (with EC50 also indicated). For each binding centre these are shown 
separately, with a final merged image that includes the model of PfAtg8. The W-pocket at the top 
and the L-pocket at the bottom. (B) and (C) Show a schematic representing the apparent 
preferred docking of the ligands to the W and L-pockets. Note for LO8 that the 2,4-O-
methyphenyl group may occupy either the W or L-pocket. However, for LO9 the 2,3-O-
methylphenyl is preferentially located in the L-pocket. 
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This molecular modelling revealed that the less potent LO8 adopted two main 
orientations, with the O-methyl substituted and unsubstituted phenyl groups located in 
either of the W and L-pockets. This docking simulation, however, was not observed in 
LO9, where the 2, 3-O-methyl phenyl group predicted to bind with L-pocket only. This 
suggests that steric hindrance based on the move from the meta to the para position for 
one of the O-methyl substitutions may play a role in how these molecules dock with 
PfAtg8. 
So far the analysis of docking data has explored how these ligands may interact with the 
PfAtg3 AIM docking region of PfAtg8, particularly with respect to the W and L-pockets. 
Each docking simulation also produces a docking score. Whilst recognising the evidence 
that agreements between docking score and compound activity rarely correlate (Grinter 
and Zou, 2014; Liu et al., 2013; Sakano et al., 2016), this was observed here for the 
compounds that structurally related. Table 4.1 reports the top docking score for each 
binding point for the three binding centres chosen (this data summarised from appendix 
3). In addition, the top scoring docking poses that include evidence of H-bond formation 
were highlighted in green. Interestingly, this highlighting clearly shows the lack of 
correlation between predicted H-bond formation and compound activity. For example, 
whilst SK1.47 and SK1.49 are the most potent compounds, but they provided the lowest 
scoring of H-bond formation. Contrastingly, this feature was greater with lower potent 
compounds such as SK1.108 and SK1.09. This may be due to exist thiourea group, and 
with two hydrogen bonds donating amines are more likely to be predicted to form H-
bonds. The same is also seen for compound 1 which includes more hydrogen donating 
and accepting groups than both SK1.47 and SK1.49. To simplify this analysis, only the 
mean of top scoring for each of the three binding centres was chosen (Table 4.2).
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                           (A) 
Target (PfAtg8) 
 Binding points in LYS48 Binding points in LEU50 Binding points in LYS47 
Comp. 
ID 
N- 
380 
C-
382 
O-
383 
C-
384 
C-
385 
C-
386 
C-
387 
N-
388 
N-
400 
C-
402 
O-
403 
C-
404 
C-
405 
C-
406 
C-
407 
N-
371 
C-
373 
O-
374 
C-
375 
C-
376 
C-
377 
C-
378 
N-
379 
SK1.49 -7.9 -7.9 -7.9 -7.9 -8.0 -7.9 -7.9 -7.9 -7.9 -7.9 -7.8 -7.9 -7.9 -8.0 -8.0 -7.9 -7.9 -7.9 -7.7 -7.9 -7.6 -7.1 -7.3 
SK1.47 -8.3 -8.3 -8.5 -8.2 -7.8 -8.5 -8.3 -8.3 -8.5 -8.0 -8.1 -8.5 -8.3 -8.3 -8.0 -8.3 -8.3 -8.3 -8.4 -8.3 -7.9 -7.5 -6.1 
SK1.108 -7.2 -7.6 -7.4 -7.3 -7.4 -7.4 -7.4 -6.8 -7.4 -7.0 -7.4 -7.3 -7.4 -6.8 -7.3 -7.6 -7.2 -7.4 -7.0 -7.2 -7.1 -7.2 -6.2 
SK1.109 -7.0 -7.6 -7.4 -7.2 -7.2 -7.5 -7.5 -6.8 -7.2 -7.2 -7.5 -7.4 -7.6 -7.0 -7.4 -7.2 -7.5 -7.1 -7.5 -5.8 -5.6 -5.9 -6.8 
SK1.63 -6.7 -6.7 -6.3 -6.3 -6.2 -6.1 -6.2 -6.1 -6.6 -6.4 -6.3 -7.3 -6.2 -6.3 -6.2 -6.1 -6.8 -6.5 -6.6 -6.2 -6.6 -6.3 -6.5 
LO9 -6.6 -6.5 -6.4 -6.6 -6.6 -6.6 -6.6 -6.8 -6.5 -6.4 -6.5 -6.1 -6.8 -6.8 -6.2 -6.5 -6.6 -6.1 -6.0 -6.0 -6.1 -6.4 -6.2 
LO8 -5.6 -6.2 -6.4 -6.2 -6.2 -5.8 -6.2 -5.2 -6.1 -5.8 -6.3 -6.1 -6.4 -6.3 -6.0 -6.3 -5.8 -6.0 -6.0 -5.2 -6.0 -5.4 -5.2 
Comp.1 -6.5 -6.3 -6.3 -6.3 -6.4 -6.3 -6.4 -6.5 -6.4 -6.0 -5.9 -5.9 -6.0 -5.9 -5.9 -6.3 -6.4 -6.6 -6.4 -6.4 -6.0 -6.0 -6.4 
 (B) 
Target (human LC3) 
 Binding points in LYS51 Binding points in LEU53 Binding points in LYS49 
Comp. 
ID 
N-
429 
C-
431 
O-
432 
C-
433 
C-
434 
C-
435 
C-
436 
N-
437 
N-
449 
C-
451 
O-
452 
C-
453 
C-
454 
C-
455 
C-
456 
N-
413 
C-
415 
O-
416 
C-
417 
C-
418 
C-
419 
C-
420 
N-
421 
SK1.49 -6.8 -7.3 -7.3 -7.3 -6.7 -7.3 -7.0 -6.8 -7.6 -7.6 -7.5 -7.3 -7.4 -7.0 -7.0 -7.0 -7.4 -6.6 -7.3 -7.3 -7.2 -6.6 -6.4 
Comp.1 -6.8 -6.7 -6.8 -6.7 -6.5 -6.6 -6.6 -6.7 -6.7 -6.2 -6.7 -6.4 -6.7 -6.7 -6.6 -6.7 -6.4 -5.9 -6.7 -6.7 -6.6 -5.5 -5.5 
 
Table 4.1 Summary of top docking scores for each binding point within the three binding centres chosen for modelling of ligand interaction with (A) 
PfAtg8 and (B) hLC3. Where the top docking pose for the respective binding centre also includes the formation of a H-bond, the docking score is highlighted 
in green. 
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Table 4.2 Shows the mean of top scoring for each of the three docking centres for ligand 
docking to PfAtg8.  The EC50 values used for the subsequent correlation were from the 3D7 strain 
of P. falciparum.  
 
In Fig. 4.17, a clear trend between the docking score and the in vitro activity against 
intraerythrocytic parasites for the library compounds can be seen. The most potent 
compounds, SK1.47 and SK1.49, have lower docking scores, indicating better predicted 
docking, than the less potent LO8 and LO9. This is encouraging, as it suggests that there 
are correlation between docking score and antiplasmodial activities. Caution in over-
interpreting due to that this trend comes from (i) the relatively few compounds were 
used to explore this trend and (ii) that compound 1 does not follow this trend. Compound 
1 has lower docking scores, but has an in vitro potency similar to that of SK1.47 and 
SK1.49 and although it is clearly distinct in its structure compared to the library 
compounds explored.  
Comp. ID EC50 (µM) 
in 3D7 
LYS48 LEU50 LYS47 
SK1.49 0.8 -7.91 -7.91 -7.66 
SK1.47 1.6 -8.27 -8.24 -7.88 
SK1.109 4.5 -7.27 -7.32 -6.67 
SK1.108 3.9 -7.31 -7.22 -7.11 
SK1.63 4.0 -6.32 -6.47 -6.45 
LO8 57.0 -5.97 -6.14 -5.73 
LO9 7.9 -6.58 -6.47 -6.23 
Comp.1 1.4 -6.37 -6.01 -6.31 
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Fig. 4.17 Exploring the correlation between the mean of top scoring for each of the three 
docking centres and the intraerythrocytic potency of the modelled library compounds. The top 
docking scores for the three binding centres (LYS47, triangle; LYS48, circle and LEU50, square) 
used for each compound are plotted against the Log10 of their EC50 determined against 
intraerythrocytic trophozoites of the 3D7 strain of P. falciparum. 
 
4.2.3 Docking SK1.49 and Compound 1 to hLC3  
Both SK1.49 and compound 1 show some selectivity in intraerythrocytic parasites over 
human HepG2 cell lines (Chapter 3 for SK1.49 and Hain et al., 2014 for compound 1). To 
provide an initial exploration of how this selectivity may arise, and given the apparent 
differences in the Atg3 AIM docking regions between PfAtg8 and hLC3, the molecular 
docking were repeated using hLC3, with the homologous binding centres in hLC3 (LYS49, 
LYS51 and LEU53) for those originally selected in PfAtg8. As with PfAtg8, docking scores, 
orientation over the W and L-pockets and H-bond predictions were recorded in appendix 
3 with the top docking scores summarised in Table 4.1. The same method of showing the 
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top scoring for docking poses for binding points in the LYS49, LYS51 and LEU53 binding 
centres was used here – with panels comparing the docking simulations for each 
compound against PfAtg8 and hLC3 shown over each other (Fig. 4.18 and 4.19). 
 
 
Fig. 4.18 Docking of SK1.49 to PfAtg8 (top panels) and hLC3 (bottom panels). Panels left to right 
represent the top scoring docking pose to the eight or seven binding points present in LYS47/48 
and LEU50 for PfAtg8 and their homologous binding centres LYS49/41 and LEU53 in hLC3. A final 
merged image that includes the model of PfAtg8 or hLC3. The W-pocket at the top and the L-
pocket at the bottom. 
 
Docking of SK1.49 to hLC3 suggested that whilst the naphthalene group is still 
preferentially located in the W-pocket, the 2,4,-trimethyl substituted phenyl group did 
not consistently occupied the L-pocket as like as PfAtg8 (Fig. 4.18). Instead, across all 
binding centres, the top scoring docking poses for each binding point adopt a range of 
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conformations, and these all have a lower docking score than the comparable binding 
points in PfAtg8 (Table 4.1). It appears that the differences in this Atg3 AIM docking 
region between PfAtg8 and hLC3 could be potentially exploited to provide selectivity for 
inhibition of the parasite PfAtg8-PfAtg3 interaction.   
Molecular modelling with compound 1, similarly reveal interesting differences (Fig. 4.19). 
Hain et al., 2014, report a selectivity index of 13.0 for this compound. According to their 
study, the pyridine group of compound 1 docks into the L-pocket of PfAtg8 and the 4-
methylphenyl group projects into the W-pocket. Interestingly, a similar docking 
simulation for compound 1 against hLC3 was obtained, where the 4-methylphenyl group 
appear to tend to dock into the W-pocket, with the pyridine group orientated towards 
the L-pocket. Whilst the docking scores for the top docking poses for each binding points 
in PfAtg8 and hLC3 do not show the same clear difference that they do for SK1.49 (Table 
4.1). The very different predictions of orientation of binding between SK1.49 and 
compound 1 may provide the basis for selectivity of compound 1 against P. falciparum 
over HepG2. 
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Fig. 4.19 Docking of compound 1 to PfAtg8 (top panels) and hLC3 (bottom panels). Panels left to 
right represent the top scoring docking pose to the eight or seven binding points present in 
LYS47/48 and LEU50 for PfAtg8 and their homologous binding centres LYS49/51 and LEU53 in 
hLC3. A final merged image that includes the model of PfAtg8 or hLC3. The W-pocket at the top 
and the L-pocket at the bottom. 
 
4.3 Conclusions 
The docking simulations of the library compounds over the PfAtg3 AIM docking region of 
PfAtg8 were assayed based on the hypothesis that these compounds bind within this 
region and act as protein-protein inhibitors. These docking models have provided 
information about the likely orientation of these compounds across the W and L-pockets 
within PfAtg3 AIM region of PfAtg8, a suggestion of a correlation between better docking 
scores and in vitro antiplasmodial activity as well as alternative models of ligands docking 
to hLC3 that may reflect the selectivity against P. falciparum. This observations, however,  
need to be supported by further analysis using either pull-down assays or SPR to explore 
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whether these compounds compete with PfAtg3 AIM peptide to interact with PfAtg8 
(Hain et al., 2012; 2014; 2016). Initials support that the Mcule software developed ligand 
binding models comparable to those used in previous studies using the alternative 
software package OpenEye (Hain et al., 2014) suggested that comparable, but not exact, 
models could be developed. These library compounds were provided to our research 
team by Dr Johannes Reynisson, an expert in molecular modelling. To provide additional 
support for our key predictions about the location and orientation of library compound 
binding to PfAtg8, his team provided models of SK1.49 and SK1.109 binding to the PfAtg3 
AIM docking region of PfAtg8 using a third ligand docking software, GOLD (Fig. 4.20).  
 
Fig. 4.20 Comparison of Mcule (upper panels) and GOLD (lower panels) models of SK1.49 and 
SK1.109 docking to PfAtg8. The upper panels are data developed in this study, the lower panel 
images provided by Dr. Reynisson’s team. To the left are docking predictions with SK1.49 and to 
the right simulations with SK1.109. In each case, the docking of the compound to the W and L-
pockets is shown with the PfAtg3 AIM peptide in green. The central panels show only a stick form 
of the compound, with predicted H-bonds to the indicated binding centre of PfAtg8.  
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Interestingly, the molecular docking in GOLD using SK1.49 and SK1.109 showed similar 
simulation to that obtained by Mcule. These include the docking of the naphthalene 
group into the large W-pocket for both molecules, while a trimethyl group from SK1.49 
projected into the L-pocket, and the amine groups form H-bonds with the indicated 
binding centres (although as shown for SK1.49 these H-bonds do not always go to the 
same binding centre) (Fig. 4.20). 
These modelling predictions can now be used to explore the relative activity of related 
compounds screened in Chapter 3. Hopefully, we be able to determine information which 
can be used subsequently to make structural modifications to optimize binding and 
enhance activity. The first aspect of this structure activity relationship is the length of 
amine/alkyl linker region between the two hydrophobic ends with prediction that these 
hydrophobic ends to dock into the W and L-pockets. This was clearly observed when 
compare four pairs of related compounds that differ only in the length of linker region 
(Fig. 4.21). In all cases, the compound with the longer linker region was more potent than 
the shorter counterpart. These data suggest that the linker region needs to be of 
sufficient length to provide efficient orientation for the hydrophobic ends to dock into the 
W and L-pockets.  
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7221498 (Dd2 EC50= 19.6 µM)                                                         7311494 (Dd2 EC50= 42.2 µM) 
(6 atoms linker > 5 atoms linker) 
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          LO9 (Dd2 EC50= 12.5 µM)                                                       7737951 (Dd2 EC50= 39.3 µM) 
(6 atoms linker > 5 atoms linker) 
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6115259 (3D7 EC50= 42.3 µM)                                                         NKLA-98 (3D7 EC50= > 50 µM) 
(5 atoms linker > 4 atoms linker) 
H
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H
N
S
O
                
H
N
H
N
S
O
 
                SK1.102 (Dd2 EC50= 18.9 µM)                                           SK1.101 (Dd2 EC50= 29.9 µM) 
(8 atoms linker > 7 atoms linker) 
Fig. 4.21 Exploring the structure activity relationship of alkyl linker length. Structure of 
compound with antiplasmodial activity (EC50) are reported. 
The docking data for SK1.63 indicated that the role of a halogen substitution on the 
phenyl group apparently competing in the docking predictions with the naphthalene 
group for the W-pocket. The compound library contained a number of related halogen 
substituted compounds which can be used to explore the potential effect of steric 
hindrance of the halogen substitutions in docking into the W and/or L-pockets. The 
H
N
OCH3
OCH3
O
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following three compounds (Fig. 4.22) all share a halogen substitution at the same para-
position on the phenyl group closest to the amine group in the linker. There is an inverse 
relationship between the size of the halogen substitution (F, 19.0 < Cl, 35.4 < Br 79.9) and 
their potency, which may reflect that the smaller halogens are able to fit into the W or L-
pocket of PfAtg8. 
N
H
O
F             
N
H
O
Cl  
                    5335716 (3D7 EC50= 17.3 µM)                                        5337355 (3D7 EC50= 32.2 µM) 
N
H
O
Br  
                                                                     5334050 (3D7 EC50= 37.8 µM) 
                                          (para-fluorophenyl > para-chlorophenyl > para-promophenyl)  
Fig. 4.22 Exploring the structure activity relationship of para-substituted halogens. Structure of 
compound with antiplasmodial activity (EC50) are reported. 
 
This potential for steric hindrance in docking to the W and L-pockets is also reflected in 
comparisons of the next three groups of related halogen substituted phenyl rings (Fig. 
4.23). All the three compounds share a bromo-substituted phenyl group, although the 
position of this substitution is different. 
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N
H
O
Br       
N
H
O
Br  
                     5334050 (3D7 EC50= 37.8 µM)                                   5328241 (3D7 EC50= > 50 µM) 
N
H
OBr
 
                                                              5328083 (3D7 EC50= > 50 µM) 
                            (para-bromophenyl > meta-bromophenyl > ortho-bromophenyl) 
Fig. 4.23 Exploring the structure activity relationship of the position of bromo substitutions. 
Structure of compound with antiplasmodial activity (EC50) are reported. 
Here the para-orientation may be considered to be more likely to fit into the W-pocket, 
with the ortho- and meta-orientations less active if the position of the halogen group 
offers some steric hindrance to this docking. This observation is also apparent in two 
additional pairs of compounds (Fig. 4.24), all of which show greater potency when the 
halogen is placed at the para position. 
N
H
O
F                         
N
H
OF
 
               5335716 (3D7 EC50= 17.3 µM)                                     5329246 (3D7 EC50= 85.6 µM)   
                                                       (para-fluorophenyl > meta-fluorophenyl) 
N
H
O
Cl                     
N
H
OCl
 
                          5337355 (3D7 EC50= 32.2 µM)                             7260078 (3D7 EC50= 44.0 µM)    
                                                          (para-chlorophenyl > meta-chlorophenyl) 
Fig. 4.24 Exploring the structure activity relationship of the position of fluoro and chloro 
substitutions. Structure of compound with antiplasmodial activity (EC50) are reported. 
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In terms of project a naphthalene group into the W-pocket, there appears to be a 
preference for the α-naphthalene over the β-naphthalene, as illustrated best between 
SK1.49 and SK1.47 (Fig. 4.25). The other active compounds, SK1.108, SK1.109 and SK1.63 
all share the same α-naphthalene orientation. One additional pair of structurally related 
compounds, SK1.50 and SK1.53, that differ only in the orientation of the naphthalene 
group also demonstrate a slightly higher potency for the α-naphthalene orientation. 
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O
CH3
CH3
CH3
CH3H3C
CH3
O
 
 
                SK1.49 (Dd2 EC50= 1.1 µM)                                                SK1.47 (Dd2 EC50= 2.1 µM) 
                SK1.49 (3D7 EC50= 0.8 µM)                                                SK1.47 (3D7 EC50= 1.6 µM) 
                                                         (α- naphthalene > β-naphthalene) 
NH O
O
OCH3
OCH3
      
NH O
O
OCH3
OCH3
 
 
SK1.50 (Dd2 EC50= 18.7 µM)                                              SK1.53 (Dd2 EC50= 26.1 µM)   
                                                           (α- naphthalene > β-naphthalene) 
 
Fig. 4.25 Exploring the structure activity relationship of α and β-naphthalene moieties. Structure 
of compound with antiplasmodial activity (EC50) are reported. 
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From modelling above, it appears that need to design compounds with two hydrophobic 
ends and linker regions to interact across PfAtg3 AIM binding site on PfAtg8. Comparison 
of the antimalarial activities of SK1.49 and SK1.70 suggests that modifications to the 
hydrophobicity or substitution of phenyl ring may increase potency  of compound. SK1.70 
lacks the trimethyl substitutions to the phenyl group that found in SK1.49 – and as such 
has a LogP of 3.7 compared to a LogP of 7.5 in SK1.49 (Fig. 4.26). It may be that the 
increased hydrophobicity of the phenyl group in SK1.49 – along with the projection of the 
hydrophobic trimethyl group deep into the L-pocket is important for the higher potency 
of this compound.  
          
H
N OO
 
 
             SK1.49 (Dd2 EC50= 1.1 µM)                                               SK1.70 (Dd2-EC50= 13.4 µM)    
 
Fig. 4.26 Exploring the structure activity relationship of trimethyl substitutions. Structure of 
compound with antiplasmodial activity (EC50) are reported. 
 
SK1.108 and SK1.109 are stereoisomers (enantiomeric forms) with the stereocenter 
located over the carbon immediately next to the naphthalene group (Fig. 4.27). 
Apparently there is no effect of this stereoisomerism on the compound potency.  
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SK1.109 (Dd2 EC50= 5.0 µM)                              SK1.108 (Dd2 EC50= 6.2 µM)  
SK1.109 (3D7 EC50= 4.5 µM)                              SK1.108 (3D7 EC50= 3.9 µM)                                                                                                                                                                                                                                                                                 
(S-enantiomeric form)                                              (R-enantiomeric form) 
                                                                        
H
N
H
N
S
O
 
                                                        SK1.106 (Dd2 EC50= > 50 µM) 
                                                             (Non-enantiomeric form)   
Fig. 4.27 Exploring the structure activity relationship of enantiomeric compounds. Structure of 
compound with antiplasmodial activity (EC50) are reported. 
 
However, comparison of these compounds with the non-enantiomeric SK1.106 does 
suggest that some modification of the carbon next to the naphthalene group increase the 
potency of the compound. In this context, all the most active compounds (SK1.47, SK1.49 
and SK1.63) in the library have a keto- group arranged over this position. Whilst no 
modelling data of SK1.106 was developed here, the potential for the importance of this 
position is noted. 
Considering these observations all together, a summary of the key observations can be 
suggested (Fig. 4.28) and these include; 
(i) Use naphthalene, or other large hydrophobic centre, is used to occupy the W-
pocket. 
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(ii) The length of alkyl linker between amine group and O atom is preferably 
greater than 3 carbons in length provides effective occupation to the region 
between the W and L-pockets.  
(iii) The amino group within the linker is important for H-bond formation. 
(iv) The carbon link between the naphthalene group and the amine group needs to 
explore the nature of substitutions here (R) noting the potential to form a 
stereocenter at this position. 
(v) The role of the oxygen at the end of the linker chain needs to be carefully 
considered as it may affect the angle at which a R1 substituted phenyl group 
will approach the L-pocket. 
 
 
 
 
 
 
 
Fig. 4.28 Schematic illustrating key structure activity relationship data developed in this study. A 
generic lead compound is docked into the W and L-pockets of PfAtg8 with H-bond being made to 
the LYS48 residue. R and R1 represent positions that require additional study (see main text).The 
enclosed region of the alkyl linker is considered the minimum to enable docking of the 
hydrophobic ends into the W and L-pockets.    
 
N 
H 
O 
R1 
R 
W-pocket 
L-pocket 
Lys48 
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(vi) The role of O that is closest to phenyl group may determine the angle of 
projection of this end (phenyl ring) into L-pocket.  
(vii) The hydrophobicity and position of substitutions on the phenyl group need to 
be explored in terms of their potential to dock into the L-pocket. 
These observations can be used to support a new way forward to developing a compound 
that could be considered a lead for development. Based on this information, in silico 
modifications to this scaffold can be generated, with potentially thousands of compounds 
screened in molecular docking studies. The principle for the success of this approach was 
demonstrated by Hain et al. (2016) who used such an approach to screen the ChemBridge 
library to discover ACL25. The distinction here is that we would have a core scaffold 
against which to make modifications.  
Small modifications on the scaffold above were performed to explore the potential of this 
approach. As a result, four compounds were generated in silico (Fig. 4.29). These 
modifications were included a slightly increase in the length of linker chain and addition 
of a pyridine ring within the linker which may enhance the binding ability of new 
compounds by reduction the of routable bonds and providing additional hydrogen 
donating site as well as halogenation of phenyl ring using trifluoromethyl which 
contributed in reduction of the LogP of the compounds to < 5 to follow Lipinski’s RO5 
(Table 4.3). These compounds were also assayed to explore the effect of the positioning 
of a trifluoromethyl substitution on the phenyl group – and how this would affect docking 
into the L-pocket. 
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Fig. 4.29 Test series of compounds designed in silico using the generic template.  
 
Importantly, all the physicochemical properties of these test compounds suggested that 
they all contain drug-like properties (Table 4.3). LogP of all compounds were lowered 
from 7.5, which found in SK1.49, to 4.8 or lower. The molecular weight remained under 
500, whereas NBA and NBD are both under 5. Additionally, the NROTB and TPSA are ≤ 10 
and ≤ 140 Å2, respectively. Interestingly, these features are all in agreement with 
Lipinski's RO5 and Veber’s rules (Table 4.3) (Lipinski et al., 1997; Veber et al., 2002). 
Compound        
ID 
MW1 HBA2 HBD3 LogP4 TPSA6 
(Å2) 
NROTB7 Vol.8 
(Å3) 
Lipinski’s 
RO5 
Veber’s 
rules 
Comp.A 438.4 4 2 4.8 50.3 7 377.9 Pass Pass 
Comp.B 438.4 3 1 4.8 50.3 8 377.9 Pass Pass 
Comp.C 438.4 4 2 4.8 50.3 7 377.9 Pass Pass 
Comp.D 370.4 4 2 3.8 50.3 6 346.6 Pass Pass 
 
Table 4.3  Physicochemical properties of 4 new suggested compounds (A, B, C and D). These 
include; 1Molecular weight (MW), 2Number of H-bond acceptor (HBA), 3Number of H-bond donor 
(HBD), 4Log partition coefficient, a measure of lipophilicity (LogP), 5Total polar surface area 
(TPSA),6Number of rotatable bond (NROTB), 7Molecular volume. The final two columns indicate 
whether they meet the RO5 or Veber’s rules criteria for predicted bioavailability. 
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Each compound was docked in Mcule against PfAtg8 using only the LYS48 binding centre 
for this short evaluation – although all binding points were tested (8 binding points) (Fig. 
4.30). The orientation of the top scoring docking poses for each binding point reveal that 
compounds C and D always placed by their naphthalene groups in the W-pocket – 
however, the positioning of the trifluoromethyl group at either the ortho- or meta-
positions potentially obstructed the insertion of this group into the L-pocket (which is 
always clearly observed for the para-position) and led to the substituted phenyl groups 
being positioned in the W-pocket. This data suggests that compound C may bind more 
consistently in the same orientation in the docking simulations and this, as well as the 
better docking scores for compound C (Table 4.4), would suggest this compound would 
be of the most interest in these four for synthesis and testing in in vitro assays.  
 Target (PfAtg8)  
Binding points in LYS48 
Comp. ID N-380 C-382 O-383 C-384 C-385 C-386 C-387 N-388 Mean 
Comp.A -8.9 -9.0 -8.9 -8.9 -8.9 -8.8 -8.6 -8.5 -8.81 
Comp.B -8.8 -8.6 -8.8 -8.5 -8.6 -8.7 -8.3 -8.2 -8.56 
Comp.C -9.2 -8.9 -9.0 -9.2 -8.9 -8.9 8.6 8.5 -8.90 
Comp.D -7.6 -7.9 -7.8 -7.7 -7.6 -7.9 -7.5 -7.6 -7.70 
 
Table 4.4 Docking scores of the top docking poses for Compounds A, B, C and D using the LYS48 
binding centre in PfAtg8.  Note that poses that predict a H-bond are highlighted in green. 
 
Whilst only a short evaluation, the intention was to demonstrate how the generic 
predicted scaffold for the interaction of these library compounds with PfAtg8 could be 
adapted to explore issues around hydrophobicity, linker length and positioning of 
substitutions to the phenyl ring can be explored relatively quickly. Certainly, a high 
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throughput modelling exercise could be used to consider a larger number of binding 
centre as well as greater modifications to the generic scaffold. In addition, and exploiting 
the idea of Hain et al. (2016), exploring how compounds may be developed that bridge to 
the A-pocket from the Atg3 AIM binding sites may lead to potent and selective 
compounds that block PfAtg3-PfAtg8 interactions.  
 
 
Fig. 4.30 Docking of compounds A to D against PfAtg8. Molecular docking of each compound 
with the eight highest top scoring docking poses for binding points in LYS48 are projected. Top 
panels show the ligands in stick form with PfAtg8 omitted, this is then added in the lower panel to 
show the W-pocket at the top and L-pocket at the bottom. 
167 
 
Chapter 5: Exploring changes to the ultrastructure of intraerythrocytic P. 
falciparum following an equipotent drug challenge 
 
5.1 Introduction  
Improvement in the ultrastructural imaging techniques such as cryo-electron microscopy, 
atomic force microscopy and technical protocols in processing time-lapse data over the 
last ten years allows to widely study the development of P. falciparum following drug 
treatment (Cyrklaff et al., 2017; Johnson et al., 2017; Riglar et al., 2011). Studies of drug 
action against intraerythrocytic parasites using TEM have been used for some thirty years 
– with Table 5.1 highlighting a number of these studies. TEM analysis of ultrastructural 
changes under normal and drug stress have provided insights into consecutive events that 
occur on action site of drugs which can be assisted to explore the mechanism of action of 
antimalarial drugs at the cellular level (Ch’ng et al., 2011; del Pilar Crespo et al. 2008; 
Hoppe et al., 2004; Chen et al., 2000; Roberts et al., 2008; Sachanonta et al., 2011). 
These studies of drug action are typically compared against untreated parasites, and 
usually focus on the trophozoite stage (Fig. 5.1 and 5.2). Here, the dominant feature of 
the parasite is the DV which has a uniform electron density, with evident electron dense 
puncta representing haemozoin (Hz) crystals within a continuous membrane. The 
cytoplasm of the parasite is heavily decorated with a dotted appearance, representing 
extensive arrangements of ribosomes throughout the cytoplasm. The nucleus typically 
has the same electron density as like as the cytoplasm, and is determined by its nuclear 
membrane (Fig. 5.1). 
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Author  Parasite strain/stage1  Method Stimulus 
(Concentration/Time)  
Key features 
Zhang and Just 
(1987) 
FCB strain / trophozoite  TEM CQ  
(10µM/45min) 
Ammonium chloride  
(20mM/2hrs) 
Accumulation of endocytic vesicles (EV) only inside 
digestive vacuole (DV), alkalization of DV, CQ did not 
interfere with haemozoin (Hz) formation at high 
concentration. CQ-like effects showed by ammonium 
chloride.  
Wu et al. (1988) NIH-7G8 strain / 
trophozoite  
TEM PYRD  
(1µM/ 30min/24hrs) 
Accumulation of EV inside DV (membranous whorls), DV 
was devoid of Hz crystals, swollen mitochondria and 
endoplasmic reticulum (ER), ribosomal depletion and 
necrotic features in some cells were observed. 
Kawai et al.  
(1996) 
SGE1 / trophozoite 
propagated in owl 
monkey 
TEM PYRD 
(40mg/kg of body 
weight) 
4-6hrs 
Significant changes in DV size, reduction of Hz crystals, 
mitochondrial dilation and accumulation of undigested 
EV inside DV.   
Chen et al. 
(2000) 
ANKA strain of 
P. berghei / hepatic 
stages 
TEM DHA  
(ED50/4-8hrs) 
 
Loss in DV membrane integrity, EV numbers slightly 
increased, evidence of ribosomal depletion, reduction 
in mitochondrial membrane integrity. 
Hoppe et al. 
(2004) 
D10 strain / trophozoite FITC-dextran and anti-
haemoglobin using 
phase-contrast 
Microscopy 
and TEM 
CQ (120nM) 
QN (1µM) 
Artemisinin 
(110nM) 
MQ (60nM) 
Ammonium chloride 
(20mM) 
For 8hrs 
 
All treatments caused loss in DV membrane integrity, an 
increase in number of cytoplasmic located EV by CQ and 
Ammonium chloride treatment, whilst QN, MQ and 
artemisinin treatment reduced EV numbers.  
Porter et al. 
(2008) 
CSC1 strain/ trophozoite TEM 40 °C (6hr) 
CQ  (100µM/4hrs) 
Staurosporine 
(5µM/5hrs) 
Swelling of DV in all treated samples, increase in 
translucent cytoplasmic EV and accumulation of 
undigested EV inside DV in CQ-treated samples.  
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Roberts et al. 
(2008) 
3D7 strain / trophozoite  
 
Anti-haemoglobin using 
immunofluorescence 
microscopy 
CQ 
AQ 
QN 
MQ 
(all 5XIC50/8hrs) 
Increase of EV numbers in CQ and AQ-treated samples, 
reduction of EV in QN, MQ-treated samples. Increase of 
haemoglobin level in CQ-treated sample while reduced 
in other drug-treated samples.  
del Pilar Crespo 
et al. (2008) 
D10 strain /  
ring and trophozoite 
TEM Artemisinin 
40XIC50/8hrs in 
trophozoite stage 
  
Artemisinin 
2XIC50/24hrs in ring  
Both treatments caused loss in DV membrane integrity, 
EV and Hz crystal numbers unchanged after 8 hrs, slight 
increase in numbers of EV and reduction in Hz level 
after 24 hrs.  
Totino et al., 
2008 
PSS1 strain/ trophozoite TEM CQ (180nM) 
SNAP (360µM) 
Staurosporine (4µM)  
For 24hrs 
All drugs showed increase of EV in the parasite 
cytoplasm.  
Sachanonta et 
al. (2011) 
AK121 strain / 
trophozoite 
TEM Artesunate (60mg/mL) 
QN (300mg/mL) 
PPQ (300mg/mL) 
(4-8hrs) 
Swelling of DV in PPQ-treated parasites, whereas 
relatively small DV in artesunate-treated parasites, 
reduction of Hz crystals with ribosomal depletion in all 
treated samples, swollen mitochondria in QN-treated 
sample only, and EV vesicles accumulated inside DV in 
PPQ-treated sample, dilation of PV in artesunate-
treated samples.  
Ch’ng et al. 
(2011) 
3D7 strain / trophozoite TEM CQ  
(3µM/4hrs) 
Intact DV membrane with discrete Hz crystals and 
undigested EV accumulated inside DV. Some cells 
showed disruption in DV membrane and Hz crystals 
being dispersed into cytoplasm.  
Klonis et al. 
(2011) 
3D7 strain / trophozoite 
 
FITC-dextran using 
immunofluorescence 
microscopy and FACS 
Artemisinin  
(IC50= 95nM/24hrs)  
(1µM/24hrs) 
EV reduced in parasite cytoplasm. Haemoglobin uptake 
reduced.  
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Tomlins et al 
(2013) 
3D7 
D10 
Strains of P. falciparum/ 
trophozoite 
Fluorescence 
microscopy, western 
blot and immuno-TEM 
Starvation Number of PfAtg8 puncta and EV increased 
 
Eickel et al. 
(2013) 
ANKA strain of P. 
berghei/ Liver stages 
Fluorescent microscopy 
and TEM 
Rapamycin 
(0.5µM)  
Number of PfAtg8 puncta did not change, but EV 
number increased.  
 
Table 5.1 Studies that have explored ultrastructural changes of P. falciparum parasite challenged with antimalarial drugs at different concentrations and 
exposure times. Endocytic vesicle (EV), digestive vacuole (DV), haemozoin (Hz), endoplasmic reticulum (ER), transmission electron microscopy (TEM). 1 
unless otherwise indicated, these are studies reported in P. falciparum. 
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Other features include; spherical electron-dense vesicles located within the cytoplasm, 
and usually termed endocytic vesicles (EV) were observed (del Pilar Crespo et al., 2008). 
Mitochondria, when observed, are elongated tubes with no evidence of cristae (Fig. 5.1).  
 
Fig. 5.1 Ultrastructural morphology of untreated trophozoite stage of P. falciparum. These 
include; digestive vacuole (termed food vacuole FV here, A and C) containing haemozoin crystals 
(H, A and C), nucleus (N, A), elongated mitochondria (M ,B and C). Parts A and C also show 
Maurer's clefts (MC) under RBC plasma membrane and knobs (K) on the exofacial surface of iRBC 
(Source: Sachanonta et al., 2011). The bar in 200nm.  
 
 
 
Fig. 5.2 TEM micrographs of untreated trophozoite stage of P. falciparum (A) and (B) illustrating 
intact digestive vacuoles (DV) membranes enveloping a uniformly dense compartment 
decorated with haemozoin crystals. The scale bars show 0.5 µm units for X11,000 and X18,000 
magnifications (Source: Ch’ng et al., 2011). 
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Although studies of ultrastructural changes following drug-treatment provide various 
outcomes in the observations seen (Table 5.1), they do agree on one key point – there is 
no evidence of necrotic, or unregulated, cell death following drug treatment. This is due 
to the absence of gross swelling of organelles, no gross loss of structural integrity 
including blebbing and not complete loss of membrane bound structures in all the studies 
undertaken. Furthermore, there is no consistent evidence of apoptotic cell death. Totino 
et al (2008) used CQ, staurosporine (as an inducer of apoptosis) as well as a nitric oxide 
donor S-nitroso-N-acetyl-penicillamine (SNAP) to induce cell death and explored whether 
the changes in nuclear morphology consistent with chromatin condensation (i.e. changes 
in nucleus shape, size or uniformity in electron density) occur. This study did not indicate 
the observations above, although cytoplasmic vacuolation (the name endocytic vesicle 
also used, and used in this thesis) was shown in all three treatments, with cytoplasmic 
vacuolation consistently described in a number of studies using CQ (Hoppe et al., 2004; 
Ch’ng et al., 2011; Porter et al., 2008; Zhang and Just 1987). On this basis, Totino et al 
(2008) suggested that all these treatments resulted in a similar autophagic-like cell death. 
However, a different study that included staurosporine and CQ treatments did not report 
any changes in cytoplasmic vacuolation, but instead reporting that both treatments 
resulted in DV swelling and, in somecases, rupture (Porter et al. 2008).  
Ultrastructural studies have mainly focussed on the action of CQ, and its effects on the DV 
in particular (Ch’ng et al., 2011; Hoppe et al., 2004; Porter et al., 2008; Totino et al., 2008; 
Zhang and Just 1987). Together these studies provided some consistent observations (Fig. 
5.3). CQ exposure results in an increase in the number of cytoplasmically located 
endocytic vesicles. These vesicles can sometimes be observed in the DV where they 
termed membranous whorls (Fig. 5.4). Within the DV, haemozoin crystals become less 
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defined and are reduced in number, with breaches of the DV membrane occasionally 
observed leading to leackage of the less electron-dense DV contents into the more 
electron-dense cytoplasm (Fig.5.4) (Ch’ng et al., 2011). 
 
Fig. 5.3 Transmission electron micrographs of untreated and drug-treated trophozoite stages of 
P. falciparum. (A) and (B) Untreated trophozoite stages of P. falciparum exhibits digestive vacuole 
(dv) and within the inset a higher magnification of a cytoplasmic vesicle (v) thought to contain 
haemoglobin from the host erythrocyte. This structure sometimes referred to as a cytosome. 
(Source: Goldberg et al., 1990). (C) and (D) CQ-treated parasites (120nM/12hrs) shows electron-
dense vesicles (white stars) distributed in the parasite cytoplasm (Source: Hoppe et al., 2004). (E) 
CQ-treated parasite (100µM/4hrs) shows translucent vesicles (white vesicles) distributed in the 
parasite cytoplasm with electron-dense vesicles (grey vesicles) located within the DV. (Source: 
Porter et al., 2008). (F) PPQ-treated parasite (300mg/mL for 8hrs) shows the same accumulation 
of electron-dense vesicles in the DV (*). Note also the Maurer’s cleft (MC) and knobs (K) under 
iRBC plasma membrane and on the surface of iRBC, respectively, and the nucleus (N). (Source: 
Sachanonta et al., 2011).  
 
Perhaps the best quantitative study of morphological changes is that performed by 
Sachanonta et al. (2011). Here, P. falciparum were exposed to artesunate, QN or PPQ at 
concentrations typically found in human serum– with 300 micrographs analysed for each 
drug treatment. Features common to all treatments included a reduction in haemozoin 
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crystal counts and patches of apparently ribosome-free cytoplasm (now appear as 
electron-translucent areas) (Fig. 5.3F). These observations were previously indicated by 
Wu et al. (1988) in PYRD-exposed parasites. A marked observation was the extensive 
accumulation of membranous whorls in the DV of PPQ-treated parasites (Fig. 5.3F), 
similar to those seen when trophozoites are exposed to high concentrations of CQ (Fig. 
5.3E), although without the accompanying electron-translucent vesicles in the cytoplasm. 
A specific effect of artesunate treatment was a swelling of the parasitophorous vacuole, 
with clear space defined between the parasite and the host erythrocyte cytoplasm (Fig. 
5.5). 
 
 
 
Fig. 5.4 Transmission electron micrographs of intraerythrocytic trophozoite stages of P. 
falciparum challenged with 3 µM CQ for 4 hrs. (A) Shows reduced levels of haemozoin crystals 
and compromise to the DV membrane leading to leak of DV materials into the cytoplasm (shown 
in more detail to the inset image on right). (B) Shows an intact DV membrane, less discrete 
haemozoin crystals and an accumulation of membranous whorls in the DV (see inset to right). ). 
The scale bars show 0.5 µm unit for X18,000 magnification, 0.2 µm unit for X36,000 magnification 
and 0.1 µm unit for X56,000 magnification (Source: Ch’ng et al., 2011). 
175 
 
 
 
Fig. 5.5 Ultrastructural micrographs of artesunate-treated intraerythrocytic trophozoite stages 
of P. falciparum. (A) and (B) show food vacuoles (FV) containing reduced numbers of haemozoin 
crystals. (A) illustrates a dilated parasitophorous vacuole (PV) with the same micrograph showing 
regions of the cytoplasm depleted of ribosomes (*). The bar is 200 nm (Source: Sachanonta et al., 
2011). 
 
An overview of these studies reveal a number of issues; (i) they are heavily bias on using 
one drug – chloroquine, (ii) whilst some inferences can be drawn from the different 
studies reporting the effect of CQ on the progress of ultrastructural changes, variations in 
parasite strain, the concentrations of CQ used and the length of exposure are all 
confounding factors, and (iii) no real attempts, beyond that of Sachanonta et al. (2011) 
have been made to do a comparative study of these treatments and then quantify these 
structural changes. The key issue in such comparative studies using different drugs is how 
to define a similar endpoint for the comparative study using drugs with different 
potencies and different rates of kill. The work done by Ullah et al. (2017) in correlating 
loss of bioluminescence signal with loss of parasite viability has been exploited here to 
overcome the issue of defining a similar endpoint, and thus facilitating a comparative 
study of ultrastructure changes. Here, a concentration of drug/compound has been 
determined that leads to a 50% reduction in parasite viability in 6 hrs. This has been 
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exploited here to do a comparative study of ultrastructural changes in the early stages of 
cell death for a range of drugs, including at least two drugs of each class for internal 
comparison, with these then compared to parasites exposed to SK1.47, SK1.49 and DBeQ 
under the same conditions. 
5.2 Results  
5.2.1 Experiment set up and initial observations  
Eight benchmark antimalarial drugs were selected for this study including; the 4-
aminoquinolines CQ and AQ and their related analogues PPQ and PYRD, the arylamino 
alcohols (QN and MQ) and artemisinins (DHA and ARM). From work described here in 
chapter 3 and linking to that performed by Ullah et al. (2017), estimation of the 
concentration of drug to reduce parasite viability by 50% in 6 hrs (LD50) were available. 
Initial experiments for preparation volumes of culture necessary for fixation and staining 
using these concentrations did not consistently provide a 50% reduction in 
bioluminescence. This more likely due to an increase in parasitaemia and haematocrit in 
the cultures used for electron microscopy in comparison to the microwell plate assays. 
Thus, empirical increases in the LD50 concentrations were tested until a range of 
concentrations were determined (Table 5.2). For each of the two biological repeats 
reported here, samples were prepared over this range and that with the remaining 
bioluminescent signal closest to 50% selected for preparation of electron micrographs 
(Fig. 5.6). 
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Drug LD50 50% kill (nM) 
CQ 790.2 900-1000 
AQ 101.1 120-140 
PPQ 297.3 350-390 
PYRD 72.0 100-120 
QN 2236.0 2500-3000 
MQ 65.3 80-100 
DHA 12.9 20-25 
ARM 15.4 20-25 
Compound LD50 50% kill (µM) 
 
DBeQ 5.4 7-8.5 
SK1.47 7.2 9-10 
SK1.49 3.6 5-6.5 
 
Table 5.2 LD50 values (from section 3.2.3) and range of 50% kill concentrations used to provide 
samples with a 50% reduction of viability after treatment.  
 
Fig. 5.6 Bioluminescence signals (normalised to untreated control) following treatment with the 
indicated drug/compound to derive samples that have a 50% loss in viability. Each dot 
represents one experiment (with the majority from experiments in chapter 6) with the line 
representing the mean, those highlighted in red for samples used to produce electron 
micrographs.  
 
Saponin-enriched trophozoites were prepared for transmission electron microscopy 
based on the protocol originally described by Beaumelle et al. (1987) (see section 2.6). In 
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brief, parasites were cultured to achieve a    10% parasitaemia and either exposed to drug 
or left untreated as a control. After treatment, the iRBCs were lysed in 0.1% (w/v) saponin 
and the released parasites were fixed overnight in 2% (w/v) glutaraldehyde. The pre-fixed 
parasites were stained with 1% (w/v) osmium tetroxide following by embedding in agar 
before dehydration and embedding in Spurr resin. Ultra-sections (80-90 nm thickness) 
were obtained and then stained with uranyl acetate. Ultrastructural images were 
captured using a Transmission Electron Microscope (JEOL-1230, USA).  
Transmission electron micrographs of untreated trophozoite parasites confirmed the 
success of the protocol and electron microscopy facilities, where features expected of 
trophozoite stage parasites observed (Fig. 5.7 and 5.8).  These observations include; (i) a 
clearly defined DV, which is surrounded by a continuous membrane that clearly stained 
and enveloping Hz crystals, (ii) the presence of electron-dense vesicles (termed here 
endocytic vesicles, EV) distributed in the parasite cytoplasm, (iii) an electron-dense 
cytoplasm enriched with ribosomes, (iv) a membrane bound nucleus that shares a similar 
electron density to the cytoplasm, (v) the presence of elongated mitochondria with a less 
electron-dense matrix and (vi) a parasitophorous vacuole (PV), a space between plasma 
membrane of the parasite and cytoplasm of iRBC, surrounding by PV membrane. 
Together, these observations suggest that the protocol employed is capable of producing 
the resolution of images to carry out the comparative study of changes to morphology 
following drug/compound treatment. 
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Fig. 5.7 Ultrastructural morphology of untreated trophozoite intraerythrocytic stages of P. 
falciparum. The images show observations previously described, including; intact membrane of 
digestive vacuole (DV) enveloping haemozoin crystals (white arrows), several electron-dense 
endocytic vesicles (EV) distributed in the parasite cytoplasm (white stars). Note that the parasite 
nucleus labelled by N. The scale bar shows 1 µm unit for X 30,000 magnification. 
 
 
 
Fig. 5.8 Ultrastructural morphology of mitochondria and parasitophorous vacuole membrane in 
trophozoite intraerythrocytic stages of P. falciparum. (A) and (B) with their associated insets 
below each panel, show single elongated mitochondrion (M) placed under parasite plasma 
membrane as well as parasitophorous vacuole (PV) in (A) that is restricted between the parasite 
plasma membrane and parasitophorous vacuole membrane. The scale bar shows 1 µm unit for X 
30,000 magnification. 
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5.2.2 Qualitative analysis of transmission electron micrographic observations. 
5.2.2.1 Concentration-dependant effects on the ultrastructural morphology of CQ-
treated parasites.  
Whilst CQ is the most used drug in electron microscopic studies of P. falciparum, 
comparisons between the effects of different concentrations, for different lengths of time 
in different strains affect the interpretation that can be made. Here, to illustrate the 
utility of defined endpoints determined using bioluminescence, trophozoites were 
exposed to concentrations of CQ that cause a 25%, 50% or 100% loss in luciferase signal 
over 6 hrs. These reductions in bioluminescence are the result of 300-450 nM, 900-1000 
nM and 8-10 µM concentrations of CQ. 
Representative images of parasites from each treatment are shown in Fig. 5.9. Features 
previously reported following CQ treatment are all found. Specifically; 
(i) An accumulation of electron-dense EV in the parasite cytoplasm. Here we 
observe a concentration-dependent effect, where more EV are observed as 
the kill effect is increased from 25% to 50% (Fig. 5.9). In contrast, the number 
of cytoplasmic electron-dense EV are reduced in parasites exposed to a 
concentration that kills 100%, with swollen DV filled with vesicles previously 
been termed membranous whorls. Additionally, similar translucent vesicles to 
those indicated by Porter et al., (2008) following treatment with supralethal 
dose of CQ now appeared in the parasite cytoplasm.   
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Fig. 5.9 Ultrastructural morphology of CQ-treated intraerythrocytic trophozoite parasites after 
exposure to increasing concentrations resulting in 25%, 50% or 100% loss of parasite viability. 
Common features include cytoplasmic located endocytic vesicles (EV) (white stars), membranous 
whorls inside swollen DV and haemozoin crystals (white arrows). In addition, for CQ-100% clearly 
apparent electron-translucent vesicles (black stars) are instead found in the cytoplasm of 
parasites. The scale bar shows 1 µm unit for X 30,000 magnification. 
 
(ii) Swelling of the DV, particularly when exposed to a 100% kill concentration, an 
apparent reduction in the presence of haemozoin crystals with evidence of a 
breach of the DV in some cases. 
(iii) Regions of the cytoplasm that are apparently depleted of ribosomes. These are 
distinct from membrane bound regions due to their irregular shape. 
Whilst these features have all been previously described, the data here does seem to 
suggest an emerging pattern. At the lowest level of CQ, the inhibition of EV trafficking to 
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the DV with cytoplasmic vacuolation phenomenon were observed (Fig. 5.9). Some DV 
function in haemoglobin digestion is evident from the formation of Hz crystals. As the 
concentration of CQ increases to produce a 50% kill, there are many more EV apparent 
with the initial emergence of the electron-translucent vesicles in the parasite cytoplasm. 
The highest concentration of CQ results in a reduction of cytoplasmic EV, with vesicles of 
the same electron density now filling an enlarged DV. These findings follow those of 
Hoppe et al. (2004) who developed a novel endocytic trafficking assay based on the 
uptake of fluorescently labelled dextrans from the RBC cytoplasm. They also showed an 
accumulation of cytoplasmic EV upon CQ treatment, suggesting disrupture of fusion 
between EV and DV membrane. However, here, we see that exposure to the highest 
concentration of CQ may not block the delivery of EV to the DV, based on the similarity in 
appearance between the cytoplasmic EV and intra-DV membranous whorls, but instead 
prevent their breakdown and thus the delivery of haemoglobin to the DV for digestion. 
This latter observation correlates with Porter et al (2008) study in that CQ treatment 
causes the accumulation of undigested vesicles in the DV of the parasite. Inhibition of 
haemozoin formation by CQ was reported to be a concentration-dependent effect using 
β-haematin inhibitory activity assay (Combrinck et al., 2012; Omodeo-Sale et al., 2009).  
 
5.2.2.2 Exploring the ultrastructural morphology of parasites exposed to the same 
endpoint treatment of antimalarial drugs and the putative autophagy inhibitors SK1.47 
and SK1.49. 
Using the LD50 concentrations of each drug, the same 50% loss of viability (based on a 
50% reduction in bioluminescence) was achieved across treatments with the antimalarial 
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drugs and the putative autophagy inhibitors. Taking the putative autophagy inhibitors 
SK1.47, SK1.49 and DBeQ first, it is readily apparent that they all share a very similar 
morphology (Fig. 5.10). 
 
 
Fig. 5.10 Ultrastructural morphology of intraerythrocytic trophozoite stages exposed to 50% kill 
concentrations of the putative autophagy inhibitors DBeQ, SK1.47 and SK1.49. Features marked 
include cytoplasmic endocytic vesicles (EV) (white stars), digestive vacuole (DV), and haemozoin 
crystals (white arrows). The scale bar shows 1 µm unit for X 30,000 magnification. 
 
The most surprising feature is the appearance of the DV. This appears less dense than 
those of untreated parasites, more swollen and contains few haemozoin crystals. In some 
images, and particularly those from parasites treated with DBeQ, some vesicles can be 
seen within the DV. These vesicles appear distinct than those observed in CQ-treated 
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parasites as they are less electron dense and less regular in appearance. Cytoplasmic EV 
are apparent, but there is no evidence of accumulation of them on compound treatment. 
Other potential observations such as ribosome free areas, swollen mitochondria 
(although mitochondria only visible in a very small proportion of all images taken) or 
compromised DV membranes were not features observed following treatments with 
these compounds. 
The 4-aminoquinoline AQ and the related PPQ and PYRD analogues share some 
morphological changes observed using high concentration of CQ (Fig. 5.11). Of these, the 
presence of electron-dense vesicles inside the DV is of particular note. Whilst several 
examples of this observation are noted in PYRD and AQ treated parasites, the 
transmission electron micrographs of PPQ-treated parasites uniformly show the presence 
of large numbers of these intra-DV vesicles. Similar feature of PPQ treatment has been 
previously reported by Sachanonta et al. (2011). Here, the DV were often observed to be 
swollen and contained the intra-DV vesicles and with fewer haemozoin crystals. AQ and 
PYRD also reported induction of swelling of DV, although recognition a clear reduction in 
haemozoin crystals is more challenging.  
The most distinguishing feature between AQ, PPQ and PYRD-treated parasites compared 
to CQ-treated parasites is the absence of EV in the cytoplasm of these parasites. 
Treatment with the 4-aminoquinoline CQ results in a large increase in EV accumulation, 
and may have been similarly expected here based on the shared chemical class. In these 
parasites, however, the numbers of EV were not significantly different to untreated 
parasites, where typically ranged from one to three (Fig. 5.11). 
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Fig. 5.11 Ultrastructural morphology of intraerythrocytic trophozoite stages exposed to 50% kill 
concentrations of amodiaquine (AQ), piperaquine (PPQ) and pyronaridine (PYRD). Features 
marked include cytoplasmic endocytic vesicles (EV) (white stars), digestive vacuole (DV), 
haemozoin crystals (white arrows) and membranous whorls (black arrows). The scale bar shows 1 
µm unit for X 30,000 magnification. 
 
For the arylamino alcohols (QN and MQ)-exposed parasites, transmission electron 
micrographs revealed ultrastructural morphology similar to that reported of AQ and 
PYRD. These changes include; no apparent change in the number of cytoplasmic EV, a 
dilated and apparently more electron translucent DV containing few Hz crystals (Fig. 
5.12). The low numbers of cytoplasmic EV agrees with the reduced levels of FITC-dextran 
endocytic transport, in QN and MQ-treated parasites compared to CQ treatment (Hoppe 
et al., 2004). Similarly, QN and MQ-treated parasites were shown to have reduced levels 
of haemoglobin in the parasite cytoplasm using anti-haemoglobin antiserum (Roberts et 
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al., 2008). Comparison of the QN-treated group from this study to those obtained by 
Sachanonta et al. (2011) provides agreement on all these features. The latter study also 
reported swollen mitochondria, this could not be confirmed here as so few mitochondria 
were imaged to make that judgement possible. 
The final comparison is for the artemisinins DHA and ARM (Fig.5.13). The TEM 
micrographs reveal few morphological changes compares to untreated controls. These 
included, no apparent difference in the number of cytoplasmic EV, the DV appears to 
have an unchanged density, no intra-DV vesicles and large numbers of haemozoin crystals 
are evident. Similar observations were indicated by Chen et al. (2000) and Haynes et al. 
(2013) using TEM and β-haematin inhibitory activity assay, respectively. By contrast, 
these findings are clearly distinct to those reported by Sachanonta et al. (2011) and del 
Pilar Crespo et al. (2008). Sachanonta et al. (2011) reported a complete loss of distinct 
organelle structure and its replacement with a dense amorphous material. This study, 
however, exposed the parasites to 20 µM of artesunate, some 1000X the concentration 
applied here. del Pilar Crespo et al. (2008) reported loss of DV membrane integrity and 
release of haemozoin into the cytoplasm using artemisinin, with them using 40X the 
concentration applied here.  
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Fig. 5.12 Ultrastructural morphology of intraerythrocytic trophozoite stages exposed to 50% kill 
concentrations of quinine (QN) and mefloquine (MQ). Features marked include cytoplasmic 
endocytic vesicles (EV) (white stars), digestive vacuole (DV), haemozoin crystals (white arrows) 
and membranous whorls (black arrows). The scale bar shows 1 µm unit for X 30,000 
magnification. 
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Fig. 5.13 Ultrastructural morphology of intraerythrocytic trophozoite stages exposed to 50% kill 
concentration of dihydroartemisinin (DHA) and artemether (ARM). Features marked include 
cytoplasmic endocytic vesicles (EV) (white stars), digestive vacuole (DV) and haemozoin crystals 
(white arrows). The scale bar shows 1 µm unit for X 30,000 magnification. 
 
 
5.2.3 Quantitative analysis of transmission electron micrographic observations 
The common assay endpoint employed here allowed us to compare how the morphology 
of drug-treated parasites changed when exposed to different drugs. The previous section 
highlighted qualitative changes seen for the different classes of drugs studied – and how 
related drugs/compounds provide similar outcomes. For each treatment, 70-80 TEM 
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images were available for a quantitative assessment of specific morphological features. 
Those chosen were; 
(i) The number of electron-dense cytoplasmic EV. These varied dramatically in 
the CQ-treated parasites and may have some role in the delivery of 
haemoglobin to the DV for digestion. 
(ii) The ratio between the DV and the parasite cytoplasm – this being used to 
make an assessment of DV swelling. 
(iii) The number of haemozoin crystals in the DV. 
These variables were selected as these features are present in almost all the imaged TEM 
graphs as well as being simple criteria to measure. Exploring the effect on mitochondria 
morphology, for example, could not be done due to few images showed recognisable 
mitochondria. Similarly, whilst ribosome depleted regions within the cytoplasm were 
observed, there were also the electron-translucent vesicles observed upon CQ treatment. 
Their morphologies are distinct, but is based on a judgement of how regular the shape is 
– and this subjectivity could be an issue. Other events, such as DV breach and dispersed Hz 
in the parasite cytoplasm are both rarely observed and subjective.  
5.2.3.1 Quantitative analysis of endocytic vesicles.  
Fig. 5.14 illustrates the quantitative assessment used. EV are defines as cytoplasmic 
located, spheroid and contain electron-dense materials. Counts of the actual number of 
EV within each parasite were made (Fig. 5.15 and Table 5.3). In addition, based on the 
distribution of the EV count, the proportions of cells with ≥ 2 EV were also determined 
(Hoppe et al., 2004) (Fig. 5.16). The analysis first revealed a concentration-dependent 
effect of CQ on EV numbers. As the concentration increases to achieve a 50% kill, there is 
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a significant increase in the number of EV. This is similarly seen when the proportion of 
cells that have ≥ 2 EV increased from 11.4% in the untreated sample to 22.8 and 43.2% in 
25% and 50% kill dose of CQ, respectively (Fig. 5.16). 
 
Fig. 5.14 Ultrastructural micrographs of trophozoite stage of P. falciparum. The numbers of 
endocytic vesicles (white stars) within the parasite cytoplasm were counted. Examples here show 
2 EV in an untreated control (A) and 12 EV in 50% kill dose CQ-treated parasites (B). Note the 
parasite nucleus (N) and digestive vacuole (DV). The scale bar shows 1 µm unit for X 30,000 
magnification. 
 
Fig. 5.15 Distribution of EV count per cell according to the kill effect and antimalrial 
drug/compound used. One-way ANOVA with a Dunnet post-test comparison to the untreated 
group. Ns, not significant; ***, p<0.0001.  
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The 100% kill dose CQ-treated parasites showed no significant difference in EV number 
compared to the untreated control and the proportion of cells that contained ≥ 2 EV falls 
to 2.8% (Fig. 5.16). This striking difference matches the qualitative observation (Fig. 5.9), 
that showed the electron-dense vesicles are instead located in the DV and those vesicles 
still present in the cytoplasm are electron-translucent and not counted here. 
 
Fig. 5.16 Bar chart representing the proportion of cells that contain ≥ 2 endocytic vesicles (EV) in 
the parasite cytoplasm following each treatment or in an untreated control. Note there are no 
error bars as all TEM images within each group (70-80images) are included in this analysis. 
 
Analysis of the distribution of EV count in all other drug treatments reveal no significant 
difference, matching the qualitative assessment in the previous section that suggested 
there were no apparent changes in EV numbers. Interestingly, the mean numbers of 
EV/cell are similar when grouped according the the class of drug/compound; i.e. SK1.49 
and SK1.47 at 0.11-0.14 EV/cell, DHA and ARM at 0.31 EV/cell and QN and MQ at 0.19-
0.21 EV/cell (Table 5.3). The distribution of data and the numbers of counts performed do 
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not make this a statistically relevant observation. Unlike CQ, all other treatments resulted 
in a lower proportion of cells with 2 or more EV, which together with the mean count and 
lower maximum numbers of EV counted suggests that whilst a significant difference 
cannot be dteremined based on the distribution of EV counts here – additional work to 
explore this effect is warranted. 
Drug/Compound Mean of EV SD Max. # EV 
CQ-25% 1.12 2.09 8 
CQ-50% 3.24 4.38 14 
CQ-100% 0.13 0.41 2 
AQ-50% 0.17 0.53 3 
PYRD-50% 0.23 0.57 3 
PPQ-50% 0.05 0.31 2 
QN-50% 0.21 0.61 3 
MQ-50% 0.19 0.54 3 
DHA-50% 0.31 0.79 4 
ARM-50% 0.31 0.92 4 
DBeQ-50% 0.14 0.45 2 
SK1.47-50% 0.14 0.45 2 
SK1.49-50% 0.11 0.43 2 
Untreated 0.44 1.22 5 
 
Table 5.3 Report of the mean, standard deviation (SD) and maximum (Max.) number of 
cytoplasmic located endocytic vesicles (EV) per cell. 
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5.2.3.2 Quantitative analysis of DV/cytoplasm ratio.  
To explore the qualitative observation that some treatments appear to lead to DV 
swelling, the ratio of the widest point of the DV compared to the widest point of the 
parasite cytoplasm was determined. Given that some images were captures at different 
magnifications and that DV size does change during normal parasite development, this 
normalisation was used to try and minimize the effect of these factors. Lengths were 
determined as pixel counts and used as follows (Fig. 5.17): 
  
 
 
Fig. 5.17 Ultrastructural image of trophozoite stage of P. falciparum challenged with 50% kill 
dose of SK1.49 to illustrate how the ratio of DV/cytoplasm is calculated. DV/cytoplasm ratio 
represents the length of longest width of DV (blue arrow)/ the length of longest width of parasite 
cytoplasm (red arrow), using online pixel ruler (https://www.rapidtables.com/web/tools/pixel-
ruler.html). The scale bar shows 1 µm unit for X 30,000 magnification.  
 
Given the datasets for each treatment consist of 70-80 images, these have been analysed 
as one dataset. To ensure whether this approach is statistically acceptable for data 
developed on different days, the DV ratio count for the two CQ treatments from two 
Length of longest width of DV (blue arrow) 
   Ratio of DV/cytoplasm = 
Length of longest width of cytoplasm (red arrow) 
 X 100 
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different days were compared. T-tests of each pair of data showed no siginificant 
difference between DV ratios developed from TEM produced on two different days (Fig. 
5.18). 
 
Fig.5.18 Shows ratio of DV/cytoplasm of trophozoite stage of P. falciparum following 50% and 
100% of CQ treatment as well as an untreated control. Columns marked 1 and 2 represent two 
different biological replicates. Comparison of these pairs reveals no significant (ns) difference 
between them. 
 
A plot of the distribution of the DV ratio for each treatment shows the wide distributions 
of DV ratio that were expected based on the potential distribution of maturation of 
parasites photographed and that sections may captured through parasites at different 
points in the DV (Fig. 5.19). CQ did not show a concentration-dependant increase in DV 
ratio, with the DV ratio apparently unchanged and not significantly different to that of 
untreated parasites. The DV ratio of the 100% kill treatment is significantly larger (P < 
0.0001) (one-way ANOVA with a Dunnett post-test) – and this result of packing with 
vesicular structures. AQ at 50% kill does provide a significant increase, although a small 
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increase, in DV ratio. This contrasts with the 50% CQ treatment where this effect was not 
observed. PYRD treatment provided no significant difference in DV ratio compared to an 
untreated control, although PPQ treatment does – and again is apparently associated 
with the presence of large numbers of intra-DV vesicles. Treatment with the arylamino 
alcohols QN and MQ both led to a significant increase in the DV ratio, with a DV swelling 
effect comparable to that found in AQ-treated parasites. Of particular note is that 
treatment with neither artemisinin derivatives led to an increase in the DV ratio 
compared to untreated controls. 
 
Fig. 5.19 Scatterplot of the ratio of DV/cytoplasm in drug-treated and untreated parasites. Each 
dot represents the measurement from one cell. Horizontal lines represent the mean. One-way 
ANOVA with a Dunnet post-test comparison to the untreated group was done for all samples. Ns, 
not significant; **, p<0.01; ***, p<0.0001.   
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The putative autophagy inhibitor DBeQ showed a large and significant change in DV ratio 
(Fig. 5.19), reflecting the massive swelling for DV (Fig. 5.10). A DV swelling effect for 
SK1.49 is also evident, although not as great as that of DBeQ. Whilst there is a slightly 
increase in the mean DV ratio for SK1.47, there is no significant difference in the 
distribution of DV ratio compared to an untreated control.   
5.2.3.3 Quantitative analysis of haemozoin crystals. 
A manual counting of haemozoin crystals was done for all treatments with Fig. 5.20 
illustrating examples images and the count of haemozoin crystals. 
 
Fig. 5.20 Ultrastructural image of trophozoite stage of P. falciparum challenged with 50% kill 
dose of putative autophagy inhibitors to illustrate haemozoin crystal counting.  (A) Untreated 
(20 crystals), (B) SK1.47 (8 crystals), (C) SK1.49 (6 crystals) and (D) DBeQ-treated (7 crystals) 
parasites. Note that Hz crystals are marked by white arrows and digestive vacuole (DV). The scale 
bar shows 1 µm unit for X 30,000 magnification. 
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A scatterplot was prepared to illustrate the distribution of haemozoin crystal counts for 
each treatment (Fig. 5.21). One-way ANOVA with a Dunnett post-test explored whether a 
significant difference in the distribution of haemozoin crystal counts compared to the 
untreated sample existed in any treatment. As expected, based on the well-established 
effect of CQ in inhibition of haemozoin formation (Combrinck et al., 2012), a 
concentration-dependent reduction in haemozoin crystal counts were observed.  
 
Fig. 5.21 Scatterplot of haemozoin crystal counts in drug-treated and untreated parasites. Each 
dot represents the measurement from one cell. Horizontal lines represent the mean. One-way 
ANOVA with a Dunnet post-test comparison to the untreated group was done for all samples. Ns, 
not significant; **, p<0.01; ***, p<0.0001.   
 
All treatments, except for the artemisinins, significantly reduced the haemozoin crystal 
count. That artemisinins did not is likely due to have no effect on haem biocrystalization 
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(Chen et al., 2000; Haynes et al., 2003). Of note is that of the four most effective 
compounds in reducing haemozoin crystal count after exposure of a 50% kill 
concentration, three were the putative autophagy inhibitors with PPQ, with the DV 
instead filled with electron-dense vesicles.  
5.3 Discussion  
We describe here a comparative study of ultrastructural changes following exposure to a 
number of antimalarial drugs that achieve a 50% reduction in parasite viability within 6 
hrs exposure time. The ability to measure a defined endpoint using a simple and quick 
assay across a range of drugs, as well as vary the concentration to achieve a different 
killing effect, offers a distinct advantage over previous attempts to carry out comparative 
studies. This is exemplified here using the 25%, 50% and 100% killing concentrations for 
CQ – an approach that is adopted more widely in the next chapter. The processing of 
samples to produce sufficient images for analysis, with over 1000 TEM images analysed 
here, restricted the extent to which this “dial a death” approach could be extended 
beyond CQ in the time available. All the phenotypes found here, however, were 
previously described, although the electron translucent cytoplasmic EV following 
exposure to high concentrations of CQ are rarely commented on, we would suggest that 
our data helps to explore the links between the observations previously made. 
Different ultrasturatural studies on P.  falciparum parasites have described morphological 
changes that  considered the parasite DV as the initial site for action for many blood stage 
antimalarial drugs (Ch’ng et al., 2011; del Pilar Crespo et al. 2008; Chen et al., 2000; 
Roberts et al., 2008; Sachanonta et al., 2011). In addition, inhibition of haemoglobin 
capture and trafficking to the DV via endocytic vesicles  have been previously described in 
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P. falciparum exposed to quinolines and artemisinin (Hoppe et al., 2004; Kawai et al., 
1996). Our observations of the effect of CQ with increasing concentrations mapped to 
their killing effect, potentially brings together these observations. As the CQ 
concentration increases up to the 50% kill, the proportions of cells with more EV 
increases. This was significantly higher compared to 25% of CQ and untreated parasites. 
This is similar to what has been found previously in D10 strain of P. falciparum following 
12 hrs post exposure of 4XIC50 of CQ (Hoppe et al., 2004). This accumulation of EV may be 
due to lysosomotropic feature of CQ, where accumolation of drug within the DV raise the 
its pH and prevents fusion between the EV and DV membrane (Gaviria et al., 2013). 
Alterations in the action of CQ at much higher concentration (e.g. 100% kill dose) included 
accumalation of EV (based on their similar size and density to cytoplasmic EV) inside a 
swollen DV is probably due to involve other targets such as the vacuolar phospholipase 
that may be responsible for digestion of EV membranes allowing their contents to be 
digested (Yayon and Ginsburg, 1983; Waite et al., 1976; Van den Bosch, 1980). Correlating 
with these structural features is that high concentrations of CQ result in the accumulation 
of undigested haemoglobin in the treated parasite (Hoppe et al., 2004; Roberts et al., 
2008). These reports would correlate with our observations of the DV/cytoplasm ratio 
and the count of haemozoin crystals, suggesting that haemoglobin within these vesicles 
are not available for digestion and as a consequence no haem is released for 
polymerization. One potentially novel feature here that needs further investigation is the 
accumulation of the electron-translucent vacuoles at the highest concentration of CQ – 
specifically whether they reflect a defect in haemoglobin feeding from the host 
erythrocyte at high concentrations of CQ. Similarly, additional studies are required to 
explore the nature of the electron dense EV induced upon exposure to CQ. In particular, 
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the use of immuno-TEM with antibodies to Atg8 – these studies attempting to correlate 
whether the Atg8 labelled puncta described in Chapter 3 are the same as the EV 
structures described in the TEM studies in this chapter. An interesting control here may 
be to extend the immuno-TEM to include imaging of parasites subjected to starvation 
conditions; conditions known to induce the distribution of Atg8 labelled puncta. 
Another objective of the comparative study was to determine ultrastructural changes 
following exposure to SK1.47, SK1.49 and DBeQ. Interestingly, they all have similar 
effects, and clearly distinct from those for the classes of antimalarial drugs tested. 
Treatment with these putative modulators of autophagy led to; 
(i) Swollen digestive vacuoles (although data for SK1.47 no significant), that have 
a reduced electron density staining with remnants of Hz crystals. Some 
electron-dense vesicles are observed in the DV of DBeQ treated parasites, 
although they do not share the same morphology as those found in PPQ and 
CQ treated parasites. No evidence of DV membrane breaches. 
(ii) No significant changes in cytoplasmic EV compared to untreated controls. The 
mean EV count and proportion of cells with 2 or more EV were actually lower 
than those of untreated cells for SK1.47, 1.49 and DBeQ, but did not reach 
significance in our analysis. 
The slight reduction in EV numbers following treatment with SK1.47, 1.49 and DBeQ, and 
their correspondingly high numbers in CQ treated parasites shares similarities with the 
numbers of Atg8-labelled vesicles in SK1.47, 1.49 and CQ treated parasites cultured in 
complete medium (as they are here for the TEM study) and imaged using 
immunofluorescence microscopy (Chapter 3). If these EV are the same as Atg8-labelled 
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vesicles, then we can start to interpret our ultrastructure findings on SK1.47, 1.49 and 
DBeQ treatment. Based on the putative function of SK1.47, 1.49 and DBeQ, by 
inhabitation the normal formation of the Atg8-labelled vesicles/EV, then we would expect 
to see less of them. Currently, there is an apparent reduction in the mean number of EV 
(75% reduction, Table 5.3), although there is insufficient data to say this is a significant 
effect. The reduced levels of Atg8-labelled vesicles/EV would reduce the amount of 
haemoglobin delivered to the DV, causing decrease of Hz count due to reduction of free 
haem that release from haemoglobin digestion. Interestingly, MQ inhibits endocytosis of 
FITC-dextran, although not via the same mechanisms as CQ. Hoppe et al. (2004) discussed 
how the inhibition of haemoglobin delivery is distinct between CQ and MQ, with MQ 
reducing haemoglobin delivery as a result of the inhibition of the formation of EV rather 
than blocking their fusion to the DV. This is probably due to the ability of MQ to bind with 
cytoplasmic phospholipids that are required for the formation of EV membrane. Such 
mechanism has also been suggested for QN and AQ, but not for CQ (Barroso et al., 2015; 
Chevli et al., 1982; Ginsburg and Krugliak, 1988; Roberts et al., 2008). If SK1.47, SK1.49 
and DBeQ similarly inhibit EV formation, and these are no longer trafficking haemoglobin, 
then the corresponding observations of a swollen, less electron-dense DV with reduced 
haemozoin crystal count for MQ, QN, SK1.47, SK1.49 and DBeQ may all be related. That 
SK1.47and SK1.49 may interfere with haemoglobin trafficking is certainly a hypothesis to 
follow up, with a research plan that aims to explore whether EV observed under TEM are 
the same as the PfAtg8-labelled puncta in immunofluorescence microscopy. If this 
hypothesis was true, then one aspect of SK1.47 and SK1.49 action may well be starvation 
of macromolecules that needed for growth, specifically in trophozoite stage parasites. In 
addition, these observations have been based only looking at the morphological changes 
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associated with a 50% kill, and yet the potential to explore the evolution of morphological 
changes using a phased 25%, 50% and 100% kill has been demonstrated here for CQ. The 
same phased 25%, 50% and 100% kill for SK1.47, SK1.49 and DBeQ to prepare TEM 
micrographs to compare to those produced in the same way for QN, MQ and perhaps AQ 
treatment may provide a start in exploring whether inhibiting EV formation is a target of 
action for these compounds. 
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Chapter 6: Monitoring biochemical markers of regulated cell death in 
intraerythrocytic P. falciparum exposed to antimalarial drugs, SK1.47 and 
SK1.49 
 
6.1 Introduction  
In the last 2 decades, there was debate about whether P. falciparum undergoes 
programmed cell death (reviewed in Deponte and Becker, 2004; Taylor-Brown and Hurd, 
2013; Sow et al., 2015). The first description on apoptotic features of P. falciparum cell 
death after exposure to CQ, specifically DNA fragmentation, was made by Picot et al. 
(1997). Later work in P. berghei described how apoptotic features such as chromatin 
condensation, DNA fragmentation and externalization of phosphatidylserine (PS) appears 
to be associated with self-limiting infections of the mosquito midgut (Al-Olayan et al., 
2012). Over this period of time there have been a range of studies (Table 6.1) 
investigating the presence of apoptotic features in intraerythrocytic P. falciparum 
exposed to a range of drug or febrile temperature stresses. Together, these reports 
described features such as chromatin condensation, DNA fragmentation, PS 
externalization, ΔΨm collapse, Ca2+ redistribution and activation of Clan CA cysteine 
protease activity (Ch’ng et al., 2010, 2011; Nyakeriga et al., 2006; Meslin et al., 2007). 
There have also, however, been reported that these apoptotic features are not evident 
following drug treatment (Nyakeriga et al., 2006; Porter et al., 2008) or that the features 
of cell death observed were more typical of autophagic-like cell death (Eickel et al., 2013; 
Gaviria et al., 2013; Totino et al., 2008). 
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Author Parasite strain 
(sensitivity to CQ)/stage 
 Method Stimulus 
(Concentration/Time)  
Key features 
Picot et al. 
(1997) 
3D7 strain (CQS) 
Lili strain (CQR) of P. 
falciparum/ Trophozoite 
Western blot  
(Agarose Gel 
Electrophoresis) 
CQ 
(IC50= 40nM/6hrs) 
(IC50= 360 nM/6hrs) 
Only 3D7 strain showed positive DNA laddering.  
Nyakeriga et al 
(2006) 
F32 strain (CQS) of P. 
falciparum/ Trophozoite 
 
FACS 
(DiOC6(3) kit) 
Western blot 
(Agarose Gel 
Electrophoresis) 
CQ (20nM) 
ATQ (2.7µM) 
 
SNAP (600 mM)  
Etoposide (6.8µM) 
20 min drug exposure did show ΔΨm depolarisation, 
except ATQ showed rapid decrease in ΔΨm.    
24 hrs drug exposures did not show DNA positive 
laddering in all treatments. 
Meslin et al. 
(2007) 
3D7 strain (CQS)  
 
 
7G8 strain (CQR) of P. 
falciparum/ Trophozoite 
Fluorescence 
microscopy  
(JC-1/TUNEL-Kit) 
CQ  
(IC90=55nM /18hrs) 
(IC90=55nM/36hrs) 
 
(IC90=1400nM/18hrs) 
(IC90=1400nM/36hrs) 
 
 20% of JC-1 positive cells  
 60% of TUNEL positive cells 
 
 12% of JC-1 positive cells 
 18% of TUNEL positive cells 
Porter et al. 
(2008) 
CSC-1 strain (CQR) of P. 
falciparum/Mature 
blood stages 
FACS  
(DiOC6-Kit) 
Western blot 
(Agarose Gel 
Electrophoresis) 
40 °C (24hrs) 
CQ (100µM/8hrs) 
Staurosporine  
(5µM/8hrs) 
All treatments caused depolarisation in ΔΨm.   
 
No DNA laddering, but reduction in the caspase positive 
cells was detected in all treatments.  
Oakley et al. 
(2007) 
 3D7 strain (CQS) of P. 
falciparum/ Schizont 
Fluorescence 
microscopy (TUNEL kit) 
41°C (2hrs) 60%  TUNEL positive cells 
Ch’ng et al. 
(2010)  
3D7 strain (CQS) of P. 
falciparum/ Late ring 
FACS 
(JC-1/ TUNEL/ CaspaTag 
kit) 
CQ (30µM/8hrs) 
Staurosporine  
(10µM/8hrs) 
31% and 25% depolarisation in ΔΨm, respectively. 27% 
and 56% TUNEL positive cells, respectively. 34% and 
32% of caspase positive cells, respectively.  
Ch’ng et al. 
(2011) 
3D7 strain (CQS)  
7G8 strain (CQR)  
K1 strain (CQR) of P. 
falciparum/ Late ring 
Fluorescence 
microscopy 
(Fluo-4 AM kit) 
 
CQ (3µM/4hrs)  66%, 62% and 25% cytoplasmic redistribution of Ca2+ 
were reported in 3D7, 7G8 and K1, respectively.  
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Pattanapany-
asat et al. 
(2010)  
TM267 strain of P. 
falciparum 
FACS 
(FITC-Annexin V kit) 
38.5-39.0 °C 
Ring stage (18hrs/PI) 
Trophozoite (32h/PI) 
Schizont (42hrs/PI) 
50.2%, 55.8% and 63.6% of PS externalization, 
respectively.  
 
 
Matthews et al. 
(2012) 
ANKA strain of P. 
berghei/Ookinete 
Fluorescence 
microscope 
(JC-1/CaspaTag/ 
/TUNEL/FITC-Annexin V 
kit) 
CQ (1mM/2h) 
 
Staurosporine 
 (15µM/30min) 
No change in ΔΨm in both treatments. 34% and 28% of 
TUNEL positive cells, respectively. 55.8% and 30% of 
caspase positive cells, respectively. 58% PS positive cells 
only in CQ-treated parasites in comparison with 
untreated control (30%).  
Engelbrecht and 
Coeltzer 
(2013) 
3D7 strain (CQS) of P. 
falciparum/Trophozoite  
FACS 
(DiOC6(3)/TUNEL/ 
Caspase kit) 
41°C (24hrs) Slightly increase in depolarised mitochondria, TUNEL 
positive cells and phosphatidylserine externalization.   
Rathore et al. 
(2015) 
3D7 strain (CQS) of P. 
falciparum/Ring stage 
Fluorescence 
microscopy(JC-1/ TUNEL 
/CaspACE/Mag-Fluo-4 
AM) 
MG-132 
(EC50= 50nM/6hrs) 
 
0.39 red/green ratio of JC-1. 43.8% and 35% of TUNEL 
and caspase positive cells, respectively.   
Gunjan et al. 
(2016) 
3D7 strain (CQS)  of P. 
falciparum/ Late ring 
FACS/ 
Fluorescence 
microscopy(JC-1/ TUNEL 
/EnzChek Caspase kit) 
 MQ 
(100nM/24hrs) 
Ratio of red/green JC-1 reduced from 6.1 in untreated 
control to 1.85 in MQ-treated cells. Slightly increase in 
TUNEL-positive cells from 26% to 37%. 76% of caspase 
positive cells were observed. 
Totino et al. 
(2008) 
SPP1 stain (CQR) of P. 
falciparum/Trophozoite  
FACS  
(Rhodamine-123/ 
TUNEL/Z-VAD-fmk-
caspase inhibitor) 
CQ (180nM/24hrs) 
Staurosporine 
(4µM/24hrs) 
SNAP (360 µM/24hrs) 
All drugs showed loss of ΔΨm, 5-9% of TUNEL positive 
cells with absence of Caspase-like activity.  
 
 
Table 6.1 Summary of the literature describing apoptotic features in P. falciparum. Chloroquine (CQ), atovaquone (ATQ), mefloquine (MQ), S-nitro-N-
acetyl-D, L-penicillamine (SNAP), Fluorescence-activated cell sorting (FACS), mitochondrial outer membrane potential (ΔΨm), post infection (PI) and 
phosphatidylserine (PS).  
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One issue within the debate is the use of language and terms associated with regulated 
cell death such as necrosis, apoptosis and autophagic. The Nomenclature Committee of 
Cell Death (NCCD) provides specific definitions for these various pathways (Galluzzi et al., 
2012; 2015). In a recent review (Proto et al., 2013), the term “unregulated cell death” was 
suggested for unicellular protozoan instead of these NCCD definitions which cannot be 
reached by these organisms. Sow et al. (2015) have countered this by saying that the 
NCCD terminology is based on observations of cell death in metazoans and the same 
criteria cannot be used to exclude the existence of regulated cell death pathways in 
unicellular protozoa. For example, the absence of a caspase in P. falciparum would 
prevent the classical definition of apoptosis, although a metacaspase PfMCA1 has been 
described by Meslin et al. (2007) which could act as an initiator of apoptosis through the 
conserved Ca2+ dependant membrane targeting and caspase recruitment domains (Meslin 
et al., 2011; Le Chat et al., 2007). An alternative protease, Clan CA cysteine proteases, 
activating apoptosis in P. falciparum has also been suggested (Ch’ng et al., 2010). 
Perhaps the best described research in this area has been authored by Ch’ng from the 
Tan laboratory in Singapore. They have published a series of papers that specifically 
investigate cell death after exposure to high concentration of CQ (concentrations at µM 
level which is more similar to lethal doses than inhibitory doses) and use a range of 
approaches to study biochemical and structural features of apoptotic cell death. The first 
report, Ch’ng et al. (2010), described how the high concentrations of CQ triggers the 
activity of Clan CA proteases, which probably induce permeabilization of the outer 
membrane of the mitochondria leading to ΔΨm collapse, with DNA fragmentation as the 
final effect. This action following CQ treatment, however, is activated by verapamil and 
was reduced in CQR parasites which led the authors to suggest that the digestive vacuole 
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is likely the source of the Clan CA proteases. This study was followed, Ch’ng et al. (2011), 
by reports describing a rapid and intensive permeabilization of the digestive vacuole 
membrane, although not always ruptured, similarly a lysosome-mediated cell death 
mechanism found in metazoans (Boya and Kroemer, 2008). Observation of Ca2+ 
redistribution from the digestive vacuole following this permeabilization was companied 
by upregulation of the Clan CA protease activity. The potential release of Clan CA 
proteases, such as falcipains as well as plasmepsin IV from the digestive vacuole was 
suggested when high concentrations of CQ used (Ch’ng et al., 2011, 2014). A summary of 
this cascade of events following exposure to high concentrations of CQ is shown in Fig. 
6.1. 
 
Fig. 6.1 Cascade of biochemical markers following exposure of intraerythrocytic P. falciparum to 
high concentrations of CQ. High doses of CQ cause swelling and permeabilization of the digestive 
vacuole (DV) to release Clan CA cysteine proteases. These lead to mitochondrial outer membrane 
permeabilization (MOMP) that triggers (through potentially a range of mechanisms) the complete 
permeabilization of the DV and a large increase in protease activity which ultimately leading to 
DNA damage. The position of inhibitors (VP, verapamil; zVAD, a cysteine protease inhibitor; 4HT, 
4-hydroxytamoxifen) used in the characterization of this cascade are shown. (Source: Ch’ng et al., 
2010).   
 
These studies also highlight two interesting features. First, the use of high concentrations 
of chloroquine to trigger cell death, and not inhibition, correlates with the work of Paul 
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Roepe who suggests that CQ action at inhibitory doses is different to that when used at 
lethal doses (reviewed in Roepe, 2014), although he implicates high concentrations of CQ 
in autophagic-like cell death (Gaviria et al., 2013).  The second is the apparent role of 
ΔΨm collapse during programmed cell death, an observation that has also been linked 
with the triggering of apoptosis by etoposide, reactive oxygen species, staurosporine and 
heat shock (Meslin et al., 2007; Oakley et al., 2007; Porter et al., 2008; Ch’ng et al., 2010). 
Rathore et al. (2011) also showed that disruption of the ΔΨm led to trigger apoptotic cell 
death as suggested by an increase in protease activity and DNA fragmentation. These 
studies led Ch’ng et al. (2013) to suggest that a “powerless” mitochondria may be early 
and common trigger of apoptotic cell death which may providing a new antimalarial drug 
target. 
These reports provide an experimental framework that describes a range of biochemical 
markers implicated in apoptosis following exposure to high concentrations of CQ. This 
framework has been exploited here for a comparative study of these same biochemical 
markers for a wider range of antimalarial drug classes. Based on the loss of 
bioluminescence following 6 hrs of exposure to these different drugs, we aim to obtain 
concentrations that cause 25%, 50% or 90% loss of viability for each drug. This approach 
allows a more effective comparison of the effects between these compounds as they 
have all been used to achieve the same endpoint in the reduction of parasite viability. The 
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same drug classes used for the ultrastructure studies in chapter 5 have been used here 
and this also similarly included SK1.47, SK1.49 and DBeQ to further explore their action 
against the intraerythrocytic trophozoite stage of P. falciparum.  
6.2 Results  
 
6.2.1 Determining the loss of viability endpoints using bioluminescence assay 
To prepare samples for processing for biochemical markers of apoptosis, we first explored 
the concentrations of drugs/compounds to be used to achieve a 25%, 50% or 90% 
reduction in bioluminescence signal. This then being defined as the kill effect. Due to 
variation in the age of erythrocytes, parasitaemia, haematocrit, and synchronicity of 
culture…etc. it was found that the best way to achieve the matched kill effect for 
processing is using 3-4 samples for each kill effect with range of concentrations reported 
in table 6.2. The sample that provided the loss of bioluminescence closest to that 
required was taken for processing. Fig. 6.2 illustrates the normalised (against untreated 
controls) luciferase signal of ten of these experiments taken for processing in the work 
described in this chapter. All comparisons of drug/compound data within the same kill 
effect (e.g. all those that produce a 25% kill) are not significant, where all comparisons 
between the different kill effects for each drug/compound (e.g. 25% v. 50% v. 90%) are 
significant (one-way ANOVA, Bonferroni post-tests, all p < 0.001). 
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Drug LD50 25% kill (nM) 50% kill (nM) 90% kill (nM) 
CQ 790.2 150-250 600-900 3000-4000 
AQ 101.1 20-35 70-100 300-450  
PPQ 297.3 50-80 200-300 800-1200  
PYRD 72.0 15-30 60-90 300-400  
QN 2236.0 400-700 1800-2200 5000-7000 
MQ 65.3 15-25 50-80 250-350  
DHA 12.9 3-5 10-15 50-80 
ARM 15.4 4-7 15-20 60-80 
Compound LD50 25% kill (µM) 50% kill (µM) 90% kill (µM) 
DBeQ 5.4 1-2  5-8 25-40 
SK1.47 7.2 1-3 6-9 30-45 
SK1.49 3.6 0.8-2 4-6 20-30 
 
Table 6.2 LD50 values (from section 3.2.3) and the range of concentrations of drug/compound 
used to provide samples with a 25%, 50% and 90% reduction of viability after treatment.  
 
Fig. 6.2 Loss of normalised bioluminescence signals used to provide matched samples of 25%, 
50% and 90% kill (see X axis for compound and the kill effect achieved) for intraerythrocytic P. 
falciparum used for studies of apoptotic markers. Data from ten experiments for each treatment 
are plotted with the mean indicated by a black bar. 
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6.2.2 Monitoring of mitochondrial outer membrane potential (ΔΨm) collapse following 
drug/compound treatment 
Exposing intraerythrocytic stage of P. falciparum to a range of antimalarial drugs induced 
a collapse of the ΔΨm (Ch’ng et al., 2010; Gunjan et al., 2016; Meslin et al., 2007; Porter 
et al., 2008; Totino et al., 2008). This feature has been assessed using both fluorescence 
microscopy and flow cytometry with range of fluorescent markers of ΔΨm, including the 
MitoProbe JC-1, DiOC6(3) and rhodamine 123. Here, we used the membrane-permeable 
fluorescent JC-1 dye, this provides a potential-dependant accumulation in the 
mitochondrial membrane, where accumulation results in an emission shift from green 
(~530 nm) to red (~590 nm). Collapse of the ΔΨm and subsequently increase in 
mitochondrial membrane permeabilization reduce the accumulation of JC-1, which 
leading to reduction of the red fluorescent signal. As a control in these experiments, the 
ionophore carbonyl cyanide m-chlorophenyl hydrazine (CCCP) was added at final 
concentration 200 µM. At this concentration a rapid collapse of ΔΨm represented by 
reduction of red/green fluorescence ratio was found (Porter, 2007).  
Initial experiments were performed using fluorescence microscopy to monitor the loss of 
a punctate red fluorescent signal (the mitochondria marker). Untreated intraerythrocytic 
cultures show a bright punctate red signal, associated with the mitochondria, and a green 
fluorescent signal associated with accumulation of lower concentrations of JC-1 in the 
cytoplasm (Fig. 6.3). In cultures exposed to CCCP (as a negative control), loss the punctate 
red signal, with observation of a green signal in the cytoplasm were found (Fig. 6.3). 
Exposure to increasing concentrations of CQ, similarly to that reported by Ch’ng et al. 
(2010), caused in a reduction and then complete loss of the red fluorescence signal (Fig. 
6.3). Three independent experiments were carried out, with 60-70 iRBCs/sample were 
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counted for each of the three kill effects (25%, 50% and 90%) for all 11 drugs/compounds. 
The mean ± SD of the iRBCs lacking a red fluorescent signal were counted and are 
reported in Fig. 6.4.   
 
 
 
Fig. 6.3 JC-1 fluorescence assay to monitor ΔΨm collapse following exposure to increasing 
concentrations of CQ. The panels illustrate the brightfield (BF), red and green fluorescence signals 
associated with aggregate and monomer JC-1 forms respectively, nuclear staining (blue) using a 
Hoechst 33342 dye, and a final merge overlay for an iRBC. The y-axis indicates the treatment (or 
untreated control) applied to the culture. The increasing concentration of CQ applied reflects the 
increasing kill effect achieved within 6 hrs.    
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Fig. 6.4 Bar chart reporting the counts of infected erythrocytes (iRBCs) with a collapsed ΔΨm 
(lacking red fluorescent signal from JC-1 aggregate) following exposure to the indicated 
drug/compound.  The key reports the kill effect achieved by the increasing concentrations of the 
drug/compound used. The bars report the mean of three independent counts, with the error bars 
reporting the SD. Below the chart is a table providing a heat map of the statistical test (one-way 
ANOVA, with Dunnett post-test) of the difference compared to the untreated control. The 
coloured boxes in which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, respectively, 
whilst a white box represents no significant difference with the untreated control. 
 
This chart provides a series of expected results, Specifically; (i) the CCCP treatment results 
in the collapse of ΔΨm in the majority (> 90%) of iRBCs (Porter, 2007; Coronado et al. 
2016), noting that a red signal will disappear or typically very small compared to the 
untreated control, (ii) a small proportion of untreated cells lack a red fluorescent signal, 
this has previously been reported (Ch’ng et al., 2010; Totino et al., 2008) and (iii) 
Drug/Comp. CQ AQ PYRD PPQ QN MQ DHA ARM DBeQ SK1.47  SK1.49 
25%                       
50%                       
90%                       
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Concentration-dependent effect for CQ, where increasing the concentration of CQ results 
in increase proportion of cells lacking red signal.  
For all drugs/compounds tested, the proportion of cells with a ΔΨm collapse increased as 
the concentration of compound/drug increases, although the range of this increase is 
clearly different. ΔΨm collapse following exposure to 90% kill dose for drugs/compounds 
was much more significant than those exposed to 25% kill dose (all P < 0.05 using a 
Bonferroni post-test of ANOVA), although the same is not true for all compounds when 
comparing the ΔΨm collapse between the 90% and 50% kill. Comparison of the 
significance of the proportion of parasites showing collapse of ΔΨm for all 
drugs/compounds treatments at three kill effects against the untreated control (one-way 
ANOVA with a Dunnett post-test) are shown as a heat map in Fig. 6.4. The data suggests 
that the extent of the ΔΨm collapse as the concentration of the drug/compound is 
increased shows a trend, where the 4-aminoquinolines and the related PPQ and PYR, 
artemisinins and DBeQ > arylamino alcohols > SK1.47 and SK1.49. 
Inconsistent effects on ΔΨm following treatment with putative autophagy inhibitors were 
observed. These differences are illustrated in Fig. 6.5, where representative fluorescence 
images are shown for DBeQ, SK1.47 and SK1.49, indicating lacking of concentration-
dependent collapse of ΔΨm with the latter two compounds.  
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Fig. 6.5 JC-1 fluorescence assay to monitor ΔΨm collapse following exposure to increasing 
concentrations of SK1.47, SK1.49 and DBeQ by fluorescence microscopy. The panels illustrate 
the brightfield (BF), red and green fluorescence signals associated with aggregate and monomer 
JC-1 forms respectively, nuclear staining (blue) using a Hoechst 33342 dye, and a final merge 
overlay for an iRBC. The y-axis indicates the compound and the kill effect applied to the culture.  
  
216 
 
Exploring ΔΨm collapse using flow cytometry offers the opportunity to monitor the 
red/green fluorescence intensity for thousands of iRBCs (Nyakeriga et al., 2006; Porter, 
2008; Ch’ng et al., 2010; Engelbrecht and Coeltzer, 2013). This was applied here, with 
samples treated as above and then processed for flow cytometry. For each sample, 
100,000 cells include infected and uninfected erythrocytes were analysed.  
Forward and side scatter were used to gate a population of erythrocytes and the 
proportion of green (excitation/emission λ= 488/525nm) and red (excitation/emission λ= 
535/575nm) fluorescent cells in this gated population determined (Fig. 6.6). Thresholds 
for the green and red fluorescence were established using the untreated and CCCP 
controls. The threshold captures the green fluorescent population (all iRBCs) in the region 
H2 for untreated cultures. The same threshold used to monitor red fluorescent 
population in region H3 and this captures the majority of the same population as H2 in 
untreated cells (red fluorescence intensity is less than that of green). The H3 red 
fluorescent population was dramatically reduced in CCCP-treated cultures. Using this 
approach, the proportion of red/green cell counts are used to determine the proportion 
of iRBCs labelled with the JC-1 aggregate (or red signal) as an indicator of normal ΔΨm. 
The cell count v fluorescence intensity plots for cultures exposed to increasing 
concentrations of CQ (Fig. 6.6). As expected, as the concentration of CQ increases the 
proportion of cells gated in H3 (red fluorescence-labelled cells) decreases, reporting an 
increase in proportion of cells with ΔΨm collapse. 
The counting of the proportion of iRBCs with a red fluorescence signal following exposure 
to three kill concentrations (25%, 50% and 90%) of each drug are plotted in Fig. 6.7. The 
untreated control suggests approximately 5% of the parasites lack a red signal, in 
agreement with the direct counts by microscopy. The CCCP treated cultures report 
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around 17% of iRBCs with JC-1 red fluorescence. This appears to be an issue with the ratio 
relying on changes to the green fluorescence signal irrespective of the treatment 
provided. Whilst it is clear that exposure to lower concentrations of compounds has a 
minimal effect on the proportion of green fluorescent parasites compared to the 
untreated control, increasing concentrations of all compounds affects the accumulation 
of JC-1 monomers and thus reduces the proportion of green fluorescent parasites. This 
means that some caution needs to be applied in interpreting Fig. 6.7. 
 
Fig. 6.6 Defining the thresholds H2 (green JC-1 monomer) and H3 (red JC-1 aggregate) used to 
monitor ΔΨm collapse by flow cytometry. Plots of event counts (y axis) versus green and red 
Log10 fluorescence intensity (x-axis) for a gated erythrocyte/infected erythrocyte population 
stained with JC-1. The gates used to count the green (H2) and red (H3) fluorescent cells (events) 
are indicated on each graph along with the treatment applied. Note – CCCP treatment, as well as 
preventing JC-1 aggregate formation (red fluorescence) also affects the accumulation of JC-1 
monomers (green fluorescence) as reflected in the left shift in the fluorescence intensity in this 
population. 
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It appears that SK1.47 and SK1.49 have a minimal effect on ΔΨm, with no significant 
differences between all concentrations used compare to untreated control. A significant 
difference between the proportions of red/green fluorescent cells in untreated cultures 
versus cultures exposed to the highest concentrations of 4 amino-quinolines, artemisinins 
and DBeQ was also evident (Fig. 6.7). These findings agree with those of the direct 
observation of treated parasites by microscopy. 
 
 
Fig. 6.7 Bar chart reporting the proportion of intraerythrocytic parasites retaining a red JC-1 
fluorescence signal following drug/compound exposure by flow cytometry. The y-axis reports 
the proportion of JC-1 red/green labelled iRBCs from analysis of flow cytometry data. The means 
of three independent experiments are shown with error bars reporting the SD. The key indicated 
the kill effect achieved for each of the drugs/compounds tested. Below the chart is a table 
providing a heat map of the statistical test (one-way ANOVA, with Dunnett post-test) of the 
difference compared to the untreated control. The coloured boxes in which red, orange and 
yellow refer to P < 0.0001, 0.001 and 0.05, respectively, whilst a white box represents no 
significant difference with the untreated control. 
Drug/Comp. CQ AQ PYRD PPQ QN MQ DHA ARM DBeQ SK1.47  SK1.49 
25%                       
50%                       
90%                       
219 
 
One potential issue with the scoring system used for fluorescence microscopy is that any 
red punctate signal is scored as a parasite with unaffected mitochondria. This was not the 
case, and is illustrated in Fig. 6.3 where the CQ-25% treated parasite has a smaller red 
punctate signal than an untreated control. This was also an issue with the flow cytometry, 
where exposure to higher concentrations of drugs/compounds (and CCCP) affected both 
the green and red fluorescence intensity, taking events below the threshold applied to be 
determined as positive for green or red fluorescence. To overcome this limitation, we 
applied a “population” rather than a “individual” cell-based approach and monitored the 
red and green fluorescence of the whole population of treated parasites using a 
fluorescence plate reader. Using a 96-well microplate format, three technical repeats of 
each treatment were done, with three biological repeats for each plate (n=9). The red 
fluorescence signal from the CCCP-treated parasites was used as a baseline with the 
subsequent mean of the red/green fluorescence ratio determined as 1 for untreated 
parasites. Thus, a reduction in the relative green/red fluorescence ratio would report a 
loss of red fluorescence signal and thus ΔΨm collapse.  
As above, all compounds/drugs at all concentrations were applied and the mean ± SD of 
the relative red/green fluorescence ratios plotted (Fig. 6.8). A concentration-dependant 
ΔΨm collapse was evident for all compounds tested except SK1.47 and SK1.49. Whilst 
exposure to the highest concentration of SK1.49 produced a significant difference in the 
relative red/green ratio compared to an untreated control, this was only a small 
difference. These results, in terms of the differences achieved and their significance, are 
more comparable to the direct counts from microscopy. However, taken together, all the 
results for the JC-1 assays similarly report;  
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(i) An apparent concentration-dependent effect on ΔΨm collapse for all 
drugs/compounds used except SK1.47 and SK1.49. 
(ii) Minimal effects on ΔΨm when exposed to concentrations of 
compounds/drugs that result in a 25% kill over 6 hrs. 
(iii) SK1.47 and SK1.49 appear to have a minor effect on ΔΨm even when used at 
highest concentrations (90%) – an observation that is very different to that for 
DBeQ. 
 
Drug/Comp. CQ AQ PYRD PPQ QN MQ DHA ARM DBeQ SK1.47  SK1.49 
25%                       
50%                       
90%                       
 
Fig. 6.8 Bar chart reporting the Relative Red/Green Fluorescence JC-1 Ratio in intraerythrocytic 
parasites exposed to the indicated treatment using plate reader. The means (n=9) are shown 
with error bars reporting the SD. The key indicates the kill effect achieved for each of the 
drugs/compounds tested. Below the chart is a table providing a heat map of the statistical test 
(one-way ANOVA, with Dunnett post-test) of the difference compared to the untreated control. 
The coloured boxes in which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, 
respectively, whilst a white box represents no significant difference with the untreated control. 
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(iv) There appears to be a consistent rank order in the effect of the chemical 
classes used in causing ΔΨm collapse, where 4-aminoquinolines, artemisinins 
and DBeQ > arylamino alcohols > SK compounds.  
6.2.3 Monitoring DNA fragmentation following drug/compound exposure  
Evidence to support existence of apoptotic-like cell death in Plasmodium parasites 
includes the detection of DNA fragmentation using the Terminal deoxynucleotidyl 
transferase dUTP Nick End Labelling (TUNEL) assay (Ch’ng et al., 2010; Meslin et al., 
2007). This assay is based on the incorporation of a fluorescein-dUTP (green fluorescence) 
by a terminal deoxynucleotidyl transferase to the free 3' OH ends of genomic DNA 
created by double-strand breaks during apoptotic cell death (Ribeiro et al., 2017). DNase 
I-treated iRBCs served as a control positive. Principally, DNase I induces break in DNA 
double strand that can be labelled (Fig. 6.9), noting that the colocalization of the green 
TUNEL and blue genomic DNA fluorescence signals was dependent for the cells that 
counted as TUNEL-positive cells.    
Initial experiments (data not shown) showed only a very small proportion of TUNEL-
positive cells following exposure to high concentrations of CQ over 6 hrs. As this was the 
case, the experiment was modified to only use concentrations of drugs/compounds that 
killed 50% and 90% of the parasite cultures in 6 hrs. In addition, only one drug from each 
class were selected for the analysis; CQ as a 4-aminoquinoline, QN as the arylamino 
alcohol and DHA for the artemisinin. Compounds SK1.47, SK1.49 and DBeQ were also 
included in all assays. The length of exposure to each concentration used was, however, 
extended to include time points at 6, 24 and 48 hrs based on previous work by Ch’ng et 
al. (2010) that would suggest that DNA fragmentation is a late stage in apoptotic cell 
death. 
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The first analysis scored TUNEL-positive cells by fluorescence microscopy. Fig. 6.9 
illustrates how this scoring was applied using CQ exposure as an example. TUNEL-positive 
cells were defined as having a distinct punctate (not dispersed) green fluorescent signal 
that overlapped with the blue fluorescence stain of genomic DNA by Hoechst 33342. 
Experiments were done in triplicate, with the proportion of TUNEL-positive cells from 
counts of 60-70 iRBCs for each drug/compound treatment scored and the mean ± SD 
plotted (Fig. 6.10). As expected, > 90% TUNEL-positive cells following DNase I treatment 
were reported. This is similar to previous work by others (Engelbrecht et al., 2012). A 
small proportion of untreated cells was also labelled by a green fluorescence – these 
reflecting either a background of dead or dying cells or an artefact of labelling in parasites 
undergoing DNA replication. The data shows a time-dependant effect, with the highest 
proportions of TUNEL-positive cells found after 48 hrs (Fig. 6.10). Concentration-
dependant effect, however, is lacking in this assay as comparison of the proportions of 
TUNEL-positive cells at equivalent timepoints for two concentrations of drugs/compounds 
are not significantly different (ANOVA, Bonferroni post-test). Comparison of TUNEL 
labelling of all samples against the untreated control only reveal a significant difference 
after 48 hrs for CQ, DHA, DBeQ and SK1.49, with the latter having the lowest proportion 
of TUNEL-labelled cells in this group (Fig. 6.10).  
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Fig. 6.9 TUNEL assay of P. falciparum infected RBCs exposed to 50% and 90% kill concentrations 
of CQ for 6 hrs using fluorescence microscopy. Panels show brightfield (BF), green fluorescein 
labelling by the TUNEL assay, nuclear DNA staining using Hoechst 33342 (blue fluorescence) and a 
merged overlay of these images. The bar in the first panel is 5 µm in size.  
 
To increase the numbers of events monitored, the assays were repeated and TUNEL-
positive iRBCs scored using flow cytometry. The assay was repeated three times, with the 
parasitaemia at the start of each experiment being determined using SYBR Green I 
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staining and counting by flow cytometry (Fig. 6.11). Counterstaining of the TUNEL assays 
with SYBR Green I was not possible as both depending on detection of green 
fluorescence. Using the forward/side scatter, the population of erythrocytes (infected and 
uninfected) were gated and the green fluorescence intensity versus side scatter plotted 
(Fig. 6.11). A fixed quadrant was established and threshold selected based on the 
detection of SYBR Green I stained iRBCs (Fig. 6.11C) and a minimum background for 
TUNEL-stained parasites in an untreated parasite culture (Fig. 6.11F). 
 
Drug 
/Comp. 
CQ-
50% 
CQ-
90% 
QN-
50% 
QN-
90% 
DHA-
50% 
DHA-
90% 
DBQ-
50% 
DBeQ-
90% 
SK1.47-
50% 
SK1.47-
90% 
SK1.49-
50% 
SK1.49-
90% 
6hrs                         
24hrs                         
48hrs                         
 
Fig. 6.10 TUNEL assay of DNA fragmentation in intraerythrocytic P. falciparum exposed to 
timecourse treatment of CQ, QN, DHA and putative autophagy inhibitors using fluorescence 
microscopy. The mean proportion of TUNEL-positive infected erythrocytes (iRBCs) scored is 
shown with ± SD (n=3). The key provides information of the length of exposure of cultures to the 
indicated drug/compound at the concentration that kills 50% and 90% of parasites after 6 hrs. 
Below the chart is a table providing a heat map of the statistical test (one-way ANOVA, with 
Dunnett post-test) of the difference compared to the untreated control. The coloured boxes in 
which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, respectively, whilst a white box 
represents no significant difference with the untreated control. 
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These parameters were used to confirm the detection of a high proportion of TUNEL-
positive parasites treated with DNase I (Fig. 6.11G). Additionally, the proportion of 
TUNEL-positive cells following 50% (Fig. 6.11H) and 90% (Fig. 6.11I) concentrations of CQ 
were reported. These parameters were saved and used to determine the proportion of all 
iRBCs (determined using SYBR Green I) and TUNEL-positive cells following exposure to 
50% and 90% kill concentrations of the drugs/compounds for 6, 24 and 48 hrs (Fig. 6.12).  
 
 
Fig. 6.11 Establishing the parameters for monitoring DNA fragmentation in compound/drug 
treated intraerythrocytic P. falciparum using the TUNEL assay using flow cytometry. A and D are 
forward and side scatter plots of untreated P. falciparum culture used to select the indicated 
gated region which is then highlighted in panels B and E, respectively. The events in the gated 
region of B are then plotted in C showing the fluorescence signal from SYBR Green I staining – this 
establishes the parasitaemia at 6.56%. The events in the gated region of E are similarly plotted in 
F to monitor the green fluorescence from the TNEL assay. Here –indicates that 3.8% (0.25/6.56) of 
the untreated parasites are TUNEL-positive. A similar plot of DNase treated parasites in G 
indicates that 82.6% (5.42/6.56) of the iRBCs are TUNEL-positive. Panels H and I represent the 
outcome following exposure to 50% (9.5%) and 90% (5.9%) of CQ for 6 hrs. 20,000 events are 
analysed in each experiment. 
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The controls in the flow cytometry analysis of TUNEL-staining provided almost identical 
results for the untreated and DNase treated controls in the direct microscopy count. 
Statistical analysis using ANOVA with a Bonferroni post-test revealed no significant 
differences when comparisons were made to explore a concentration-dependant effect 
of each compound/drug (compare matched timepoints between the 50% and 90% kill) or 
a time-dependant effect (compare timepoint data for each concentration of 
compound/drug). This outcome reflects the range of TUNEL-positive data between 5-
15%, with comparisons against the untreated control revealing no consistent pattern of 
significant differences on treatment with different drugs/compounds over different 
timepoints (Fig. 6.12).  
 
Drug 
/Comp. 
CQ-
50% 
CQ-
90% 
CQ-
100µM 
QN-
50% 
QN-
90% 
DHA-
50% 
DHA-
90% 
DBQ-
50% 
DBeQ-
90% 
SK1.49-
50% 
SK1.49-
90% 
SK1.47-
50% 
SK1.47-
90% 
6hrs                           
24hrs                           
48hrs                           
 
Fig. 6.12 TUNEL assay of DNA fragmentation in intraerythrocytic P. falciparum exposed to 
timecourse treatment of CQ, QN, DHA and putative autophagy inhibitors using flow cytometry. 
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The mean proportion of TUNEL-positive infected erythrocytes (iRBCs) scored by flow cytometry is 
shown with ± SD (n=3). The key provides information of the length of exposure of cultures to the 
indicated drug/compound at the concentration that kills the indicated % of parasites after 6 hrs. 
Below the chart is a table providing a heat map of the statistical test (one-way ANOVA, with 
Dunnett post-test) of the difference compared to the untreated control. The coloured boxes in 
which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, respectively, whilst a white box 
represents no significant difference with the untreated control. 
 
The outcome reflects no clear evidence of DNA fragmentation following exposure to CQ, 
and this correlates with Totino et al. study (2008), although differs from Ch’ng et al. 
(2010). Given the potential that the lethal effect even at concentrations that kill 90% of 
parasites in 6 hrs was not enough, the analysis was repeated using a supralethal dose of 
100 µM (Fig. 6.12). Again, no significant differences in TUNEL-positive cells compared to 
an untreated control were found. Resetting the fluorescence thresholds used to 
determine TUNEL-positivity cells did not change these observations (data not shown). 
6.2.4 Monitoring protease activity following drug/compound exposure  
Ch’ng et al. (2010, 2011) reported an increase in a Clan CA cysteine protease activity in 
intraerythrocytic trophozoite stage of P. falciparum following exposure to high 
concentrations of CQ, with similar observations of increased protease activity in 
mefloquine-treated parasites (Gunjan et al., 2016). Again, there are also reports that 
described the absence of protease activity in CQ-treated parasites (Nyakeriga et al., 2006; 
Porter et al., 2008; Totino et al., 2008). Clan CA cysteine protease activity was defined by 
Ch’ng et al., (2010) based on the use of different inhibitors of protease classes. Typically, 
a CaspaTag-Pan Caspase assay employs a sulforhodamine-labelled peptide inhibitor (SR-
VAD-FMK) of the caspase enzyme complex (typically a dimer). Irreversible binding of the 
inhibitor to the proteolytic cleavage site keeps the sulforhodamine-labelled peptide 
inhibitor in the cell after a series of wash steps (Fig. 6.13). The fluorescent signal being 
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monitored using a range of techniques include; fluorescence microscopy and flow 
cytometry. The caspase assay typically used in P. falciparum is the CaspaTag Pan-Caspase 
In Situ – a general assay format that does not readily distinguish between cysteine 
protease classes.  
 
 
Fig. 6.13 CaspaTag staining of intraerythrocytic trophozoite stage of P. falciparum exposed to 
CQ. The panels show brightfield (BF), CaspaTag (red fluorescence from sulforhodamine), Hoechst 
33342 (nuclear stain) and a merged overlay. The y axis indicates either the untreated control or 
experiments using concentrations of CQ that provide a 50% or 90% kill. Next to each line is 
whether this would be determined as a CaspaTag-labelled cell or not.  Row from the top, 
untreated control, CQ-50% and CQ-90% treated parasites for 24 hrs. The bar is 5 µm.    
 
However, to explore the action of protease activity following exposure to these 
drugs/compounds, the same CaspaTag Pan-Caspase In Situ assay format, utilising a 
sulforhodamine (red) fluorescent marker was employed. As with the TUNEL assay, initial 
data suggested low levels of proteases activity (Fig. 6.14). As such, the same approach 
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was adopted; using CQ and QN at 50% and 90% kill concentrations, but the time of assay 
extended to monitor effects at 6, 24 and 48 hrs. Three independent experiments, each 
counting approximately 60-70 iRBCs/sample, were done, with the mean ± SD of 
CaspaTag-positive cells plotted (Fig. 6.14). 
 
Drug CQ-50% CQ-90% QN-50% QN-90% 
6hrs         
24hrs         
48hrs         
 
Fig. 6.14 Timecourse of CaspaTag staining of intraerythrocytic P. falciparum exposed to CQ and 
QN. The mean proportion of CaspaTag-positive cells (n=3) are shown with the SD as error bars. 
The key indicates the timepoint the determination presented was done. Below of the chart is a 
table providing a heat map of the statistical test (one-way ANOVA, with Dunnett post-test) of the 
difference compared to the untreated control. The coloured boxes in which red, orange and 
yellow refer to P < 0.0001, 0.001 and 0.05, respectively, whilst a white box represents no 
significant difference with the untreated control. 
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Whilst the overall proportion of CaspaTag-labelled parasites is low, a slight trend using CQ 
does emerge. Exposure to a higher concentration of CQ or for a longer time does result in 
a higher proportion of CaspaTag-labelled parasite, although the variance in data means 
not significant for all comparisons. These trends are not evident using QN. Comparison of 
the CaspaTag labelling to an untreated control does not reveal a consistent pattern of 
significant time-dependant labelling.  
For further exploring of protease activity, CaspaTag assay was repeated for one 
antimalarial drugs in each class (CQ, QN and DHA) as well as included DBeQ, SK1.47 and 
SK1.49 using flow cytometry. As with the TUNEL assay, the parasitaemia of the untreated 
parasite culture was determined using SYBR Green I fluorescence staining (Fig. 6.15). By 
using the similar forward and side scatter parameters, the population of infected and 
uninfected erythrocytes were gated and counts of the SYBR Green I or sulforhodamine 
fluorescent parasites determined to provide a determination of the proportion of 
CaspaTag-labelled parasites (Fig. 6.15).   
The mean proportion of CaspaTag-labelled cells from three independent experiments was 
plotted (Fig. 6.16). Our analysis suggests that assays performed at 48 hrs tend to have 
more CaspaTag-labelled parasites than those determined after only 6 hrs, although the 
variance in the data doesn’t allow a significant trend to be established for all treatments. 
The data also shows that the highest concentrations of QN and the two SK compounds at 
48 hrs exposure have significantly higher proportions of CaspaTag-labelled parasites 
compared to the untreated control. This observation, however, is balanced by the 
inconsistencies in the same data for DHA, where a longer incubation results in a decrease 
in the proportion of CaspaTag-labelled parasites. Again, based on the work of Ch’ng et al. 
(2010), we also included a supralethal concentration (100 µM) of CQ which again did not 
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provide any evidence of an appreciable change in the proportion of CaspaTag-labelled 
parasites at any timepoint. Readjustment the thresholds again did not provide any 
evidence of consistent trends.  
 
 
Fig. 6.15 Establishing the parameters for monitoring cysteine protease activity in 
compound/drug treated intraerythrocytic trophozoite stage of P. falciparum using the CaspaTag 
assay. A and D are forward and side scatter plots of untreated P. falciparum culture used to select 
the indicated gated region which is then highlighted in panels B and E, respectively. The events in 
the gated region of B are then plotted showing the fluorescence signal from SYBR Green I staining 
– this establishes the parasitaemia at 5.9%. The events in the gated region of E are similarly 
plotted in F to monitor the red fluorescence from the CaspaTag assay. Here this indicates that 3% 
(0.18/5.91) of the untreated parasites are CaspaTag-positive. Panels G, H and I represent the 
outcome following exposure to 50% (9.5%) and 90% (8.0%) of CQ or 90% (11.7%) of QN, kill 
effects respectively. 20,000 events are analysed in each experiment. 
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CQ-
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CQ-
100µM 
QN-
50% 
QN-
90% 
DHA-
50% 
DHA-
90% 
DBQ-
50% 
DBeQ-
90% 
SK1.49-
50% 
SK1.49-
90% 
SK1.47-
50% 
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Fig. 6.16 CaspaTag assay of cysteine protease activity in intraerythrocytic P. falciparum exposed 
to timecourse treatment of CQ, QN, DHA and putative autophagy inhibitors. The mean 
proportion of CaspaTag-positive infected erythrocytes (iRBCs) scored by flow cytometry is shown 
with ± SD (n=3). The key provides information of the length of exposure of cultures to the 
indicated drug/compound at the concentration that kills the indicated % of parasites after 6 hrs. 
Below the chart is a table providing a heat map of the statistical test (one-way ANOVA, with 
Dunnett post-test) of the difference compared to the untreated control. The coloured boxes in 
which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, respectively, whilst a white box 
represents no significant difference with the untreated control. 
 
6.2.5 Assessment of Ca2+ redistribution following drug/compound exposure 
The parasite digestive vacuole provides a dynamic store of Ca2+ in intraerythrocytic 
trophozoite stages of P. falciparum and plays a critical role in parasite development by 
controlling intracellular Ca2+ signalling (Biagini et al., 2003). Ch’ng et al. (2011) suggested 
that the high concentration of CQ causes partial permeabilization of the digestive 
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vacuole, leading to a redistribution of Ca2+ from this compartment into the parasite 
cytoplasm which may acts as a trigger for subsequent apoptotic processes. Similarly, 
Caridha et al. (2008) demonstrated a redistribution of Ca2+ in mammalian cells following 
exposure to MQ. To explore the early effects of antimalarial drugs/compounds on Ca2+ 
distribution, the Ca2+ indicator Fluo-4-AM was used with fluorescence microscopy. 
Parasite cultures were initially exposed to 25%, 50% and 90% kill concentrations of CQ 
and the distribution of the green fluorescent Fluo-4-AM dye monitored by fluorescence 
microscopy (Fig. 6.17). Untreated control parasites have a punctate green fluorescent 
signal, spatially separated from the nucleus that represents the concentration of Ca2+ 
stores in the digestive vacuole (Biagini et al., 2003; Ch’ng et al., 2011) as visualised with 
the dense hemozoin material in the brightfield image. In exposure to increasing 
concentrations of CQ, this Ca2+ store is redistributed to the cytoplasm, losing its distinct 
punctate distribution that does not overlap with the nucleus, where often an unlabelled 
space representing the position of the digestive vacuole is left. At the highest 
concentrations of CQ, this latter unlabelled compartment was lost in small proportion of 
iRBCs, suggesting that complete permeabilization of the digestive vacuole occurred and 
the Ca2+ distributed throughout the parasite cytoplasm.  
Using the same protocol and scoring process, the distribution of Ca2+ following treatment 
with 25%, 50% and 90% kill concentrations of the benchmark antimalarials and putative 
autophagy inhibitors was assayed. The mean proportion of digestive vacuole and 
cytoplasm that stained with Fluo-4-AM or unlabelled (i.e. nuclear stain only observed) for 
three independent experiments is shown (Fig. 6.18). The untreated sample predominantly 
consists of digestive vacuole labelling (mean of 85%), with smaller proportions showing 
cytoplasmic staining (9%) or unlabelled (5%). As expected from the work reported by 
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Fig. 6.17 Monitoring of Ca2+ distribution in intraerythrocytic P. falciparum exposed to 25%, 50% 
and 90% kill concentration of CQ. Panels show brightfield (BF), Fluo-4 AM (green) fluorescence 
located either as a punctate signal collocated with the hemozoin of the digestive vacuole (white 
arrows) in untreated or 25% CQ killed parasites or distributed throughout the cytoplasm (CQ>50% 
kill), Hoechst 33342-stained nucleus (blue fluorescence) and a merged overlay. The bar is 5 µm.  
 
 
235 
 
Ch’ng et al. (2011), a cytoplasmic redistribution of Ca2+ appears to follow a concentration 
dependent trend. This appears to be feature for the 4-aminoquinolines CQ, AQ, PPQ and 
PYRD treatment (Fig. 6.18), but less obviously for the other drugs/compounds tested.  
 
Fig. 6.18 Monitoring of Ca2+ distribution in intraerythrocytic P. falciparum following exposure to 
benchmark antimalarials and putative autophagy inhibitors. The mean proportion of parasites 
exhibiting either cytoplasmic (red bar), digestive vacuole (blue bar) or no Fluo-4-AM staining (grey 
bar) are reported. The indicated kill concentration used is indicated on the x-axis for the indicated 
drug/compound. Data represent means from three replicate experiments, each counting 60-70 
infected erythrocytes (iRBCs). 
 
To explore this trend, the mean ± SD of the cytoplasmic distribution of Ca2+ were plotted 
separately and a statistical analysis (one way-ANOVA with a Dunnett post-test) of these 
data, compared to the untreated control done (Fig. 6.19). The data indicates a clear 
evidence of statistically significant concentration-dependent redistribution of Ca2+ into 
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the cytoplasm at 50% and 90 kill concentrations for the 4-aminoquinolines tested. The 
significant difference in the redistribution of Ca2+ into the cytoplasm are only otherwise 
observed for the highest concentrations of DHA, although the extent of this redistribution 
is much lower than that observed for the 4-aminoquinolines (Fig. 6.19). 
 
Drug/Comp. CQ AQ PYRD PPQ QN MQ DHA ARM DBeQ SK1.47  SK1.49 
25%                       
50%                       
90%                       
 
Fig. 6.19 Proportion of intraerythrocytic parasites showing cytoplasmic redistribution of Ca2+ 
following drug/compound treatment. Note this data is a subgroup of that presented in Fig. 6.18 
and reports the mean proportion ± SD of infected erythrocytes with cytoplasmic distribution of 
Fluo-4-AM green fluorescence. Below the chart is a table providing a heat map of the statistical 
test (one-way ANOVA, with Dunnett post-test) of the difference compared to the untreated 
control. The coloured boxes in which red, orange and yellow refer to P < 0.0001, 0.001 and 0.05, 
respectively, whilst a white box represents no significant difference with the untreated control. 
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6.2.6 Assessment of phosphatidylserine externalization following compound/drug 
treatment 
A well described feature of apoptosis in higher eukaryotes is the externalization of 
phosphatidylserine (PS), normally restricted to the inner surface of a lipid layer, to act as a 
signal for a damaged cell to be phagocytosed. Whilst the redistribution of PS onto the 
exofacial surface of iRBCs was not specifically studied in the Ch’ng et al. (2010, 2011, 
2013) studies, this phenomenon has been described in P. falciparum following heat shock 
(Pattanapanyasat et al., 2010; Engelbrecht and Coetzer, 2013) or in P. berghei ookinetes 
within the mosquito midgut under normal growth condition (Al-Olayan et al., 2012). 
Externalization of PS was assayed in iRBCs following drug and heat stresses using a FITC-
labelled Annexin V, a protein with a high binding affinity for PS, with fluorescence 
microscopy. Initial experiments were done using 50% and 90% kill concentrations of CQ, 
QN, DHA and DBeQ.  
Two independent experiments were imaged using these conditions, with the fluorescence 
microscopy revealed no evidence of FITC-Annexin V staining of infected erythrocytes. Fig. 
6.20 illustrates images collected for CQ and QN treatments, with that for DBeQ and DHA 
not shown. Quantitative analysis was not done as there is no evidence of PS 
externalization.  
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Fig. 6.20 Fluorescent microscopy of CQ and QN treated intraerythrocytic parasites to monitor 
phosphatidylserine (PS) externalization. Panels illustrate untreated and treated cultures (see y-
axis for drug and concentration used) as brightfield (BF), FITC-Annexin V (green fluorescence) and 
Hoechst 33343 nuclear stain as well as a merged overlay.  
 
For further exploring, the assay was repeated using a heat shock treatment previously 
reported to induce PS externalization from mature intraerythrocytic trophozoite parasites 
using flow cytometry (Engelbrecht and Coetzer, 2013). Trophozoite parasites were 
exposed to 40 °C for 2, 4 or 8 hrs and replaced at 37 °C. Imaging of PS  externalization was 
performed at 8 or 48 hrs timepoint to explore whether this was an early or late effect of 
cell death. Both timepoints did not show any evidence of PS externalization (Fig. 6.21 and 
Fig. 6.22), despite the bioluminescence assay clearly showing both treatments provide a 
time-dependant loss of parasite viability (Fig. 6.23).  
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Fig. 6.21 Fluorescent microscopy of heat-shock treated intraerythrocytic parasites to monitor 
phosphatidylserine (PS) externalization at 8 hrs timepoint. Panels illustrate untreated and 
treated cultures (see y-axis for drug and concentration used) as brightfield (BF), FITC-Annexin V 
(green fluorescence) and Hoechst 33343 nuclear stain as well as a merged overlay. Cultures were 
exposed to 40 °C for the indicated time and returned to 37 °C for the time indicated in brackets. 
All images were developed after 8 hrs.  
 
 
 
Fig. 6.22 Fluorescent microscopy of heat-shock treated intraerythrocytic parasites to monitor 
phosphatidylserine (PS) externalization at 48 hrs timepoint. Panels illustrate untreated and 
treated cultures (see y-axis for drug and concentration used) as brightfield (BF), FITC-Annexin V 
(green fluorescence) and Hoechst 33343 nuclear stain as well as a merged overlay. Cultures were 
exposed to 40 °C for the indicated time and returned to 37 °C for the time indicated in brackets. 
All images were developed after 8 hrs. 
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Fig. 6.23 Relative growth of trophozoite stage of P. falciparum following heat shock (40°C). 
Relative growth (treated versus control maintained at 37 °C) following heat shock (40 °C) for 2, 4 
or 8 hrs and assessment at (A) 8 hrs or (B) 48 hrs after the start of the experiment. Heat-shocked 
cultures were returned to 37 °C after heat shock until the assay period. Mean ± SD of three 
independent replicates. 
 
6.3 Discussion  
The research in this chapter was based on the experimental framework proposed by 
Ch’ng et al. (2010; 2011) to explore apoptotic features in trophozoite stages of 3D7 (CQS) 
P. falciparum exposed to high concentrations of CQ. Some of their observations were 
described here in Dd2 (CQR), specifically; 
(i) That high concentrations of CQ result in a significant concentration-
dependant collapse of ΔΨm. 
(ii) That high concentrations of CQ result in a significant concentration-
dependant redistribution of Ca2+ from the DV into the parasite cytoplasm, 
indicating a partial permeabilization of the DV membrane. 
The evidence that support an increase in Clan CA cysteine protease activity or DNA 
fragmentation was less clear. In both cases, the fluorescence microscopy data suggested 
that the highest levels of both was achieved using the highest concentration of CQ for the 
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longer period of time, although the flow cytometry data did not report any significant 
evidence for this trend. The absence of these observations here is supported by that 
originally reported by Nyakeriga et al. (2006) who argued for the absence of apoptotic cell 
death following CQ treatment, although the concentrations we use here are much higher 
than the 20 nM that used in their study. In our study, using a different strain that is CQR 
should not be a contributing factor to these differences as the concentrations of CQ that 
used are high – and were shown to be able to kill 50% and 90% of the parasites. Of note, 
however, is that drawing a comparison to Ch’ng et al. (2010; 2011) has to be done 
carefully as their reports do not describe the kill effects they achieved in the CQS 3D7 
parasite strain used – although 3 µM should kill at least 90% of this strain. For both the 
CaspaTag and TUNEL experiments a supralethal dose of CQ (100 µM) was also used in 
Dd2luc, and this did not change the observations of the low levels of cysteine protease or 
DNA fragmentation activities. These data was again agreed with those obtained by Porter 
et al. (2008) using supralethal dose (100 µM) of CQ for 8 hrs. The effects explored here 
were established to specifically examine early cell death effects, i.e. most assays were 
carried out within 6 hrs. The CaspaTag and TUNEL assays were extended to 48 hrs, as 
these effects may be later events in cell death, but again these did not provide high 
statistically significant evidence of cysteine protease activity or DNA fragmentation 
beyond the trend outlined above. Based on these factors, it seems that there is no 
evidence of apoptotic features of cysteine protease activity or DNA fragmentation 
following treatment with high concentration of CQ.  
It is perhaps important to explore the potential limitations of the framework of 
experiments used here. Ch’ng et al. (2011 and 2012) explore the CQ concentration-
dependant collapse of ΔΨm using the JC-1 dye. Whilst JC-1 accumulation within discrete 
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cellular compartments, the mitochondria, is evident in imaging assays, there is likely 
membrane-potential accumulation of JC-1 due to membrane potential over the parasite’s 
plasma membrane (Antoine et al., 2013). Indeed, Figure 6.3 and 6.5 illustrate some 
accumulation across the parasite cytoplasm (green fluorescence signal) after the JC-1 dye 
has been removed by washing. This green fluorescence signal may mask low levels of JC-1 
accumulation in the mitochondria following drug exposure. Thus, addition of a specific 
inhibitor of vacuolar-type (H+)-ATPases that generate the plasma membrane potential, 
using bafilomycin A1 or concanamycin A (Antoine et al., 2013), could be considered here. 
Similarly, fluorescent imaging studies of sub-cellular compartments, particularly the 
digestive vacuole with Fluo-4 AM based dyes needs to recognise that haem may 
quench fluorescence emissions below 600 nm (Esposito et al., 2008). 
Perhaps the most novel aspect of this study was the use of the bioluminescence assay of 
parasite viability to provide samples exposed to concentrations of different benchmark 
antimalarial drugs that provide a comparable kill. This comparison is drawn out in the 
next conclusions chapter as it allows the electron micrographic study of ultrastructural 
changes to be integrated. That said, one point that is worth mentioning here is that the 
analysis of the different biochemical markers of parasites exposed to a 25% kill indicated, 
in general, showed no significant difference compare to the untreated control. Whilst the 
25% kill concentrations used were the lowest of the three tested, they are close to the 
EC50 concentrations. This observation seems to agree with the key point that Ch’ng and 
his colleagues were made, including that high concentrations of the drug are required to 
trigger biochemical markers associated with apoptotic cell death, with lower 
concentrations, more similar to EC50 concentrations unlikely to trigger apoptosis.    
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The including of SK1.47 and SK1.49 in this chapter was done to explore whether their 
action was linked to apoptotic markers of cell death, and how distinct their features were 
to those of CQ. The data for both compounds indicated; 
(i) Neither compound appeared to provide for a significant concentration-
dependant collapse of ΔΨm. 
(ii) Neither compound appeared to provide for a significant concentration-
dependant redistribution of Ca2+ from the DV into the parasite cytoplasm, 
indicating no apparent effect on DV membrane permeabilization. 
(iii) Neither compound provided evidence of induction of cysteine protease 
activity or DNA fragmentation. Although these features were not evident for 
antimalarial drug treatment as well.  
This would suggest that the rapid cell death triggered by exposure to high concentrations 
of SK1.47 or SK1.49 does not share hallmark features of apoptosis and appear to undergo 
a mechanism of cell death distinct from the benchmark antimalarial drugs that tested 
here. Perhaps not unexpected as we would support a role for these compounds in 
inhibiting autophagy, but this need not necessarily implicate autophagic cell death as the 
route of cell death using these compounds. This is perhaps is more interesting when 
comparing the results of SK1.47 and SK1.49 with those of DBeQ. The ultrastructure 
studies suggested that these three compounds share same effects, where all resulted in a 
swollen DV, no increase in EV vesicles and a decrease in Hz crystals in the DV. Yet here we 
see that DBeQ does cause a significant concentration-dependant collapse of ΔΨm with 
the highest concentration appearing to double the proportion of TUNEL-positive cells 
after 48 hrs. Interestingly, like SK1.47 and SK1.49, there was no apparent evidence of Ca2+ 
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redistribution following DBeQ treatment, despite the electron micrographs suggesting 
that the DV were swollen. It appears that swelling of the DV not include loss in their 
membrane integrity as this was supported by no significant evidence of Ca2+ 
redistribution, instead this being a feature of the 4-aminoquinolines and closely related 
drugs.  
The absence of PS externalization following drug/compound exposure required a positive 
control of the assay to confirm that the Annexin V assay was working. This, we thought, 
would be provided by the heat shock experiment. Yet, despite evidence that the heat 
shock conditions used, the same as previously reported by Engelbrecht and Coetzer 
(2013), provided a time-dependant loss of parasite viability, no evidence of PS 
externalization was observed in our study. One observation made during the fluorescent 
microscopy did support that the assay was functional. For a small proportion of parasites, 
marked with the Hoechst (a DNA dye), a green fluorescent signal was seen – although 
brightfield examination indicated that these parasites were not intracellular (Fig. 6.24). 
Here the brightfield image along with the propidium iodide staining of the parasite 
nucleus clearly demarcates three parasites within a membrane stained with FITC-Annexin 
V. Principally, for propidium iodide to stain the parasite nucleus, the host erythrocyte 
membrane must be compromised (Mendiratta et al., 2006). This would similarly suggest 
that Annexin V has access to internal PS labelled membranes. This was also shown by 
extensive Annexin V staining following treatment of a culture with 1% (w/v) saponin (data 
not shown). We would suggest that the methodology of the Annexin V assay needs to 
carefully consider whether it could lead to access of the stain into the infected 
erythrocyte – for example by exposure to potential hypotonic shock during staining or 
shear pressure during flow cytometry. Where fluorescent microscopy has been used to 
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report Annexin V staining of infected erythrocytes elsewhere (Pattanapanyasat et al., 
2010), comparison of these images with our own suggest that these may not be 
intraerythrocytic parasites (Note in lower panel B of Fig. 6.24 that the indicated 
trophozoite stage parasite is imaged next to an out of focus erythrocyte). 
 
 
Fig. 6.24 Fluorescent microscopy of PS staining. The top panels represent images developed in 
this study showing brightfield (BF), red fluorescent propidium iodide (PI)-stained nucleus, green 
fluorescent Annexin V-stained phosphatidylserine and overlay. Note that images in the bottom 
panels represent red fluorescent propidium iodide and green fluorescent Annexin V staining of (A) 
ring, (B) trophozoite and (C) schizont stage of intraerythrocytic parasites (Pattanapanyasat et al., 
2010) prepared for flow cytometry. Note the size of the erythrocyte in panel B and the presence 
of haemozoin stained DV in the ring stage parasite (panel A).  
 
Whilst PS externalization is not a marker of cell death in P. falciparum, data presented 
here suggests that the comparative approach adopted here has some potential in 
exploring the potential for a time-dependant cascade of biochemical markers of cell 
death – with  ΔΨm collapse as a key initial marker of this event. Additional timepoints 
before and after the 6 hrs used here would be useful. In addition, exploring the effect of 
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these benchmark antimalarial drugs, particularly the 4-aminoquinolines in a CQS strain 
would be interesting (M. Hmoud has created a NF54luc strain (CQS) in our laboratory using 
the same luciferase reporter cassette used to genetically modify the Dd2luc strain that 
used here). Particularly to explore whether the same concentration dependant effects on 
ΔΨm collapse and Ca2+ redistribution happen in CQR and CQS parasites exposed to 
concentrations of CQ that produce the same kill effect in both parasite strains. In the 
same way, altering the expression of the luciferase reporter gene to take place in ring 
stage parasites would extend the comparative analysis into explore whether cell death 
markers are evident following high concentration exposure of antimalarial compounds, 
with artemisinins of particular interest here.  
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Chapter 7: Moving forward 
 
This study set out with the aim to explore whether the PfAtg8-PfAtg3 interaction that 
provides for the phosphatidylethanolamine labelling of PfAtg8 offers some potential as a 
drug development target. A compound library was designed to act as inhibitors of 
autophagy protein-protein interaction in human cells were screened and two structurally 
related hits, SK1.47 and SK1.49, were identified. The key observations following 
treatment with these two hits included;  
(i) Both compounds inhibit intraerythrocytic development in both CQR and CQS 
P. falciparum with a moderate EC50 potency of 1-2 µM. 
(ii) Both compounds produce a cytocidal kill rate comparable to that of CQ, which 
achieving the minimal rate of kill criteria for TCP1. 
(iii) Both compounds revealed trophozoite stage-dependent effects, although 
delays in ring stage development were evident. 
(iv) Both compounds appear to have promising selectivity for intraerythrocytic 
parasites when compared to HepG2. 
(v) Inhibition the numbers and distribution of starvation-induced PfAtg8-labelled 
is a key proof of concept data that indicates these compounds inhibit the 
phosphatidylethanolamine labelling of PfAtg8. 
(vi) Modelling of the potential interaction of both compounds to the PfAtg3 
interaction region of PfAtg8 indicates that the naphthalene group docks into 
the W-pocket with the 2,4,-trimethyl substituted phenyl group docking into 
the L-pocket. This modelling also suggests key aspects of the SAR of the 
screened library compounds with respect to docking into the W and L-pockets. 
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(vii) Absence of ultrastructural and biochemical evidences of apoptotic and 
necrotic-cell death following treatment with both compounds were indicated. 
The role of the incomplete canonical autophagy cascade in P. falciparum is the subject of 
debate (Cervantes et al., 2014; Gaviria et al., 2013; Kitamura et al., 2012; Navale et al., 
2014; Tomlins et al., 2013; Walczak et al., 2018). Our study, with its focus on only the 
potential of inhibition of PfAtg8-PfAtg3 as a drug target does not provide evidence for the 
presence or absence of autophagy. Induction of PfAtg8-labelled vesicles formation in 
starved parasites, suggesting that this feature may represent a type of adaptation to 
nutrient stress with autophagosome-like vesicle could be produced (Gaviria et al., 2013). 
To well define whether this cytoplasmic vacuolation represent macroautophagy or not, 
the contents of PfAtg8-labelled vesicles need to be determined. For example, recycling of 
cytoplasm components of the parasite as nutrients via these vesicles would proof that. In 
addition, whilst the very preliminary observation indicated that PfAtg3 AIM peptides bind 
less well to PfAtg8 in the presence of SK1.47 and SK1.49 (Jürgen Bosch, pers. comm.), this 
is not suggesting that SK1.47 and SK1.49 bound with PfAtg3 binding region of PfAtg8 and 
blocked this interaction. This still requires biophysical data to support the modelling data 
reported in this thesis.  
SK1.47 and SK1.49 do offer, however, chemical probes to explore the action of PfAtg8 in 
P. falciparum and, given the apparent structural similarity of Atg8 amongst apicomplexan 
parasite (Hain et al., 2016), and more widely for other parasite systems. These chemical 
probes, complemented by compound 1 (MMV007907) and ACL25 (Hain et al., 2014, 
2016), could be used to explore better the apparent recycling of invasion organelles 
following the sporozoite invasion of hepatocytes (Jayabalasingham et al., 2010; Meis et 
al., 1985), the trafficking of vesicles within the intraerythrocytic stages (Gaviria et al., 
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2013), the role of Atg8 in function and biogenesis of apicoplast (Cervantes et al., 2014; 
Kitamura et al., 2012) as well as whether the PfAtg8-labelled vesicles induced on 
starvation do indeed represent autophagosomes (Tomlins et al., 2013). The current 
moderate antiplasmodial activity of SK1.47 and SK1.49 as well as their high lipophilicity 
mean that they are not realistic leads for further development. For this reason, additional 
studies need to take them forward for a more comprehensive evaluation of toxicity, 
serum stability and proof-of-concept in a murine malaria model were not considered 
here. In chapter 4, however, it has been illustrated how these compounds (SK1.47 and 
SK1.49) could be taken forward. Much like Hain et al. (2016), the potential for in silico 
modelling of interactions of small molecules to the PfAtg3 interacting region of PfAtg8 
could be exploited here. Chapter 4 concludes with an analysis of the core SK1.47 and 
SK1.49 scaffold, suggesting the opportunities to modify this scaffold based on the SAR of 
the data developed in this study. This can readily exploit to generate in silico thousands of 
virtual analogues that can be docked against PfAtg8, noting that benchmark docking 
scores and EC50 activities for a range of analogues of SK1.47 and SK1.49 exist. This work 
would provide a library of compounds that would warrant synthesis to allow, (i) 
confirmation of more potent antiplasmodial activity, (ii) confirmation of proof-of-principle 
of action using the PfAtg8 immunofluorescence assay following starvation and (iii) 
comparison their relative rate of kill against SK1.47 and SK1.49 as changes in the relative 
rate of kill may suggest changes in the mode of action (DBeQ is a good example of this – a 
potential autophagy inhibitor that has distinct rate of kill dynamics as well as differences 
in the induction of biochemical markers of cell death) and (iv) materials for potential SPR, 
isothermal colorimetry and X-ray crystallography to explore the physical interaction with 
PfAtg8. 
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A second major part of my research explored the comparative effect of high 
concentrations of antimalarial drugs during early cell death events. This study was 
supported by a framework of studies using a high concentration of CQ to induce a 
temporal cascade of apoptotic markers (Ch’ng et al., 2010, 2011). This study was 
supported by a bioluminescence- based assay for parasite viability, initially developed in 
our laboratory by Ullah et al. (2017). Importantly, this assay allowed different 
concentrations of different drugs to be compared against a defined and titratable, killing 
effect with 25%, 50% and 90% kill effect were dependent. This provides a novel tool to 
explore the effect of different drugs (as well as SK1.47, SK1.49 and DBeQ) at the same 
endpoint, providing the means to carry out a potential comparative analysis. In this way, I 
was able to explore the effect of CQ, and compare it to what has previously been 
reported by Ch’ng et al. (2010, 2011). This approach also allowed to use other 4-
aminoquinolines AQ and related analogues, PPQ and PYRD as well as pairs of compounds 
from two other major classes of antimalarial drugs; the arylamino alcohols MQ and QN 
and the artemisinins DHA and ARM.  
Fig. 7.1 provides a simplified traffic light (Red-Amber-Green) rating of the observations 
made by Ch’ng et al. (2010; 2011) compared to their model of the predicted apoptotic 
cascade (Ch’ng et al., 2010). Where green indicates there is absolute correlations with our 
datasets reported in chapters 5 and 6 and red indicates no correlation, while amber 
means existence an intermediate correlation. As discussed in chapters 5 and 6, 50% and 
9%-100% kill concentrations provided ultrastructural evidence of digestive vacuole 
swelling, and potentially leakage of DV contents into the cytoplasm, and biochemical 
evidence for the release of Ca2+ stores from the digestive vacuole and ΔΨm collapse. The 
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absence of an increase in cytoplasmic Clan CA cysteine protease activity and DNA 
fragmentation has already been discussed in chapter 6.  
 
 
Fig. 7.1 Traffic light analysis comparing the observations linked to the (A) Ch’ng et al. (2010) 
model describing an apoptotic cascade in intraerythrocytic P. falciparum following exposure to 
high concentrations of CQ and (B) observations reported in this thesis using 50% and 90% kill 
concentrations of CQ modelled onto this framework. 
 
The same traffic light analysis of the high concentration of CQ framework has been 
applied for the remaining 4-aminoquinolines and related analogues (Fig. 7.2A), arylamino 
alcohols (Fig. 7.2B), artemisinins (Fig. 7.2C) and the putative autophagy inhibitors 
(Fig.7.3). This analysis allows the following features to be identified; 
(i) The analysis included pairs of closely related compounds predicted to share the 
same mode of action. These included QN and MQ, DHA and ARM and SK1.47 and 
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SK1.49. For all pairs of compounds the same pattern of ultrastructural and 
biochemical marker changes were observed. This provides some additional 
confidence in the observations made and the conclusions that can be drawn from 
them. 
 
Fig. 7.2 Traffic light analysis comparing the observations linked to the Ch’ng et al. (2010) model 
describing an apoptotic cascade in intraerythrocytic P. falciparum following exposure to high 
concentrations of CQ. (A) Comparison using high concentrations of the 4-aminoquinolines AQ, 
PYRD and PPQ. (B) Comparison using high concentrations of the arylamino alcohols QN and MQ. 
(C) Comparison using high concentrations of the artemisinins DHA and ARM.   
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Fig. 7.3 Traffic light analysis comparing the observations linked to the Ch’ng et al. (2010) model 
describing an apoptotic cascade in intraerythrocytic P. falciparum following exposure to high 
concentrations of CQ using the potential autophagy inhibitors SK1.47, SK1.49 and DBeQ.  
 
(ii) There are some speculations regarding to the targets of AQ, PPQ and PYRD, 
although based on their structural similarity to CQ this is predicted they likely 
inhibit haem polymerization (Combrinck et al., 2012; Omodeo-Sale et al., 2009).  
Targeting the digestive vacuole is clearly featured from the ultrastructural 
changes to digestive vacuole following AQ and PPQ treatment, but not for PYRD 
over the 6 hrs timeframe. This is also case for all of these drugs with a 
concentration-dependent redistribution of Ca2+ stores from the digestive vacuole 
to the cytoplasm. These drugs also shared a concentration-dependent ΔΨm 
collapse as like as CQ. 
(iii) Interestingly, ultrastructural changes to the digestive vacuole, such as significant 
swelling in the case of QN, MQ, SK1.49 and DBeQ, did not result in its 
permeabilization as suggested by the lack of a significant concentration-
dependent redistribution of Ca2+ stores from the digestive vacuole into the 
cytoplasm. Thus, evidence of ultrastructural changes to the digestive vacuole 
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(swelling) cannot be assumed to be a marker of digestive vacuole membrane 
damage. 
(iv) It appears that ΔΨm collapse has a central role in cell death. This potential has 
previously been explored by Pasini et al. (2013) who developed an antiplasmodial 
growth assay using JC-1 fluorescence to estimate EC50. This study specifically used 
ARM and CQ (as done here), but also included atovaquone which was not 
included here as it was considered unlikely to see markers of cell death within 6 
hrs given the apparent lag phase for the action of this drug (Sanz et al., 2012; 
Ullah et al., 2017). Interestingly, whilst we may conclude that ΔΨm collapse may 
be a common marker of drug-induced cell death in intraerythrocytic P. 
falciparum, and by extension that this cell death is related to a form of apoptosis, 
this is indeed not true for SK1.47 and SK1.49. Thus, we see some markers of 
apoptotic cell death following treatment with some compounds and we never see 
ultrastructural features that would be characteristic of necrotic cell death.  
Together, the comparative approach adopted here and the observations made provide 
what may be a start to a description of cell death phenotypes in P. falciparum that could 
start to systematically address the debate between apoptotic cell death and incidental 
cell death (Deponte and Becker, 2004; Proto et al., 2012; Taylor-Brown and Hurd, 2013; 
Sow et al., 2015). To take this work forward, I would suggest; (i) that the better 
differentiation of cell death events using high concentrations of drugs/compounds could 
focus on 50%, 75%, 90% and 99-100% kill concentrations (based on the absence of any 
evidence of changes at 25% kill concentrations), (ii) In addition, this study was limited by 
the stage-specific expression of the luciferase reporter gene within the trophozoite stages 
of intraerythrocytic development (Wong et al., 2011; Ullah et al., 2017), (iii) To explore 
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longer exposures to drug/compound or even their effects in intraerythrocytic ring or 
other life cycle stages, the luciferase reporter cassette would need to be modified to 
create new genetically modified strains for study. Finally, the utility of the comparative 
ultrastructural and biochemical marker studies used here could be dramatically extended 
by the incorporation of more advanced post-genomic approaches such as transcriptomic 
(Birkholtz et al., 2008; Natalang et al., 2008; Mok et al., 2014; Shaw et al., 2015) 
proteomics (Gisselberg et al., 2017; Ismail et al., 2016; Mogire et al., 2017; Wright et al., 
2014) and metabolomics (Allman et al., 2016; Cowell et al., 2018; Creek et al., 2016 
Tewari et al., 2017). 
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Appendix 1 (Chapter 3) 
Table shows compound ID, EC50 in both Dd2
luc (CQR) and 3D7 (CQS) with chemical 
structures for 131 synthetic putative autophagy inhibitors.  
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EC50 (µM) in 
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(95% Confidence 
intervals) 
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(95% Confidence 
intervals) 
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Appendix 2 (Chapter 3) 
Illustrating EC50 values of library compounds in 3D7 (A) and Dd2
luc (B) trophozoite stage of P. 
falciparum using malaria SYBR Green I Fluorescence assay. 
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Appendix 3 (Chapter 4) 
Table shows docking scores for compounds docked to three binding centres (LYS47, 
LYS48 and LEU50 within PfAtg8 and LYS49, LYS51 and LEU53 of hLC3) with 7-8 binding 
points for each one of these binding centres as well as indicated H-bond formation and 
whether docked (docking status) into W and/or L-pockets.  
 
Comp. 
ID 
+target 
Binding 
centre-
binding 
points 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+PfAtg8 LYS48-N380 1 #1 -7.9   Docked 
    2 #2 -7.1   Docked 
    3 #3 -7.1   W-only 
    4 #4 -6.9   L-only 
  LYS48-C381   Nil       
      Nil       
      Nil       
      Nil       
  LYS48-C382 5 #1 -7.9   Docked 
    6 #2 -7.7   W-only 
    7 #3 -7.3   Docked 
    8 #4 -7.0   W-only 
  LYS48-O383 9 #1 -7.9   W-only 
    10 #2 -7.5   W-only 
    11 #3 -7.2   W-only 
    12 #4 -7.2   W-only 
  LYS48-C384 14 #1 -7.9   Docked 
    15 #2 -7.5   Docked 
    16 #3 -7.5   W-only 
    17 #4 -7.3   W-only 
  LYS48-C385 18 #1 -8.0   Docked 
    19 #2 -7.6   Docked 
    20 #3 -7.3   W-only 
    21 #4 -7.2   W-only 
  LYS48-C386 22 #1 -7.9   Docked 
    23 #2 -7.7   W-only 
    24 #3 -7.5   W-only 
    25 #4 -7.3   W-only 
  LYS48-C387 26 #1 -7.9   docked 
    27 #2 -7.5   docked 
    28 #3 -7.1   Docked 
    29 #4 -6.9 H-bond Docked 
  LYS48-N388 30 #1 -7.9   W-only 
    31 #2 -7.6   W-only 
    32 #3 -7.5   W-only 
    33 #4 -7.5   Docked 
 
299 
 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+PfAtg8 LEU50-N400 34 #1 -7.9 
 
Docked 
  
35 #2 -7.5 
 
W-only 
  
36 #3 -7.3 
 
Docked 
  
37 #4 -7.1 
 
W-only 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 38 #1 -7.9 
 
W-only 
  
39 #2 -7.5 
 
Docked 
  
40 #3 -7.2 
 
Docked 
  
41 #4 -7.1 
 
Docked 
 
LEU50-O403 42 #1 -7.8 
 
Docked 
  
43 #2 -7.2 
 
Docked 
  
44 #3 -7.1 
 
Docked 
  
45 #4 -6.9 
 
Docked 
 
LEU50-C404 46 #1 -7.9 
 
Docked 
  
47 #2 -7.7 
 
Docked 
  
48 #3 -7.1 
 
Docked 
  
49 #4 -6.5 H-bond Docked 
 
LEU50-C405 50 #1 -7.9 
 
Docked 
  
51 #2 -7.3 
 
W-only 
  
52 #3 -6.6 
 
Docked 
  
53 #4 -6.6 
 
W-only 
 
LEU50-C406 54 #1 -8.0 
 
Docked 
  
55 #2 -7.4 
 
Docked 
  
56 #3 -7.0 
 
Docked 
  
57 #4 -6.9 
 
W-only 
 
LEU50-C407 58 #1 -8.0 H-bond Docked 
  
59 #2 -7.6 
 
W-only 
  
60 #3 -7.2 
 
Docked 
  
61 #4 -6.7 H-bond Docked 
 
 
 
 
 
300 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+PfAtg8 LYS47-N371 62 #1 -7.9 
 
Docked 
  
63 #2 -7.4 
 
Docked 
  
64 #3 -7.2 
 
W-only 
  
65 #4 -6.8 
 
Docked 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 66 #1 -7.9 
 
Docked 
  
67 #2 -7.2 
 
W-only 
  
68 #3 -6.8 H-bond W-only 
  
69 #4 -6.6 
 
Docked 
 
LYS47-O374 70 #1 -7.9 
 
W-only 
  
71 #2 -7.6 
 
W-only 
  
72 #3 -7.5 
 
Docked 
  
73 #4 -7.5 
 
Docked 
 
LYS47-C375 74 #1 -7.7 
 
Docked 
  
75 #2 -7.3 
 
W-only 
  
76 #3 -7.0 
 
Docked 
  
77 #4 -6.8 
 
W-only 
 
LYS47-C376 78 #1 -7.9 
 
Docked 
  
79 #2 -7.5 
 
W-only 
  
80 #3 -7.3 
 
W-only 
  
81 #4 -7.2 
 
W-only 
 
LYS47-C377 82 #1 -7.6 
 
W-only 
  
83 #2 -7.3 H-bond W-only 
  
84 #3 -7.2 
 
W-only 
  
85 #4 -6.7 
 
Out 
 
LYS47-C378 86 #1 -7.1 H-bond W-only 
  
87 #2 -7.1 
 
W-only 
  
88 #3 -6.8 
 
W-only 
  
89 #4 -6.8 
 
W-only 
 
LYS47-N379 90 #1 -7.3 
 
W-only 
  
91 #2 -7.2 
 
W-only 
  
92 #3 -6.9 
 
Out 
  
93 #4 -6.9 
 
Out 
 
 
 
 
301 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.47 
+PfAtg8 LYS48-N380 94 #1 -8.3 H-bond W-only 
  
95 #2 -8.3 
 
Docked 
  
96 #3 -8.2 H-bond Docked 
  
97 #4 -8.2 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 98 #1 -8.3 
 
W-only 
  
99 #2 -8.0 
 
Docked 
  
100 #3 -6.2 
 
W-only 
  
101 #4 5.9 
 
L-only 
 
LYS48-O383 102 #1 -8.5 
 
Docked 
  
103 #2 -8.4 
 
Docked 
  
104 #3 -8.2 
 
Docked 
  
105 #4 -7.6 
 
Docked 
 
LYS48-C384 106 #1 -8.2 
 
W-only 
  
107 #2 -7.0 
 
W-only 
  
108 #3 -7.0 
 
W-only 
  
109 #4 -6.7 
 
W-only 
 
LYS48-C385 110 #1 -7.8 
 
W-only 
  
111 #2 -7.6 
 
Docked 
  
112 #3 -7.4 
 
W-only 
  
113 #4 -7.3 
 
Docked 
 
LYS48-C386 114 #1 -8.5 
 
Docked 
  
115 #2 -8.3 
 
Docked 
  
116 #3 -8.0 
 
L-only 
  
117 #4 -7.4 
 
W-only 
 
LYS48-C387 118 #1 -8.3 
 
Docked 
  
119 #2 -8.3 
 
Docked 
  
120 #3 -7.2 
 
Docked 
  
121 #4 -6.9 
 
W-only 
 
LYS48-N388 122 #1 -8.3 
 
W-only 
  
123 #2 -7.7 
 
W-only 
  
124 #3 -7.7 
 
W-only 
  
125 #4 -7.4 
 
W-only 
 
 
 
 
302 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.47 
+PfAtg8 LEU50-N400 126 #1 -8.5 
 
W-only 
  
127 #2 -8.3 
 
Docked 
  
128 #3 -7.7 
 
Docked 
  
129 #4 -7.5 
 
W-only 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 130 #1 -8.0 
 
W-only 
  
131 #2 -7.8 
 
W-only 
  
132 #3 -7.7 
 
Docked 
  
133 #4 -7.4 
 
Docked 
 
LEU50-O403 134 #1 -8.1 
 
Docked 
  
135 #2 -8.0 
 
W-only 
  
136 #3 -7.7 
 
Docked 
  
137 #4 -7.4 
 
L-only 
 
LEU50-C404 138 #1 -8.5 H-bond Docked 
  
139 #2 -8.4 
 
Docked 
  
140 #3 -8.2 
 
Docked 
  
141 #4 -7.6 
 
W-only 
 
LEU50-C405 142 #1 -8.3 
 
W-only 
  
143 #2 -7.7 
 
W-only 
  
144 #3 -7.6 
 
Docked 
  
145 #4 -7.6 
 
W-only 
 
LEU50-C406 146 #1 -8.3 
 
W-only 
  
147 #2 -7.5 
 
Docked 
  
148 #3 -7.5 
 
W-only 
  
149 #4 -7.2 
 
W-only 
 
LEU50-C407 150 #1 -8.0 
 
W-only 
  
151 #2 -7.9 
 
Docked 
  
152 #3 -6.9 
 
L-only 
  
153 #4 -6.8 
 
Docked 
 
 
 
 
 
 
 
303 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.47 
+PfAtg8 LYS47-N371 154 #1 -8.3 
 
W-only 
  
155 #2 -7.7 
 
Docked 
  
156 #3 -7.4 
 
W-only 
  
157 #4 -6.8 
 
W-only 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 158 #1 -8.3 
 
W-only 
  
159 #2 -7.6 
 
L-only 
  
160 #3 -7.5 
 
Docked 
  
161 #4 -7.2 
 
Docked 
 
LYS47-O374 162 #1 -8.3 
 
W-only 
  
163 #2 -7.7 
 
Docked 
  
164 #3 -7.4 
 
Docked 
  
165 #4 -7.2 
 
Docked 
 
LYS47-C375 166 #1 -8.4 
 
Docked 
  
167 #2 -8.0 
 
W-only 
  
168 #3 -8.0 
 
Docked 
  
169 #4 -7.9 
 
W-only 
 
LYS47-C376 170 #1 -8.3 H-bond Docked 
  
171 #2 -7.9 
 
W-only 
  
172 #3 -7.7 
 
W-only 
  
173 #4 -7.1 
 
W-only 
 
LYS47-C377 174 #1 -7.9 
 
W-only 
  
175 #2 -7.5 
 
W-only 
  
176 #3 -7.4 
 
W-only 
  
177 #4 -6.9 
 
Out 
 
LYS47-C378 178 #1 -7.5 
 
W-only 
  
179 #2 -7.5 H-bond W-only 
  
180 #3 -6.9 
 
W-only 
  
181 #4 -6.7 
 
W-only 
 
LYS47-N379 182 #1 -6.1 
 
W-only 
  
183 #2 -5.6 
 
Out 
  
184 #3 -5.5 
 
Out 
  
185 #4 -5.5 
 
W-only 
 
 
 
304 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.109 
+PfAtg8 LYS48-N380 186 #1 -7.0 H-bond Docked 
  
187 #2 -7.0 
 
Docked 
  
188 #3 -6.9 
 
W-only 
  
189 #4 -6.8 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 190 #1 -7.6 
2H-
bonds Docked 
  
191 #2 -7.0 
 
W-only 
  
192 #3 -6.8 
 
Docked 
  
193 #4 -6.7 H-bond Docked 
 
LYS48-O383 194 #1 -7.4 
2H-
bonds Docked 
  
195 #2 -7.2 
 
Docked 
  
196 #3 -6.7 
 
Docked 
  
197 #4 -6.5 
 
W-only 
 
LYS48-C384 198 #1 -7.2 H-bond Docked 
  
199 #2 -7.1 H-bond Docked 
  
200 #3 -7.1 H-bond Docked 
  
201 #4 -6.8 
 
W-only 
 
LYS48-C385 202 #1 -7.2 H-bond Docked 
  
203 #2 -7.1 
 
Docked 
  
204 #3 -6.6 H-bond W-only 
  
205 #4 -6.6 
 
W-only 
 
LYS48-C386 206 #1 -7.5 
 
Docked 
  
207 #2 -6.5 
 
W-only 
  
208 #3 -6.2 
 
W-only 
  
209 #4 -6.2 
 
W-only 
 
LYS48-C387 210 #1 -7.5 H-bond Docked 
  
211 #2 -6.8 H-bond W-only 
  
212 #3 -6.6 
 
W-only 
  
213 #4 -6.4 
 
W-only 
 
LYS48-N388 214 #1 -6.8 
 
W-only 
  
215 #2 -6.6 
 
W-only 
  
216 #3 -6.6 
 
W-only 
  
217 #4 -6.4 
 
W-only 
 
 
 
305 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.109 
+PfAtg8 LEU50-N400 218 #1 -7.2 
 
Docked 
  
219 #2 -6.6 
 
Docked 
  
220 #3 -6.5 
 
W-only 
  
221 #4 -6.2 
 
W-only 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 222 #1 -7.2 
 
Docked 
  
223 #2 -7.0 
 
L-only 
  
224 #3 -6.3 
 
W-only 
  
225 #4 -6.2 
 
L-only 
 
LEU50-O403 226 #1 -7.5 H-bond Docked 
  
227 #2 -7.2 
 
Docked 
  
228 #3 -7.2 
 
L-only 
  
229 #4 -6.9 
 
L-only 
 
LEU50-C404 230 #1 -7.4 
 
Docked 
  
231 #2 -7.1 
 
Docked 
  
232 #3 -7.1 H-bond W-only 
  
233 #4 -6.8 H-bond Docked 
 
LEU50-C405 234 #1 -7.6 H-bond Docked 
  
235 #2 -6.8 H-bond W-only 
  
236 #3 -6.6 
 
Docked 
  
237 #4 -6.6 
 
W-only 
 
LEU50-C406 238 #1 -7.0 H-bond Docked 
  
239 #2 -6.8 
 
Docked 
  
240 #3 -6.6 
 
L-only 
  
241 #4 -6.0 
 
Docked 
 
LEU50-C407 242 #1 -7.4 
 
Docked 
  
243 #2 -7.2 H-bond Docked 
  
244 #3 -7.0 
 
W-only 
  
245 #4 -6.8 
 
W-only 
 
 
 
 
 
 
306 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.109 
+PfAtg8 LYS47-N371 246 #1 -7.2 H-bond Docked 
  
247 #2 -6.8 H-bond Docked 
  
248 #3 -6.6 
 
Docked 
  
249 #4 -6.1 
 
W-only 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 250 #1 -7.5 
 
W-only 
  
251 #2 -6.4 H-bond W-only 
  
252 #3 -6.4 H-bond W-only 
  
253 #4 -6.1 
 
Docked 
 
LYS47-O374 254 #1 -7.1 
 
Docked 
  
255 #2 -6.9 
 
Docked 
  
256 #3 -6.2 
 
W-only 
  
257 #4 -5.8 
 
L-only 
 
LYS47-C375 258 #1 -7.5 
 
Docked 
  
259 #2 -7.4 
 
Docked 
  
260 #3 -6.2 
 
W-only 
  
261 #4 -6.1 H-bond Docked 
 
LYS47-C376 262 #1 -5.8 
 
W-only 
  
263 #2 -5.6 H-bond Docked 
  
264 #3 -5.3 
 
W-only 
  
265 #4 -5.1 
 
W-only 
 
LYS47-C377 266 #1 -5.6 
 
W-only 
  
267 #2 -5.6 
 
W-only 
  
268 #3 -5.3 
 
W-only 
  
269 #4 -5.3 
 
W-only 
 
LYS47-C378 270 #1 -5.9 
 
W-only 
  
271 #2 -5.8 
 
W-only 
  
272 #3 -5.3 
 
W-only 
  
273 #4 -5.1 
 
W-only 
 
LYS47-N379 274 #1 -6.8 
 
W-only 
  
275 #2 -6.3 
 
W-only 
  
276 #3 -6.2 
 
W-only 
  
277 #4 -5.6 
 
Out 
 
 
 
307 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.108 
+PfAtg8 LYS48-N380 278 #1 -7.2 H-bond Docked 
  
279 #2 -7.2 H-bond Docked 
  
280 #3 -7.0 
 
Docked 
  
281 #4 -6.9 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 282 #1 -7.6 H-bond Docked 
  
283 #2 -7.2 
2H-
bonds Docked 
  
284 #3 -6.8 
 
W-only 
  
285 #4 -6.4 
 
W-only 
 
LYS48-O383 286 #1 -7.4 H-bond Docked 
  
287 #2 -7.3 
 
Docked 
  
288 #3 -6.9 
 
Out 
  
289 #4 -6.8 
 
W-only 
 
LYS48-C384 290 #1 -7.3 H-bond Docked 
  
291 #2 -7.1 
 
W-only 
  
292 #3 -7.0 H-bond W-only 
  
293 #4 -6.8 
 
W-only 
 
LYS48-C385 294 #1 -7.4 
 
Docked 
  
295 #2 -7.1 
 
W-only 
  
296 #3 -7.1 
 
Docked 
  
297 #4 -7.0 H-bond Docked 
 
LYS48-C386 298 #1 -7.4 H-bond Docked 
  
299 #2 -7.2 
 
Docked 
  
300 #3 -7.0 
 
W-only 
  
301 #4 -6.9 
 
W-only 
 
LYS48-C387 302 #1 -7.4 
 
Docked 
  
303 #2 -7.0 
 
W-only 
  
304 #3 -6.8 
 
W-only 
  
305 #4 -6.8 
 
W-only 
 
LYS48-N388 306 #1 -6.8 
 
W-only 
  
307 #2 -6.8 
 
W-only 
  
308 #3 -6.6 
 
W-only 
  
309 #4 -6.5 
 
W-only 
 
 
308 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.108 
+PfAtg8 LEU50-N400 310 #1 -7.4 H-bond Docked 
  
311 #2 -7.3 
 
Docked 
  
312 #3 -6.8 
 
W-only 
  
313 #4 -6.2 
 
Docked 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 314 #1 -7.0 
 
Docked 
  
315 #2 -7.0 
 
Docked 
  
316 #3 -6.9 H-bond Docked 
  
317 #4 -6.7 
 
W-only 
 
LEU50-O403 318 #1 -7.4 
2H-
bonds Docked 
  
319 #2 -7.4 
 
Docked 
  
320 #3 -7.2 
 
Docked 
  
321 #4 -6.9 
 
W-only 
 
LEU50-C404 322 #1 -7.3 
 
Docked 
  
323 #2 -6.9 H-bond Docked 
  
324 #3 -6.4 
 
Docked 
  
325 #4 -6.3 
 
W-only 
 
LEU50-C405 326 #1 -7.4 H-bond Docked 
  
327 #2 -7.4 
 
Docked 
  
328 #3 -6.8 
 
W-only 
  
329 #4 -6.7 
 
L-only 
 
LEU50-C406 330 #1 -6.8 
 
Docked 
  
331 #2 -6.6 
 
Docked 
  
332 #3 -6.4 
 
W-only 
  
333 #4 -6.3 
 
W-only 
 
LEU50-C407 334 #1 -7.3 
2H-
bonds Docked 
  
335 #2 -7.0 H-bond Docked 
  
336 #3 -6.4 
 
W-only 
  
337 #4 -6.3 
 
W-only 
 
 
 
 
309 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.108 
+PfAtg8 LYS47-N371 338 #1 -7.6 
 
Docked 
  
339 #2 -7.5 
 
Docked 
  
340 #3 -6.8 
 
W-only 
  
341 #4 -6.5 
 
Docked 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 342 #1 -7.2 
 
Docked 
  
343 #2 -7.1 
 
Docked 
  
344 #3 -6.8 
 
W-only 
  
345 #4 -6.5 
 
W-only 
 
LYS47-O374 346 #1 -7.4 
 
Docked 
  
347 #2 -7.0 
 
Docked 
  
348 #3 -6.5 
 
Docked 
  
349 #4 -6.6 
 
Docked 
 
LYS47-C375 350 #1 -7.0 
 
Docked 
  
351 #2 -6.8 
 
W-only 
  
352 #3 -6.8 H-bond Docked 
  
353 #4 -6.6 H-bond Docked 
 
LYS47-C376 354 #1 -7.2 
 
Docked 
  
355 #2 -7.2 
 
Docked 
  
356 #3 -7.0 
 
W-only 
  
357 #4 -6.4 
 
Out 
 
LYS47-C377 358 #1 -7.1 H-bond W-only 
  
359 #2 -6.6 
 
W-only 
  
360 #3 -6.6 
 
W-only 
  
361 #4 -6.2 
 
W-only 
 
LYS47-C378 362 #1 -7.2 
 
W-only 
  
363 #2 -6.7 
 
W-only 
  
364 #3 -6.5 
 
W-only 
  
365 #4 -6.4 
 
W-only 
 
LYS47-N379 366 #1 -6.2 
 
W-only 
  
367 #2 -6.2 
 
Out 
  
368 #3 -6.2 
 
W-only 
  
369 #4 -6.1 
 
Out 
 
 
 
 
310 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.63 
+PfAtg8 LYS48-N380 370 #1 -6.7 
 
W-only 
  
371 #2 -6.6 
 
Docked 
  
372 #3 -6.4 
 
W-only 
  
373 #4 -6.2 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 374 #1 -6.7 
 
W-only 
  
375 #2 -6.5 H-bond Docked 
  
376 #3 -6.4 
 
W-only 
  
377 #4 -6.4 
 
W-only 
 
LYS48-O383 378 #1 -6.3 
 
W-only 
  
379 #2 -6.1 
 
W-only 
  
380 #3 -6.0 
 
W-only 
  
381 #4 -5.8 
 
W-only 
 
LYS48-C384 382 #1 -6.3 
 
W-only 
  
383 #2 -6.0 
 
W-only 
  
384 #3 -6.0 
 
W-only 
  
385 #4 -5.9 
 
W-only 
 
LYS48-C385 386 #1 -6.2 
 
W-only 
  
387 #2 -5.8 
 
W-only 
  
388 #3 -5.7 
 
W-only 
  
389 #4 -5.7 
 
W-only 
 
LYS48-C386 390 #1 -6.1 
 
W-only 
  
391 #2 -6.1 
 
W-only 
  
392 #3 -5.9 H-bond W-only 
  
393 #4 -5.8 
 
W-only 
 
LYS48-C387 394 #1 -6.2 
 
W-only 
  
395 #2 -5.9 
 
W-only 
  
396 #3 -5.7 
 
W-only 
  
397 #4 -5.7 
 
W-only 
 
LYS48-N388 398 #1 -6.1 
 
W-only 
  
399 #2 -6.0 
 
W-only 
  
400 #3 -6.0 
 
W-only 
  
401 #4 -5.8 
 
W-only 
 
 
 
 
311 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.63 
+PfAtg8 LEU50-N400 402 #1 -6.6 
 
W-only 
  
403 #2 -6.5 
 
W-only 
  
404 #3 -6.2 
 
Docked 
  
405 #4 -6.0 
 
W-only 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 406 #1 -6.4 
 
W-only 
  
407 #2 -6.3 
 
Docked 
  
408 #3 -6.1 
 
L-only 
  
409 #4 -6.1 
 
L-only 
 
LEU50-O403 410 #1 -6.3 
 
W-only 
  
411 #2 -6.2 
 
W-only 
  
412 #3 -6.1 
 
W-only 
  
413 #4 -6.1 
 
W-only 
 
LEU50-C404 414 #1 -7.3 H-bond Docked 
  
415 #2 -7.2 
 
W-only 
  
416 #3 -7.1 
 
L-only 
  
417 #4 -6.8 
 
W-only 
 
LEU50-C405 418 #1 -6.2 
 
W-only 
  
419 #2 -6.1 
 
W-only 
  
420 #3 -6.1 
 
Docked 
  
421 #4 -6.0 
 
W-only 
 
LEU50-C406 422 #1 -6.3 
 
W-only 
  
423 #2 -6.3 
 
W-only 
  
424 #3 -6.2 
 
W-only 
  
425 #4 -6.2 
 
W-only 
 
LEU50-C407 426 #1 -6.2 
 
W-only 
  
427 #2 -6.2 
 
Docked 
  
428 #3 -6.0 
 
W-only 
  
429 #4 -6.0 
 
W-only 
 
 
 
 
 
 
312 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.63 
+PfAtg8 LYS47-N371 430 #1 -6.1 
 
W-only 
  
431 #2 -6.0 
 
W-only 
  
432 #3 -5.9 
 
W-only 
  
433 #4 -5.7 
 
W-only 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 434 #1 -6.8 
 
Docked 
  
435 #2 -6.8 
 
W-only 
  
436 #3 -6.7 
 
Docked 
  
437 #4 -6.5 
 
W-only 
 
LYS47-O374 438 #1 -6.5 
 
W-only 
  
439 #2 -6.5 
 
W-only 
  
440 #3 -6.4 
 
W-only 
  
441 #4 -6.3 
 
W-only 
 
LYS47-C375 442 #1 -6.6 
 
Docked 
  
443 #2 -6.5 
 
W-only 
  
444 #3 -6.2 
 
W-only 
  
445 #4 -6.0 
 
W-only 
 
LYS47-C376 446 #1 -6.2 
 
W-only 
  
447 #2 -6.1 
 
W-only 
  
448 #3 -6.1 
 
W-only 
  
449 #4 -6.0 
 
W-only 
 
LYS47-C377 450 #1 -6.6 
 
W-only 
  
451 #2 -6.5 
 
W-only 
  
452 #3 -6.4 
 
W-only 
  
453 #4 -6.3 
 
W-only 
 
LYS47-C378 454 #1 -6.3 
 
W-only 
  
455 #2 -6.1 
 
W-only 
  
456 #3 -6.0 
 
W-only 
  
457 #4 -6.0 
 
W-only 
 
LYS47-N379 458 #1 -6.5 
 
W-only 
  
459 #2 -6.4 
 
W-only 
  
460 #3 -6.2 
 
W-only 
  
461 #4 -6.1 
 
Out 
 
 
 
313 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO9 
+PfAtg8 LYS48-N380 462 #1 -6.6 
 
W-only 
  
463 #2 -5.8 H-bond Docked 
  
464 #3 -5.8 
 
W-only 
  
465 #4 -5.7 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 466 #1 -6.5 
 
Docked 
  
467 #2 -6.3 
 
W-only 
  
468 #3 -6.2 
 
W-only 
  
469 #4 -6.1 
 
Docked 
 
LYS48-O383 470 #1 -6.4 
 
Docked 
  
471 #2 -5.7 
 
W-only 
  
472 #3 -5.7 
 
W-only 
  
473 #4 -5.6 
 
W-only 
 
LYS48-C384 474 #1 -6.6 H-bond Docked 
  
475 #2 -6.5 
 
W-only 
  
476 #3 -6.4 H-bond W-only 
  
477 #4 -6.1 
 
W-only 
 
LYS48-C385 478 #1 -6.6 
 
W-only 
  
479 #2 -6.0 
 
W-only 
  
480 #3 -5.6 
 
W-only 
  
481 #4 -5.2 
 
W-only 
 
LYS48-C386 482 #1 -6.6 H-bond Docked 
  
483 #2 -6.6 H-bond Docked 
  
484 #3 -6.5 
 
W-only 
  
485 #4 -6.1 
 
W-only 
 
LYS48-C387 486 #1 -6.6 
 
Docked 
  
487 #2 -6.4 
 
W-only 
  
488 #3 -6.3 
 
W-only 
  
489 #4 -6.1 H-bond Docked 
 
LYS48-N388 490 #1 -6.8 H-bond Docked 
  
491 #2 -6.1 
 
W-only 
  
492 #3 -5.9 
 
W-only 
  
493 #4 -5.7 
 
W-only 
 
 
 
314 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO9 
+PfAtg8 LEU50-N400 494 #1 -6.4 
 
W-only 
  
495 #2 -6.4 
 
W-only 
  
496 #3 -5.9 
 
W-only 
  
497 #4 -5.8 
 
W-only 
 
LEU50-C401 
 
Nil  
  
   
Nil  
  
   
Nil  
  
   
Nil  
  
 
LEU50-C402 498 #1 -6.4 
 
Docked 
  
499 #2 -6.2 
 
W-only 
  
500 #3 -6.0 
 
W-only 
  
501 #4 -5.8 
 
Docked 
 
LEU50-O403 502 #1 -6.5 
 
Docked 
  
503 #2 -6.5 H-bond W-only 
  
504 #3 -6.3 
 
W-only 
  
505 #4 -6.3 
 
W-only 
 
LEU50-C404 506 #1 -6.1 
 
Docked 
  
507 #2 -6.1 
 
W-only 
  
508 #3 -6.0 
 
W-only 
  
509 #4 -5.9 
 
W-only 
 
LEU50-C405 510 #1 -6.8 
 
W-only 
  
511 #2 -6.5 H-bond Docked 
  
512 #3 -6.3 H-bond Docked 
  
513 #4 -6.3 H-bond Docked 
 
LEU50-C406 514 #1 -6.8 H-bond Docked 
  
515 #2 -6.6 
 
W-only 
  
516 #3 -6.3 
 
W-only 
  
517 #4 -5.9 
 
W-only 
 
LEU50-C407 518 #1 -6.2 
 
Docked 
  
519 #2 -6.0 
 
W-only 
  
520 #3 -5.9 
 
W-only 
  
521 #4 -5.8 H-bond W-only 
 
 
 
 
 
 
315 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO9 
+PfAtg8 LYS47-N371 522 #1 -6.5 H-bond W-only 
  
523 #2 -6.1 H-bond W-only 
  
524 #3 -6.1 
 
W-only 
  
525 #4 -5.9 
 
W-only 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 526 #1 -6.6 H-bond W-only 
  
527 #2 -6.5 H-bond Docked 
  
528 #3 -6.3 H-bond W-only 
  
529 #4 -5.9 
 
W-only 
 
LYS47-O374 530 #1 -6.1 H-bond Docked 
  
531 #2 -5.9 
 
W-only 
  
532 #3 -5.4 
 
W-only 
  
533 #4 -5.2 
 
W-only 
 
LYS47-C375 534 #1 -6.0 
 
W-only 
  
535 #2 -5.8 
 
W-only 
  
536 #3 -5.7 
 
W-only 
  
537 #4 -5.7 
 
Docked 
 
LYS47-C376 538 #1 -6.0 
 
W-only 
  
539 #2 -5.8 
 
W-only 
  
540 #3 -5.6 
 
W-only 
  
541 #4 -5.6 
 
W-only 
 
LYS47-C377 542 #1 -6.1 
 
W-only 
  
543 #2 -5.9 
 
W-only 
  
544 #3 -5.7 
 
W-only 
  
545 #4 -5.6 
 
W-only 
 
LYS47-C378 546 #1 -6.4 
 
W-only 
  
547 #2 -5.7 
 
W-only 
  
548 #3 -5.5 
 
W-only 
  
549 #4 -5.5 
 
W-only 
 
LYS47-N379 550 #1 -6.2 
 
W-only 
  
551 #2 -5.7 
 
W-only 
  
552 #3 -5.4 
 
W-only 
  
553 #4 -5.2 
 
Out 
 
 
 
316 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO8 
+PfAtg8 LYS48-N380 554 #1 -5.6 
 
W-only 
  
555 #2 -5.1 
 
W-only 
  
556 #3 -5.0 
 
W-only 
  
557 #4 -4.9 
 
Docked 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 558 #1 -6.2 
 
W-only 
  
559 #2 -5.9 
 
W-only 
  
560 #3 -5.9 
 
Docked 
  
561 #4 -5.7 
 
W-only 
 
LYS48-O383 562 #1 -6.2 H-bond Docked 
  
563 #2 -6.2 
 
W-only 
  
564 #3 -6.0 
 
W-only 
  
565 #4 -5.8 
 
Docked 
 
LYS48-C384 566 #1 -6.4 
 
W-only 
  
567 #2 -6.2 H-bond W-only 
  
568 #3 -6.0 
 
W-only 
  
569 #4 -5.8 
 
W-only 
 
LYS48-C385 570 #1 -6.2 
 
W-only 
  
571 #2 -5.9 
 
W-only 
  
572 #3 -5.7 
 
W-only 
  
573 #4 -5.1 
 
W-only 
 
LYS48-C386 574 #1 -5.8 
 
W-only 
  
575 #2 -5.8 
 
W-only 
  
576 #3 -5.5 
 
W-only 
  
577 #4 -5.4 
 
W-only 
 
LYS48-C387 578 #1 -6.2 
 
Docked 
  
579 #2 -6.0 
 
Docked 
  
580 #3 -5.8 
 
W-only 
  
581 #4 -5.6 
 
W-only 
 
LYS48-N388 582 #1 -5.2 
 
Docked 
  
583 #2 -5.2 
 
W-only 
  
584 #3 -5.0 
 
W-only 
  
585 #4 -4.8 
 
W-only 
 
 
 
 
317 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO8 
+PfAtg8 LEU50-N400 586 #1 -6.1 
 
Docked 
  
587 #2 -6.1 
 
Docked 
  
588 #3 -5.9 
 
Docked 
  
589 #4 -5.8 
 
W-only 
 
LEU50-C401 
 
Nil  
  
   
Nil  
  
   
Nil  
  
   
Nil  
  
 
LEU50-C402 590 #1 -5.8 
 
Docked 
  
591 #2 -5.8 
 
Docked 
  
592 #3 -5.7 
 
W-only 
  
593 #4 -5.5 
 
W-only 
 
LEU50-O403 594 #1 -6.3 
 
Docked 
  
595 #2 -6.2 H-bond Docked 
  
596 #3 -5.3 
 
W-only 
  
597 #4 -5.3 
 
W-only 
 
LEU50-C404 598 #1 -6.1 
 
Docked 
  
599 #2 -5.8 
 
W-only 
  
600 #3 -5.7 
 
W-only 
  
601 #4 -5.5 
 
W-only 
 
LEU50-C405 602 #1 -6.4 
 
Docked 
  
603 #2 -6.4 H-bond W-only 
  
604 #3 -6.2 
 
W-only 
  
605 #4 -6.2 
 
W-only 
 
LEU50-C406 606 #1 -6.3 
 
Docked 
  
607 #2 -6.1 
 
W-only 
  
608 #3 -5.9 
 
W-only 
  
609 #4 -5.8 
 
W-only 
 
LEU50-C407 610 #1 -6.0 
 
Docked 
  
611 #2 -5.4 
 
W-only 
  
612 #3 -5.2 
 
W-only 
  
613 #4 -5.0 
 
W-only 
 
 
 
 
 
 
318 
 
Comp. ID 
+target 
Binding centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
LO8 
+PfAtg8 
LYS47-N371 614 #1 -6.3 
 
W-only 
 
615 #2 -6.2 
 
Docked 
  
616 #3 -6.0 
 
W-only 
  
617 #4 -6.0 
 
W-only 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 618 #1 -5.8 
 
W-only 
  
619 #2 -5.8 
 
W-only 
  
620 #3 -5.7 
 
W-only 
  
621 #4 -5.6 
 
Docked 
 
LYS47-O374 622 #1 -6.0 
 
W-only 
  
623 #2 -6.0 
 
W-only 
  
624 #3 -5.8 
 
W-only 
  
625 #4 -5.8 
 
W-only 
 
LYS47-C375 626 #1 -6.0 
 
Docked 
  
627 #2 -6.0 
 
W-only 
  
628 #3 -5.8 
 
W-only 
  
629 #4 -5.4 
 
W-only 
 
LYS47-C376 630 #1 -5.2 
 
Docked 
  
631 #2 -5.0 
 
W-only 
  
632 #3 -4.8 
 
W-only 
  
633 #4 -4.7 
 
W-only 
 
LYS47-C377 634 #1 -6.0 
 
W-only 
  
635 #2 -5.9 
 
W-only 
  
636 #3 -5.0 
 
Out 
  
637 #4 -5.0 
 
Out 
 
LYS47-C378 638 #1 -5.4 
 
W-only 
  
639 #2 -5.4 
 
W-only 
  
640 #3 -5.2 
 
W-only 
  
641 #4 -5.0 
 
W-only 
 
LYS47-N379 642 #1 -5.2 
 
W-only 
  
643 #2 -5.2 
 
W-only 
  
644 #3 -5.1 
 
W-only 
  
645 #4 -5.0 
 
W-only 
 
 
 
 
319 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+PfAtg8 
LYS48-N380 646 #1 -6.5 
 
W-only 
 
647 #2 -6.0 
 
W-only 
  
648 #3 -5.8 H-bond W-only 
  
649 #4 -5.7 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 650 #1 -6.3 
 
W-only 
  
651 #2 -6.2 
 
W-only 
  
652 #3 -5.7 
 
W-only 
  
653 #4 -5.7 
 
W-only 
 
LYS48-O383 654 #1 -6.3 
 
W-only 
  
655 #2 -6.2 
 
W-only 
  
656 #3 -6.2 
 
W-only 
  
657 #4 -6.1 
 
Docked 
 
LYS48-C384 658 #1 -6.3 
 
W-only 
  
659 #2 -6.0 
 
W-only 
  
660 #3 -5.9 H-bond Docked 
  
661 #4 -5.7 
 
W-only 
 
LYS48-C385 662 #1 -6.4 
 
W-only 
  
663 #2 -5.9 
 
W-only 
  
664 #3 -5.7 
 
W-only 
  
665 #4 -5.4 
 
W-only 
 
LYS48-C386 666 #1 -6.3 
 
W-only 
  
667 #2 -6.0 H-bond W-only 
  
668 #3 -5.9 
 
W-only 
  
669 #4 -5.9 H-bond W-only 
 
LYS48-C387 670 #1 -6.4 
 
W-only 
  
671 #2 -6.0 
 
W-only 
  
672 #3 -5.9 
 
W-only 
  
673 #4 -5.9 
 
Docked 
 
LYS48-N388 674 #1 -6.5 
 
W-only 
  
675 #2 -6.1 
 
Docked 
  
676 #3 -5.9 
 
W-only 
  
677 #4 -5.7 
 
W-only 
 
 
 
 
320 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+PfAtg8 
LEU50-N400 678 #1 -6.4 
 
W-only 
 
679 #2 -5.9 
 
W-only 
  
680 #3 -5.9 
 
W-only 
  
681 #4 -5.8 
 
W-only 
 
LEU50-C401 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU50-C402 682 #1 -6.0 
 
W-only 
  
683 #2 -6.0 
 
W-only 
  
684 #3 -5.9 
 
W-only 
  
685 #4 -5.8 
 
W-only 
 
LEU50-O403 686 #1 -5.9 
 
W-only 
  
687 #2 -5.8 H-bond Docked 
  
688 #3 -5.8 
 
W-only 
  
689 #4 -5.7 
 
W-only 
 
LEU50-C404 690 #1 -5.9 
 
W-only 
  
691 #2 -5.9 
 
W-only 
  
692 #3 -5.8 
 
W-only 
  
693 #4 -5.8 H-bond docked 
 
LEU50-C405 694 #1 -6.0 
 
W-only 
  
695 #2 -5.9 H-bond W-only 
  
696 #3 -5.7 
2H-
bond Docked 
  
697 #4 -5.5 
 
W-only 
 
LEU50-C406 698 #1 -5.9 
 
W-only 
  
699 #2 -5.8 
 
W-only 
  
700 #3 -5.8 
 
W-only 
  
701 #4 -5.7 H-bond W-only 
 
LEU50-C407 702 #1 -5.9 
 
W-only 
  
703 #2 -5.9 
 
W-only 
  
704 #3 -5.8 
 
W-only 
  
705 #4 -5.8 H-bond Docked 
 
 
 
 
 
 
321 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+PfAtg8 
LYS47-N371 706 #1 -6.3 
 
W-only 
 
707 #2 -6.1 
 
W-only 
  
708 #3 -6.0 
 
W-only 
  
709 #4 -5.8 H-bond Docked 
 
LYS47-C372 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS47-C373 710 #1 -6.4 
 
W-only 
  
711 #2 -6.0 
 
W-only 
  
712 #3 -5.6 
 
W-only 
  
713 #4 -5.6 
 
Out 
 
LYS47-O374 714 #1 -6.6 
 
W-only 
  
715 #2 -6.1 
 
W-only 
  
716 #3 -5.8 
2 H-
bond Docked 
  
717 #4 -5.8 H-bond Docked 
 
LYS47-C375 718 #1 -6.4 
 
W-only 
  
719 #2 -5.8 
 
W-only 
  
720 #3 -5.8 
 
Docked 
  
721 #4 -5.6 
 
Out 
 
LYS47-C376 722 #1 -6.4 
 
W-only 
  
723 #2 -6.0 
 
W-only 
  
724 #3 -5.9 
 
Docked 
  
725 #4 -5.9 
 
W-only 
 
LYS47-C377 726 #1 -6.0 
 
W-only 
  
727 #2 -5.9 
 
W-only 
  
728 #3 -5.9 
 
W-only 
  
729 #4 -5.7 
 
Out 
 
LYS47-C378 730 #1 -6.0 
 
W-only 
  
731 #2 -5.9 
 
W-only 
  
732 #3 -5.8 
 
Docked 
  
733 #4 -5.6 H-bond Out 
 
LYS47-N379 734 #1 -6.4 
 
W-only 
  
735 #2 -6.0 
 
W-only 
  
736 #3 -5.6 
 
W-only 
  
737 #4 -5.4 
 
Out 
 
 
 
322 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+hLC3 
LYS51-N429 738 #1 -6.8 
 
W-only 
 
739 #2 -6.6 
 
W-only 
  
740 #3 -6.2 
 
W-only 
  
741 #4 -6.1 
 
W-only 
 
LYS51-C430 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS51-C431 742 #1 -7.3 
 
W-only 
  
743 #2 -7.2 
 
Docked 
  
744 #3 -6.9 
 
W-only 
  
745 #4 -6.8 
 
W-only 
 
LYS51-O432 746 #1 -7.3 
 
Docked 
  
747 #2 -7.2 
 
W-only 
  
748 #3 -7.0 
 
W-only 
  
749 #4 -6.8 
 
W-only 
 
LYS51-C433 750 #1 -7.3 
 
W-only 
  
751 #2 -7.2 
 
W-only 
  
752 #3 -7.1 
 
W-only 
  
753 #4 -7.0 
 
W-only 
 
LYS51-C434 754 #1 -6.7 
 
W-only 
  
755 #2 -6.6 
 
W-only 
  
756 #3 -6.2 
 
W-only 
  
757 #4 -6.0 
 
W-only 
 
LYS51-C435 758 #1 -7.3 
 
W-only 
  
759 #2 -7.0 
 
W-only 
  
760 #3 -6.8 
 
W-only 
  
761 #4 -6.6 
 
W-only 
 
LYS51-C436 762 #1 -7.0 
 
W-only 
  
763 #2 -7.0 
 
W-only 
  
764 #3 -6.8 
 
W-only 
  
765 #4 -6.5 
 
W-only 
 
LYS51-N437 766 #1 -6.8 
 
W-only 
  
767 #2 -6.5 
 
W-only 
  
768 #3 -6.2 
 
W-only 
  
769 #4 -5.9 
 
W-only 
 
 
 
 
323 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+hLC3 
LEU53-N449 770 #1 -7.6 
 
Docked 
 
771 #2 -7.6 
 
Docked 
  
772 #3 -7.2 
 
W-only 
  
773 #4 -7.1 
 
W-only 
 
LEU53-C450 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU53-C451 774 #1 -7.6 
 
Docked 
  
775 #2 -7.3 
 
W-only 
  
776 #3 -7.3 
 
W-only 
  
777 #4 -7.2 
 
W-only 
 
LEU53-O452 778 #1 -7.5 
 
W-only 
  
779 #2 -7.3 
 
W-only 
  
780 #3 -7.3 
 
W-only 
  
781 #4 -7.1 
 
W-only 
 
LEU53-C453 782 #1 -7.3 
 
W-only 
  
783 #2 -7.3 H-bond W-only 
  
784 #3 -7.0 
 
W-only 
  
785 #4 -6.8 
 
W-only 
 
LEU53-C454 786 #1 -7.4 
 
W-only 
  
787 #2 -7.3 H-bond Docked 
  
788 #3 -7.2 
 
Docked 
  
789 #4 -7.1 
 
W-only 
 
LEU53-C455 790 #1 -7.0 
 
W-only 
  
791 #2 -7 H-bond W-only 
  
792 #3 -6.9 
 
W-only 
  
793 #4 -6.7 
 
Docked 
 
LEU53-C456 794 #1 -7.0 
 
Docked 
  
795 #2 -7.0 
 
Docked 
  
796 #3 -6.8 
 
Docked 
  
797 #4 -6.4 
 
Docked 
 
 
 
 
 
 
 
324 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking pose 
Docking 
score 
H-bond 
Docking 
status 
SK1.49 
+hLC3 
LYS49-N413 798 #1 -7.0 
 
W-only 
 
799 #2 -7.0 
 
Out 
  
800 #3 -6.8 
 
Out 
  
801 #4 -6.7 
 
Out 
 
LYS49-C414 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS49-C415 802 #1 -7.4 
 
W-only 
  
803 #2 -7.2 
 
Out 
  
804 #3 -6.9 
 
Out 
  
805 #4 -6.8 
 
Out 
 
LYS49-O416 806 #1 -6.6 
 
Out 
  
807 #2 -6.5 
 
W-only 
  
808 #3 -6.1 
 
W-only 
  
809 #4 -5.7 
 
Out 
 
LYS49-C417 810 #1 -7.3 
 
Out 
  
811 #2 -7.1 
 
W-only 
  
812 #3 -6.9 
 
W-only 
  
813 #4 -6.6 
 
Out 
 
LYS49-C418 814 #1 -7.3 
 
W-only 
  
815 #2 -7.2 
 
W-only 
  
816 #3 -7.1 
 
W-only 
  
817 #4 -6.8 
 
W-only 
 
LYS49-C419 818 #1 -7.2 
 
W-only 
  
819 #2 -7.1 
 
W-only 
  
820 #3 -7 
 
W-only 
  
821 #4 -6.7 
 
W-only 
 
LYS49-C420 822 #1 -6.6 
 
W-only 
  
823 #2 -6.8 
 
W-only 
  
824 #3 -6.6 
 
Out 
  
825 #4 -6.3 
 
Out 
 
LYS49-N421 826 #1 -6.4 
 
L-only 
  
827 #2 -6.4 
 
Out 
  
828 #3 -6.1 
 
Out 
  
829 #4 -6 
 
Out 
 
 
 
 
325 
 
Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+hLC3 
LYS51-N429 830 #1 -6.8 
 
W-only 
 
831 #2 -6.4 
 
W-only 
  
832 #3 -5.8 
 
Out 
  
833 #4 -5.8 
 
W-only 
 
LYS51-C430 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS51-C431 834 #1 -6.7 H-bond Docked 
  
835 #2 -6.0 
 
W-only 
  
836 #3 -6.0 
 
W-only 
  
837 #4 -5.2 
 
L-only 
 
LYS51-O432 838 #1 -6.8 H-bond Docked 
  
839 #2 -6.5 
 
W-only 
  
840 #3 -6.0 
 
W-only 
  
841 #4 -5.9 
 
W-only 
 
LYS51-C433 842 #1 -6.7 
 
W-only 
  
843 #2 -6.2 
 
W-only 
  
844 #3 -5.9 
 
Out 
  
845 #4 -5.6 
 
Out 
 
LYS51-C434 846 #1 -6.5 
 
W-only 
  
847 #2 -6.1 
 
Out 
  
848 #3 -6.0 H-bond W-only 
  
849 #4 -5.9 
 
W-only 
 
LYS51-C435 850 #1 -6.6 
 
W-only 
  
851 #2 -6.2 
 
Docked 
  
852 #3 -5.9 
 
W-only 
  
853 #4 -5.8 
 
W-only 
 
LYS51-C436 854 #1 -6.6 
 
Docked 
  
855 #2 -6.2 
 
W-only 
  
856 #3 -5.9 H-bond W-only 
  
857 #4 -5.8 
 
W-only 
 
LYS51-N437 858 #1 -6.7 H-bond Docked 
  
859 #2 -6.5 
 
Docked 
  
860 #3 -6.0 
 
W-only 
  
861 #4 -6.0 H-bond W-only 
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Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+hLC3 
LEU53-N449 862 #1 -6.7 H-bond Docked 
 
863 #2 -6.5 H-bond W-only 
  
864 #3 -6.2 
 
W-only 
  
865 #4 -6.0 
 
W-only 
 
LEU53-C450 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LEU53-C451 866 #1 -6.2 H-bond Docked 
  
867 #2 -6.2 
 
Docked 
  
868 #3 -6.0 
 
W-only 
  
869 #4 -5.9 H-bond Docked 
 
LEU53-O452 870 #1 -6.7 
 
W-only 
  
871 #2 -6.1 
 
W-only 
  
872 #3 -6.1 
 
W-only 
  
873 #4 -5.8 H-bond Docked 
 
LEU53-C453 874 #1 -6.4 H-bond Docked 
  
875 #2 -6.2 
 
W-only 
  
876 #3 -6.1 
 
W-only 
  
877 #4 -5.9 H-bond Docked 
 
LEU53-C454 878 #1 -6.7 H-bond Docked 
  
879 #2 -6.0 H-bond W-only 
  
880 #3 -5.9 
 
Docked 
  
881 #4 -5.7 
 
Docked 
 
LEU53-C455 882 #1 -6.7 H-bond Docked 
  
883 #2 -6.5 H-bond Docked 
  
884 #3 -6.0 H-bond W-only 
  
885 #4 -6.0 
 
W-only 
 
LEU53-C456 886 #1 -6.6 H-bond Docked 
  
887 #2 -6.5 H-bond Docked 
  
888 #3 -5.5 
 
W-only 
  
889 #4 -5.0 
 
L-only 
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Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.1 
+hLC3 
LYS49-N413 890 #1 -6.7 H-bond Docked 
 
891 #2 -6.0 H-bond W-only 
  
892 #3 -5.8 
 
Out 
  
893 #4 -5.6 
 
Out 
 
LYS49-C414 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS49-C415 894 #1 -6.4 
 
Out 
  
895 #2 -6.1 H-bond Out 
  
896 #3 -5.8 H-bond Out 
  
897 #4 -5.6 H-bond Out 
 
LYS49-O416 898 #1 -5.9 
 
Out 
  
899 #2 -5.7 H-bond Out 
  
900 #3 -5.6 
 
Out 
  
901 #4 -5.4 
 
Out 
 
LYS49-C417 902 #1 -6.7 H-bond Docked 
  
903 #2 -6.1 
 
W-only 
  
904 #3 -5.5 
 
W-only 
  
905 #4 -5.5 H-bond Out 
 
LYS49-C418 906 #1 -6.7 H-bond Docked 
  
907 #2 -6.1 
 
W-only 
  
908 #3 -5.7 
 
W-only 
  
909 #4 -5.4 
 
W-only 
 
LYS49-C419 910 #1 -6.6 
 
W-only 
  
911 #2 -6.2 
 
W-only 
  
912 #3 -6.0 H-bond W-only 
  
913 #4 -5.5 
 
Out 
 
LYS49-C420 914 #1 -5.5 
 
Out 
  
915 #2 -5.5 H-bond Docked 
  
916 #3 -5.4 
 
Out 
  
917 #4 -4.9 
 
Out 
 
LYS49-N421 918 #1 -5.5 
 
Out 
  
919 #2 -5.4 
 
Out 
  
920 #3 -5.3 
 
Out 
  
921 #4 -5.3 
 
Out 
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Comp. 
ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.A 
+PfAtg8 LYS48-N380 996 #1 -8.9 
 
Docked 
 
 
997 #2 -8.8 
 
Docked 
 
 
998 #3 -8.4 
 
W-only 
 
 
999 #4 -7.8 
 
W-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 1000 #1 -9.0 H-bond Docked 
  
1001 #2 -8.8 
 
Docked 
  
1002 #3 -8.4 H-bond Docked 
  
1003 #4 -7.7 
 
W-only 
 
LYS48-O383 1004 #1 -8.9 H-bond Docked 
  
1005 #2 -8.8 H-bond Docked 
  
1006 #3 -8.4 
 
Docked 
  
1007 #4 -8.0 H-bond W-only 
 
LYS48-C384 1008 #1 -8.9 
 
Docked 
  
1009 #2 -8.7 
 
Docked 
  
1010 #3 -8.3 
 
Docked 
  
1011 #4 -8.3 
 
Docked 
 
LYS48-C385 1012 #1 -8.9 
 
Docked 
  
1013 #2 -8.8 
 
Docked 
  
1014 #3 -8.2 
 
W-only 
  
1015 #4 -8.1 
 
W-only 
 
LYS48-C386 1016 #1 -8.8 
 
Docked 
  
1017 #2 -8.5 
 
Docked 
  
1018 #3 -8.3 
 
Docked 
  
1019 #4 -7.9 
 
Docked 
 
LYS48-C387 1020 #1 -8.6 
 
Docked 
  
1021 #2 -8.4 H-bond Docked 
  
1022 #3 -8.2 H-bond Docked 
  
1023 #4 -8.0 H-bond Docked 
 
LYS48-N388 1024 #1 -8.5 H-bond W-only 
  
1025 #2 -8.2 
 
W-only 
  
1026 #3 -7.8 
 
W-only 
  
1027 #4 -7.8 
 
W-only 
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Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
status 
Comp.B 
+PfAtg8 LYS48-N380 1028 #1 -8.8 
 
Docked 
 
 
1029 #2 -8.5 
 
Docked 
 
 
1030 #3 -8.2 
 
W-only 
 
 
1031 #4 -7.9 
 
Docked 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 1032 #1 -8.6 
 
Docked 
  
1033 #2 -8.4 
 
Docked 
  
1034 #3 -8.3 
 
Docked 
  
1035 #4 -8.2 
 
Docked 
 
LYS48-O383 1036 #1 -8.8 H-bond Docked 
  
1037 #2 -8.4 
 
Docked 
  
1038 #3 -8.0 
 
W-only 
  
1039 #4 -7.9 H-bond W-only 
 
LYS48-C384 1040 #1 -8.5 
 
Docked 
  
1041 #2 -8.5 
 
Docked 
  
1042 #3 -8.4 
 
Docked 
  
1043 #4 -7.7 
 
W-only 
 
LYS48-C385 1044 #1 -8.6 H-bond Docked 
  
1045 #2 -8.5 
 
Docked 
  
1046 #3 -8.5 H-bond Docked 
  
1047 #4 -8.3 
 
Docked 
 
LYS48-C386 1048 #1 -8.7 
 
Docked 
  
1049 #2 -8.4 
 
Docked 
  
1050 #3 -7.8 
 
W-only 
  
1051 #4 -7.7 
 
W-only 
 
LYS48-C387 1052 #1 -8.3 
 
W-only 
  
1053 #2 -8.1 
 
W-only 
  
1054 #3 -8.1 
 
Docked 
  
1055 #4 -8.0 
 
Docked 
 
LYS48-N388 1056 #1 -8.2 
 
W-only 
  
1057 #2 -7.7 
 
W-only 
  
1058 #3 -7.5 
 
W-only 
  
1059 #4 -7.5 
 
Docked 
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Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
Status 
Comp.C 
+PfAtg8 LYS48-N380 1060 #1 -9.2 H-bond Docked 
 
 
1061 #2 -8.6 H-bond Docked 
 
 
1062 #3 -8.2 
 
L-only 
 
 
1063 #4 -8.1 
 
Docked 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 1064 #1 -8.9 
 
Docked 
  
1065 #2 -8.6 
 
Docked 
  
1066 #3 -8.3 H-bond Docked 
  
1067 #4 -8.2 H-bond W-only 
 
LYS48-O383 1068 #1 -9.0 
 
Docked 
  
1069 #2 -8.6 
 
Docked 
  
1070 #3 -8.0 
 
W-only 
  
1071 #4 -7.4 H-bond W-only 
 
LYS48-C384 1072 #1 -9.2 
 
Docked 
  
1073 #2 -8.8 
 
Docked 
  
1074 #3 -8.2 H-bond Docked 
  
1075 #4 -7.6 
 
W-only 
 
LYS48-C385 1076 #1 -8.9 
 
Docked 
  
1077 #2 -8.5 
 
Docked 
  
1078 #3 -8.1 
 
W-only 
  
1079 #4 -7.7 
 
W-only 
 
LYS48-C386 1080 #1 -8.9 
 
Docked 
  
1081 #2 -8.4 
 
Docked 
  
1082 #3 -8.1 
 
Docked 
  
1083 #4 -7.5 
 
W-only 
 
LYS48-C387 1084 #1 -8.6 H-bond Docked 
  
1085 #2 -8.4 
 
W-only 
  
1086 #3 -7.9 
 
Docked 
  
1087 #4 -7.7 
 
W-only 
 
LYS48-N388 1088 #1 -8.5 
 
Docked 
  
1089 #2 -7.9 
 
W-only 
  
1090 #3 -7.8 
 
W-only 
  
1091 #4 -7.8 H-bond W-only 
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Comp. ID 
+target 
Binding 
centre 
Pose 
No. 
Docking 
pose 
Docking 
score 
H-bond 
Docking 
Status 
Comp.D 
+PfAtg8 LYS48-N380 1092 #1 -7.6 
 
Docked 
 
 
1093 #2 -7.6 H-bond Docked 
 
 
1094 #3 -7.4 
 
Docked 
 
 
1095 #4 -7.2 
 
L-only 
 
LYS48-C381 
 
Nil 
   
   
Nil 
   
   
Nil 
   
   
Nil 
   
 
LYS48-C382 1096 #1 -7.9 
 
W-only 
  
1097 #2 -7.7 H-bond Docked 
  
1098 #3 -7.4 
 
W-only 
  
1099 #4 -7.1 
 
W-only 
 
LYS48-O383 1100 #1 -7.8 
 
Docked 
  
1101 #2 -7.7 
 
W-only 
  
1102 #3 -7.6 
 
Docked 
  
1103 #4 -7.0 
 
Docked 
 
LYS48-C384 1104 #1 -7.7 
 
Docked 
  
1105 #2 -7.6 
 
W-only 
  
1106 #3 -7.4 
 
W-only 
  
1107 #4 -7.4 
 
W-only 
 
LYS48-C385 1108 #1 -7.6 
 
Docked 
  
1109 #2 -7.3 
 
W-only 
  
1110 #3 -7.0 
 
W-only 
  
1111 #4 -6.8 
 
W-only 
 
LYS48-C386 1112 #1 -7.9 
 
Docked 
  
1113 #2 -7.6 
 
Docked 
  
1114 #3 -7.5 
 
W-only 
  
1115 #4 -7.1 
 
W-only 
 
LYS48-C387 1116 #1 -7.5 
 
Docked 
  
1117 #2 -7.4 
 
W-only 
  
1118 #3 -7.1 
 
W-only 
  
1119 #4 -7.1 
 
W-only 
 
LYS48-N388 1120 #1 -7.6 
 
W-only 
  
1121 #2 -7.4 
 
W-only 
  
1122 #3 -7.2 
 
W-only 
  
1123 #4 -6.8 
 
W-only 
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